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Abstract 
This thesis describes the advancement of a flexible and convergent gold-catalysed synthesis of 
trisubstituted oxazoles, and its application to the synthesis of novel polycyclic compounds. Following 
on from the initial discovery of this reaction, its scope and limitations have been have been explored, 
leading to a significant increase in the range of functionality which can be incorporated into the 
products. 
This reaction, and the novel structure of the 4-amido oxazole products, was then exploited to 
allow the construction of other complex molecules. A one-pot reaction cascade has been developed, 
in which the oxazole formation is followed by an intramolecular Diels-Alder reaction, allowing the 
rapid construction of polyheterocyclic compounds from simple starting materials. Finally, the 
synthesis of the first oxazole-annulated imidazolium salts is described. These salts act as precursors 
to prochiral nucleophilic heterocyclic carbene ligands, the organometallic chemistry of which has 
been investigated. 
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1.1: Synthetic Routes to Trisubstituted Oxazoles 
Oxazoles are commonly encountered heterocycles which are prevalent in a variety of natural 
products[1] and pharmaceuticals[2] (Figure 1). A common biosynthetic pathway for their formation is 
believed to involve an enzyme-assisted cyclodehydration of a serine or threonine residue 1 to form 
an oxazoline 3, which may then either be oxidised to the oxazole 4 or reduced to an oxazolidine 5 
(Scheme 1).[3] A large number of methods are available to chemists for the synthesis of oxazoles, 
however the development of mild and convergent strategies remains an active area of research.[4] 
The first half of this introduction will briefly describe some of the reactions which are commonly used 
to access fully substituted oxazoles, as well as recent developments in this area. 
 
Figure 1: Examples of pharmaceuticals which contain oxazoles.
[2]
 
 
 
Scheme 1: Biosynthetic pathway for oxazoles and related heterocycles from serine or threonine residues.
[3]
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1.1.1: Intramolecular Cyclisations 
 
Figure 2: The O–C5 disconnection as a strategy for oxazole synthesis. 
The majority of trisubstituted oxazoles are synthesised by intramolecular cyclisations which construct 
the O–C5 bond (Figure 2). The cyclodehydration of α-acylaminoketones 6 using either sulfuric acid or 
PCl5 was reported independently by Robinson and Gabriel in 1909.
[5] Since this time a number of 
other dehydrating reagents have been reported (including P2O5, POCl3 and SOCl2).
[6] 18O labelling 
experiments have confirmed that it is the amide oxygen which is incorporated into the oxazole 
(Scheme 2).[7] Despite the necessity of relatively harsh dehydrating agents, this reaction continues to 
be one of the most widely used methods for the construction of trisubstituted oxazoles.[8] 
 
Scheme 2: The Robinson-Gabriel oxazole synthesis.
[5,7]
 
One particularly important extension of the Robinson-Gabriel method was introduced by 
Wipf and Miller, where alcohols 10 are oxidised to their respective ketones 6 using Dess-Martin 
periodinane, and the reaction mixture filtered through alumina into a solution of PPh3, I2 and NEt3 to 
carry out the cyclodehydration.[9] This process is generally milder, more efficient and faster than the 
cyclisation of 10 to oxazolines such as 3, followed by oxidation to oxazoles, and allows the efficient 
construction of oxazoles within peptides.[10] 
 
Scheme 3: Oxidation of an alcohol followed by Robinson-Gabriel oxazole synthesis.
[9-10]
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α-Acylaminoketones 6 may also be accessed by the rhodium(II)-catalysed reaction of 
amides 11 with α-diazo ketones 12 developed by the Moody group.[11] This allows a relatively 
convergent construction of oxazoles, which is again carried out by cyclodehydration of 6 using PPh3, 
I2 and NEt3, and has been exploited in the total synthesis of several natural products.
[12] 
 
Scheme 4: Two-step oxazole synthesis by the rhodium-catalysed reaction of α-diazo ketones and amides 
followed by a Robinson-Gabriel cyclisation.
[11]
 
A different intramolecular approach is the oxidative cyclisation of enamides 13 with 
PhI(OAc)2 (Scheme 5).
[13] The proposed mechanistic cycle is initiated by attack of the enamide onto 
the iodine species to give intermediate 14, this may cyclise through formation of six-membered 
intermediate 16, followed by reductive elimination of iodobenzene to give the oxazole. Where an 
electron-withdrawing substituent is α- to the amide, an alternative five-membered intermediate 17 
is also reasonable. This represents a convenient method for the synthesis of tri- and disubstituted 
oxazoles, including the anti-inflammatory drug Oxaprozin, from a relatively simple starting material. 
 
Scheme 5: Oxidative cyclisation of enamides by PhI(OAc)2.
[13]
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1.1.2: Two-Component Reactions 
1.1.2.1: By formation of the O–C2 and N–C4 bonds 
 
Figure 3: The O–C2 and N–C4 disconnections as a strategy for oxazole synthesis. 
One of the most common intramolecular approaches to trisubstituted oxazoles is the metal-
catalysed reaction of α-diazo ketones 12 with nitriles 18 (Scheme 6). This reaction was first 
introduced by Helquist using Rh2(OAc)4 as the catalyst.
[14] The substrate scope has since been widely 
explored, predominantly using either rhodium(II) or copper(II) catalysts.[4a] The mechanism involves 
the formation of a metal carbene 19, which is then attacked by the nitrile to generate 20. Cyclisation 
to 21 may then be followed by loss of the catalyst to give the product oxazole 6. Again, this method 
has been applied in a number of natural product syntheses.[12b,12c,15] One issue with this strategy is 
the epimerisation of stereogenic centres attached to the 2-position of the oxazole, which are 
prevalent in natural products;[11a,b] this can be avoided by using the methodology described in 
Schemes 3-4. 
 
Scheme 6: Metal-catalysed oxazole formation using α-diazo ketones and nitriles.
[4a,14]
 
Alternatively, the reaction of 1,3-dicarbonyls 22 with benzylamines 23 and I2 produced 
intermediate 25, which could undergo a copper-catalysed oxidative cyclisation to oxazoles 28 
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(Scheme 7).[16] The reaction is limited to oxazoles bearing a carbonyl substituent at the 4-position and 
an aryl group at the 2-position. The authors suggested that only benzylamines were successful as 
these groups more easily underwent oxidation from 25 to 26. 
 
Scheme 7: Oxazole formation from 1,3-dicarbonyls and benzylamines.
[16]
 
1.1.2.2: By formation of the O–C5 and N–C4 bonds 
 
Figure 4: The O–C5 and N–C4 disconnections as a strategy for oxazole synthesis. 
Buchwald and co-workers have described a one-pot synthesis of trisubstituted oxazoles from 
amides 11 and vinyl iodides 29 (Scheme 8).[17] The sequence begins with a copper-catalysed cross-
coupling to form enamide 6, treatment with iodine and base facilitates the formation of oxazoline 31, 
which undergoes loss of HI when heated with DBU to give oxazole 9. Where oxazoline 31 contained 
an alkyl substituent at the 4-position, HI elimination gave kinetic product 32; this was isomerised to 
the desired oxazole 9 by refluxing in toluene with TsOH prior to its purification. The E/Z geometry of 
the vinyl iodide 29 proved unimportant, and the reaction could also be carried out from vinyl 
bromides (in which case the initial cross-coupling was carried out in toluene at 100 °C). It is also 
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noteworthy that iodination occurred selectively at the electron-rich enamide, allowing the synthesis 
of oxazoles with alkene- or thiophene-containing substituents. 
 
Scheme 8: One-pot copper-catalysed coupling of amides with vinyl iodides followed by oxazole formation.
[17]
 
Moses and co-workers described a silver-mediated reaction of amide 33 and bromopyruvate 
ester 34; only one trisubstituted oxazole 35 was synthesised, alongside several 2,4-disubstituted 
oxazoles (Scheme 9).[18] One equivalent of a silver(I) salt was required for this process, without which 
no reaction occurred, leading to a proposed mechanism where the silver ion assists in the cleavage of 
the C–Br bond of 34, allowing the formation of imminium 36, which can cyclise to oxazoline 37 and 
undergo acid-catalysed dehydration to oxazole 35. The scope of the reaction was limited to products 
containing sp2-hybridised carbon atoms at the 2-substituent; however the AgBr produced could 
easily be collected and recycled. 
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Scheme 9: Silver-mediated oxazole formation from an amide and ethyl 3-bromo-2-oxobutanoate.
[18]
 
1.1.2.3: Alternative disconnections 
The Zhu group have reported a novel, two-component approach to 5-aminooxazoles by the 
Lewis acid-catalysed reaction of aldehydes 38 with isocyanides 39 (Scheme 10).[19] Yields were 
generally good for oxazoles with a morpholine substituent at the 5-position, however other tertiary 
amines tested resulted in lower yields due to instability of the products. 
 
Scheme 10: Synthesis of 5-aminooxazoles from isocyanides and aldehydes.
[19]
 
Intramolecular cyclisations of propargyl amides to oxazoles have been widely explored under 
gold[20] and palladium[21] catalysis, however these are generally limited to the construction of 
2,5-disubstituted oxazoles. A notable exception is the synthesis of oxazoles from α-chloroglycine 
esters 42 and dimethylaluminium acetylides 43 (Scheme 11 – top).[22] The intermediate propargyl 
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amides 44 were isolable, but underwent rapid cycloisomerisation to oxazoles 45 during basic 
work-up. This methodology was used to construct trisubstituted oxazoles in the total syntheses of  
(–)-muscoride A[22] and siphonazoles A and B.[23]  
Alternatively the reaction of primary amides 11 with propargyl alcohols 46 also generated 
propargyl amides 47 in situ, with TsOH catalysing both this transformation and the subsequent 
cyclisation of 47 into oxazoles 48 (Scheme 11 – bottom).[24] This is an efficient method for the 
construction of all-carbon-substituted oxazoles from relatively simple starting materials. As with all 
cyclisations of propargyl amides, one limitation is that the products must have a methylene 
substituent at the 5-position of the oxazole. 
 
Scheme 11: Cyclisation of propargyl amides.
[22,24]
 
1.1.3: Three-Component Reactions. 
 
Figure 5: The N–C4, O–C2 and O–C5 disconnections as a strategy for oxazole synthesis. 
Saito and co-workers recently reported a three-component synthesis of oxazoles from alkynes, 
nitriles and PhIO (Scheme 12).[25] The use of internal alkynes presents a regioselectivity challenge, 
however single isomers were formed in all cases examined using this methodology. The selectivity is 
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governed by the initial formation of a C–I bond at the less sterically hindered end of the alkyne to 
give intermediate 51. Addition of the nitrile to form 53 is followed by the formation of the 
6-membered intermediate 16 and reductive elimination of iodobenzene to give the oxazole. The 
evidence provided for this mechanism includes the isolation of an intermediate of type 52, and its 
subsequent conversion to an oxazole when heated in H2O/MeCN. Although the regioselectivity for 
this reaction is impressive, the yields were variable, and a limited substrate scope was demonstrated 
at both the 2- and 4-positions. 
 
Scheme 12: Three-component oxazole synthesis from alkynes, nitriles and PhIO.
[25]
 
An alternative oxidative cyclisation of alkynes and nitriles has been demonstrated by Jiang 
and co-workers (Scheme 13).[26] Isotopic labelling studies confirmed the oxygen atom in the oxazole 
ring came from water, allowing a similar mechanism as above to be suggested. Again the use of 
Chapter 1 
11 
 
unsymmetrical alkynes resulted in the formation of single regioisomers, dictated by addition of the 
nitrile β- to the more electron-withdrawing group on the alkyne to give intermediate 56. Addition of 
water to 56 allows the formation of 6-membered intermediate 59. Finally, reductive elimination of 
the catalyst from 59 gives the product 9, whilst the copper is oxidised back to Cu(II) by molecular 
oxygen. Compared to Saito’s methodology (Scheme 12), a slightly wider substrate scope was 
demonstrated at the 2-position as only three equivalents of the nitrile were required. Attempts to 
synthesise disubstituted oxazoles from terminal alkynes gave only trace amounts of product. 
 
Scheme 13: Oxidative cyclisation of alkynes and nitriles.
[26]
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1.1.4: Conclusion 
Fully substituted oxazoles are most often synthesised by Robinson-Gabriel type cyclodehydration 
reactions, however these generally require the treatment of a highly substituted precursor with 
harsh reagents. More recent developments in this field have allowed the convergent construction of 
these heterocycles using relatively mild conditions. There is still a need to develop new 
methodologies which increase the variety of substituents which can be directly incorporated onto 
oxazoles, ideally using robust and easily constructed starting materials. 
Chapter 1 
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1.2: Pyridinium Ylides in Gold-Catalysed Oxygen or Nitrene Transfer 
One particularly fertile area in the burgeoning field of gold catalysis has stemmed from the ability to 
access electrophilic α-oxo gold carbenes 62 from alkynes.[27] Initial work in this area largely focussed 
on the use of tethered sulfoxides[28] or N-oxides (oximes/nitrones,[29] amine N-oxides,[30] and nitro 
groups[31]) as intramolecular oxidants, however pyridine-N-oxides and their derivatives have emerged 
as the most common intermolecular oxidants of choice. Activation of an alkyne by gold renders it 
electrophilic,[32] allowing attack of the oxidant to generate intermediate 61 (Scheme 14), loss of the 
pyridine delivery group then gives the gold carbene 62, which can be trapped either inter- or 
intramolecularly (see below for examples). These versatile intermediates are otherwise accessible 
only from α-diazo ketones 63, which are often toxic and significantly less stable and easily installed 
than alkynes. 
 
Scheme 14: Access to α-oxo gold carbenes by treatment of alkynes with pyridine-N-oxide under gold 
catalysis, or from α-diazo ketones, and adaptation of the strategy to the synthesis of α-imino gold carbenes. 
This strategy has since been adapted to the synthesis of α-imino gold carbenes 66 from pyridine-N-
aminides 64, which are pertinent to this work (see below). It is worth noting that, whilst this route 
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has been significantly less widely explored, other methods for generating intermediates related to 66 
under gold catalysis (primarily employing azides in place of 64) have also been demonstrated.[33] 
1.2.1: The Nature of Gold Carbenes 
The precise nature of gold carbenes and where they should be invoked in reaction 
mechanisms is the subject of continuing debate.[34] As shown in Scheme 14, such intermediates can 
be drawn as one of two resonance extremes, the metal carbene form 62 and the carbocationic 
form 62’. Several gold carbenes have been isolated and characterised by X-ray diffraction (Figure 
6).[34b] Whilst many of the earlier examples seemed to very much resemble carbocations (due to the 
low rotational barrier in the C–Au bond[35] and bond lengths similar to that of Csp2–Au σ bonds
[36]), 
these examples featured an electron-donating group conjugated to the electron-deficient carbon 
atom (for example the OMe group in 67/67’). These groups stabilise the carbocationic contribution, 
and reduce the possibility of Au→C backbonding, decreasing the π-character of the C–Au bond. 
Recently Straub and co-workers characterised a dimesityl gold carbene complex 68/68’, stabilised by 
a very bulky N-heterocyclic carbene ligand, which features an appreciably shorter C–Au bond.[37] 
 
Figure 6: Top Left: A gold carbene isolated by Fürstner and co-workers, C–Au = 2.046 Å.
[35]
 Top Right: Straub 
and co-workers’ complex, C–Au = 2.014 Å.
[37]
 Bottom: Key interactions in the bonding model for (LAu(I)CR2)
+
 
complexes proposed by Toste and co-workers (where L is a neutral, two-electron donor ligand).
[38]
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Similar observations were predicted computationally, where experiments showed that the 
C–Au bond has both σ and π character, the contribution from each of which can be influenced by the 
nature of both the substrate and the ligand, however in most cases the bond order remains close to 
one.[38] The term “gold carbenoid” is often used to describe this structure which is intermediate 
between a carbene and a carbocation, however this term is used inconsistently in the literature, with 
some suggesting that it should be reserved for distinctly different organogold species, which have no 
carbene character, but may show similar reactivity (such as 61 or 65).[34b] 
The picture for α-oxo/imino gold carbenes is even more complex, no such compounds have 
been isolated and recent gas-phase experiments failed to observe them by mass spectrometry.[39] 
Alternative pathways have been proposed for several reactions that originally appeared to proceed 
through α-oxo carbenes,[40] for example DFT calculations predicted that the cyclisation of 69 
proceeds directly from carbenoid 70 to give 71 (Scheme 15 – top).[40b] Evidence in favour of the 
intermediacy of α-oxo gold carbenes includes reactions that have very similar outcomes whether 
these supposed intermediates are generated by the oxidation of alkynes or from α-diazo ketones, for 
example the synthesis of 75 from either 73 or 76 (Scheme 15 – bottom).[41] 
 
Scheme 15: Top: Calculated lowest energy route for an example reaction.
[40b]
 Bottom: Synthesis of a 
cyclopentenone from different starting materials.
[41b]
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Although many of the reaction mechanisms described in this chapter feature α-oxo or 
α-imino gold carbenes, it should be kept in mind that these intermediates have considerable 
carbocationic character, and that in some cases alternative routes can be argued (particularly SN2’ 
type reactivity of 61 or 65). 
1.2.2: Applications of α-Oxo Gold Carbenes Generated from Pyridine-N-Oxides 
The use of pyridine-N-oxides as intermolecular oxidants in gold catalysis was first 
demonstrated by Zhang and co-workers in the oxidative cyclisations of propargyl and homopropargyl 
alcohols to give oxetanones[42] and dihydrofuranones[43] respectively (Scheme 16). The gold carbene 
78 is formed on the terminus of the alkyne, allowing predictable control of the ring size formed. 
 
Scheme 16: Oxidative cyclisation of propargyl and homopropargyl alcohols.
[42-43]
  
Whilst terminal alkynes generally provide excellent levels of regioselectivity under gold 
catalysis, this can also be achieved by using ynamides 84 (or otherwise electronically biased alkynes). 
In these cases the electronics of the gold-activated intermediate 85/85’ dictate that the nucleophile 
will add α- to the amide if possible (Scheme 17).[44] This allows access to more highly substituted 
intermediates 86 than those generated from terminal alkynes. 
 
Scheme 17: Regiocontrol in nucleophilic attack onto gold-activated ynamides. 
Chapter 1 
17 
 
This gold-catalysed oxidation of ynamides with pyridine-N-oxides was first introduced by 
Davies and co-workers,[45] where double oxidation of a phenyl-substituted ynamide 84a with two 
equivalents of pyridine-N-oxide to give 87 was achieved, but more interestingly a 1,2-C–H insertion 
with an alkyl-substituted ynamide 84b gave α,β-unsaturated imide 88, the initial oxidation 
proceeding with complete regioseletctivity (Scheme 18). Optimisation of this process allowed access 
to a family of compounds of type 90 using either the commercial and bench-stable catalyst 
dichloro(2-pyridinecarboxylato)gold (Au(pic)Cl2) at 70 °C or AuBr3 at room temperature. This reaction 
was later reported independently by Zhang and co-workers using sterically biased all-carbon-
substituted alkynes in place of ynamides.[46] 
 
Scheme 18: Gold-catalysed oxidation of ynamides followed by 1,2-C–H insertion.
[45]
 
Since the publication of these seminal works a plethora of other applications of α-oxo gold 
carbenes generated from the gold-catalysed oxidation of alkynes or ynamides with pyridine-N-oxides 
have been described, just a few of which are shown in Scheme 19.[47] 
Chapter 1 
18 
 
 
Scheme 19: Diverse reactivity initiated by gold-catalysed oxidation of alkynes or ynamides by 
pyridine-N-oxides. Clockwise from top-left: Friedel-Crafts substitution,
[47a]
 furan synthesis,
[47b]
 Doyle-Kirmse 
reaction
[47c]
 and cyclopropanation.
[47d]
 
1.2.3: Applications of α-Imino Gold Carbenes Generated from Pyridine-N-Aminides 
Li and Zhang demonstrated a modification of this approach where the pyridine-N-oxide is 
replaced by an N-tosyl pyridine-N-aminide 91 (Scheme 20).[48] This effectively allows the transfer of 
an N-tosyl nitrene onto an ynamide. Again, initial attack of the ylide proceeds with complete 
regioselectivity, to give α-imino gold carbene 92, which is quenched by a 1,2-C–H insertion from the 
alkyl group attached to the alkyne, forming amidines 93. 
 
Scheme 20: Gold-catalysed nitrene transfer onto ynamides followed by 1,2-C–H insertion.
[48]
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The use of these nitrogen-nitrogen ylides allowed the development of a new strategy where 
the α-imino gold carbene could be quenched by a group appended to the nucleophilic nitrogen. This 
was introduced by Davies and co-workers in a formal [3+2] cycloaddition of ynamides 84 and N-acyl 
pyridine-N-aminides 94 for the synthesis of oxazoles 95, which is a key reaction for this thesis 
(Scheme 21).[49] Several mechanistic pathways can be suggested for this process, all start with 
regioselective attack of the of the ylide 94 onto a gold-activated ynamide to give 96. This may then 
follow path (1), and undergo cyclisation with concerted loss of pyridine to furnish intermediate 98. 
Alternatively, loss of pyridine could occur prior to cyclisation to give carbene 99, which could cyclise 
either through path (2): a 4π electrocyclisation; or path (3): attack of the carbonyl oxygen onto the 
electrophilic carbon. The oxazole would finally be formed by a deaurative aromatisation of 98. 
 
Scheme 21: Synthesis of 4-amido oxazoles.
[49]
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An alternative mechanism which proceeds through an electrophilic metal nitrene 100 is less 
likely, as this would be expected to give isomeric oxazoles 103 (Scheme 22).[50] Additionally, given 
that a 1.5 fold excess of aminide 94 is employed in this reaction, if nitrene 100 were formed, further 
reaction of 100 with alkene-containing products would be expected,[51] however this is not observed. 
 
Scheme 22: Proposed alternative reactivity of a gold nitrene. 
Additional mechanistic information was also provided by the divergent reactivity of ynol 
ether 104, which formed oxazole 105; and ynol ether 106 which instead gave 1,2-C–H insertion 
product 107 (Scheme 23). The reactivity in the latter case is related to that described in Scheme 20, 
and strongly supportive of the formation of an intermediate analogous to 96 (Scheme 21). 
 
Scheme 23: Reactions of ynol ethers with N-acyl pyridine-N-aminides.
[49]
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Although substrate 106 was designed to favour 1,2-C–H insertion over oxazole formation, in 
principle these reactions can compete whenever an sp3 hybridised C–H group is adjacent to the 
alkyne. In the original communication of this work, several 5-alkyl-substituted oxazoles were 
successfully synthesised without the isolation of competing products, it was not determined whether 
1,2-C–H insertion generally competes with oxazole formation in these cases. 
Overall this methodology allows the efficient synthesis of trisubstituted oxazoles via a [3+2] 
cycloaddition from simple starting materials, and has also provided access to the first oxazoles 
bearing a nitrogen atom at the 4-position. In addition, as it is highly convergent, employs fairly robust 
starting materials and has a good functional group tolerance, the substituents on the amide and on 
the other two positions of the oxazole can be varied widely. 
In the course of the studies detailed in this thesis, co-workers in the research group 
investigated other ways to exploit this strategy. Chatzopoulou and Davies showed that the oxazole 
synthesis could also be carried out using other electron-rich alkynes, most of which were of type 108, 
which are activated by conjugation to indole rings (Scheme 24).[52] These substrates provided the 
same level of selectivity as ynamides (only the oxazole with the electron-rich aromatic group in the 
4-position is ever observed), however their reaction required higher temperatures, longer reaction 
times and re-optimisation of the catalyst. 4-Alkynyl anilines were also successful substrates in this 
reaction; however alkynes bearing anisoles and other only moderately electron-rich aromatic groups 
were unreactive. The use of alkyl-substituted alkynes generated a complex and inseparable mixture 
of oxazole and 1,2-C–H insertion products, and so these were not suitable substrates, despite the 
fact that oxazole formation was still the preferred pathway. This methodology complements the 
previous work to give all-carbon-substituted oxazoles 109, however it is important that one 
substituent of the alkyne still must be strongly electron-donating. 
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Scheme 24: Synthesis of all-carbon-substituted oxazoles.
[52]
 
Garzón and Davies recently reported the use of a related class of nucleophiles 110, in which 
the acyl group is replaced by a pyridine derivative, in the synthesis of imidazole-fused 
heterocycles 111 (Scheme 25).[53] Ynamides and 3-alkynyl indoles were suitable substrates. Alkyl-
substituted ynamides could be used in these reactions, as the competing 1,2-C–H insertion products 
were separable from the imidazoles; changing from the gold(I) pre-catalyst to Au(pic)Cl2 reduced the 
amount of this undesired side-reaction, allowing higher yields of the heterocycles to be achieved. 
 
Scheme 25: Synthesis of heterocycle-fused imidazoles.
[53] 
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1.2.4: Conclusion 
A new method for the synthesis of oxazoles has been developed in the research group. The following 
chapter describes how the substrate scope for this reaction has been explored and enhanced. In 
Chapter 3 describes how the convergency of this process has been exploited to allow the synthesis of 
oxazoles tethered to dienophiles, followed by subsequent study of their Diels-Alder chemistry, which 
facilitates the rapid construction of polyheterocyclic systems. Finally, in Chapter 4 novel ligand 
structures incorporating these oxazoles are described. 
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CHAPTER 2: 
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2.1: Introduction: Starting Materials for Oxazole Synthesis 
2.1.1: Applications of and Synthetic Routes to N-Acyl Pyridine-N-Aminides 
Other than their use in the synthesis of oxazoles, N-acyl pyridine-N-aminides 94 have a wide 
variety of applications. Early work with these ylides focussed on their photochemical ring expansion 
to diazapines 112.[54] A number of reactions which functionalise the pyridinium ring have since been 
investigated (Scheme 26). Partial reduction of 94 to tetrahydropyridines 113 can be achieved by 
treatment with NaBH4.
[55] This reaction may be preceded by the regioselective ortho- addition of 
Grignard reagents to give more heavily substituted products 114 in a diastereoselective fashion.[56] 
Alternatively, a highly enantioselective hydrogenation of the pyridinium ring to 115 has also been 
demonstrated,[57] both 114 and 115 are precursors to functionalised piperidines 116.[56] The presence 
of the acyl group in 94 facilitates ortho selective C–H activation of the pyridinium ring, to allow 
metal-catalysed cross-coupling with aryl[58] or alkenyl[59] halides, or in situ-generated copper 
carbenes;[60] the resulting products 117 can be deprotected to give substituted pyridines 118.[58] 
Finally, N-alkylation of 94 to 119, followed by intramolecular cyclisation with an enolate, generates 
1,2-dihydropyrazolo[1,5-a]pyridines 120.[61] 
 
Scheme 26: Reactions of the pyridinium ring of N-acyl pyridine-N-aminides. 
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Ylides 94 have also been employed in a number of cycloaddition reactions, where they 
function primarily as 1,3-C,N-dipoles (Scheme 27). Reaction of 94 with an electron-deficient alkyne 
gives pyrazolo[1,5-a]pyridines 121.[62] The analogous reaction can also be carried out with in situ 
generated benzynes or silver acetylides, to give products 122[63] and 123[64] respectively. More 
recently, diastereoselective nickel-catalysed addition of isoquinolinium-N-aminides across 
cyclopropanes has been demonstrated,[65] the use of a chiral nickel catalyst allowed kinetic resolution 
of chiral cyclopropanes to give highly enantioenriched tricyclic structures 124.[66] The 
enantioselective reaction of 94 with vinylogous rhodium carbenes to form tetrahydropyridazine 
derivatives 125 has also recently been reported.[67] A rare example of the use of 94 as a  
1,3-N,O-dipole (other than in the synthesis of oxazoles), provides oxazines 126 by the reaction of 94 
with diphenylcyclopropenone.[68] 
 
 
Scheme 27: Cycloaddition reactions of N-acyl pyridine-N-aminides. 
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The above examples show how many of the applications of these ylides focus on increasing 
the complexity of the pyridinium ring, whilst the acyl group is often cleaved or makes up a protecting 
group in the final product. As such, the synthesis of ylides with functionalised pyridinium rings has 
been studied, whilst relatively little structural diversity at the acyl substituent has been 
demonstrated. In the case of the oxazole synthesis described in Scheme 21, the nature of the acyl 
group dictates the substituent on the 2-position of the oxazole, whilst the pyridinium ring is not 
incorporated into the product. For this project it was therefore necessary to conveniently access 
ylides with a diverse range of functionality at the acyl substituent. 
The first described synthesis of an ylide of type 94 was by the reaction of an acyl azide 127 
with pyridine (Scheme 28 – route A).[69] Alternatively, they have also been accessed by attack of 
N-acyl hydrazines 128 onto 2,4-dinitrophenylpyridinium chloride 129 (route B).[55] Deprotonation of 
an amino pyridinium salt 130, followed by acylation with an appropriate reagent 131 (route C) has 
become the most common strategy to construct 94.[55,61,70] In most cases the latter route requires the 
least complex starting materials, as N-aminopyridinium iodide is commercially available[71] and, if 
required, functionalised pyridines can be readily aminated.[72] 
 
Scheme 28: General methods for the synthesis of N-acyl pyridine-N-aminides. 
2.1.2: The Synthesis of Ynamides 
The use of ynamides has grown in prominence in recent years due to the high and predictable 
reactivity of their electron-rich π-system, and the increasing ease with which they can be accessed.[73] 
An electron-withdrawing group is generally employed on the nitrogen atom in order to increase the 
stability of these molecules. The chemistry of more reactive ynamines has been studied, however 
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these are often subject to rapid hydration or polymerisation reactions.[74] Throughout the course of 
these studies it was possible to access a wide variety of ynamides for use in oxazole synthesis by 
using already reported methods for their synthesis (Scheme 29). 
The Hsung[75] and Danheiser[76] groups independently reported the first copper-catalysed 
cross-couplings of amides and haloalkynes. Whilst Danheiser’s protocol required fairly harsh 
conditions, and Hsung’s procedure was initially fairly limited in scope, further optimisation by Hsung 
and co-workers produced one of the most attractive modern methods for the synthesis of ynamides 
(Scheme 29 – top).[77] This method is particularly convenient as the conditions are relatively mild, the 
starting materials are easily accessed, and no large excess of either reagent is required. Additionally 
the substrate scope is fairly wide (increasing the temperature and catalyst loading allows the use of 
otherwise challenging amides including acyclic carbamates and phophoramidates),[78] however 
protected anilines often produce poor yields using this method. 
 
Scheme 29: Modern methods for ynamide synthesis 
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Although many terminal alkynes are commercially available, more complex systems are often 
synthesised from aldehydes using either the Corey-Fuchs[79] or Seyferth-Gilbert[80] reactions. In such 
scenarios the use of the Evano group’s methodology is attractive, as it allows the ynamide to be 
accessed more quickly from an aldehyde via a dibromoalkene 134.[81] 
Stahl and co-workers have developed a more direct copper-catalysed oxidative cross-
coupling of amides 135 and terminal alkynes 132.[82] In order to suppress the formation of the Glazer-
Hay product 136, and increase the yield of the desired ynamide 84, a large excess of the amide is 
used, and a solution of the alkyne is injected slowly into the reaction mixture over four hours. 
Although these requirements make the reaction inherently less convenient than the above methods, 
this is balanced by the direct use of terminal alkynes, and that, unlike other protocols, sulfonyl 
anilines generally give excellent yields when they are employed as the amide in this process. 
Additionally the excess amide can be recovered in the same purification process as the ynamide 
product. 
Finally, a less convergent route has been demonstrated by Brückner,[83] where 
dichloroenamides 138 are converted to lithium acetylides, and trapped with various electrophiles. 
This allows significant structural diversity to be obtained at the C-terminus of the ynamide.[84] 
Although Scheme 29 covers all of the methods used to access the ynamides employed in this thesis, 
these are by no means exclusive, and the synthesis of ynamides remains an active area of 
research.[85] 
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2.2: Results and Discussion 
In the initial communication of the gold-catalysed oxazole synthesis from ynamides a fairly 
limited substrate scope at the oxazole 2-position was demonstrated, this was in part due to the ease 
with which a diverse set of N-acyl pyridine-N-aminides 94 could be accessed.[49] In this chapter the 
modification of conditions for the synthesis of these ylides has been investigated in order to allow a 
wider range of functionality to be tested in the oxazole synthesis. Additionally, significant variation of 
the ynamide at both the N- and C-terminus has been explored above that which was originally 
reported, leading to an enhanced understanding of the scope and limitations of this reaction. Finally, 
the presence of competing 1,2-C–H insertion reactions in the synthesis of 5-alkyl oxazoles has been 
confirmed, and the levels of these side reactions quantified with different substrates. 
2.2.1: Expanding the Scope at the Oxazole 2-Position 
2.2.1.1: Modified conditions for the synthesis of polar pyridine-N-aminides 
One of the most common modern methods for the synthesis of ylides 94 is the treatment of 
N-aminopyridinium iodide 139 with aqueous sodium hydroxide and an acid chloride.[49,72] These 
conditions were successfully applied in order to access 94c in a good yield (Scheme 30 – equation 
(1)). However 94b, which was originally shown to be among the most reactive ylides in the oxazole 
synthesis, could not be reproducibly synthesised by this method, a likely problem being 94b’s high 
water solubility making extraction from water difficult. A further, more general limitation is that the 
synthesis of acid chlorides in acid-sensitive molecules is problematic, as can be avoiding their 
hydrolysis during purification and storage. 
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Scheme 30: (1): Synthesis of an ylide in aqueous NaOH, (2): Streith’s synthesis of 94b,
[86]
 (3)&(4): Modified 
conditions for the synthesis of polar ylides. 
94b has previously been synthesised by Streith and co-workers using a freshly prepared 
ethanolic solution of the unstable ylide 141 (Scheme 30 – equation (2)).[86] Combining this procedure 
with the in situ generation of 141 resulted in an efficient route to 94b using N-aminopyridinium 
iodide 139, methyl chloroformate 142 and K2CO3 in methanol. When this reaction was originally 
attempted in ethanol, the isolated sample of ylide 94b was contaminated with ~10% of the 
transesterification product (the CO2Et-substituted ylide). For this synthesis of 94b, optimisation of 
the purification protocol was key, as the product was too water soluble to allow aqueous work-up 
and too polar for chromatography on silica gel, a simple filtration of the crude residue through 
alumina in CH2Cl2/MeOH proved successful. This route was also applied to the synthesis of tert-
butoxy-substituted ylide 94d, where the yield was also excellent. 
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2.2.1.2: Oxazol-2-one formation 
Oxazol-2-ones are found in several pharmaceutically active compounds[87] and are potent synthetic 
intermediates.[88] It was anticipated that if ylide 94d could be used to synthesise oxazoles 143, 
bearing a tert-butoxy group in the 2-position, the products could in turn be used to access oxazol-2-
ones 144. Similar reactivity has been used to produce pyridin-2-ones such as 146 (Scheme 31).[89]  
 
Scheme 31: Top: Planned route to oxazolones. Bottom: Literature synthesis of a pyridinone.
[89d]
 
In an initial attempt towards this end, ylide 94d was found to be highly reactive, allowing the 
rapid synthesis of oxazole 143a (Scheme 32). Although 143a was fairly unstable it allowed conditions 
to be tested for oxazolone formation. Treatment of 143a with either TsOH in toluene or simply 
heating in methanol led to consumption of the oxazole, however the resulting crude residue was 
insoluble in most common solvents and so could not be readily purified. 
 
Scheme 32: Initial attempts at oxazolone formation. 
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As a result a second ynamide 84d was investigated, and attempts were made to optimise a 
one-pot process in which unstable oxazole 143b was formed and then converted into 
oxazolone 144b (Table 1). Significant levels of oxazole 143b remained when warming was continued 
in a 2:1 methanol:toluene mixture (Table 1, entry 2), or when one equivalent of trifluoroacetic acid 
or 20 mol% of TsOH were added to the reaction mixture (Entries 3-4). Near complete consumption of 
143b was observed when one equivalent of TsOH was employed (Entry 5). The cleanest conversion 
to 144b was observed when the catalyst and excess ylide were removed by filtration through silica 
gel, and the crude oxazole heated in neat methanol (Entry 6). 
Unfortunately when this reaction was scaled up from 0.1 to 1.0 mmol, 144b could not be 
adequately purified. The synthesis of several other substrates was attempted following the same 
route using various ynamides 84e-g (Figure 7), however all met similar problems, if anything 
producing more complex mixtures, perhaps due to instability of the products. As such, no further 
attempts at oxazolone synthesis were made. 
Table 1: Optimisation of oxazolone formation 
 
Entry Additive after 1 hour 143b 144b 
1 reaction stopped 67% <5% 
2 MeOH (2 mL) 42% 24% 
3 TFA (1 eq.) 68% <5% 
4 TsOH·H2O (20 mol%) 74% <5% 
5 TsOH·H2O (1 eq.) <5% 36% 
6 
Filter through silica, evaporate toluene 
and then add MeOH (2 mL) 
<5% 65% (<53%) 
Using 84d (0.1 mmol), 94d (0.15 mmol) and Au(pic)Cl2 (5 mol%) in toluene (1 mL) at 90 °C for 1 hour before 
cooling to 55 °C and adding the stated additive. NMR yields calculated against 1,2,4,5-tetramethylbenzene as 
an internal standard (isolated yield of a product with ~90% purity from a reaction starting with 1 mmol 84d). 
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Figure 7: Other ynamides from which oxazolone synthesis was attempted. 
2.2.1.3: Synthesis of functionalised pyridine-N-aminides from esters and of their respective oxazoles 
Returning to the synthesis of oxazoles with structural diversity at the 2-position, the use of 
alternative electrophiles for the synthesis of the required ylides was investigated. Esters were 
identified as ideal substrates as their relative stability allows them to be easily synthesised or 
modified and to be stored for long periods. Ethyl esters have previously been reported to be active 
electrophiles in the synthesis of these ylides using very similar conditions to the ones developed 
here, however yields were generally moderate (possibly due to the low solubility of K2CO3 and 
N-aminopyridinium iodide in CHCl3 which was used as the solvent) and this method has not gained 
widespread popularity.[61,70] Pleasingly the use of methyl esters in the K2CO3/methanol protocol was 
found to be generally applicable to a range of ylides with diverse functionality (Scheme 33). 
 
Scheme 33: Synthesis of ylides from methyl esters. *Ethyl formate was used as the electrophile. 
Protected amino acid derivatives 94e-g were accessed in satisfactory yields, which was 
important as variations on these substrates are used extensively in both of the subsequent chapters. 
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Unfortunately 94h, bearing a secondary amine, lacked thermal stability and could not be adequately 
purified. Ethyl formate proved a cheap and effective formylating agent to generate 94i, however this 
product had limited solubility in most common organic solvents, resulting in a reduced yield 
following purification. The dimethyl acetal-containing product 94j was synthesised in a very good 
yield. The high reactivity of esters conjugated to electron-deficient aromatic systems gave pyridine- 
and quinoline-containing substrates 94k-l in good yields. Electron-rich aromatic groups proved 
considerably more challenging, with 2-thiophenyl substrate 94m formed in a low yield and an ester 
conjugated to an azaindole giving no product 94n; in both cases large amounts of unreacted 
ester 147 was recovered, and so a more reactive electrophile was needed for these substrates. 
Fortunately a variation on these conditions in which a mixed anhydride is generated from a 
carboxylic acid and used in the same pot had been developed by co-worker Raju Jannapureddy, to 
allow the direct synthesis of ylides from N-Boc-protected amino acids.[90] This procedure allowed 
thiophene-2-carboxylic acid 148 to be converted into ylide 94m in one step, with a significantly 
improved yield compared to using the less reactive ester (Scheme 34 – top). 
 
Scheme 34: Use of alternative electrophiles. 
Isocyanate 150 also reacted cleanly to give the urea-type ylide 94o (Scheme 34 – bottom). In 
this case the reaction was carried under an inert atmosphere in dry acetonitrile to avoid the 
possibility of the addition of water or methanol to 150 competing with product formation, a strategy 
that may be generally applicable to other sensitive electrophiles. 
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As these ylides have several applications (see above), the potential benefits of this improved 
methodology for their synthesis are significant; here they were applied in the gold-catalysed 
synthesis of oxazoles from ynamides described in Scheme 21. Alkyl, vinyl, aryl and alkoxy groups had 
previously been successfully incorporated into the 2-position of the oxazole using this 
methodology.[49] In order to probe the scope at the oxazole 2-position further, the ylides described 
above were tested alongside a standard ynamide 84g in the synthesis of oxazoles 151 (Scheme 35). 
 
Scheme 35: Expanded scope at the oxazole 2-position. 
In the original work, the oxazole synthesis was carried out using 1.5 equivalents of ylide 94 
and 5 mol% of the gold catalyst with respect to the ynamide.[49] When using ylide 94b, which had 
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previously been shown to be among the most reactive of the ylides trialled, the amounts of reagent 
were successfully cut to 1.2 equivalents of ylide and 2 mol% of catalyst whilst retaining an impressive 
yield of 151a (Scheme 35). The incorporation of secondary amides was successful with 151b-d all 
synthesised in good to excellent yields, however no consumption of the ynamide was observed when 
ylide 94h was employed. It is unclear whether this is due to 94h’s lack of stability, or catalyst 
deactivation by the amine. Despite earlier solubility concerns, ylide 94i reacted efficiently to give the 
first 4,5-disubstituted oxazole 151f synthesised by this method. The sensitive dimethyl acetal could 
also be incorporated into 151g in a high yield. Remarkably the catalyst retained its activity to furnish 
oxazoles 151h-i, despite the fact that both the starting materials and products resemble good 
bidentate ligands. Related pyridinyl-oxazolines have been used as ligands for gold(III),[91] and metal 
complexes of pyridine-N-aminides are also known.[92] 2-Thiophenyl ylide 94m was also highly 
reactive, giving 151j in an excellent yield. Finally the use of 94o resulted in rapid consumption of 
ynamide 84g, however a large amount of an insoluble by-product was also produced, resulting in a 
reduced yield of 151k. 
Overall these results represent a substantial increase in the scope of the reaction with 
regards to substituents at the 2-position, and applications of compounds related to 151b-d as well as 
of 151g are featured in later chapters of this thesis. Importantly they also show that a high level of 
reactivity can be obtained when a decreased excess of ylide and/or catalyst loading is employed.  
In order to determine whether the process could be made even more efficient at larger scale 
two further reactions were performed on gram (4.8 mmol) scale (Scheme 36). The first showed that 
1.21 g of oxazole 151g could be obtained using only 1.1 equivalent of ylide 94j and a 2 mol% catalyst 
loading, albeit in a slightly reduced yield. Secondly a reaction was performed in an open flask using 
standard grade solvent and only 1 mol% of catalyst and 1.1 equivalent of ylide 94c. This reaction 
proceeded cleanly to give a 59% yield of product 151l, however it did not reach completion within 
two days (most of the unreacted ynamide was recovered). For comparison, an 87% yield of 
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oxazole 151l was achieved by Raju Jannapureddy using 1.1 equivalents of 94c and 5 mol% of 
Au(pic)Cl2 in dry toluene, under an argon atmosphere,
[90] indicating that there is some benefit from 
excluding air and/or moisture in this process. 
 
Scheme 36: Large-scale oxazole synthesis. 
To assess the general suitability of amino acid-derived substrates the enantiomeric ratio of 
151c was determined to be 97:3 by chiral HPLC against a racemic sample (synthesised from racemic 
alanine as described in Scheme 37). In contrast the sample of ester 147f used to synthesise 94f was 
shown to be enantiopure using the same method (HPLC traces and conditions for these compounds 
can be found on pages 208-209). Conditions could not be found to separate the two enantiomers of 
ylide 94f by HPLC. 
 
Scheme 37: Racemic synthesis of 151c 
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Several control experiments were carried out in order to determine the reason for the small 
loss enantiopurity which occurs between ester 147f and oxazole 151c: 
Theory 1: A small amount of racemisation of ylide 94f occurs during its purification. 
Experimental result: Stirring 94f with silica gel for 24 hours in 1:1 CH2Cl2:MeOH did not result in a 
reduction in its observed specific rotation (before [α]D
20 = −30.7 °dm-1g-1cm3,  
after [α]D
20 = −32.8 °dm-1g-1cm3). 
Theory 2: A small amount of racemisation of ylide 94f occurs by reaction with the gold catalyst 
and/or pyridine generated in the reaction mixture, prior to its reaction with ynamide 84g. 
Experimental result: Heating 94f (0.23 mmol) with pyridine (0.25 mmol) and Au(pic)Cl2 (5 mol% 
with respect to ynamide) in toluene (1.5 mL) for one hour at 90 °C, before the addition of 
ynamide 84g (0.15 mmol) produced a sample of oxazole 151c with an er of 98:2 
Theory 3: A small amount of racemisation of oxazole 151c occurs by reaction with the gold catalyst 
and/or pyridine generated in the reaction mixture. 
Experimental result: Heating the original sample of 151c (0.2 mmol) with pyridine (0.2 mmol) and 
Au(pic)Cl2 (2 mol%) in toluene (2 mL) at 90 °C for 24 hours, followed by filtration through silica 
gel recovered 151c with an unchanged er of 97:3. 
From these results it is apparent that neither 94f nor 151c is particularly susceptible to racemisation 
under the relevant reaction conditions, and the cause of the loss of enantiopurity remains unknown. 
Possible explanations are that a short lived reactive intermediate in the oxazole formation is prone to 
racemisation, or that racemisation of 147f or 94f occurs very slowly during the synthesis of 94f. 
2.2.1.4: Bidentate ligands incorporating oxazoles 
Attempts were made to synthesise palladium(II), copper(II) and gold(III) complexes of 151h-I; 
related complexes featuring oxazolines in place of the oxazole have been described and used in 
catalysis.[91,93] Insoluble solids which could not be properly purified or characterised were isolated in 
all cases, this did at least indicate that some form of complexation had taken place (Figure 8). 
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(151h)PdCl2 was soluble in DMSO, in which the 
1H-NMR spectrum showed a mixture of free and 
metalated 151h, despite prior washing of the crude solid with CH2Cl2, indicating that exchange of 
DMSO and the ligand occurred using this solvent. 
 
Figure 8: Targeted metal complexes of bidentate ligands. 
2.2.2: Expanding the Scope at the Oxazole 4-Position 
In the original publication, ynamides derived from sulfonamides or oxazolidinone were shown to be 
successful substrates for oxazole formation (Scheme 21).[49] The exploration of alternative amides 
was required in order to widen the scope at the oxazole 4-position. Several ynamides were 
synthesised bearing diverse substituents on the nitrogen atom and a standard phenyl group on the 
opposite end of the alkyne (Scheme 38). Acyclic carbamates such as 135d, and phosphoramidates 
such as 135e, have been shown to be challenging substrates in ynamide formations, however this 
can be overcome by following the Hsung group’s protocol with increased catalyst loadings;[77b,78] 
pleasingly allowing the synthesis of ynamides 84h and 84i in good yields. Lactam 135f was converted 
into ynamide 84j using dibromoalkene 134a following a literature procedure for this substrate.[81] 
Indole could also be coupled with bromophenylacetylene 133b to produce the stable alkyne 84k. The 
isolated yield of 84k was poor as this ynamide could not be separated from 133b by column 
chromatography, and so an unoptimised recrystallisation was performed instead; this problem was 
also encountered by Iwasawa and co-workers in the one previously reported synthesis of 84k.[94] 
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Scheme 38: Synthesis of ynamides from various amides. Ynamide 84i was synthesised by Joshua Priest. 
The use of these ynamides in the gold-catalysed oxazole formation produced mixed results 
(Table 2). No oxazole formation was observed when 84h was employed; however slow formation of 
oxazolone 155 did occur (Entry 1). The gold-catalysed formation of oxazolones by 
cyclisation/fragmentation of ynamides derived from tert-butyl carbamates has previously been 
reported.[95] In this analogous reaction of 84h it seems likely that, following cyclisation to 158, 
demthylation is assisted either by ylide 94c or by water, with protodemetalation of 160 furnishing 
155 (Scheme 39). Given that there should be fairly little water or acid in the mildly basic reaction 
mixture, it also seems likely that one or both of the demethylation (158 to 160) or protodemetalation 
(160 to 155) steps would be slow. This would have the effect of not only producing the low yield of 
155, but possibly also tying up the gold catalyst so that oxazole formation does not occur. In support 
of this theory, vinyl gold species related to 160 have been shown to be remarkably stable under basic 
conditions.[96] 
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Table 2: Use of ynamides from Scheme 38 in oxazole formation. 
 
Entry Ynamide Time / h Oxazole 
Recovered 
ynamide 
Side product 
1 84h 24 0% 67% 
 
155, 14% 
2 84i 5 154a, 81% N/A - 
3 84j 24 0% 59% 
 
156, 16% 
4 84k 96 154b, 64% 28% - 
Using 84 (0.4 mmol), 94c (0.6 mmol) and Au(pic)Cl2 (5 mol%) in toluene (4 mL) at 90 °C for the stated time. 
Isolated yields after flash column chromatography. 
 
Scheme 39: Proposed mechanistic pathway for formation of oxazolone 155. 
The reaction of phosphoramidate-derived ynamide 84i was much more successful, giving 
oxazole 154a in a good yield with no competing side reactions observed, providing a valuable 
alternative to the use of sulfonamides in this position (Table 2 – entry 2). The lactam-derived 
Chapter 2 
43 
 
ynamide 84j was fairly unreactive, with only starting material and some hydration product 156 
recovered (Entry 3). As 156, with the ketone β- to the amide, is not the expected isomer for direct 
hydration of an ynamide,[97] an alternative mechanism for its formation is proposed (Scheme 40). 
Again this is initiated by attack of the carbonyl oxygen onto the alkyne to give cation 162, hydration 
then reforms the lactam in 163, with protodemetalation giving enol 164 which can tautomerise to 
the observed product 156. A similar mechanism has been proposed by Hammond and co-workers in 
the gold-catalysed regioselective hydration of 165 to form γ-keto ester 166 (Scheme 41).[98] It should 
be noted that ynamide 84j is unusually susceptible to hydration, which was also observed by TLC 
analysis when a solution in toluene was left for 24 hours; in this case a similar mechanism can be 
proposed where the gold catalyst in Scheme 40 is replaced with a proton. It is possible that the 
formation of 162 (not all of which can undergo hydration due to the lack of available water in the 
reaction mixture) prevents 161 from undergoing oxazole formation. 
 
Scheme 40: Proposed mechanistic pathway for the hydration of 84j. 
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Scheme 41: Regioselective hydration of an alkyne directed by a neighbouring ester by Hammond and 
co-workers.
[98]
 
The alkynyl-indole 84k reacted much more slowly than most ynamides which participate in 
the oxazole formation, however leaving the reaction for four days allowed a useful amount of 
oxazole 154b to be obtained (Table 2 – entry 4). This reactivity may be explained by delocalisation of 
the nitrogen lone pair of 154 into the indole, resulting in a less electron-rich alkyne in this substrate 
than in the other reactive ynamides. This appears to be the first reaction of an N-alkynyl indole under 
gold catalysis. 
2.2.3: Expanding the Scope at the Oxazole 5-Position 
The use of alternative functionality at the C-terminus of the ynamide was also investigated. Alkyl and 
aryl groups had previously been employed here, as were substituted vinyl groups and an alkyne.[49] 
Raju Jannapureddy later showed that esters and thioethers could be incorporated into the 5-position 
of the oxazole.[90] In order to investigate other non-carbon substituents at this position, the silylated 
ynamides 84l-m were synthesised, which also allowed access to terminal ynamide 84n (Scheme 42). 
 
Scheme 42: Synthesis of silylated and terminal ynamides. 
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Ynamide 84n successfully furnished oxazole 167, meaning that both 2,4- and 4,5-
disubstituted oxazoles can be synthesised using this methodology (Scheme 43). The use of 84m 
resulted in a mixture of recovered starting material and oxazole 167, presumably formed via slow 
desilylation of 84m to 84n, the other silyl ynamide 84l was unreactive. The reason for the lack of 
reactivity of ynamides 84l-m may well be steric in nature, this is supported by the fact that Raju 
Jannapureddy also found mesityl ynamide 84o to be unreactive in this chemistry. 
 
Scheme 43: Synthesis of a 2,4-disubstituted oxazole and failed synthesis of oxazoles from bulky ynamides 
(Ynamide 84o was synthesised and trialled in the oxazole formation by Raju Jannapureddy). 
The synthesis of a 5-bromo oxazole was also attempted, which required the preparation of a 
previously unreported bromine-substituted ynamide. Attempts at bromination of terminal ynamide 
84n afforded a complex mixture, but elimination of HBr from dibromoenamide 169 was more 
successful, leading to the formation of 84q (Scheme 44). As 84q degraded rapidly it was used without 
purification, providing oxazole 170, albeit in a modest yield. 
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Scheme 44: Synthesis of a 5-bromooxazole. 
2.2.4: Competing 1,2-C–H Insertion Pathway 
5-Alkyl oxazoles had previously been synthesised using this methodology, where a competing 
1,2-C–H insertion product was only isolated in one special case (Scheme 23).[49] The yields for 5-alkyl 
oxazoles were generally slightly depressed compared to when aryl substituents were employed in 
this position, and in subsequent similar reactions the competing 1,2-C–H insertion reactions were 
generally observed (Schemes 24-25).[52-53] In order to determine whether 1,2-insertion always 
competes in the synthesis of oxazoles from ynamides bearing alkyl chains, and if so what factors 
affect the level to which it competes, several such ynamides were synthesised (Scheme 45). 
 
Scheme 45: Synthesis of alkyl-substituted ynamides. 
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The ynamides 171a-c were investigated in reactions with ylides 94b and 94c, and attempts 
were made to isolate all of the products (Table 3). In each reaction a mixture of isomers was formed, 
in which the oxazole 172 was the major component. When ylide 94b was employed, the only 
observed side product was the expected 1,2-insertion product 173 as a mixture of E and Z isomers. In 
two cases (Entries 1-2) the 1,2-insertion products were inseparable from the oxazoles by column 
chromatography. Where ynamide 171c was employed alongside ylide 94b the resulting oxazole could 
be separated from the side-products (Entry 3). In contrast, the major side-products with ylide 94c 
were dienes 174, tautomers of the expected 1,2-insertion products (Entries 4-6). Whilst in no cases 
could 174 be isolated cleanly, all 3 oxazoles were separable from the side-products. 
Table 3: Competing oxazole formation and 1,2-insertion reactions. 
 
Entry Ynamide Ylide R R’ 172 173 174 
1 171a 94b Me OMe 
inseparable – 83%[a] 
-[b] (64: 33(E):3(Z)) 
2 171b 94b Bn OMe 
inseparable – 77%[a] 
-[b] (85: 15(E):trace(Z)) 
3 171c 94b Ph OMe 66% 21% (E/Z:15/1) -[b] 
4 171a 94c Me Ph 68% -[b] <15%[c] 
5 171b 94c Bn Ph 62% -[b] <8%[c] 
6 171c 94c Ph Ph 76% <4%[c] <3%[c] 
Using 171 (0.4 mmol), 94 (0.6 mmol) and Au(pic)Cl2 (5 mol%) in toluene (4 mL) at 90 °C. Isolated yields. 
[a] Isolated as an inseparable mixture. [b] Product not observed. [c] Isolated as the major component of a 
complex mixture. 
Ynamide 84r was also investigated with both ylides, giving near identical results in each case 
(Scheme 46). Alongside oxazoles 175, the only side products were enols 176 which were derived 
from the expected 1,2-C–H insertion reaction, followed by hydrolysis of the resulting enol ether, 
possibly during purification by column chromatography. Only the conjugated enol tautomers of 176 
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were observed by spectroscopic analysis, in which the Z form was predominant, possibly due to the 
presence of an internal hydrogen bond. 
 
Scheme 46: Effect of a benzyl ether on oxazole formation vs. C–H-insertion. 
 
Scheme 47: Possible mechanisms for 1,2-C–H insertion. 
Although it is unclear whether either oxazole formation or 1,2-insertion proceeds through 
carbenoid 178 or carbene 179, pathways for the competing reaction can be suggested from either 
intermediate (Scheme 47). Plausible mechanisms for the formation of 183 include a concerted 
1,2-hydride shift/loss of gold (A1 or B1) or a stepwise mechanism where the hydride shift generates 
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carbocation 181, which is then quenched by loss of the metal (A2 or B2). Alternatively elimination of a 
proton may be followed by protodemetalation (A3 or B3). The benzyl ether in ynamide 84r would be 
expected to stabilise carbocation 181, however its reactivity was very similar to that of ynamide 
171a, suggesting that pathway 2 is less likely than pathway 1. 
Regarding the substituent on the sulfonamide, the formation of 1,2-insertion products 
appears to be accelerated by the presence of the smaller N-methyl group, although an overall 
pattern is not clear (Table 3). It is worth noting that remarkably large remote steric effects have been 
observed in 1,2-hydride and -aryl shifts onto rhodium carbenes.[99] In the present case it must also be 
considered that the conformation of 178 as previously drawn may undergo either oxazole formation 
or 1,2-insertion, however the alternative conformation 178’ could only undergo 1,2-insertion, the 
relative concentrations of these conformations may well be affected by the size of the substituents 
on the amide (Scheme 48). 
 
Scheme 48: Reactive pathways for different conformations of the gold carbenoid. 
These results demonstrate that, where alkyl chains are incorporated into the 5-position of 
the oxazole, 1,2-C–H insertion competes in all cases, as it does in the similar reactions which were 
later reported.[52-53] The heterocycle is always the major product and can usually be isolated from the 
mixture by chromatography (nine additional examples in the original publication[49] as well as those 
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described here), and so the effect is generally to depress the yield of the desired oxazole. On two 
occasions the oxazole could not be separated from the side products (Table 3 – entries 1-2). The 
presence of products 183 is consistent with the mechanism for oxazole formation presented in 
Scheme 21, showing that the reaction initially proceeds through formation of the C–N bond rather 
than in a concerted fashion. The relatively high yields of oxazole obtained where competing reactions 
are possible, suggest that the formation of the C–O bond must then be relatively rapid compared to 
1,2-C–H insertion. 
2.2.5: Conclusion 
The scope of an existing reaction for the synthesis of trisubstituted oxazoles has been significantly 
widened at each position. This was allowed by the improvement of routes towards the required 
starting materials, especially pyridine-N-aminides. At the 2-position the reaction was found to 
tolerate groups such as secondary amides/anilines, an acetal and even products which may act as 
bidentate ligands. At the 4-position the incorporation of a phosphoramidate and an indole was 
demonstrated, whilst the challenging synthesis of a 5-bromo oxazole was also achieved. Additionally 
both 2,4- and 4,5-disubstituted oxazoles can now be accessed using this reaction. 
Some limitations to this chemistry have been found, notably including the incorporation of 
large substituents at the 5-position of the oxazole or of unprotected amines. Ynamides derived from 
lactams or acyclic carbamates were also found to be unsuitable for oxazole synthesis. In several cases 
products of competing reactions have been isolated, especially those of a 1,2-C–H insertion reaction, 
which allow some mechanistic insight into this process. 
This reaction is a key step in the formation of the products described in Chapters 3 and 4 of 
this thesis, where this work has been applied to the synthesis of polycyclic molecules. 
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CHAPTER 3: 
SYNTHESIS AND DIELS-ALDER REACTIONS OF 
OXAZOLES – DEVELOPMENT OF A ONE-POT 
REACTION CASCADE FOR THE CONSTRUCTION OF 
POLYHETEROCYCLIC MOLECULES 
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3.1: Introduction: Intramolecular Diels-Alder Reactions of Oxazoles 
The Diels-Alder reaction of oxazoles is a powerful method for the rapid construction of 
(poly)heterocyclic systems.[100] Where the dienophile is an alkene these can be either oxo-bridged 
tetrahydropyridines, or pyridines which are derived from their fragmentation. Alternatively, the 
cycloaddition of oxazoles with alkynes is normally followed by a retro Diels-Alder reaction to form 
furans. Generally these reactions take place under normal electron demand and are significantly 
accelerated by the presence of electron-donating groups on the oxazole and/or with the use of 
electron-deficient dienophiles. 
3.1.1: To Generate oxo-Bridged Tetrahydropyridines 
The oxo-bridged tetrahydropyridines 187, which can be formed by an intermolecular Diels-Alder 
reaction of an oxazole and an alkene are shown in Scheme 49. In comparison, intramolecular variants 
of this reaction are often more facile and usually allow for greater regio- and diastereocontrol, as 
well as allowing the formation of products fused to an additional ring system. 
 
Scheme 49: Generic intermolecular Diels-Alder reaction of an oxazole and an alkene. 
Shimada and Toju first demonstrated the intramolecular Diels-Alder reaction to form stable 
oxo-bridged tetrahydropyridines, using oxazoles with dienophiles tethered at the 5-position.[101] 
These included oxazoles 188 bearing O-allyl carbamates, which gave products 189 when heated at 
140 °C (Scheme 50). The yields were heavily dependent on the substituents on both the alkene and 
the oxazole, with less substituted products (especially those derived from terminal alkenes: R3=H) 
generally formed more efficiently. Interestingly, each of the products was isolated as a single 
diastereoisomer, although the relative stereochemistry was determined only for 189a. Here the 
Chapter 3 
53 
 
steric constraints of the tether between the heterocycle and the alkene lead to exclusive formation 
of the exo product. 
 
Scheme 50: Intramolecular Diels-Alder reaction of oxazoles with tethered alkenes.
[101]
 
Zhu and co-workers have developed a multicomponent reaction for the synthesis of 
oxazoles, including those which subsequently undergo reactions with tethered dienophiles.[102] In a 
typical example the oxazole synthesis begins with a condensation of a substituted allyl amine 190 
with an aldehyde (Scheme 51 – top).[102c]. The resulting iminium species 192 is attacked by isonitrile 
191 to give intermediate 193, which cyclises to oxazole 194. Finally 194 undergoes an intramolecular 
Diels-Alder cyclisation to give the product 195. Remarkably the whole process is completed within 
two hours, in one-pot, at room temperature and forms 195 as a single diastereoisomer, which 
exhibits the same relative stereochemistry at the ring junction as previously described in Scheme 50. 
This demonstrates how the Diels-Alder reaction of oxazoles can be accelerated where an 
electron-donating group is present at the 5-position of the heterocycle, and an electron-deficient 
alkene is employed. 
In contrast, when diallylamine 196 was tested, the reaction stopped at oxazole 199  
(Scheme 51 – middle). The final cycloaddition of oxazole 199 with the unactivated alkene was only 
triggered upon heating this substrate to 80 °C, and was followed by loss of morpholine to give 
pyridine 200 (this type of fragmentation is discussed below). 
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Scheme 51: Multicomponent reactions which synthesise oxo-bridged tetrahydropyridines via oxazoles.
[100c-d] 
Starting from amines 201, the analogous reaction for the synthesis of Diels-Alder adducts 
fused to piperidines 203 has also been carried out (Scheme 51 – bottom).[102d] In this case most of the 
products were isolated in a ~2:1 diastereomeric ratio, and the yields of 203 were slightly less 
impressive than those for 195, which can be explained by the increased flexibility of the longer chain 
alkene. 
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The same group has developed a similar one-pot protocol which is highly enantioselective 
(Scheme 52).[102f] Starting from aldehydes and primary anilines 204, the resulting imine 205 is 
activated by a chiral phosphoric acid. It was proposed that the enantioselectivity for this reactions 
arises from addition of the isonitrile 207 to chiral iminium salt 206. Which is followed by cyclisation 
of the resulting species 208 to give enantioenriched oxazole 209. 209 is then acylated and undergoes 
a Diels-Alder reaction to form pyrrolidinone-fused products 211. The diastereoselectivity of the final 
step was governed by the nature of the substituent originally derived from the aldehyde. When 
R1 = cyclohexyl the diastereomeric ratio was between 6:1 and 12:1, whilst a larger tert-butyl group in 
this position resulted in the formation of the enantioenriched products 211 as single 
diastereoisomers. 
 
Scheme 52: Enantioselective one-pot synthesis of oxo-bridged tetrahydropyridines.
[102f]
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3.1.2: To Generate Pyridines (the Kondrat’eva Pyridine Synthesis) 
As mentioned above, the adducts 187 can be converted into pyridines through several pathways. 
This process may be triggered thermally or by the addition of either acid or base, and is known as the 
Kondrat’eva pyridine synthesis (Scheme 53).[100a] The classic, and often targeted, fragmentation is 
dehydration to pyridines 212, however other pathways may compete depending on the nature of the 
substituents on 187. These include the loss of the group which originates from the oxazole 5-position 
(R3) to give pyridinol 213, or where this substituent is a proton it may facilitate elimination with its 
adjacent substituent (Y) to give 214, or reduction to 215. 
 
Scheme 53: Possible pathways for aromatisation of tetrahydropyridines. 
An example of how these competing pathways can be controlled can be found in the total 
synthesis of eupolauramine by Levin and Weinreb (Scheme 54).[103] When oxazole 216 was heated in 
1,2-dichlorobenzene, the reduction product 218 was produced alongside pyridinol 219, despite the 
absence of any obvious oxidant. The reaction was attempted in several (degassed) solvents at various 
temperatures, with the only observed difference being that lower temperatures increased the ratio 
of 218:219 (suggesting that 219 is likely a product of decarboxylation of 218). Addition of the base 
DBN to the reaction mixture changed the fragmentation pathway, resulting in exclusive formation of 
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the desired dehydration product 220. The intramolecular Kondrat’eva pyridine synthesis has since 
been incorporated into several other natural product syntheses.[104] 
 
Scheme 54: Intramolecular Kondrat’eva pyridine synthesis as a key step in Levin and Weinreb’s synthesis of 
eupolauramine.
[103]
 
The dehydration of oxo-bridged tetrahydropyridines may also be triggered under acid 
catalysis. Addition of trifluoroacetic acid at low temperature to the multicomponent synthesis of 195 
described in Scheme 51 led to the isolation of pyridine products 221 (Scheme 55).[102c] This is in 
contrast to the loss of morpholine which followed the Diels-Alder reaction of 199 in the absence of 
either acid or, possibly importantly, the ester substituent (Scheme 51). 
 
Scheme 55: Multicomponent synthesis of pyridines.
[102c]
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3.1.3: To Generate Furans 
The first cycloadditions of oxazoles with alkynes employed 5-ethoxy-oxazoles of type 222 and 
dimethyl acetylenedicarboxylate 223 (Scheme 56).[105] The resulting adduct 224 was not observed 
before it underwent a rapid retro-Diels-Alder reaction to give furan products 225, with loss of either 
a nitrile or hydrogen cyanide. 
 
Scheme 56: Intermolecular Diels-Alder reactions of oxazoles with an alkyne
[105]
 and a benzyne.
[106]
 
The reaction of 4-phenyl oxazole 228 with benzyne gave the unusually stable Diels-Alder 
adduct 229 (Scheme 56 – bottom).[106] Compound 229 could be stored for several days at room 
temperature, however heating 229 produced the very reactive isobenzofuran 230, which was 
trapped with N-methyl maleimide as 232. A likely reason for the stability of 230 is the relatively small 
gain in aromatic character on going from 230 to 232 compared to going from 224 to 225.
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The Jacobi group have studied the intramolecular variant of this reaction and exploited it in 
the racemic synthesis of a number of furanosesquiterpene natural products, with the construction of 
the furan representing a robust and often efficient final step (Scheme 57).[107] Intramolecular furan 
syntheses of this type have also been employed at an earlier stage in a number of other natural 
product syntheses.[108] 
 
Scheme 57: Construction of the furan ring as the final step in the synthesis of furanosesquiterpene natural 
products.
[107]
 
Zhu and co-workers have developed a multicomponent synthesis of fully substituted furans 
239 using a route analogous to that described in Scheme 51, in which the alkene is replaced by an 
alkyne (Scheme 58).[109] A higher temperature was required for efficient conversion than for the 
reactions with alkenes, additionally the use of an electron-withdrawing group on the dienophile was 
essential to facilitate its reaction with the oxazole (terminal alkynes did not undergo the Diels-Alder 
reaction). 
 
Scheme 58: Multicomponent syntheses of fully substituted furans and benzenes.
[109]
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3.1.4: Conclusion 
The intramolecular Diels-Alder reaction of oxazoles allows the construction of oxo-bridged 
tetrahydropyridines, pyridines or furans fused to an additional newly formed ring system. The 
cycloaddition usually takes place under normal electron demand and can be accelerated by the use 
of electron-rich oxazoles and/or electron-deficient dienophiles. As no additional reagents or catalysts 
are generally required, these reactions are ideally suited to incorporation into one-pot, multi-step 
cascade processes for the rapid construction of polycyclic molecules.  
3.2: Results and Discussion 
Chapter 2 showed how oxazoles bearing diverse substituents could be convergently constructed. The 
substrate scope was explored particularly widely at the 2-position, for which an improved synthesis 
of pyridine-N-aminides has been developed. It was therefore anticipated that a variety of oxazoles 
tethered to dienophiles at the 2-position could be accessed by this gold-catalysed cycloaddition. This 
would allow the Diels-Alder chemistry of the new 4-amido oxazoles to be explored, and potentially 
facilitate the construction of heavily substituted polycyclic compounds such as 
tetrahydropyridine 242, pyridine 243 or furan 247 (Scheme 59). The ultimate aim of this project 
would be to carry out both the synthesis of the oxazole and its subsequent Diels-Alder reaction in a 
one-pot process. 
 
Scheme 59: Proposed route to polycyclic products from pyridine-N-aminides. 
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3.2.1: Initial Synthesis of Furans and oxo-Bridged Tetrahydropyridines 
The synthesis of oxazoles 151b-d was described in Chapter 2 (Scheme 35). It is noteworthy that no 
Diels-Alder reaction of 151d was observed either during in its initial synthesis or when it was heated 
to higher temperatures in a sealed tube (Scheme 60). This lack of reactivity is in contrast with that of 
the similar substrates 210 (Scheme 52), however it can be explained by the reduced number of 
substituents on and α- to the nitrogen in the tether, which raises the relative energy of the required 
reactive rotamer. This cyclisation is further sterically disfavoured by the presence of large phenyl 
groups on both the alkene and at the 5-position of the oxazole. 
 
Scheme 60: Previously synthesised oxazoles including one tethered to an alkene which does not undergo a 
Diels-Alder reaction. 
With the steric considerations above in mind, the first successful Diels-Alder reaction was 
carried out using the alkyne-tethered oxazole 250 (Scheme 61). In an unoptimised procedure the 
protecting group of oxazole 151c was first cleaved, and the resulting primary amine was treated with 
excess propargyl bromide at 50 °C to give dipropargylated product 250. Upon heating to 100 °C, 
some conversion of 250 was observed by TLC. The reaction was stopped after 24 hours (before the 
full consumption of oxazole, as some degradation was also obvious at this point), leading to the 
isolation of furan 253. In keeping with the literature reviewed above, the final retro-Diels-Alder 
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reaction which furnished this furan appeared to be extremely rapid, as the initial intermediate 251 
was not observed at any stage. Nitrile 252 was also isolated, although not with high purity. 
 
Scheme 61: First Diels-Alder reaction of a 4-amido oxazole, generating a furan. 
Given the problems with the small amount of racemisation of 94f/151c (Chapter 2 – Scheme 
37), and the possibility of forming up to four diastereoisomers of oxo-bridged tetrahydropyridines 
from chiral pyridine-N-aminides, it was preferable to continue these early investigations from the 
glycine-derived oxazole 151b, with the intention of returning to substrates based on chiral amino 
acids following further optimisation.  
A more straightforward alkylation strategy than that described above was to treat 151b with 
NaH and the appropriate alkyl bromide. The propargylation of 151b appeared to proceed smoothly 
by, as evidenced by TLC analysis, so this reaction mixture was then heated to facilitate the following 
cycloaddition in the same pot (Scheme 62). The resulting furan 255 was isolated in a low yield, 
however this is likely to be due to the instability of this product. Following purification, further 
degradation of furan 255 occurred even at room temperature. 
 
Scheme 62: One-pot propargylation and Diels-Alder reaction of an oxazole. 
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Scheme 63: Successful Diels-Alder reaction of an oxazole tethered to an alkene. 
When the alkene tethered oxazole 256a was heated to reflux in toluene, it pleasingly gave 
the stable tetrahydropyridine 257a as a single diastereoisomer (Scheme 63, evidence for the relative 
stereochemistry drawn for products 257 is discussed from page 71). The selectivity for the exo 
product is attributed to increased strain in the tether between the oxazole and the alkene for the 
endo transition state 259 (Scheme 64). This selectivity is the same as that displayed by similar 
oxazoles 194[102c] (Scheme 51) and 210[102f] (Scheme 52), and by related furans.[110] 
 
Scheme 64: Favoured and disfavoured transition states in the Diels-Alder reaction of oxazoles 256. 
It is interesting to note the increased reactivity of 256a over 151d, despite 256a containing 
the more electron-rich alkene. As inverse electron demand Diels-Alder reactions of oxazoles are 
known only for very deactivated heterocycles,[111] it appears that the steric effect of substituents on 
the oxazole-dienophile tether and/or on the alkene is very important, although further investigation 
into the electronics of this reaction were required. 
The relative stability of the tetrahydropyridines, and the initial success in their synthesis, 
meant that these substrates were next targeted as part of a cascade process. 
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3.2.2: Cascade Reactions to Synthesise Tetrahydropyridines in One-Pot from Ynamides 
3.2.2.1: Screen of protecting groups 
Having found a suitably reactive substrate in 256a, ylides based on protected N-allyl glycines were 
targeted so that such oxazoles could be prepared directly from ynamides, and the Diels-Alder 
reaction carried out in the same reaction vessel. Several protecting groups were investigated in order 
to find a highly reactive ylide which could be easily accessed. 
Protected glycines 147e and 262 were allylated in an unoptimised procedure by treatment 
with allyl bromide and sodium hydride. These reactions produced fairly complex mixtures from which 
isolation of the product was difficult, resulting in disappointing yields of 263a-b (Scheme 65). A likely 
reason for this is that excess NaH was used, allowing enolate formation, which may lead to additional 
allylation adjacent to the carbonyl and/or Claisen condensation. In contrast, the more acidic 
secondary sulfonamides 264 and 265 could be allylated using K2CO3 when heated with allyl bromide 
in acetonitrile.[112] The reactions of the sulfonamides were particularly clean and 263c-d could be 
purified simply by aqueous extraction following each of the two steps, making these far more easily 
accessed substrates. 
 
Scheme 65: Synthesis of protected N-allyl glycine methyl esters. 
Esters 263a-d were next used in the synthesis of ylides 263a-d. Moderate yields were 
obtained for 266a-b whilst there was a significant difference in the yield of sulfonated products 
266c-d (Table 4). Nitrobenzenesulfonamides are typically deprotected by nucleophilic substitution at 
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the carbon-sulfur bond with strong nucleophiles (usually thiolates), followed by loss of SO2.
[113] Side-
products believed to be derived from this deprotection using the nucleophile generated by 
deprotonation of 139 were observed in the synthesis of 266c, explaining the significantly lower yield 
for this substrate than for 266d. 
Table 4: Effect of the glycine protecting group on ylide synthesis and the cascade oxazole formation / 
Diels-Alder reaction. 
 
Entry PG 266 Yield 257 Yield 
1 Boc 266a 45% 257a 68% 
2 CBz 266b 36% 257b 63% 
3 p-Ns 266c 12% 257c 36% 
4 Ts 266d 62% 257d 69% 
 
Ylides 266a,b,d all retained the very high reactivity of the similar glycine-derived ylide 94e 
(Chapter 2 – Scheme 35); TLC analysis showed that ynamide 84g was consumed within 45 minutes to 
cleanly form intermediate oxazoles 256, which were heated for three days at reflux to give 
tetrahydropyridines 257a,b,d in consistently good yields (Table 4 – entries 1,2 and 4). Again the yield 
was fairly poor using the para-nitrobenzenesulfonamide (Entry 3). In this case ylide 263c did not 
consume ynamide 84g as evidenced by TLC analysis within four hours at 90 °C, the reason for this is 
unclear as nitrobenzenesulfonamides have previously been well tolerated in the gold-catalysed 
oxazole synthesis.[49] 
A number of important conclusions could be drawn from this study. Firstly, as envisioned, it 
was possible to carry out the oxazole synthesis and a subsequent Diels-Alder reaction with a tethered 
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N-allyl group in a one-pot protocol. This process allows a remarkably rapid increase in complexity, 
generating four new ring systems and three new stereogenic centres with complete 
diastereoselectivity for the exo product. 
Secondly, N-Boc, -Cbz and -tosyl protecting groups on the amino acid can all be used in this 
cascade with little variation in the yield, allowing the potential development of different strategies if 
subsequent products containing an unprotecting pyrrolidine were desired. In these successful 
reactions the remaining material in the reaction mixture was mostly comprised of the intermediate 
oxazole 256, for which complete consumption was never achieved (recovering the oxazoles 256 in 
high purity from these reactions was challenging, partially due to the small amount present). It is 
clear that for these substrates a balance must be struck between the required reaction time and 
temperature, and obtaining a good yield of the product. Identifying oxazole/dienophile combinations 
which more readily underwent the Diels-Alder reaction remained an objective. 
It is also interesting to note that very similar yields of 257a were obtained whether 
oxazole 256a was isolated and used as the starting material (Scheme 62), or formed in situ from the 
ynamide (Table 4 – entry 1). As the formation of oxazoles 256a,b,d directly by gold catalysis 
appeared by TLC analysis to proceed in a near quantitative fashion (as it had for related oxazole 151b 
– Chapter 2 – Scheme 35), this implied no significant effect of the gold catalyst on the Diels-Alder 
reaction, and also no benefit in isolating the intermediate oxazole. 
Finally, considering both the yield for the formation of ylide 266d, and the fact that its 
required ester 263d could be accessed extremely easily, 266d was an ideal substrate to continue 
investigating the scope of this process. The absence of carbamate rotamers in the tosylated 
products, which complicated the NMR spectra of tetrahydropyridines 257a-b, was an additional 
factor in this decision. 
Before moving on to testing other ynamides, two further experiments were carried out with 
ynamide 84g. The reactions shown in Table 4 employed 0.2 mmol of ynamide. A 1.5 mmol scale 
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reaction showed that the yield of 257d remained consistent, whilst providing nearly half a gram of 
this substrate for subsequent investigation of its chemistry (Scheme 66). 
 
Scheme 66: Large-scale synthesis of an oxo-bridged tetrahydropyridine. 
Secondly the reaction of 84g with 266a was repeated, however after 45 minutes (by which 
time all of 256a had been consumed as evidenced by TLC) DBU was added to the reaction mixture 
(Scheme 67). 257a was obtained from this reaction in a practically unchanged yield from the base-
free reaction (Table 4 – entry 1) and no formation of any pyridine products was observed. Although 
such a dehydration has been triggered by the addition of DBU[102b] or DBN (Scheme 54)[103] to similar 
substrates, a key difference is that the Diels-Alder reaction of oxazole 256a was carried out without 
an electron-withdrawing group attached to the alkene. Therefore, in the resulting product 257a, 
none of the protons on the tetrahydropyridine ring are acidic enough to readily facilitate base-
catalysed dehydration. 
 
Scheme 67: Addition of DBU to the Diels-Alder reaction does not result in dehydration of the product. 
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3.2.2.2: Variation of the ynamide 
Having already established the types of ynamides which cleanly formed oxazoles in Chapter 2, a 
range of these substrates were synthesised in order to investigate the effect of altering the 
substituents on the oxazole 4- and 5-position on their Diels-Alder reactions (Scheme 68). 
 
Scheme 68: Synthesis of ynamides for use in the oxazole formation/Diels-Alder reaction. Ynamide 84a was 
synthesised by Mickaël Dos Santos.
[47c]
 
With several ynamides in hand, as well as 84n and 171c which were previously described 
(Chapter 2 – Schemes 42 and 45), the synthesis of oxo-bridged tetrahydropyridines 257e-l was 
investigated (Scheme 69). The nature of combining two or more reactions into one process often 
makes it difficult to explain the relative reactivity of different substrates, as there are always several 
factors at play (efficiency of conversion of 84 to 256 and of 256 into 257, as well as stability of both 
256 and 257). One particular problem in this case is that the amount of oxazole 256 remaining at the 
end of the reaction could usually only be roughly estimated. Levels of 256 could not be quantified by 
1H-NMR spectroscopic analysis of the crude reaction mixtures, due to overlap of the easily 
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identifiable resonances with either those of the product 267 or of unconsumed ylide 266d. Attempts 
to isolate 256 were laborious and rarely gave pure oxazole. 
 
Scheme 69: Synthesis of oxo-bridged tetrahydropyridines from various ynamides. [a]: Result from Table 4 
provided for comparison. [b]: Approx. 95% purity. [c]: Complex mixture from which no pure compounds 
could be isolated. [d]: Reaction stopped after 6 hours at 110 °C when all 256l was consumed as evidenced by 
TLC. 
Increasing the size of the substituents on the nitrogen of the ynamide could disfavour the 
approach of the dienophile, however it could also affect the ability of the nitrogen lone pair to 
overlap with the π-system of the oxazole ring. Tetrahydropyridines 257e-f were both formed in a 
reduced yield compared to 257d, however the slightly improved yield of 257f over 257e means there 
is no obvious pattern in these results. 
The low yield of 257g is curious, as all of ynamide 84t was consumed within 45 minutes and 
only <9% of impure oxazole 256g was also isolated from this reaction. It may be that the electron-
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rich aromatic substituent allows degradation of 257g by facilitating cleavage of the adjacent C-O 
bond; indeed this product could not isolated with high purity, however no degradation products 
(pyridines or otherwise) could be isolated or identified. The reduced yield of 257h compared to 257d 
is expected, assuming the Diels-Alder reaction takes place under normal electron demand (in both 
cases the ynamide was consumed within 45 minutes at 90 °C, however the amount of remaining 
oxazole was not quantified). 
Terminal ynamide 84h was previously shown to be reactive in the oxazole synthesis (Scheme 
43) and was cleanly transformed into one product (presumably oxazole 256i) on reaction with 263d 
within 45 minutes at 90 °C. The presence of a proton on the oxazole 5-position potentially opens up 
pathways for conversion of 257i into a 3-hydroxypyridine (Scheme 53), however continued heating at 
110 °C led to the formation of an extremely complex mixture from which no compounds could be 
isolated or identified. Similar behaviour was observed when ynamide 171c was employed (further 
complicated by the presence of 1,2-C–H insertion products), and so none of product 257j could be 
isolated. 
The conversion of ynamides 84v and 84w into oxazoles has been demonstrated by Raju 
Jannupureddy, although the reactivity of ester-substituted ynamides was heavily dependent on the 
ylide with which they were partnered.[90] Reaction of 84v with 263d formed a complex mixture 
without full consumption of the ynamide over 90 minutes at 90 °C. Heating was continued for three 
days at 110 °C for consistency, but no pure compounds could be isolated after this time. 
Ynamide 84w was completely consumed within 45 minutes at 90 °C and, unlike in the other 
reactions, both oxazole 256l and tetrahydropyridine 257l were apparent by TLC analysis at this point. 
Continued heating at 110 °C for six hours led to complete consumption of the oxazole (this was not 
achieved within three days for any other reaction), and allowed 257l to be isolated in an excellent 
yield. 
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As well as identifying some ynamides which are not well suited to this cascade process, this 
study indicates that the Diels-Alder reaction of these 4-amido oxazoles probably proceeds under 
normal electron demand given the reduced yield of 257h compared to 257d and the especially high 
reactivity of oxazole 256l. 
3.2.2.3: Diastereochemical assignment 
Only one diastereoisomer of the tetrahydropyridines 257 was observed in each of the reactions 
described above. These have been assigned as the exo products based on the following observations. 
Tetrahydropyridine 257m was synthesised by Matthew Ball and produced crystals suitable for single 
crystal X-ray diffraction, which confirmed the relative stereochemistry of this molecule (Scheme 70). 
 
 
Scheme 70: Synthesis of an oxo-bridged tetrahydropyridine by Matthew Ball and its X-ray structure. 
Ellipsoids at 50% probability, hydrogens omitted except at the ring junction, X-ray data was obtained and 
solved by Dr Louise Male. 
Key features of the 1H- and 13C-NMR spectra of the Diels-Alder adducts were then compared 
(Table 5). Only relatively small changes were observed in the chemical shifts of the proton and 
tertiary carbon at the ring junction were observed. The H-H coupling constants near to the ring 
junction were also very consistent across the products. Only 257l showed notable deviation in this 
respect, however these changes are more likely due to the significantly different substituent (R’ = 
SPh) in this compound, rather than a reversal of the diastereoselectivity in its formation. This data 
strongly suggests that the same relative stereochemistry is present in all the products 257a-m. 
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Table 5: Comparison of NMR data for Diels-Alder adducts 
 
257 EWG R R’ R’’ 
δCA 
/ppm 
δHA/ 
ppm 
3J(HA-HB)/ 
Hz 
3J(HA-Hc)/ 
Hz 
2J(HB-HC) 
/Hz 
257a[a] Ms Me Ph Boc 45.2, 44.5 2.62-2.48 - - - 
257b[a] Ms Me Ph Cbz 45.2, 44.5 2.62-2.48 - - - 
257c Ms Me Ph p-Ns 45.5 2.59-2.49 7.6 3.2 12.2 
257d Ms Me Ph Ts 45.6 2.49-2.40 7.7 3.2 12.0 
257e Ts Me Ph Ts 45.6 2.46-2.33 7.6 3.2 12.0 
257f Ts Ph Ph Ts 45.6 2.53-2.44 7.6 3.2 12.0 
257g Ms Me 4-OMe-C6H4 Ts 45.7 2.49-2.41 7.6 3.3 12.0 
257h Ms Me 4-NO2-C6H4 Ts 45.5 2.55-2.46 7.6 3.1 12.0 
257l Ms Me SPh Ts 45.3 2.36-2.28 7.1 2.6 12.6 
257m Ms Me Ph Ms 45.8 2.68-2.60 7.6 3.2 12.2 
[a]: Due to the carbamate protecting groups two rotamers were observed in the NMR spectra of these 
compounds. As such, two values are given for δC
A
 and the H-H coupling constants could not be determined due 
to peak overlap. 
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3.2.2.4: Attempted synthesis of enantioenriched tetrahydropyridines from chiral starting materials 
The tetrahydropyridines described so far have all been synthesised as a racemic mixture of a single 
diastereoisomer. The use of chiral starting materials should allow access to enantioenriched Diels-
Alder adducts, however the formation of additional diastereoisomers would then be possible. 
 
Scheme 71: Synthesis of ylides derived from proteced N-allyl alanine and N-allyl tryptophan. 
The most obvious candidates for this strategy were ylides derived from amino acids other 
than glycine. Alanine- and tryptophan- based ylides 266f-g were synthesised using the same methods 
as those described above (Scheme 71). Disappointingly the final step in each case was inefficient; the 
presence of large groups α- to the ester may disfavour substitution at this position. Purification of 
these substrates was also challenging and required a recrystallisation following flash column 
chromatography. Finally, given the previously encountered problem of possible racemisation of a 
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related compound (Scheme 37), the specific rotation of 266f was disconcertingly low  
([α]D
20 = −8.3 °dm-1g-1cm3). This measurement could not be made for 266g due to its lack of room 
temperature solubility in an appropriate solvent. 
Ylides 266f-g were then tested with ynamide 84g in the cascade oxazole formation and Diels-
Alder reaction (Scheme 72). Each reaction produced a mixture of two diastereoisomers (in a roughly 
2:1 ratio), which presumably had the relative stereochemistry illustrated in general substrates 274 
and 274’. Whilst these compounds could be separated, all four products were contaminated with low 
levels of other unidentified impurities, and none showed any optical activity. The combined yield of 
the products 276 was also poor; this can be at least partially explained by the failure of this reaction 
to consume all of ynamide 84g, which is possibly due to the steric bulk of the ylide or its low 
solubility. Although not properly quantified, the apparent ease with which these substrates 
underwent racemisation compared to 94f/151c (Chapter 2 – Scheme 37) is intriguing, and likely due 
to the increased acidity of the proton α to an N-Ts group over an N-Boc group. 
 
Scheme 72: Reactions of chiral ylides with an ynamide. 
Chapter 3 
75 
 
Given the low yield of the ylide synthesis, problems with the products’ purification and 
probable racemisation, and the moderate diastereoselectivity of these reactions, no further 
investigations were undertaken with these substrates. 
Chiral ynamide 84x, derived from (-)-camphor sultam, was also tested in this reaction 
(Scheme 73). A much more promising diastereoselectivity of 4:1 was observed for the formation of 
tetrahydropyridines 277, however the products were not easily separated in this case. Additionally, 
the overall recovery of this reaction was poor given that ynamide 84x was all consumed within one 
hour as evidenced by TLC, but only <8% of the impure intermediate oxazole was isolated alongside 
products 277. No products of competing reactions were identified. 
 
Scheme 73: Reaction of a chiral ynamide with ylide 263d. 
 
3.2.2.5: Increased ring size 
The final aspect of the Diels-Alder reaction which was investigated was the impact of increasing the 
length of the tether between the oxazole and the alkene; this would have the effect of increasing the 
size of the ring fused to the oxo-bridged tetrahydropyridine products. To this end, ylides 266h-i were 
synthesised (Scheme 74). 
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Scheme 74: Glycine-derived ylides with tethered alkenes. 
The formation of a piperidine ring using 266h was successful, furnishing 278 in a 52% yield 
(Scheme 75). Again only one diastereoisomer was observed and the X-ray structure of 278 revealed 
that it had the same relative stereochemistry as the products fused to pyrrolidine rings described 
above. The formation of 7-membered rings is known to be significantly more challenging than that of 
their 5- or 6-membered equivalents.[114] This was the case in the reaction of 266i and ynamide 84g, 
which were efficiently transformed into oxazole 279, however no subsequent Diels-Alder reaction 
occurred. 
  
Scheme 75: Left: Synthesis of a Diels-Alder adduct fused to a piperidine. The reaction stops at the oxazole 
when a longer tether is used. Right: X-ray structure of 278. Ellipsoids at 50% probability, hydrogens omitted 
except at the ring junction, X-ray data was obtained and solved by Dr Louise Male. 
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3.2.3: Reactions of the Tetrahydropyridine Products 
3.2.3.1: Treatment with acid 
As base-catalysed dehydration of 257a had been unsuccessful (Scheme 66), this reaction was 
instead attempted with 257d using trifluoroacetic acid (Scheme 76), as described for similar 
substrates 195 (Scheme 55).[102c] No reaction of 257d was observed, which can again be explained by 
the lack of an electron-withdrawing group on the tetrahydropyridine ring. In the case of 195 it is 
likely that the enol tautomer 281 assists in the in cleavage of the first C–O bond to give 
dihydropyridine 282, which then readily undergoes dehydration. This pathway is not available to 
257d. This illustrates that whilst Diels-Alder reactions between oxazoles and unactivated alkenes are 
more challenging than with electron-deficient alkenes, they do result in products with considerably 
greater acid/base stability. 
 
Scheme 76: Top: Treatment of 257d with trifluoroacetic acid does not result in dehydration.  
Bottom: Proposed mechanism for the dehydration of 195 described by Zhu and co-workers.
[102c]
 
In contrast, 257d was consumed within twenty minutes when treated with TsOH in methanol 
to generate hydration product 283, the X-ray structure of which revealed it to be formed by 
hydrolysis of the amidine (Scheme 77). It is not clear whether this reaction was triggered by the use 
of the stronger acid or by the change in solvent. 
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Scheme 77: Left: Acid-catalysed hydrolysis of the amidine. Right: X-ray structure of 283. Ellipsoids at 50% 
probability, hydrogens omitted except at the ring junction, X-ray data was obtained and solved by Dr Louise 
Male. 
The hydrolysis of related cyclic amidines[115] and acetimidates[116] has previously been 
reported. The presence of the additional nitrogen or oxygen atom attached to the imine carbon 
prevents the reversal of these reactions from dominating, which is observed for simple six-
membered cyclic imines, unless the primary amine in the product is trapped by another reagent.[117] 
As oxo-bridged tetrahydropyridines have not previously been synthesised with a heteroatom 
attached to the imine carbon, this appears to be the first example of the hydrolysis of such a C=N 
bond. The stability of 257d towards acid-catalysed dehydration is also important to achieving this 
reactivity. 
The efficiency and simplicity of this step makes for a powerful method for accessing 
substituted tetrahydrofurans fused to pyrrolidines in a diastereoselective fashion. Although this was 
achieved towards the end of the experimental work described in this thesis, a potential future line of 
enquiry would be to see whether the hydration reaction could be combined with deprotection of 
acid-sensitive protecting groups on the Diels-Alder product (eg. N-Boc on the pyrrolidine and/or 
N-PO(OR)2 on the amidine). 
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3.2.3.2: Reduction with LiAlH4 
Amidine 257d underwent an interesting reaction with LiAlH4, where reduction of the amidine 
functionality was followed by hydrogenolysis of both the resulting aminal and the hemiaminal ether 
to give 284, which was isolated as a single diastereoisomer (Scheme 78). In order to obtain X-ray 
quality crystals 284 was treated with HCl, allowing the relative stereochemistry of the resulting salt 
to be unambiguously determined. 
 
Scheme 78: Reduction of 257d with LiAlH4 and X-ray structure of 284.HCl. Ellipsoids at 50% probability, 
hydrogens omitted except at the ring junction, X-ray data was obtained and solved by Dr Louise Male. 
As with the acid-catalysed hydration, this reaction opens up a number of possibilities which 
there was not time to investigate. These include testing alternative reduction conditions (such as 
hydrogenation) in an effort to improve the yield, and attempting the reaction with N-Cbz protected 
substrates such as 257c to give deprotected pyrrolidines fused to piperidines. It also shows a 
potential advantage of optimising the diastereoselective synthesis of the oxo-bridged 
tetrahydropyridines from chiral ynamides (Scheme 73), as this should allow a chiral auxiliary 
approach to enantioenriched products of the type 284. It is noteworthy that the bicyclic system in 
284 can also be found in the antibacterial agent Moxifloxacin, albeit with different relative 
stereochemistry at the ring junction.[118] 
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Figure 9: Chemical structure of the antibacterial agent Moxifloxacin. 
3.2.4: Conclusion 
The reaction of ynamides with pyridine-N-aminides tethered to alkenes allows the synthesis and 
Diels-Alder reaction of oxazoles in one-pot to form oxo-bridged tetrahydropyridines fused to 
pyrrolidines or piperidines as single diastereoisomers. Overall, good yields are obtained considering 
the rapidly increased complexity of the products, however the Diels-Alder reaction only reached 
completion when the intermediate oxazole had a thioether substituent at the 5-position. 
Acid-catalysed hydration of the products was demonstrated, as was their reduction by LiAlH4, 
providing diastereoselective routes to saturated bicyclic systems. The possibility of carrying out the 
Diels-Alder reaction using alkynes as the dienophile, in order to give furan-containing products, was 
also confirmed. 
Future work to develop the substrate scope of this reaction could focus on several areas. 
Altering the nature of the tether between the alkene and the oxazole may allow access to oxo-
bridged tetrahydropyridines fused to alternative heterocycles, whilst further investigation of more 
substituted alkenes could also be undertaken. It is likely that the Diels-Alder reaction could be 
accelerated by the use of more electron deficient alkenes, although the increased steric demand of 
these substrates may be problematic. Finally, deprotection of the amides present in the Diels-Alder 
adducts, as well as the products of their hydration or reduction, could also be investigated. 
 81 
 
 
 
 
 
 
 
CHAPTER 4: 
SYNTHESIS OF NOVEL OXAZOLE-ANNULATED 
IMIDAZOLIUM SALTS AND INVESTIGATION OF 
THEIR ORGANOMETALLIC CHEMISTRY 
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4.1: Introduction: NHCs Fused to Aromatic Rings 
Nucleophilic heterocyclic carbenes (also knowns as N-heterocyclic carbenes or NHCs) 287 are 
carbenes stabilised by flanking heteroatoms which are commonly employed either as 
organocatalysts[119] or as ligands in transition metal catalysis;[120] their most common classes, 288-
291, are shown in Figure 10. 
 
Figure 10: Common structures for monocyclic and polycyclic NHCs. 
Polycyclic NHC systems have attracted considerable interest,[121] these include 
benzimidazolylidines and benzthiazolylidines 292 where the steric effect of the additional benzene 
ring is small; however variation of its substituents can exert a measurable electronic impact.[122] 
Among structures containing saturated ring systems 1,5-fused to the NHC, 293 and 294 have 
provided extremely successful architectures for asymmetric organocatalysis.[123] Promising 
enantioselectivities have also been achieved using ligands such as 295 and 296 in transition metal 
catalysis.[124] These ligands rely on the influence of stereogenic centres near to the ring junction, 
allowing the formation of a chiral environment which is rigid and well-defined in the area close to the 
carbene, the lack of which is often supposed to be a reason for poor asymmetric induction from 
other chiral NHCs.[125] 
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By contrast the 1,5-annulation of aromatic rings, as in 297, puts the substituent ortho to the 
ring junction (R’) in the same plane as, and close to, the carbene and any metals to which it is bound. 
This allows the design of ligands 297 where the R’ substituent has a predictable steric impact, or 
functions as a second donor atom in bidentate ligands. Additionally the fused aromatic ring in 297 
may be used to tune the electronic properties of the NHC.[126] 
The synthesis of carbenes 297 and their respective azolium salts, as well as their applications 
as ligands is discussed in this introduction; whilst novel imidazolium salts which are fused to oxazoles 
are introduced in the results and discussion for this chapter. 
4.1.1: Synthesis of Imidazolium Salts Fused to Aromatic Rings 
The majority of imidazolylidenes fused to aromatic systems are accessed via 
imidazo[1,5-a]pyridinium salts 298, which are generally synthesised using one of three routes 
(Scheme 79). 
 
Scheme 79: General routes to imidazo[1,5-a]pyridinium salts. 
N-Alkylation of imidazo[1,5-a]pyridine using methyl iodide (route A), was first described by 
Miyashita and co-workers in 1996,[127] although few experimental details were given. The Lassaletta 
group later showed that this approach was very efficient in the synthesis of salts of type 303, 
although it was most suitable for simple and easily accessed imidazopyridine starting materials with 
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unhindered alkyl halides (Scheme 80).[128] Kunz and co-workers expanded this methodology to allow 
the synthesis of bidentate NHC precursors 305 and 306.[129] 
 
Scheme 80: Alkylations of imidazopyridines (Route A).
[128-129]
 
Lassaletta and co-workers also described a modified Vilsmeier-Haack reaction (Scheme 79: 
route B), which allowed direct formation of the imidazolium ring onto pyridines or quinolines, with a 
range of N-substituents having been prebuilt into the formamide moiety (Scheme 81).[128] Where 
necessary, the resulting imidazolium chlorides 308 could also be converted to their respective PF6 
salts 309. Variations on this technique have recently been described in which triflate salts such as 311 
were synthesised from the same starting materials by using triflic anhydride, leading to a reduction in 
the required reaction temperature compared to the use of phosphoryl chloride.[130] 
 
Scheme 81: Synthesis of imidazolium rings from formamides (Route B).
[128,130b]
 
Glorius and co-workers introduced the final method, (Scheme 79: route C), where 
iminopyridines 313 were treated with chloromethyl pivalate (Scheme 82).[131] Suzuki couplings could 
be carried out using one of these products 315, allowing significant variation at the substituent close 
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to the masked carbene through a divergent route. It is noteworthy that 316b appeared to exist as a 
mixture of two atropisomers, however attempts to separate these were unsuccessful. The 
combination of chloromethyl pivalate and silver(I) triflate has since been employed to produce 
optically active derivates 318,[132] and the first thiazole-annulated imidazolium salt 320.[133] 
Scheme 82: Synthesis of imidazolium rings using chloromethyl pivalate (Route C).
[131-133]
 
The formation of monocyclic imidazolium salts 321 from bisimines 322 is typically carried out 
using formaldehyde and acid (Scheme 83).[134] The use of iminopyridines 301 as bisimine equivalents 
is attractive, as these can be readily prepared from picolinaldehydes, and the application of this 
route to the synthesis of imidazopyridinium salts and their derivatives has become relatively 
common, such as in the synthesis of 325 and 328.[135] A one-pot procedure for the rapid construction 
of the imidazolium ring from picolinaldehyde derivatives 329 and primary amines has also been 
developed,[136] this strategy was later applied to the synthesis of bidentate NHC precursor 332.[137] 
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Scheme 83: Construction of imidazolium rings using formaldehyde (Route C).
[135-137]
 
4.1.2: Isolation of Resulting Carbenes 
Many NHCs are stable enough to be handled under an inert atmosphere, some even at high 
temperatures.[138] Lassaletta’s imidazolium salts 333 provided the first precursors for isolation and 
characterisation of free carbenes fused to an aromatic system.[128] Interestingly, the presence of an 
ortho-substituent on the pyridine ring was essential to confer room-temperature stability on 
carbenes 334, perhaps to prevent dimerization, however this problem was avoided by Kunz and 
co-workers by handling 336 at low temperature.[139] 
 
Scheme 84: Isolation of free carbenes.
[128,139]
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4.1.3: Applications as Ligands 
Many of the azolium salts described above were subsequently transformed into their respective 
NHC-metal complexes. The impact of a substituent next to the ring junction was first described by 
Glorius and co-workers, where the X-ray structure of iridium complex 328 showed secondary 
interactions between the metal and the proximal benzene ring (Scheme 85).[131] Additionally, of the 
ligands described in this work, the palladium complex generated in situ from the most sterically 
demanding imidazolium salt 316b was the most effective in the Suzuki coupling of a hindered aryl 
chloride 329. 
Recently the Lassaletta group reported the synthesis of silver(I) complex 334, alongside 
several gold, silver and copper complexes featuring related ligands.[140] In 334, large substituents, 
both adjacent to the ring junction and on the other nitrogen of the NHC resulted in, by one measure, 
the most sterically crowded monodentate NHC-metal complexes described to date (for discussion of 
the percentage buried volume (%Vbur) method see page 106). 
 
Scheme 85: Use of imidazolylidenes with bulky substituents next to the ring junction.
[131,140]
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The use of appropriate substitution next to the ring junction can also allow the design of 
multidentate ligands such as those featured in 335,[141] 336,[135c] and 337[137] (Figure 11). In each case 
the N–M bond length suggested a relatively weak interaction (for comparison a (1,10-
phenanthroline)Cu(I) complex related to 335 had average N–Cu bond lengths of 2.05 Å).[141] 
 
Figure 11: Metal complexes featuring multidentate ligands.
[135c,137,141]
 
Many of the more interesting applications of these ligands are in asymmetric transition metal 
catalysis. There has been considerable interest in the copper-catalysed hydroboration of enones 338. 
The results of several successful attempts at this reaction are summarised in Table 6, however it 
must be noted that differences in the conditions used and substrates tested makes direct 
comparison difficult. Among the most successful chiral ligands employed in this process are 341[142] 
and 296,[124d] investigated by the Hoveyda and McQuade groups respectively. However results with 
the imidazopyridine-derived carbene 342a were similarly impressive; interestingly it proved 
significantly more selective than the less sterically demanding ligand 342b.[143] The authors proposed 
a model for this selectivity where the key intermediate 344 was disfavoured compared to 345 due to 
interactions between the alkene’s substituents and bulky parts of the ligand (specifically the methyl 
group on the pyridine unit and tert-butyl group on the oxazoline, Figure 12). The β-pinene-derived 
carbene 343 was also investigated by Wang and co-workers, for which a modest enantioselectivity 
was observed.[135d] 
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Table 6: Asymmetric β-borylation of enones catalysed by (NHC)Cu(I) complexes. 
 
Entry Ligand R1 R2 R3 
Average Yield 
(best yield) 
Average ee 
(best ee) 
Ref. 
   1[a] 341 Ar or alkyl Me or Et Ph, Me, OEt or SEt 83% (98%) 83% (99%) [142] 
   2 296 Ar or alkyl H OAlkyl 91% (95%) 91% (96%) [124d] 
   3[b] 342a Ar or alkyl H OAlkyl 85% (95%) 92% (97%) [143] 
   4 343 Ph H OEt 72% 62% [135d] 
[a]: The lower average yields and enantioselectivities for Entry 1 must be set against the wider substrate scope 
which was investigated in this work. [b]: The products 340 were oxidised to their respective alcohols using 
NaBO3·4H2O before determination of the yield and enantioselectivity. 
 
 
 
Figure 12: Selectivity model for Cu(I)-catalysed β-borylation of enones using ligand 342a.
[143]
 
The Fernández and Lassaletta groups have investigated several chiral NHCs with N-linked 
thioethers as C-S ligands in transition metal catalysis.[144] Palladium complex 346 showed promising 
enantioselectivity in an allylic substitution reaction to form 347 (Scheme 86),[144b] however an 
enantioexcess of 98.5% for this reaction was reported in 1993 using a bidentate chiral oxazoline 
based N-P ligand.[145] 
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Scheme 86: Allylic substitution of 1,3-diphenylpropenyl acetate with dimethyl malonate.
[144b]
 
A particularly exciting new ligand scaffold was recently reported by Lassaletta and 
co-workers. The ligand 351 employs a triazolylidene fused to an isoquinoline bearing a naphthyl 
substituent, placing the metal in a rigid chiral pocket (Scheme 87).[146] (351)AuCl was an impressive 
precatalyst for the enantioselective Diels-Alder reaction of allenamide 355, outperforming several 
gold complexes bearing NHCs 352-354 which have been successful in other areas (Table 7).[147] 
 
Scheme 87: Top: Synthesis of an axially chiral gold complex. Bottom: Other chiral ligands used for 
comparison.
[146]
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Table 7: Catalyst performance in the enantioselective Diels-Alder reaction of an allenamide. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Minor optimisation of the reaction conditions allowed a family of products 362 to be 
synthesised in good yields with excellent enantioselectivities (Scheme 88). 
 
Scheme 88: Optimised conditions for the enantioselective Diels-Alder reaction of allenamides. 
4.1.4: Conclusion 
NHCs fused to additional aromatic rings (usually a pyridine derivative) have increased in prominence 
since the introduction of convenient methods for their synthesis from 2005.[128,131] Their planar 
geometry forces substituents ortho to the ring junction to sit alongside the carbene and any metals 
to which it is bound; this allows the design of ligands with versatile and predictable rigid steric 
environments.  
The results and discussion section of this chapter describes efforts to synthesise novel 
imidazolium salts which are fused to oxazoles, and their respective metal complexes. The ligands’ 
(NHC) Yield ee 
351 81% 90% 
352 76% 23% 
353 51% 24% 
354 91% 16% 
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steric and electronic properties have been quantified, and a preliminary study of their reactivity has 
been investigated in the gold-catalysed hydration of an unsymmetrical alkyne. 
4.2: Results and Discussion 
4.2.1: Ligand Design 
Given the convergent nature of the gold-catalysed oxazole synthesis it was envisioned that oxazole-
annulated imidazolium salts of the type 363.HX could be rapidly constructed from an appropriately 
highly functionalised oxazole 364 (Scheme 89). These salts could be converted into their respective 
NHC-metal complexes, in which the amide would be placed close to the metal, allowing the design of 
tuneable steric environments. Additionally, this would be the first example of an NHC fused to an 
oxazole, and would therefore potentially have interesting electronic properties which may be 
affected by varying the oxazole’s substituents. 
 
Scheme 89: Proposed route to oxazole-annulated NHCs. 
4.2.2: Synthesis of Imidazolium Salts 
As shown in the introduction to this chapter, there are several possible strategies for the annulation 
of imidazolium rings to nitrogen-containing heterocycles. In order to accomplish this from oxazoles, 
the first challenge was to incorporate appropriate functionality into the oxazole 2-position, which 
would require the synthesis of a similarly functionalised pyridine-N-aminide, and its use in gold 
catalysis. The relatively low nucleophilicity of the oxazole nitrogen, in comparison to that of pyridines 
(on which the annulation of imidazolium rings has most often been demonstrated) was also a 
potential issue. 
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4.2.2.1: Attempted synthesis of imidazolium salts from anilines 
The first route to an imidazolium salt of type 363.HX investigated was to attempt the annulation of 
the imidazolium ring onto an oxazole tethered to a secondary amine or aniline 365, which would be 
derived from an ylide of type 366 (Scheme 90). 
 
Scheme 90: Route to an imidazolium salt using an oxazole tethered to an amine or aniline. 
Previous attempts to access ylide 94h, bearing a secondary amine, gave an impure product 
which could not be used in gold catalysis (Chapter 1 – Scheme 33 and 35). In contrast, the use of a 
bulky aniline, which was ideal for incorporation into NHCs, was significantly more successful. The 
synthesis of ylide 94p in two steps from commercially available reagents proved straightforward 
(Scheme 91). Pleasingly this unprotected aniline was tolerated by the gold-catalysed oxazole 
formation, providing a rapid route to oxazole 151m. 
 
Scheme 91: Synthesis of an oxazole tethered to an aniline. 
Heating oxazole 151m with triethylorthoformate and acid led to the formation of a small 
amount of precipitate, however this was mostly composed of formamide 371a, and none of the 
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desired imidazolium salt 363a.HX was observed (Scheme 92). The formation of 371a shows that the 
initial reaction of the aniline with HC(OEt)3 occurs, however it is not followed by the desired 
formation of the second N–C bond. 
 
Scheme 92: Reaction of the aniline-tethered oxazole with CH(OEt)3. 
The use of trialkylorthoformates in the synthesis of azolium salts is common,[134b] however 
the mostly closely related starting materials to oxazole 151m which have been employed in these 
reactions are hydrazines 374 (Scheme 93).[148] The construction of imidazolium rings from starting 
materials of general structure 376 has not been demonstrated, possibly due to the relatively low 
nucleophilicity of the nitrogen of the unactivated imine/heterocycle, a problem which would be 
exacerbated by using oxazoles. 
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Scheme 93: Examples of the use of trialkylorthoformates in the synthesis of azolium salts.
[134b,148]
 
Given the lack of reactivity of 151m, and that other routes with more encouraging literature 
precedent were available, no further experiments were carried out using this oxazole. 
4.2.2.2: Synthesis of imidazolium chloride salts from formamides 
Formamide-tethered oxazole 371 was an alternative type of substrate for the construction of 
oxazole-annulated imidazolium salts, which could be constructed from an ylide of type 378 (Scheme 
94). 
 
Scheme 94: Route to an imidazolium salt using an oxazole tethered to a formamide. 
Ester 147q was synthesised by formylation of 147p and allowed access to ylide 94q (Scheme 
95). Although the yield of 94q was moderate, this reaction was scaled up to give 2.75 g of this ylide, 
which would later allow access to several oxazoles. 
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Scheme 95: Route to ylide 94q. 
The formation of oxazoles 371a-b from ylide 94q was efficient using only 1.2 equivalents of 
the ylide and 2 mol% of the gold catalyst (Scheme 96). Although oxazoles of the type 371 could 
usually be purified, they were generally susceptible to slow degradation, and so were used within a 
couple of days of their purification. 
 
Scheme 96: Synthesis of an oxazole tethered to a formamide. 
Initial attempts to cyclise 371a with POCl3 following a literature procedure were 
unsuccessful,[128] with no reaction at 80 °C in toluene or on heating to reflux (Table 8 – entry 1). 
Presumably this was again because the nitrogen atom within the oxazole ring is significantly less 
nucleophilic than that of a pyridine. Raising the temperature to 165 °C did facilitate formation of 
363a.HCl (Entry 2), however this could not be adequately purified despite repeated attempts at 
column chromatography and recrystallisations. Attempts to use impure 363a.HCl as an NHC 
precursor led to the formation of a similarly impure copper complex. Oxazole 371b was next 
investigated as a starting material in the hope that modifying the substrate would facilitate 
Chapter 4 
97 
 
purification of the products. It was found that an intermediate temperature of 140 °C gave much 
cleaner conversion of the oxazole to the imidazolium salt (Entry 3), a method that was generally 
applicable to other substrates (see below), however 363b.HCl also could not be completely purified. 
Table 8: Formation of the imidazolium ring from formamides 
 
Entry 371 Reagent Solvent Temperature Time X Yield 
1 371a POCl3 toluene 80 or 110 °C 24 h Cl NR 
2 371a POCl3 mesitylene 165 °C 3 days Cl <56% (impure) 
3 371b POCl3 m-xylene 140 °C 3 days Cl <95% (impure) 
4 371b Tf2O/NEt3 CH2Cl2 0→40 °C 24 h OTf 0% 
5 371b Tf2O/NEt3 1,4-dioxane 100 °C 24 h OTf trace 
6 371b Tf2O/NEt3 toluene 110 °C 24 h OTf 0% 
 
This purification issue for related ammonium/azolium.HCl salts formed by POCl3-mediated 
reactions has also by the Alder and Organ groups, with the suggestion that contamination may be 
due to the presence of one or more phosphorus-containing anions.[130a,149] In an attempt to exchange 
these anions, the impure 363.HCl salts were treated with Dowex® 22 chloride anion exchange resin. 
Despite subsequent reports of the use of this resin as part of the purification protocol in the 
synthesis of imidazo[1,5-a]pyridinium salts using POCl3 (such as 333, Scheme 85),
[140] it had no 
observable effect in this case. 
Triflic anhydride, which has been used in place of POCl3 in a related reaction and allowed a 
significant reduction in the required reaction temperature (Scheme 81),[130b] was investigated for the 
synthesis of 363b.HOTf, however only trace amounts of product were observed using this reagent, 
even at 110 °C (Table 8 – entries 4-6). As a more successful protocol had by this point been 
established (see below), no further attempts were made at the synthesis of imidazolium triflate salts. 
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4.2.2.3: Synthesis of imidazolium hexafluorophosphate salts from formamides 
Although the synthesis of imidazolium hexafluorophosphate salts by the salt metathesis of chloride 
salts following POCl3-mediated cyclisation of formamides was described in the original work of the 
Lassaletta group (Scheme 81),[128] these salts were not initially investigated due to the effect of 
changing the chloride ion to a PF6 ion on desired subsequent organometallic reactions (described 
below in Schemes 101 and 106). 
Applying this approach did however allow the highly crystalline salts 363a-d.HPF6 to be 
obtained, and their purity was established by elemental analysis (Scheme 97). To carry out the salt 
metathesis reaction, the 363.HCl salts were dissolved in boiling water and some insoluble material 
removed by filtration, following which the 363.HPF6 salts were precipitated by the addition of KPF6 to 
the filtrate and purified by recrystallisation from acetone/Et2O. Whilst the POCl3-mediated cyclisation 
was generally highly efficient, the necessity to carry out this second step led to a significant drop in 
yield in all cases. Addition of larger apolar groups to the sulfonamide as in 363c-d was particularly 
problematic, due to the lack of water solubility of the 363.HCl salts, leading to a further reduction in 
yield. It is noteworthy that a 31P-NMR spectrum taken prior to the recrystallisation of 363b.HPF6 
showed several small resonances which were not due to the PF6 ion, providing evidence for the 
presence of phosphorus-containing impurities which arise from the reaction with POCl3.  
This method represents a highly convergent route to previously unknown oxazole-annulated 
imidazolium salts which could be explored as NHC precursors, it was also the only successful method 
found which allowed the purification of these compounds. 
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Scheme 97: Synthesis of NHC.HPF6 salts. 
4.2.2.4: Attempted synthesis of imidazolium salts from imines 
Given the initial difficulties in synthesising pure imidazolium salts using formamides, it was 
envisioned that 363.HX could instead be accessed from oxazoles which are tethered to an imine 380 
(Scheme 98). 
 
Scheme 98: Route to an imidazolium salt using an oxazole tethered to an imine. 
The synthesis of such an oxazole was initially attempted using ylide 94r, which could be 
formed from ester 383; however 94r was highly susceptible to imine hydrolysis, and material free of 
2,6-diisopropylaniline 368 could not be obtained (Scheme 99). No reaction of ylide 94r with ynamide 
84g occurred under gold catalysis, possibly due to catalyst poisoning by the aniline impurity. 
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Scheme 99: Synthesis of an oxazole tethered to an imine. 
Pleasingly the acetal-containing oxazole 151g described in Chapter 1 could be converted into 
the desired imine 151n in a quantitative yield (Scheme 99). Additionally, the synthesis of oxazole 
151g, using ylide 94j and ynamide 84g, could be followed by imine formation to give 151n in a 
one-pot procedure. Given the ease with which ylide 94j could be accessed, and the efficiency of 
subsequent steps, the synthesis of oxazole 151n is considerably more straightforward than that of its 
formamide bearing analogue 371a, despite the requirement of an extra late-stage synthetic 
operation. Additionally, 151n was not overly sensitive to imine hydrolysis and could be stored for 
several months without degradation. For these reasons, a route to imidazolium salts using this imine 
was highly attractive. Imine 151n also represents a potentially interesting bidentate ligand structure 
in its own right, although its use for this purpose was not investigated.[150] 
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Table 9: Attempted cyclisation of an imine tethered to an oxazole. 
 
Entry Reagent Solvent Temperature[a] X Yield 
1 379 MeCN 81 °C Cl 0% 
2 379 Ph2O 195 °C Cl 0% 
3 379, AgOTf CH2Cl2 40 °C OTf 0% 
4 379, AgOTf 1,4-dioxane 120 °C OTf 0% 
5 379, NaI MeCN 70 °C I 0% 
6 379, NaI, ZnCl2 MeCN 70 °C I 0% 
7 (CH2O)n, ZnCl2, HCl THF 60 °C Cl 0% 
8 (CH2O)n, TMSCl EtOAc 77 °C Cl 0% 
9 CH2I2 MeCN 100 °C I 0% 
10 CH2I2, 2AgOTf toluene 110 °C I 0% 
[a] Reactions above the normal boiling point of the solvent were carried out in a sealed tube. 
Several unsuccessful attempts at the formation of the imidazolium ring from 151n were 
made (Table 9). These included the use of chloromethyl pivalate 379 either on its own (Entries 1-2), 
or activated by AgOTf (Entries 3-4) or NaI (Entries 5-6), under literature conditions,[131,133] as well as at 
elevated temperatures. Paraformaldehyde[134a,135] (Entries 7-8) and CH2I2
[151] (Entries 9-10) were also 
trialled as the carbon donor without success. Generally the only isolable compounds from the 
reaction mixtures were the starting material 151n, and (in some cases) the products of imine 
hydrolysis. Following Hutt and Aron’s multicomponent reaction protocol from acetal 151g only 
resulted in the formation of imine 151n, even at elevated temperature (Scheme 100).[136a] 
 
 
Scheme 100: Unsuccessful formation of an imidazolium salt from acetal 151g. 
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Again the failure of these reactions to form the imidazolium ring despite success on other 
systems is attributed to the relatively low nucleophilicity of the oxazole nitrogen. In line with this 
hypothesis the chloroiminium species 384 generated by the treatment of 371a with POCl3 would be 
expected to be significantly more electrophilic than any of the intermediates 386 generated by the 
reactions described in Table 9 (Scheme 101). As such the reaction of oxazoles 371 with POCl3, 
followed by purification by anion exchange remained the only viable route to the desired NHC 
precursors. 
 
 
Scheme 101: Proposed mechanisms for the formation of the imidazolium ring. 
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4.2.3: Organometallic Complexes 
With the 363.HPF6 salts in hand, investigation of their conversion into NHC-metal complexes was 
undertaken, with the aim of examining the steric and electronic properties of the ligands, as well as 
their behaviour in catalysis. 
4.2.3.1: Synthesis of gold and copper complexes 
As the 363.HCl salts could not be purified, a commonly employed route for synthesising the desired 
(NHC)MCl complexes by transmetalation from (NHC)AgCl complexes was unavailable; treatment of 
NHC.HPF6 salts with Ag2O results in the formation of [(NHC)2Ag]PF6 complexes, which in turn give 
bis-NHC metal complexes following reaction with transition metal halides (Scheme 102).[152] 
 
 
Scheme 102: Anion effect in the general synthesis of NHC complexes by a common transmetalation route.
[152]
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Recent reports have shown that gold(I) and copper(I) NHC halide complexes of the type 
(NHC)MCl can be synthesised by direct treatment of imidazolium salts and the appropriate metal 
halides with K2CO3 at room or slightly elevated temperatures.
[153] Whilst following these procedures 
directly using the newly synthesised imidazolium salts resulted in the formation of complex mixtures, 
simply changing the base to NEt3 and extending the reaction time from one to sixteen hours allowed 
access to (363a)AuCl and (363c)AuCl in high yields, as well as (363a)CuCl in a reasonable yield. 
 
Scheme 103: Synthesis of (363)MCl complexes. 
The purity of all three metal complexes was established by elemental analysis and their 
structures were examined by single crystal X-ray diffraction (Figures 13-15). The X-ray structures 
show that the two non-oxazole substituents of the sulfonamide sit in a plane approximately 
perpendicular to that of the metal and the biaryl unit. No co-ordination from the sulfonamide to the 
metal is suggested as N–M interatomic distances are between 3.53 and 3.66 Å. There is little 
difference in the key bond lengths or angles in the two gold complexes, whilst the slightly decreased 
ligand–M and M–Cl bond lengths in (363a)CuCl are a possible reason for the more pronounced 
deviation from linearity in the C–M–Cl bond angle in the copper complex. 
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Figure 13: X-ray structure of (363a)AuCl. Ellipsoids drawn at 50% probability. C1–Au: 1.98 Å, Au–Cl: 2.28 Å,  
N2–Au: 3.65 Å. N1–C1–N3: 102.7°, N3–C1–Au: 129.5°, N1–C1–Au: 127.1°, C1–Au–Cl: 175.8°. 
 
Figure 14: X-ray structure of (363c)AuCl. Ellipsoids drawn at 50% probability. C1–Au: 1.97 Å, Au–Cl: 2.28 Å,  
N2–Au: 3.66 Å. N1–C1–N3: 102.6°, N3–C1–Au: 129.4°, N1–C1–Au: 127.9°, C1–Au–Cl: 177.7°. 
 
Figure 15: X-ray structure of (363a)CuCl co-crystallised with a molecule of CDCl3. Ellipsoids drawn at 50% 
probability. C1-Cu: 1.88 Å, Cu–Cl: 2.11 Å, N3–Cu: 3.53 Å. N1–C1–N2: 102.0°, N1–C1–Cu: 131.7°,  
N2–C1–Cu: 126.2°, C1–Cu–Cl: 173.3°. 
                                                          
X-ray data for (363a)AuCl and (363c)AuCl was obtained by Dr Louise Male (University of Birmingham) whilst 
data for (363a)CuCl was obtained by the UK National Crystallography Service (University of Southampton), all 
structures were solved by Louise Male. 
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4.2.3.2: Calculation of percentage buried volume 
The most common method for measuring the steric bulk of NHC ligands is the percentage buried 
volume (%Vbur) method developed by the Cavallo and Nolan groups, which can also be used for other 
monodentate ligands (Figure 16).[154] This value can be generated using a set of Cartesian coordinates 
for the ligand and a calculator made freely available online by the Cavallo group.[155] The set of 
coordinates can be generated by DFT calculations but most commonly come from an X-ray structure 
of either the free ligand or one of its metal complexes. As the %Vbur is a property purely of the ligand, 
in the latter case the metal and any additional ligands must be deleted before running the 
calculation; however this can be advantageous as it leaves behind a ligand structure in a real 
conformation for metal coordination (note that the choice of metal and ancillary ligands can 
therefore affect the result). 
 
Figure 16: Representation of the %Vbur method reproduced from reference [154a]. 
For the calculation itself an imaginary metal is placed at a defined distance from the 
coordinating atom and a sphere of a defined radius placed around this. This sphere is divided into 
sections by a cubic mesh and each section is checked for whether its edges are within the Van der 
Waals radius of any atom of the ligand, if so the cube is assigned as buried, if not it is assigned as 
free, and from this the percentage buried volume is calculated. 
This calculation was carried out for ligands 363a and 363c using the crystal structures for 
their gold(I) chloride complexes, and compared against literature values for several common and 
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particularly bulky ligands (Figure 17).[140,156] Only literature examples also derived from (NHC)AuCl 
complexes were selected, where in all cases a bond distance of 2.0 Å and a sphere radius of 3.5 Å was 
employed. The values for 363a and 363c were 44.9% and 43.6% respectively; similar to the ligand IPr, 
which is one of the most commonly used NHCs in transition metal catalysis. This perhaps unexpected 
result, that by this measurement 363a is marginally more bulky than 363c, can be explained by the 
fact that the sulfonamide and its substituents lie on the edge and mostly outside of the standardly 
used 3.5 Å sphere. When the radius of this sphere was increased this relationship was reversed, 
illustrating the unavoidably arbitrary nature of such measurements (Table 10). 
 
Figure 17: Gold complexes from which the %Vbur has been calculated for NHCs – comparison of 363a and 
363c with some common and very bulky ligands from the literature. Parameters: sphere radius = 3.5 Å; 
distance from sphere = 2.0 Å; mesh spacing, = 0.05 Å; H atoms omitted; Bondi radii scaled by 1.17 Å.
[140,156]
 
Table 10: %Vbur for NHCs at various sphere radii (r) 
 %Vbur at r = 
Ligand 3.5 Å 4.0 Å 4.5 Å 5.0 Å 
IPr 44.5 46.8 47.8 47.2 
363a 44.9 45.6 45.1 43.5 
363c 43.6 45.8 46.8 46.7 
Parameters other than sphere radius are as in Figure 17. The values for IPr were calculated using a published 
X-ray structure for (IPr)AuCl: CCDC-258274.
[157]
 
Chapter 4 
108 
 
4.2.3.3: Impact of metal coordination on ligand flexibility 
It is apparent from the NMR spectra of (363a)AuCl, (363c)AuCl and (363a)CuCl that there is a 
loss of symmetry in the diisopropyl phenyl group on conversion of the imidazolium salts to their 
metal complexes. Due to restricted rotation in the isopropyl group, the 1H-NMR resonances in the 
imidazolium salts appear as one CH apparent heptet and two methyl doublets, but when the metal is 
coordinated these are separated into two CH apparent heptets and four methyl doublets (Figure 18). 
This effect is most pronounced in the spectra of (363a)CuCl and (363c)AuCl, however it can also be 
observed in (363a)AuCl despite there being considerably more overlap of the peaks. No coalescence 
of these resonances was observed when the 1H-NMR spectrum of (363a)AuCl was recorded at 
110 °C. The separation of the four methyl signals is also apparent in the 13C-NMR spectra of all three 
metal complexes. 
These observations can be explained by restriction of rotation around C–N bond at the 
oxazole C4 position upon coordination of the metal. This results in a racemic mixture of enantiomeric 
atropisomers, which no longer possess the plane of symmetry in the axis of the fused ring system, 
therefore rendering the two isopropyl groups diastereotopic (Scheme 104). Whilst slow 
interconversion of the atropisomers cannot be ruled out on the basis of these NMR experiments 
alone, the crystal structures of the metal complexes suggest there is little space for the required 
bond rotation to occur. 
 
 
Scheme 104: Enantiomers of (363a)AuCl. 
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Figure 18: Section of the 
1
H-NMR spectra of imidazolium salts 363a.HPF6 and 363c.HPF6 and their gold and 
copper complexes which show the desymmetrisation of the two isopropyl groups upon binding to a metal. 
363a.HPF6, d6-Acetone, 400 MHz, 22 °C
(363a)AuCl, d2-1,1,2,2-tetrachloroethane, 400 MHz, 30 °C
(363a)AuCl, d2-1,1,2,2-tetrachloroethane, 400 MHz, 110 °C
(363a)CuCl, CDCl3, 400 MHz, 22 °C
363c.HPF6, CDCl3, 400 MHz, 20 °C
(363c)AuCl, CD2Cl2, 400 MHz, 20 °C
residual 
d5-acetone
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The racemic mixture of enantiomers described in Scheme 104 was also apparent in the X-ray 
structures of these complexes. (363a)AuCl (Figure 13) and (363a)CuCl (Figure 15) were in 
centrosymmetric space groups with two molecules of each enantiomer present in the unit cell. 
(363c)AuCl (Figure 14) was in a chiral space group which was refined as an inversion twin with a 1:1 
mixture of enantiomers. 
 
Scheme 105: Attempted synthesis of chiral imidazolium salts. 
In order to assess whether this effect could be exploited in the synthesis of enantiomerically 
pure metal complexes, the synthesis of chiral imidazolium salts 363e-f.HPF6 was attempted. The 
respective chiral NHCs could potentially co-ordinate diastereoselectively to a metal, particularly in 
the case of 363e, where the rigid camphorsultam unit should significantly favour one conformation in 
the presence of a metal. Analytically pure samples of oxazoles 371e-f were not obtained due to their 
limited stability; however the formation of their respective imidazolium chloride salts appeared to 
proceed successfully. Unfortunately the effect which led to the reduced yield of 363c-d.HPF6, namely 
the lack of water solubility of imidazolium chlorides bearing large apolar groups at the oxazole C4 
position, was even more pronounced for these substrates, meaning that no 363e-f.HPF6 salts could 
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be obtained. Attempts to carry out the salt metathesis of 363e.HCl in acetonitrile were unsuccessful, 
as were attempts to purify the chloride salts by further chromatography or by recrystallisation. 
4.2.3.4: Attempted synthesis of a platinum complex from ligand 363d 
Given the low yield of 363d.HPF6, only enough was made for a single attempt at the synthesis of a 
metal complex. (363d)PtCl2 was targeted in order to assess whether any coordination between the 
N-allyl unit and the metal could be observed. Unfortunately, where an adapted literature procedure 
for this type of reaction was followed,[158] only a complex mixture, from which no (363d)PtCl2 could 
be isolated, was formed (Scheme 106). 
 
Scheme 106: Failed synthesis of (363d)PtCl2 
4.2.3.5: Synthesis of iridium complexes and their use in the electronic characterisation of ligands 
Attempts to quantify the electronic effect that NHCs have on metals are routinely reported in the 
literature, in order to lead to more accurate rationalisation of structure with catalytic activity. The 
various methods employed for electronic characterisation have been reviewed by Dröge and 
Glorius[159] and most recently by Nelson and Nolan.[160] 
Tolman’s Electronic Parameter (TEP) is the value for the symmetrical carbonyl stretching 
frequency in (L)Ni(CO)3 complexes.
[161] The synthesis of (NHC)Ni(CO)3 complexes is relatively rarely 
attempted due to the propensity of some ligands to instead form (NHC)Ni(CO)2 complexes, as well as 
the high toxicity of the volatile Ni(CO)4 starting material.
[162] By far the most common piece of 
electronic characterisation data available for NHCs in the literature comes from the infra-red spectra 
of (NHC)Ir(CO)2Cl or (NHC)Rh(CO)2Cl complexes. Work by the Nolan group has allowed extrapolation 
of TEP values using the spectra of these complexes (Figure 19).[160,162] 
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Figure 19: Nelson and Nolan’s equations for the correlation of the infrared stretching frequencies of metal 
carbonyl compounds used in the calculation of Tolman’s Electronic Parameter.
[160]
 av is the average 
wavenumber of the two CO stretches observed in the iridium or rhodium complexes. 
A lower TEP value is indicative of more M→CO π* back-bonding, and so more electron-
donation from the ligand to the metal. Criticisms of the TEP method are that a relatively low range of 
values is obtained in comparison to the sensitivity of the experiment,[163] and that secondary orbital 
interactions directly between the ligand under investigation and the CO being measured may affect 
the results,[164] however it is the most commonly employed measurement for the electronic 
characterisation of NHCs. 
The required iridium or rhodium complexes are usually accessed from their respective 
(NHC)M(cod)Cl complexes (cod = 1,5-cyclooctadiene), which can be readily synthesised from an 
imidazolium chloride salt and the required [M(cod)Cl]2 species by treatment with sodium or 
potassium tert-butoxide (Scheme 107).[162] There is again an anion effect in these reactions, for 
example where the above procedure was followed by Lassaletta and co-workers using 390.HPF6, the 
resulting product was the bis-NHC complex [(390)2Rh(cod)]PF6, attributed to the chloride scavenging 
ability of potassium ions.[128] A solution to this problem was demonstrated by the same group in the 
synthesis of (391)Rh(cod)Cl from the more acidic triazolium salt 391.BF4 by using triethylamine as the 
base.[165] 
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Scheme 107: Effect of the choice of base and counterion on reactions of azolium salts with 
[Rh(cod)Cl]2.
[128,165]
 
The measurement of a TEP value for NHCs 363a-b would allow a comparison with those in 
the literature, and would show whether there was any measurable impact on the electronic donating 
ability of the ligands by substitution at the oxazole 5-position. As shown in Figure 19, TEP values can 
be estimated by extrapolation of the average value for the two C≡O stretching frequencies in 
(L)Ir(CO)2Cl complexes onto the scale for nickel, whilst when rhodium complexes are used an extra 
extrapolation of rhodium to iridium is first carried out. 
As such, (363a-b)Ir(CO)2Cl were targeted. Surprisingly no reaction was observed between 
363a.HPF6 and [Ir(cod)Cl]2 in the presence of NEt3 (Scheme 108). An alternative procedure was 
carried out inside a nitrogen-filled glovebox: the imidazolium salts were treated with NaOtBu and the 
sodium salts removed by filtration, to give solutions containing the free carbenes 363a or 363b, 
which were added to the [Ir(cod)Cl]2. After stirring for one hour the reactions were removed from 
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the glovebox, and following column chromatography of the (363)Ir(cod)Cl complexes, these were 
treated with CO to give the desired complexes (363a-b)Ir(CO)2Cl. 
 
Scheme 108: Synthesis of (363a-b)Ir(CO)2Cl complexes. 
It is noteworthy that during the synthesis of (363b)Ir(cod)Cl a minor by-product with a 
characteristic red colour was also formed. Although this product could not be properly purified or 
characterised, the 1H-NMR spectrum was very similar to that of (363b)Ir(cod)Cl – with the notable 
difference that the N-methyl signal was replaced by an AB quartet which accounted for only two 
protons. This is indicative of a C–H insertion by the metal at this methyl group. Related 
intramolecular insertions into aliphatic C–H bonds for (NHC)Ir(III) complexes have been reported, and 
indicate that the formation of this minor product may have occurred by the reaction of 
(363b)Ir(cod)Cl with NaOtBu.[166] The propensity of these related cyclometalated compounds to 
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undergo elimination of HCl (or HI) following C–H insertion, allows a tentative assignment of the side-
product formed in the synthesis of (363b)Ir(cod)Cl as (363b’)Ir(cod) (Figure 20). 
 
Figure 20: Potential structure of a side-product formed in the synthesis of (363b)Ir(cod)Cl. 
The purity of the new (363a-b)Ir(CO)2Cl complexes was established by elemental analysis, 
however their 1H-NMR spectra showed three distinct sets of N-methyl and N-methylsulfonyl signals 
(the major one of which accounted for approximately 80% of the total in both cases). A likely 
explanation for this is that as well as the locked rotation around the oxazole C4–N bond, there is also 
some form of restricted rotation around the metal carbene bond. In the absence of crystallographic 
or high temperature NMR data it is difficult to say whether these different species should be properly 
referred to as rotamers or diastereoisomers. 
Despite the above observations only two sharp C≡O stretching frequencies were observed in 
the infra-red spectra of each iridium complex. It is essential that the IR spectra are recorded in CH2Cl2 
in order to compare these values with those in the literature; measurement in the solid state can 
lead to a difference of ~10 cm-1 compared to measurement in CH2Cl2.
[133] On comparing the newly 
synthesised iridium complexes the difference for each peak was only a fraction of a wavenumber, 
indicating no real effect of the methoxy group in 363b on the amount of electron density donated by 
the NHCs to the metal. 
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Figure 21: Comparison of estimated TEP values for 363a-b with those from the literature.
[128,133,162-163]
 In some 
cases TEP values estimated using iridium complexes have been used even where the exact value from 
(L)Ni(CO)3 complexes was available, so as to aid fair comparison of the ligands. 
Comparison of the TEP values for ligands 363a-b with those for related, common, and 
electronically diverse NHCs is given in Figure 21. The TEP values for the new ligands fall slightly 
towards the electron-deficient end, but well within the normal range for imidazolylidenes.  
Given the similarity between 363a and 363b, and the range of ligands available on either side 
of the TEP scale, it is unlikely that this route to NHCs could be used to produce a ligand that is either 
more or less strongly electron-donating than already available imidazolylidenes, however their 
unique structure may still lead to interesting outcomes in catalysis. 
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4.2.3.5: Gold-catalysed hydration of an unsymmetrical alkyne 
Nolan and co-workers have shown (IPr)AuX catalysts to be extremely efficient for the hydration of 
alkynes, even at very low catalyst loadings (Scheme 109).[167] Whilst terminal alkynes such as 132c 
reliably give methyl ketones, there is scope for improvement in the selectivity of hydration of 
unsymmetrical disubstituted alkynes such as 400. 
 
Scheme 109: Gold-catalysed hydration of unsymmetrical alkynes by Nolan and co-workers.
[167a]
 
For the hydration reactions illustrated in Scheme 109 there is a remarkably large difference 
in the catalytic activity of gold complexes bearing various NHCs, for example (IMes)AuCl does not 
catalyse this type of reaction at all.[156,167a] With this in mind, alkyne 404 was prepared and its 
hydration was carried out using (IPr)AuCl, (363a)AuCl and (363c)AuCl to test both the activity and 
selectivity of the new catalysts (Table 11). 
Table 11: Gold-catalysed hydration of an unsymmetrical alkyne. 
 
Entry NHC 
Combined 
yield 
405:406 
1 IPr 87% 1.0:1.0 
2 363a 76% 1.1:1.0 
3 363c 56% 1.8:1.0 
4 no gold NR - 
Isolated yield of a mixture of two isomers. Ratio determined by 
1
H-NMR spectroscopy following purification. 
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(IPr)AuCl was the most active precatalyst of the three, and the only one to consume all of the 
starting material. The yield then decreased as the ligand was varied from IPr to 363a to 363c. Analysis 
of the crude 1H-NMR spectra for these reactions showed that this reduction in yield could be entirely 
attributed to reduced conversion of starting material, rather than the presence of side-reactions. No 
reaction occurred in the absence of gold. 
Interestingly (IPr)AuCl showed no selectivity in the hydration of alkyne 404, perhaps 
indicating that the origin of the selectivity for the hydration of 400 is more steric than electronic, an 
effect that may well be diminished with 404. 363aAuCl and especially 363cAuCl did show some 
selectivity for the benzyl ketone 405 over the phenyl ketone 406, the same type of selectivity 
achieved by (IPr)AuCl in the hydration of 400. 
 
Scheme 110: Possible pathways in the gold-catalysed hydration of aryl-alkyl alkynes. 
DFT studies have shown that the attack of water onto gold-activated alkynes is both the rate- 
and product-determining step for this reaction, so large ligands on the metal may reduce catalytic 
activity, but may also increase selectivity by creating greater differentiation between the energies of 
409 and 411 (Scheme 110).[168] It is interesting to note that the order of selectivity (363c>363a>IPr) 
cannot be correlated with the percentage buried volume values for these NHCs (Table 10), showing 
that this measure of the steric demand of ligands is not always relevant to their behaviour in 
catalysis, as it does not take into account either their shape or symmetry. 
In the absence of a directing group or strong electronic activation within the substrate, the 
regioselective gold-catalysed hydration of aryl-alkyl alkynes remains an unsolved problem.[169] 
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4.2.4: Conclusion 
Investigation of several synthetic routes has allowed the highly convergent synthesis of the first 
imidazolium salts annulated to oxazoles. A current limitation of this approach is that if the 
imidazolium chloride salts generated by POCl3-mediated cyclisation are not water soluble, then their 
purification is challenging. 
Gold, copper and iridium NHC complexes have been prepared, allowing the steric and 
electronic characterisation of these ligands using the %Vbur and Tolman Electronic Parameter 
approaches respectively. The ligands have also been shown to be prochiral, due to a loss of rotational 
freedom upon metal binding. Finally, the gold complexes were successful in catalysing the hydration 
of an unsymmetrical alkyne, showing enhanced regioselectivity over the commonly used (IPr)AuCl, 
albeit with reduced activity. 
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5.1: Synthetic Procedures and Characterisation Data for all Compounds 
5.1.1: General Information 
Commercially available chemicals/reagents were purchased from major suppliers and used without 
further purification except where stated. All reactions were stirred using Teflon-coated magnetic 
stirrer bars. Where reactions are stated as being under an argon atmosphere, glassware was 
pre-dried using a heat gun at high vacuum and the solvents were dried as follows: CH2Cl2, THF, 
toluene, MeCN and MeOH using a Pure Solv-MD solvent purification system; DMF, 1,4-dioxane and 
m-xylene over 4 Å Linde type molecular sieves (activated by heating with a heat gun under high 
vacuum). The following cooling baths were used: 0 °C (ice/water), −10 °C (ice/NaCl) and −78 °C (dry 
ice/acetone). For reactions above room temperature pre-heated paraffin oil baths or metal heating 
blocks on stirrer hotplates were employed and the temperature was controlled using an external 
probe. Reactions were monitored by thin layer chromatography using Merck silica gel 60 F254 
(aluminium support) TLC plates which were developed using standard visualising agents: UV 
fluorescence (254 nm), potassium permanganate /Δ or vanillin /Δ. Flash column chromatography was 
carried out on silica gel except where the use of alumina is stated. Melting points were measured in 
open capillaries using a Stuart Scientific melting point apparatus and are uncorrected. Specific 
rotations were determined using a PolAAr 2001 instrument and are given in units of °dm-1g-1cm3 with 
concentrations (c) given in g / 100 cm3. Infra-red spectra were recorded using a Perkin-Elmer 
Spectrum 100 FTIR spectrometer using an ATR attachment; only selected absorbances (νmax) are 
reported. NMR spectra were recorded using Bruker AV300 or AVIII300 (1H = 300 MHz, 19F = 282 MHz, 
31P = 121 MHz) and Bruker AV400 or AVIII400 (1H = 400 MHz, 13C = 101 MHz) spectrometers in 
commercial, TMS free, deuterated solvents. Chemical shifts (δ) are given in ppm relative to TMS and 
are calibrated using residual solvent peaks.[170] 13C-NMR spectra were recorded using the UDEFT or 
PENDANT pulse sequences from the Bruker standard pulse program library. 13C DEPT spectra and 2D 
COSY, HSQC and HMBC spectra were recorded in order to assist with NMR assignment when 
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necessary. NMR spectra were processed using MestReNova software. Where NMR spectra are 
assigned for a mixture of two rotamers these are given in the format: “4.25 and 4.13 (s, 2H)” where 
the two chemical shift values correspond to one singlet from each rotamer and the sum total of their 
relative integrations is two. Mass spectra were obtained using Waters GCT Premier (EI), 
Waters LCT (ES) or Waters Synapt (ES) spectrometers. High resolution spectra used a lock-mass to 
adjust the calibrated mass scale. 
5.1.2: Precursors to Pyridine-N-Aminides 
Ester 147e 
Di-tert-butyl dicarbonate (2.74 g, 12.6 mmol) was dissolved in CH2Cl2 (40 mL) and 
NEt3 (4.4 mL, 31.6 mmol) and glycine methyl ester hydrochloride (1.97 g, 
14.1 mmol) were added successively. The suspension was stirred for 18 hours at room temperature. 
The reaction mixture was cooled to 0 °C and then transferred to a separating funnel and washed with 
ice-cold 0.5 M HCl(aq) solution (2 x 50 mL). The organic phase was dried over Na2SO4 and concentrated 
under reduced pressure to give carbamate 147e as a colourless oil (2.34 g, 92%); IR (neat): ν = 3371, 
2979, 1753, 1697, 1513, 1367, 1207, 1156, 1056 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 5.00 (br s, NH), 
3.92 (d, J = 5.6 Hz, 2H), 3.75 (s, 3H), 1.45 (s, 9H); 13C-NMR (101 MHz, CDCl3): δ = 170.9 (C), 155.8 (C), 
80.0 (C), 52.2 (CH3), 42.3 (CH2), 28.3 (3CH3). Spectroscopic data matched those reported.
[171] 
Ester 147f 
Following a literature procedure[171] solutions of NaHCO3 (840 mg, 10.0 mmol) in 
H2O (15 mL) and di-tert-butyl dicarbonate (2.19 g, 10.0 mmol) in CHCl3 (5 mL), and 
NaCl (2.00 g), were added to a suspension of alanine methyl ester hydrochloride (1.41 g, 10.0 mmol) 
in CHCl3 (15 mL). The biphasic solution was stirred vigorously at reflux for 2 hours. After cooling to 
room temperature, the reaction mixture was extracted with CHCl3 (2 x 15 mL). The combined organic 
fractions were washed with water (20 mL), dried over Na2SO4, concentrated under reduced pressure 
and purified by flash column chromatography (4:1 hexane:EtOAc) to yield carbamate 147f as a white 
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solid (1.38 g, 67%); mp: 25-26 °C (lit.[172] 31-33 °C); IR (neat): ν = 3361, 2980, 1743, 1696, 1514, 1366, 
1160, 1068 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 5.04 (br s, NH), 4.37-4.24 (m, 1H), 3.73 (s, 3H), 1.43 
(s, 9H), 1.37 (d, J = 7.2 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ = 174.0 (C), 155.2 (C), 80.0 (C), 52.5 
(CH3), 49.3 (CH), 28.5 (CH3), 18.8 (3CH3), 99% ee (HPLC trace and conditions given on page 208); 
Spectroscopic data matched those reported.[173] 
Ester 147g 
Adapted from a literature procedure[174] trans-cinnamic acid (742 mg, 
5.0 mmol), MeCN (15 mL) and NEt3 (700 µL, 5.0 mmol) were added to a 
flask under an atmosphere of argon and cooled to −10 °C. Isobutyl chloroformate (650 µL, 5.0 mmol) 
was added over 2 minutes and the resulting mixture was stirred for 5 minutes. MeCN (15 mL), 
NEt3 (700 µL, 5.0 mmol) and glycine methyl ester hydrochloride (628 mg, 5.0 mmol) were then added 
before the reaction mixture was allowed to warm to room temperature and stirred for 20 hours. The 
solvent was removed under reduced pressure and the resulting residue was taken up in satd. 
NaHCO3(aq) solution (20 mL) and extracted with CH2Cl2 (3 x 20 mL). The combined organic fractions 
were dried over Na2SO4, concentrated under reduced pressure and purified by flash column 
chromatography (1:1 EtOAc:Hexane) to give ester 147g as a white solid (785 mg, 72%); mp: 82-83 °C; 
IR (neat): ν = 3242, 3061, 2945, 1746, 1655, 1616, 1544, 1200, 1178, 1046, 967, 857 cm-1; 
1H-NMR (300 MHz, CDCl3): δ = 7.63 (d, J = 15.7 Hz, 1H), 7.49-7.42 (m, 2H), 7.37-7.28 (m, 3H), 
6.66 (br t, NH), 6.51 (d, J = 15.7 Hz, 1H), 4.18 (d, J = 5.3 Hz, 2H), 3.75 (s, 3H); 
13C-NMR (101 MHz, CDCl3): δ = 170.7 (C), 166.2 (C), 141.8 (CH), 134.7 (C), 129.9 (CH), 128.9 (2CH), 
128.0 (2CH), 119.9 (CH), 52.5 (CH2), 41.5 (CH3); HRMS (EI): m/z calculated for C12H13NO3: 219.0895, 
found 219.0893 (M)+. 
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Ester 147h 
Following a literature procedure,[175] methyl bromoacetate (475 µL, 5.0 mmol), 
THF (5 mL), NEt3 (1.4 mL, 10.0 mmol) and benzylamine (570 µL, 5.2 mmol) were 
added sequentially to a flask and the reaction mixture was stirred for 20 hours at room temperature. 
The precipitate was removed by filtration and the filtrate was concentrated under reduced pressure 
and purified by flash column chromatography (33→50% EtOAc in hexane) to give amine 147h as a 
colourless oil (508 mg, 56%); IR (neat): ν = 3337, 1737, 1454, 1436, 1196, 1178, 1139, 735, 698 cm-1; 
1H-NMR (300 MHz, CDCl3) δ = 7.38-7.23 (m, 5H), 3.84 (s, 2H), 3.73 (s, 3H), 3.44 (s, 2H), 2.39 (br s, NH); 
13C-NMR (101 MHz, CDCl3) δ = 172 .6 (C), 132.4 (C) 128.7 (2CH), 128. 6 (2CH), 127.5 (CH), 53.2 (CH2), 
52.0 (CH3), 49.7 (CH3). Spectroscopic data match those reported.
[176] 
Ester 147j 
Following a literature procedure,[177] TsOH·H2O (400 mg, 2.1 mmol) was added to a 
solution of glyoxylic acid monohydrate (2.00 g, 22 mmol) in trimethyl orthoformate 
(12 mL, 109 mmol) and the mixture was stirred for 3 hours at room temperature. K2CO3 (400 mg, 
2.9 mmol) was added and stirring was continued for 0.5 hours before isolation of the product by 
distillation directly from the reaction flask (b.p. 63-64 °C at 25-28 mbar [lit.[177] 64-67 °C at 27 mbar], 
note that a solvent-containing fraction was collected at 25-28 mbar at room temperature prior to 
collection of the product fraction) to give ester 147j as a clear oil (2.07 g, 71%); IR (neat) ν = 3005, 
2955, 2839, 1750, 1440, 1226, 1195, 1116, 1065, 1017, 981, 913, 800 cm-1; 1H-NMR (300 MHz, CDCl3) 
δ = 4.83 (s, 1H), 3.81 (s, 3H), 3.42 (s, 6H); 13C-NMR (101 MHz, CDCl3) δ = 167.7 (C), 99.0 (CH), 54.1 
(2CH3), 52.6 (CH3). Spectroscopic data match those reported.
[177] 
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Ester 147l 
Quinaldic acid (866 mg, 5.0 mmol), MeOH (10 mL) and H2SO4 (500 µL, 
9.3 mmol) were added to a flask and the reaction mixture was heated at reflux 
for 18 hours. After cooling to room temperature, the reaction mixture was concentrated under 
reduced pressure and partitioned between satd. NaHCO3(aq) solution (20 mL) and CH2Cl2 (20 mL). 
Following separation of the two layers the aqueous phase was extracted with CH2Cl2 (2 x 10 mL) and 
the combined organic fractions were dried over Na2SO4 and filtered through a 5 cm pad of silica gel 
(eluting with CH2Cl2). Concentration of the filtrate under reduced pressure afforded ester 147l as a 
white solid (562 mg, 60%); mp: 80-81 °C (lit.[178] 79-80 °C); IR (neat): ν = 2953, 1710, 1449, 1317, 
1299, 1196, 1140, 1106, 772 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 8.35-8.27 (m, 2H), 8.20 (d, J = 8.5 
Hz, 1H), 7.92-7.85 (m, 1H), 7.79 (appt. td, J = 7.6, 1.4 Hz 1H), 7.65 (appt. td, J = 7.6, 1.4 Hz, 1H), 4.08 
(s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 166.1 (C), 148.1 (C), 147.7 (C), 137.5 (CH), 130.9 (CH), 130.4 
(CH), 129.5 (C), 128.8 (CH), 127.7 (CH), 121.2 (CH), 53.3 (CH3). Spectroscopic data matched those 
reported.[178] 
Ester 147m 
Thiophene-2-carboxylic acid (1.28 g, 10.0 mmol), MeOH (20 mL) and H2SO4 (1 mL, 
12.0 mmol) were added to a flask and the reaction mixture was heated at reflux for 
24 hours. After cooling to room temperature, satd. NaHCO3(aq) solution (30 mL) was added and the 
mixture was extracted with CH2Cl2 (2 x 20 mL), dried over Na2SO4 and concentrated under reduced 
pressure to yield ester 147m as an orange oil (1.20 g, 84%); IR (neat): ν = 2952, 1704, 1525, 1436, 
1416, 1360, 1286, 1259, 1093 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 7.81 (dd, J = 3.8, 1.1 Hz, 1H), 7.55 
(dd, J = 5.0, 1.1 Hz, 1H), 7.10 (dd, J = 5.0, 3.8 Hz, 1H), 3.89 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 
162.8 (C), 133.7 (C), 133.6 (CH), 132.5 (CH), 127.9 (CH), 52.3 (CH3). Spectroscopic data matched those 
reported.[179] 
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Ester 147n 
7-Azaindole-3-carboxylic acid (239 mg, 1.5 mmol), MeOH (5 mL) and H2SO4 (100 µL, 
1.9 mmol) were added to a flask and the reaction mixture was heated at reflux for 
14 hours. After cooling to room temperature, satd. NaHCO3(aq) solution (20 mL) was 
added and the mixture was extracted with CH2Cl2 (3 x 20 mL), dried over Na2SO4 and concentrated 
under reduced pressure to yield ester 147n as a pale orange solid (97.4 mg, 38%); mp: 204-205 °C; 
IR (neat): ν = 3105, 1689, 1526, 1311, 1163, 1049 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 12.05 
(br s, NH), 8.51 (dd, J = 7.9, 1.6 Hz, 1H), 8.41 (dd, J = 4.8, 1.5 Hz, 1H), 8.13 (s, 1H), 7.28 (dd, J = 7.9, 
4.8 Hz, 1H), 3.94 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 165.1 (C), 148.9 (C), 143.8 (CH), 131.8 (CH), 
130.7 (CH), 119.2 (C), 118.1 (CH), 107.4 (C), 51.4 (CH3); HRMS (ES): m/z calculated for C9H9N2O2: 
177.0664, found 177.0667 (M+H)+. 
Carbamate 262 
Benzyl chloroformate (700 µL, 4.6 mmol) was added to a suspension of glycine 
methyl ester hydrochloride (628 mg, 5.0 mmol) and NEt3 (1.4 mL, 10.0 mmol) in 
CH2Cl2 (30 mL). The reaction mixture was stirred for 15 hours at room temperature and then washed 
sequentially with 0.5 M HCl(aq) solution (20 mL) and brine (20 mL). The organic phase was dried over 
Na2SO4, concentrated under reduced pressure and purified by flash column chromatography 
(15→20% EtOAc in hexane) to give carbamate 262 as a clear oil (537 mg, 48%); IR (neat): ν = 3351, 
2954, 1706, 1524, 1276, 1207, 1054, 1005 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 7.43-7.28 (m, 5H), 
5.29 (br s, NH), 5.13 (s, 2H), 3.99 (d, J = 5.6 Hz, 2H), 3.75 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 170.6 
(C), 156.4 (C), 136.3 (C), 128.7 (2CH), 128.3 (2CH), 128.2 (CH), 67.3 (CH2), 52.5 (CH3), 42.8 (CH2). 
Spectroscopic data matched those reported.[180] 
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Sulfonamide 264 
4-Nitrobenzenesulfonyl chloride (2.21 g, 10 mmol) was added to a suspension of 
glycine methyl ester hydrochloride (1.25 g, 10 mmol) and NEt3 (2.8 mL, 20 mmol) 
in CH2Cl2 (75 mL). The reaction mixture was stirred for 18 hours at room temperature and then 
washed with 1 M HCl(aq) solution (100 mL). The organic phase was dried over Na2SO4 and 
concentrated under reduced pressure. The resulting residue was purified by recrystallisation from 
EtOAc to give sulfonamide 264 as a white solid (2.09 g, 76%); mp: 145-147 °C; IR (neat): ν = 3256, 
1727, 1528, 1348, 1334, 1311, 1225, 1157, 1130, 826, 735 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 8.37 
(d, J = 8.9 Hz, 2H), 8.06 (d, J = 8.9 Hz, 2H), 5.29 (br s, NH), 3.88 (s, 2H), 3.67 (s, 3H); 13C-NMR (101 
MHz, CDCl3): δ = 169.1 (C), 145.5 (C), 130.4 (C), 128.6 (2CH), 124.5 (2CH), 53.0 (CH3), 44.1 (CH2). 
Spectroscopic data matched those reported.[181] 
Sulfonamide 265 
para-Toluenesulfonyl chloride (3.80 g, 20 mmol) was added to a suspension of 
glycine methyl ester hydrochloride (2.70 g, 21.5 mmol) and NEt3 (6.0 mL, 43 mmol) 
in CH2Cl2 (120 mL). The reaction mixture was stirred for 20 hours at room temperature and then 
washed with 1 M HCl(aq) solution (100 mL). The organic phase was dried over Na2SO4, concentrated 
under reduced pressure to ca. 20 mL and filtered through a 5 cm pad of silica gel (eluting with 
CH2Cl2). Evaporation of the solvent under reduced pressure gave sulfonamide 265 as a white solid 
(4.49 g, 93%); mp: 87-88 °C (lit.[182] 89-91 °C); IR (neat): ν = 3273, 1727, 1338, 1350, 1318, 1250, 1160, 
1108. 1091, 809 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 7.75 (d, J = 8.2 Hz, 2H), 7.31 (d, J = 8.2 Hz, 2H), 
5.01 (br t, NH), 3.78 (d, J = 5.5 Hz, 2H), 3.64 (s, 3H), 2.43 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 169.4 
(C), 144.0 (C), 136.2 (C), 129.9 (2CH), 127.4 (2CH), 52.8 (CH3), 44.2 (CH2), 21.7 (CH3). Spectroscopic 
data matched those reported.[183] 
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Sulfonamide 271 
para-Toluenesulfonyl chloride (4.77 g, 25 mmol) was added to a suspension of 
alanine methyl ester hydrochloride (4.19 g, 30 mmol) and NEt3 (8.4 mL, 60 mmol) 
in CH2Cl2 (100 mL). The reaction mixture was stirred for 24 hours at room temperature and then 
washed sequentially with 2 M HCl(aq) solution (2 x 100 mL) and brine (100 mL). The organic phase was 
dried over Na2SO4, concentrated under reduced pressure and partially purified by flash column 
chromatography (20→30% EtOAc in hexane). The resulting oil was further purified by precipitation 
from tert-butyl methyl ether with hexane, yielding sulfonamide 271 as a white solid (2.85 g, 44%); 
mp: 90-92 °C (lit.[184] 94-95 °C); IR (neat): ν = 3226, 1731, 1438, 1363, 1336, 1226, 1164, 1135, 1091, 
991 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 7.72 (d, J = 8.1 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 5.16 (br d, J = 
8.5 Hz, NH), 4.05-3.92 (m, 1H), 3.54 (s, 3H), 2.42 (s, 3H), 1.38 (d, J = 7.2 Hz, 3H); 13C-NMR (101 MHz, 
CDCl3): δ = 172.8 (C), 143.8 (C), 136.9 (C), 129.8 (2CH), 127.4 (2CH), 52.7 (CH), 51.6 (CH3), 21.7 (CH3), 
20.0 (CH3). Spectroscopic data matched those reported.
[184] 
Sulfonamide 273 
para-Toluenesulfonyl chloride (4.77 g, 25 mmol) was added to a suspension of 
tryptophan methyl ester hydrochloride (6.55 g, 30 mmol) and NEt3 (8.4 mL, 
60 mmol) in CH2Cl2 (100 mL). The reaction mixture was stirred for 24 hours at 
room temperature and then washed with 2 M HCl(aq) solution (2 x 100 mL) and 
brine (100 mL). The organic phase was dried over Na2SO4, concentrated under reduced pressure, and 
recrystallised from MeOH to give sulfonamide 273 as a white solid (6.14 g, 66%); mp: 126-128 °C; 
IR (neat): ν = 3395, 3283, 1735, 1456, 1446, 1426, 1343, 1335, 1250, 1221, 1165, 1091, 741 cm-1; 
1H-NMR (300 MHz, CDCl3): δ = 8.09 (s, NH), 7.60 (d, J = 8.3 Hz, 2H), 7.43 (d, J = 8.1 Hz, 1H), 7.32 
(d, J = 8.1 Hz, 1H), 7.20-7.14 (m, 3H), 7.10-7.06 (m, 1H), 7.04-7.01 (m, 1H), 5.13 (br d, J = 8.9 Hz, NH), 
4.30-4.20 (m, 1H), 3.43 (s, 3H), 3.23 (d, J = 5.5 Hz, 2H), 2.37 (s, 3H); 13C-NMR (101 MHz, CDCl3): 
δ = 171.8 (C), 143.6 (C), 136.7 (C), 136.2 (C), 129.6 (2CH), 127.3 (C), 127.2 (2CH), 123.5 (CH), 
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122.3 (CH), 119.8 (CH), 118.7 (CH), 111.3 (CH), 109.2 (C), 56.1 (CH), 52.5 (CH3), 29.4 (CH2), 21.6 (CH3). 
Spectroscopic data matched those reported.[185] 
Ester 263a 
Under an argon atmosphere, allyl bromide (1.3 mL, 15 mmol) was added to a 
solution of ester 147e (1.90 g, 10 mmol) in DMF (20 mL). The reaction was 
cooled to 0 °C and NaH (60% dispersion, 600 mg, 15 mmol) was added in portions over 5 minutes. 
The reaction mixture was stirred for 6 hours at room temperature and then quenched by addition of 
1:1 H2O:satd. NH4Cl(aq) solution (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic 
phases were washed with brine (5 x 30 mL), dried over Na2SO4, concentrated under reduced pressure 
and purified by flash column chromatography (5→10% EtOAc in hexane) to give ester 263a as a 
colourless oil (750 mg, 33%); IR (neat): ν = 2978, 1754, 1696, 1397, 1367, 1247, 1200, 1164, 
1142 cm-1; NMR shows a mixture of two rotamers: 1H-NMR (300 MHz, CDCl3): δ = 5.86-5.70 (m, 1H), 
5.22-5.07 (m, 2H), 3.99-3.91 (m, 2H), 3.91-3.81 (m, 2H), 3.72 (s, 3H), 1.46 and 1.43 (s, 9H); 
13C-NMR (101 MHz, CDCl3): δ = 170.7 (C), 155.2 (C), 133.9 and 133.8 (CH), 117.8 and 117.0 (CH2), 
80.5 (C), 52.10 and 52.07 (CH3), 50.9 and 50.4 (CH2), 48.0 and 47.7 (CH2), 28.44 and 28.39 (3CH3). 
Spectroscopic data matched those reported.[186] 
Ester 263b 
Under an argon atmosphere, allyl bromide (200 µL, 2.3 mmol) was added to a 
solution of ester 262 (435 mg, 1.9 mmol) in DMF (5 mL). The reaction was 
cooled to 0 °C and NaH (60% dispersion, 85 mg, 2.1 mmol) was added in portions over 5 minutes and 
the mixture was stirred for 4 hours at room temperature. The reaction was quenched H2O (25 mL) 
and extracted with EtOAc (25 mL). The organic phase was washed with brine (2 x 25 mL), dried over 
Na2SO4, concentrated under reduced pressure and purified by flash column chromatography 
(9:1 EtOAc:hexane) to give ester 263b as a colourless oil (296 mg, 58%); IR (neat): ν = 2923, 2852, 
1752, 1702, 1455, 1407, 1240, 1204 cm-1; NMR shows a mixture of two rotamers in a ∼ 1:1 ratio: 
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1H-NMR (400 MHz, CDCl3): δ = 7.40-7.28 (m, 5H), 5.86-5.70 (m, 1H), 5.23-5.09 (m, 4H), 4.05-
3.91 (m, 2H), 3.74 and 3.66 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 170.3 (C), 136.6 (C), 133.3 and 
133.2 (CH), 128.6 (2CH), 128.2 (CH and C), 127.9 (2CH), 118.3 and 117.7 (CH2), 67.7 and 67.6 (CH2), 
52.3 and 52.2 (CH3), 51.0 and 50.6 (CH2), 48.0 and 47.6 (CH2); HRMS (ES): m/z calculated for 
C14H17NO4Na: 286.1055, found 286.1052 (M+Na)
+.  
5.1.2.1: General procedure for alkylation of sulfonamides (GP1) 
 
Following a literature procedure,[112] under an argon atmosphere a flask was charged sequentially 
with sulfonamide (1.0 eq.), K2CO3 (2.0 eq.), MeCN (0.1 M with respect to sulfonamide) and alkyl 
bromide (1.5 eq.). The reaction mixture was stirred for 18 hours at 70 °C and the volatiles were then 
removed under reduced pressure. The resulting solid was taken up in 1:1 EtOAc:H2O and the organic 
phase was separated, washed with brine, dried over Na2SO4 and concentrated under reduced 
pressure. The crude product was purified either by filtration through a 5 cm pad of silica gel eluting 
with CH2Cl2 or by flash column chromatography to give the alkylated sulfonamide. 
Ester 263c 
Following GP1 using sulfonamide 264 (960 mg, 3.5 mmol), K2CO3 (970 mg, 
7.0 mmol) and allyl bromide (450 µL, 5.2 mmol). Purification by flash column 
chromatography (20→25% EtOAc in hexane) gave ester 263c as a white solid (1.05 g, 95%); 
mp: 62-63 °C; IR (neat): ν = 3114, 2957, 1753, 1610, 1545, 1348, 1313, 1203, 1160 cm-1; 
1H-NMR (300 MHz, CDCl3): δ = 8.36 (d, J = 9.0 Hz, 2H), 8.05 (d, J = 9.0 Hz, 2H),  
5.71 (ddt, J = 16.9, 10.2, 6.5 Hz, 1H), 5.30-5.16 (m, 2H), 4.12 (s, 2H), 3.93 (d, J = 6.5 Hz, 2H), 
3.64 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 169.1 (C), 150.2 (C), 145.8 (C), 131.6 (CH), 128.8 (2CH), 
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124.3 (2CH), 120.8 (CH2), 52.5 (CH3), 50.9 (CH2), 46.9 (CH2); HRMS (ES): m/z calculated for 
C12H15N2O2S: 315.0651, found 315.0656 (M+H)
+. 
Ester 263d 
Following GP1 using sulfonamide 265 (1.80 g, 7.4 mmol), K2CO3 (2.04 g, 
14.8 mmol) and allyl bromide (960 µL, 11.1 mmol). Purification by filtration 
through a 5 cm pad of silica gel (eluting with CH2Cl2) gave ester 263d as a colourless oil (1.88 g, 89%); 
IR (neat): ν = 2924, 2853, 1753, 1338, 1157, 1092, 922 cm-1; 1H-NMR (300 MHz, CDCl3): δ =  
7.73 (d, J = 8.2 Hz, 2H), 7.30 (d, J = 8.2 Hz, 2H), 5.68 (ddt, J = 16.8, 10.4, 6.5 Hz, 1H), 5.22-5.12 (m, 2H), 
4.02 (s, 2H), 3.89 (d, J = 6.5 Hz, 2H), 3.63 (s, 3H), 2.43 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 
169.5 (C), 143.6 (C), 136.9 (C), 132.4 (CH), 129.7 (2CH), 127.5 (2CH), 120.0 (CH2), 52.2 (CH3), 
50.9 (CH2), 47.0 (CH2), 21.7 (CH3). Spectroscopic data matched those reported.
[186] 
Ester 263f 
Following GP1 using sulfonamide 271 (1.29 g, 5.0 mmol), K2CO3 (1.38 g, 
10 mmol) and allyl bromide (650 µL, 7.5 mmol). Purification by filtration 
through a 5 cm pad of silica gel (eluting with CH2Cl2) gave ester 263f as a colourless oil (1.44 g, 97%); 
αD
20 = −33.3 (CHCl3, c = 1.1); IR (neat): ν = 2988, 2953, 1740, 1337, 1154, 1090, 1071 cm
-1; 
1H-NMR (300 MHz, CDCl3): δ = 7.71 (d, J = 8.2 Hz, 2H), 7.28 (d, J = 8.2 Hz, 2H), 5.81 (ddt, J = 17.1, 10.2, 
6.1 Hz, 1H), 5.23-5.14 (m, 1H), 5.13-5.07 (m, 1H), 4.66 (q, J = 7.3 Hz, 1H), 3.98-3.77 (m, 2H), 
3.55 (s, 3H), 2.42 (s, 3H), 1.40 (d, J = 7.3 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ = 172.1 (C), 143.5 (C), 
137.3 (C), 135.2 (CH), 129.6 (2CH), 127.6 (2CH), 117.7 (CH2), 55.1 (CH), 52.2 (CH3), 48.2 (CH2), 
21.7 (CH3), 16.6 (CH3); HRMS (ES): m/z calculated for C14H19NO4SNa: 320.0932, found 320.0935 
(M+Na)+. 
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Ester 263g 
Following GP1 using sulfonamide 273 (1.86 g, 5.0 mmol), K2CO3 (1.38 g, 
10 mmol) and allyl bromide (650 µL, 7.5 mmol). Purification by flash column 
chromatography (20→50% EtOAc in hexane) gave ester 263g as a white solid 
(1.72 g, 83%); [α]D
20 = −10.5 (CHCl3, c = 1.2); mp: 82-84 °C; IR (neat): ν = 3392, 
1742, 1151, 1087 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 8.00 (s, NH), 7.68-7.53 (m, 3H), 
7.35 (d, J = 8.0 Hz, 1H), 7.23-7.06 (m, 5H), 5.76 (ddt, J = 17.0, 10.3, 6.3 Hz, 1H), 5.22-5.11 (m, 1H), 
5.84-5.67 (m, 1H), 4.90 (appt. t, J = 7.5 Hz, 1H), 4.05-3.84 (m, 2H), 3.48 (s, 3H), 3.46 (dd, J = 14.9, 
7.5 Hz, 1H), 3.15 (dd, J = 14.9, 7.5 Hz, 1H), 2.39 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 171.4 (C), 
143.3 (C), 137.3 (C), 136.2 (C), 135.0 (CH), 129.4 (2CH), 127.6 (2CH), 127.3 (C), 123.3 (CH), 122.3 (CH), 
119.7 (CH), 118.7 (CH), 117.9 (CH2), 111.3 (CH), 110.8 (C), 59.7 (CH), 52.0 (CH3), 48.4 (CH2), 26.8 (CH2), 
21.7 (CH3); HRMS (ES): m/z calculated for C22H24N2O4SNa: 435.1354, found 435.1347 (M+Na)
+. 
Ester 263h 
Following GP1 using sulfonamide 265 (1.00 g, 4.1 mmol), K2CO3 (1.14 g, 
8.2 mmol) and 4-bromo-1-butene (625 µL, 6.2 mmol). Purification by flash 
column chromatography (4:1 hexane:EtOAc) gave ester 263h as a colourless oil (672 mg, 55%); 
IR (neat): ν = 2924, 2852, 1753, 1337, 1209, 1155, 1091, 926 cm-1; 1H-NMR (300 MHz, CDCl3): 
δ = 7.71 (d, J = 8.2 Hz, 2H), 7.29 (d, J = 8.2 Hz, 2H), 5.69 (ddt, J = 17.1, 10.3, 6.8 Hz, 1H), 5.10-4.98 (m, 
2H), 4.06 (s, 2H), 3.62 (s, 3H), 3.30 (t, J = 7.4 Hz, 2H), 2.41 (s, 3H), 2.34-2.24 (m, 2H); 
13C-NMR (101 MHz, CDCl3): δ = 169.5 (C), 143.5 (C), 136.9 (C), 134.5 (CH), 129.6 (2CH), 127.5 (2CH), 
117.4 (CH2), 52.2 (CH3), 48.2 (CH2), 47.9 (CH2), 32.7 (CH2), 21.6 (CH3). Spectroscopic data matched 
those reported.[186] 
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Ester 263i 
Following GP1 using sulfonamide 265 (1.00 g, 4.1 mmol), K2CO3 (1.14 g, 8.2 
mmol) and 5-bromo-1-pentene (730 µL, 6.2 mmol). Purification by flash 
column chromatography (4:1 hexane:EtOAc) gave ester 263i as a colourless oil (722 mg, 56%); 
IR (neat): ν = 2923, 2852, 1754, 1339, 1207, 1156, 1091 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 7.71 (d, 
J = 8.2 Hz, 2H), 7.29 (d, J = 8.2 Hz, 2H), 5.74 (ddt, J = 17.0, 10.3, 6.6 Hz, 1H), 5.04-4.93 (m, 2H), 
4.04 (s, 2H), 3.63 (s, 3H), 3.22 (t, J = 7.4 Hz, 2H), 2.42 (s, 3H), 2.10-2.01 (m, 2H), 1.71-1.59 (m, 2H); 
13C-NMR (101 MHz, CDCl3): δ = 169.6 (C), 143.5 (C), 137.5 (CH), 136.8 (C), 129.7 (2CH), 127.5 (2CH), 
115.5 (CH2), 52.3 (CH3), 48.11 (CH2), 48.06 (CH2), 30.7 (CH2), 27.2 (CH2), 21.7 (CH3). Spectroscopic data 
matched those reported.[186] 
Ester 147p 
Adapted from a literature procedure,[187] methyl bromoacetate (950 µL, 
10 mmol) was added to a mixture of 2,6-diisopropylaniline (1.9 mL, 10 mmol) 
and NaOAc (821 mg, 10 mmol) in methanol (1.5 mL) and the reaction mixture 
was heated at 55 °C for 6 hours. After cooling to room temperature, the reaction mixture was filtered 
through cotton, concentrated under reduced pressure and purified by flash column chromatography 
(3:17 Et2O:hexane) to give ester 147p as a red oil (2.20 g, 88%); IR (neat): ν = 2961, 2870, 1742, 1621, 
1438, 1344, 1214 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 7.13-7.06 (m, 3H), 3.79 (s, 3H), 3.74 (s, 2H), 
3.28 (hept, J = 6.8 Hz, 2H), 1.25 (d, J = 6.8 Hz, 12H); 13C-NMR (101 MHz, CDCl3): δ = 172.5 (C), 
142.6 (C), 142.2 (2C), 124.1 (CH), 123.8 (2CH), 52.4 (CH2), 52.3 (CH3), 28.0 (2CH), 24.3 (4CH3); 
HRMS (EI): m/z: calculated for C15H23NO2: 249.1729, found 249.1727 (M)
+. 
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Ester 147q 
 
Methyl bromoacetate (6.0 mL, 63 mmol) was added to a mixture of 2,6-diisopropylaniline (11.6 mL, 
62 mmol) and NaOAc (6.0 g, 118 mmol) in methanol (9.3 mL) and the reaction mixture was heated at 
65 °C for 16 hours. After cooling to room temperature, satd. NaHCO3(aq) solution (100 mL) was added 
and the aqueous phase was extracted with CH2Cl2 (3 x 30 mL). The combined organic fractions were 
dried over Na2SO4 and concentrated under reduced pressure to give the crude ester 147p as a red oil. 
Formic acid (8.9 mL, 236 mmol) and Ac2O (7.9 mL, 84 mmol) were mixed for 1.5 hours at room 
temperature and this mixture was added to a solution of the crude ester 147p in CH2Cl2 (30 mL). The 
resulting reaction mixture was stirred for 16 hours at room temperature and 3 hours at 40 °C. After 
cooling to room temperature, satd. NaHCO3(aq) solution (200 mL) was added, the phases were 
separated and the aqueous phase was extracted with CH2Cl2 (2 x 30 mL). The combined organic 
phases were dried over Na2SO4, concentrated under reduced pressure and purified by flash column 
chromatography (10→20% EtOAc:hexane) to give ester 147q as a white solid (8.88 g, 52% over two 
steps); mp: 70-72 °C; IR (neat): ν = 2964, 2869, 1763, 1666, 1459, 1329, 1204 cm-1; 
1H-NMR (300 MHz, CDCl3): δ = 8.13 (s, 1H), 7.42-7.33 (m, 1H), 7.25-7.17 (m, 2H), 4.21 (s, 2H), 3.76 (s, 
3H), 3.23 (hept, J = 6.8 Hz, 2H), 1.21 (d, J = 6.8 Hz, 6H), 1.17 (d, J = 6.8 Hz, 6H); 13C-NMR (101 MHz, 
CDCl3): δ = 168.2 (C), 163.7 (CH), 148.0 (2C), 135.7 (C), 129.8 (CH), 124.7 (2CH), 52.4 (CH3), 49.9 (CH2), 
28.2 (2CH), 25.0 (2CH3), 24.2 (2CH3); HRMS (ES): m/z: calculated for C16H23NO3Na: 300.1576, found 
300.1578 (M+Na)+. 
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Imine 383 
Under an argon atmosphere Na2SO4 (500 mg, 3.5 mmol), 2,6-diisopropylaniline 
(950 µL, 5.0 mmol), ethyl glyoxylate (50% solution in toluene, 1.0 mL, 4.9 mmol) 
and toluene (10 mL) were added squentially to a 2-neck flask fitted with a reflux 
condenser and the reaction mixture was heated for 1 hour at 110 °C. After cooling to room 
temperature, the Na2SO4 was removed by filtration through cotton and the filtrate was concentrated 
under reduced pressure and purified by flash column chromatography (95:5:1 hexane:Et2O:NEt3) to 
give imine 383 as a yellow oil (1.16 g, 90%); IR (neat): ν = 2962, 2932, 2870, 1751, 1723, 1283, 1195, 
1032 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 7.64 (s, 1H), 7.17-7.12 (m, 3H), 4.44 (q, J = 7.1 Hz, 2H), 
2.84 (hept, J = 6.9 Hz, 2H), 1.43 (t, J = 7.1 Hz, 3H), 1.16 (d, J = 6.9 Hz, 12H); 13C-NMR (101 MHz, CDCl3): 
δ = 162.7 (C), 154.7 (CH), 146.9 (C), 136.7 (2C), 125.5 (CH), 123.2 (2CH), 62.2 (CH2), 27.9 (2CH), 
23.6 (4CH3), 14.2 (CH3); HRMS (ES): m/z: calculated for C16H24NO2: 262.1807, found 262.1812 (M+H)
+. 
5.1.3: Pyridine-N-Aminides 
Ylide 94c 
Following a literature procedure,[49] a solution of NaOH (10% in H2O, 100 mL) was 
cooled to 0 °C and N-aminopyridinium iodide (2.22 g, 10.0 mmol) was added. Once 
the N-aminopyridinium iodide had dissolved, benzoyl chloride (2.3 mL, 19.8 mmol) was added and 
the reaction mixture was stirred for 16 hours at room temperature and then extracted with CH2Cl2 (3 
x 50 mL). The combined organic phases dried over Na2SO4 and concentrated under reduced pressure 
to yield ylide 94c as a pale yellow solid (1.81 g, 91%); mp: 175-177 °C (lit.[49] 187-189 °C); 1H-NMR 
(300 MHz, CDCl3): δ = 8.86-8.79 (m, 2H), 8.19-8.12 (m, 2H), 7.92 (tt, J = 7.7, 1.3 Hz, 1H), 7.72-7.64 (m, 
2H), 7.46-7.38 (m, 3H). 13C-NMR (101 MHz, CDCl3): δ = 170.8 (C), 143.5 (2CH), 137.2 (C), 137.0 (CH), 
130.3 (CH), 128.1 (2CH), 128.0 (2CH), 126.1 (2CH); MS (EI): m/z = 198.3 (M+, 8%), 196.3 (100), 
120.6 (64) 78.7 (43). Spectroscopic data matched those reported.[49] 
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Ylide 94b 
N-Aminopyridinium iodide (497 mg, 2.2 mmol) and K2CO3 (650 mg, 4.7 mmol) 
were suspended in MeOH (15 mL), methyl chloroformate (350 µL, 4.53 mmol) was 
added and the reaction mixture was stirred for 3 days at room temperature. The MeOH was removed 
under reduced pressure and the residue was suspended in 95:5 CH2Cl2/MeOH and filtered through a 
5 cm pad of basic alumina. The filtrate was concentrated under reduced pressure to give ylide 94b as 
pink needles (323 mg, 95%); mp: 84-85 °C (lit.[49] 92-94 °C); 1H-NMR (300 MHz, CDCl3): δ = 8.88-8.83 
(m, 2H), 7.83 (tt, J = 7.7, 1.2 Hz, 1H), 7.64-7.58 (m, 2H), 3.75 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 
164.1 (C), 142.4 (2CH), 135.3 (CH), 126.0 (2CH), 51.9 (CH3); MS (EI): m/z = 152.1 (M
+, 27%), 121.0 (59) 
79.0 (100). Spectroscopic data matched those reported.[49] 
Ylide 94d 
Di-tert-butyl dicarbonate (1.09 g, 5.0 mmol), N-aminopyridinium iodide (1.00 g, 
4.5 mmol) and K2CO3 (1.37 g, 9.9 mmol) were suspended in MeOH (40 mL) and the 
reaction mixture was stirred for 3 days at room temperature. The MeOH was removed under 
reduced pressure and the residue was suspended in 95:5 CH2Cl2/MeOH and filtered through a 5 cm 
pad of basic alumina. The filtrate was concentrated under reduced pressure to give ylide 94d as a 
pale purple powder (816 mg, 93%); mp: 129-130 °C (lit.[188] 131 °C); IR (neat): ν = 3140, 3042, 2978, 
1608, 1472, 1361, 1279, 1148 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 8.90-8.85 (m, 2H), 7.75 (tt, J = 7.7, 
1.2 Hz, 1H), 7.59-7.51 (m, 2H), 1.54 (s, 9H); 13C-NMR (101 MHz, CDCl3): δ = 163.5 (C), 142.4 (2CH), 
134.6 (CH), 125.9 (2CH), 77.9 (C), 28.9 (3CH3); HRMS (ES): m/z calculated for C10H14N2O2Na: 217.0953, 
found 217.0943 (M+Na)+. 
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5.1.3.1: General procedure for synthesis of pyridine-N-aminides from esters (GP2) 
 
N-Aminopyridinium iodide (1.0 eq.) and K2CO3 (2.4 eq.) were suspended in MeOH (0.13 M with 
respect to N-Aminopyridinium iodide) and the methyl ester (1.2 eq.) was added. The reaction 
mixture was stirred for 3 days at room temperature at which point the MeOH was removed under 
reduced pressure and the residue was suspended in 9:1 CH2Cl2/MeOH and filtered through a 5 cm 
pad of basic alumina. The filtrate was concentrated under reduced pressure and, where necessary, 
purified by flash column chromatography or recrystallisation. 
Ylide 94e 
Following GP2 using N-aminopyridinium iodide (1.00 g, 4.5 mmol), K2CO3 
(1.49 g, 10.8 mmol) and ester 147e (1.02 g, 5.4 mmol). Purification by flash 
column chromatography (5→10% MeOH in CH2Cl2) yielded ylide 94e as a pale brown solid (694 mg, 
61%); mp: 164-166 °C; IR (neat): ν = 3233, 3036, 2970, 1713, 1582, 1542, 1471, 1363, 1269, 1244, 
1153, 934 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 8.71-8.63 (m, 2H), 7.92 (tt, J = 7.7, 1.2, Hz, 1H), 
7.70-7.61 (m, 2H), 5.35 (br s, NH), 3.92 (d, J = 4.8 Hz, 2H), 1.44 (s, 9H); 13C-NMR (101 MHz, CDCl3): δ = 
172.6 (C), 156.0 (C), 143.2 (2CH), 137.3 (CH), 126.2 (2CH), 79.1 (C), 44.2 (CH2), 28.6 (3CH3); 
HRMS (ES): m/z calculated for C12H18N3O3: 252.1348, found 252.1353 (M+H)
+. 
Ylide 94f 
Note: To avoid degradation, room temperature water baths should be used 
when evaporating solvent from this compound. Following GP2 using 
N-aminopyridinium iodide (666 mg, 3.0 mmol), K2CO3 (995 mg, 7.2 mmol) and ester 147f (732 mg, 
3.6 mmol). Purification by flash column chromatography (0→10% MeOH in CH2Cl2) yielded ylide 94f 
as a pale pink solid (550 mg, 69%); mp: 120-121 °C; [α]D
20 = −30.6 (c=1.2, CHCl3); IR (neat): ν = 3240, 
3043, 2972, 2923, 1698, 1585, 1540, 1475, 1247, 1169, 1067, 1012, 782 cm-1; 
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1H-NMR (300 MHz, CDCl3): δ = 8.71-8.65 (m, 2H), 7.93 (tt, J = 7.7, 1.3 Hz, 1H), 7.70-7.63 (m, 2H), 
5.49 (br d, NH), 4.42-4.26 (m, 1H), 1.51-1.42 (m, 12H); 13C-NMR (101 MHz, CDCl3): δ = 176.3 (C), 
155.4 (C), 143.2 (2CH), 137.3 (CH), 126.2 (2CH), 78.9 (C), 50.4 (CH), 28.6 (3CH3), 20.8 (CH3); 
HRMS (ES): m/z calculated for C13H19N3O3Na: 288.1324, found 288.1316 (M+Na)
+. 
Ylide 94g 
Following GP2 using N-aminopyridinium iodide (222 mg, 1.0 mmol), 
K2CO3 (346 mg, 2.5 mmol) and ester 147g (265 mg, 1.2 mmol). 
Purification by flash column chromatography (0→10% MeOH in CH2Cl2) yielded ylide 94g as a white 
foam (176 mg, 63%); IR (neat): ν = 3304, 3060, 1659, 1618, 1564, 1472, 1355, 1265, 1223, 1033, 
1223, 978, 730 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 8.71-8.63 (m, 2H), 7.93 (tt, J = 7.7, 1.3 Hz, 1H), 
7.70-7.64 (m, 2H), 7.61 (d, J = 15.7 Hz, 1H), 7.50-7.43 (m, 2H), 7.38-7.29 (m, 3H), 6.82 (br t, NH), 
6.50 (d, J = 15.7 Hz, 1H), 4.18 (d, J = 4.7 Hz, 2H); 13C-NMR (101 MHz, CDCl3): δ = 172.2 (C), 165.7 (C), 
143.2 (2CH), 140.5 (CH), 137.6 (CH), 135.2 (C), 129.6 (CH), 128.9 (2CH), 127.9 (2CH), 126.4 (2CH), 
121.2 (CH), 43.4 (CH2); HRMS (ES): m/z calculated for C16H16N3O2: 282.1243, found 282.1248 (M+H)
+. 
Ylide 94i 
Following GP2 using N-aminopyridinium iodide (444 mg, 2.0 mmol), K2CO3 (664 mg, 
4.8 mmol) and ethyl formate (200 µL, 2.5 mmol). Filtration was carried out using 
4:1 CH2Cl2/MeOH. Purification by flash column chromatography on neutral alumina (0→10% MeOH 
in CH2Cl2) gave ylide 94i as a red solid (130 mg, 53%); mp: 100-102 °C; IR (neat): ν = 3107, 3073, 3028, 
3012, 2949, 2817, 1620, 1581, 1567, 1473, 1355, 1265, 1241, 881, 773, 751 cm-1; 
1H-NMR (400 MHz, d6-DMSO): δ = 8.73 (d, J = 5.6 Hz, 2H), 8.19-8.12 (m, 1H), 7.90-7.84 (m, 2H), 
7.83 (s, 1H); 13C-NMR (101 MHz, d6-DMSO): δ = 164.2 (CH), 143.0 (2CH), 138.7 (CH), 126.8 (2CH); 
HRMS (ES): m/z calculated for C6H7N2O: 123.0558, found 123.0562 (M+H)
+. 
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Ylide 94j 
Following GP2 using N-aminopyridinium iodide (666 mg, 3.0 mmol), K2CO3 
(995 mg, 7.2 mmol) and ester 147j (486 mg, 3.6 mmol). Purification by flash 
column chromatography (100:0:1→90:10:1 CH2Cl2:MeOH:NEt3) yielded ylide 94j as a white powder 
(496 mg, 84%); mp: 90-92 °C; IR (neat): ν = 3110, 3086, 2968, 2926, 2832, 1617, 1600, 1568, 1467, 
1399, 1339, 1268, 1198, 1151, 1106, 1044, 983, 900, 851, 779, 749 cm-1; 1H-NMR (300 MHz, CDCl3): 
δ = 8.62-8.57 (m, 2H), 7.86 (tt, J = 7.7, 1.1 Hz, 1H), 7.64-7.55 (m, 2H), 4.76 (s, 1H), 3.39 (s, 6H); 
13C-NMR (101 MHz, CDCl3): δ = 170.7 (C), 142.9 (2CH), 137.6 (CH), 126.1 (2CH), 102.0 (CH), 
53.7 (2CH3); HRMS (ES): m/z calculated. for C9H13N2O3: 197.0926, found 297.0929 (M+H)
+. 
Ylide 94k 
Following GP2 using N-aminopyridinium iodide (444 mg, 2.0 mmol), K2CO3 
(665 mg, 4.8 mmol) and methyl picolinate (332 mg, 2.4 mmol). The filtration 
through basic alumina was carried out using 95:5 CH2Cl2/MeOH to give ylide 94k as a red solid 
(378 mg, 94%); mp: 178-181 °C (lit.[55a] 178-181 °C); IR (neat): ν = 3056, 3026, 1577, 1548, 1461, 1348, 
1338, 1186, 1186, 989, 909, 766, 749 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 9.00-8.90 (m, 2H), 8.76 
(appt. br s, 1H), 8.26 (appt. br d, J = 7.4 Hz, 1H), 7.99 (t, J = 7.5 Hz, 1H), 7.88 (appt. td, J = 7.7, 1.6 Hz, 
1H), 7.79-7.69 (m, 2H), 7.47-7.37 (m, 1H); 13C-NMR (101 MHz, CDCl3): δ = 169.4 (C), 154.7 (C), 
148.9 (CH), 143.6 (2CH), 137.5 (CH), 137.1 (CH), 126.2 (2CH), 125.0 (CH), 123.5 (CH); HRMS (ES): m/z 
calculated for C11H10N3O: 200.0824, found 200.0826 (M+H)
+. 
Ylide 94l 
Following GP2 using N-aminopyridinium iodide (222 mg, 1.0 mmol), K2CO3 
(333 mg, 2.4 mmol) and ester 147l (226 mg, 1.2 mmol). Following the 
filtration, the crude residue was dissolved in CH2Cl2 and the product was precipitated by addition of 
hexane to give ylide 94l as a white solid (192 mg, 77%); mp: 142-144 °C; IR (neat): ν = 3395, 3060, 
1617, 1582, 1552, 1468, 1349, 1317, 1212, 1182, 918, 845, 767 cm-1;  
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1H-NMR (400 MHz, CDCl3): δ = 8.88 (d, J = 6.2 Hz, 2H), 8.36-8.28 (m, 2H), 8.24 (d, J = 8.5 Hz, 1H), 
7.93 (t, J = 7.6 Hz, 1H), 7.82 (d, J = 7.8 Hz, 1H), 7.74-7.65 (m, 3H), 7.53 (appt. t, J = 7.8 Hz, 1H); 
13C-NMR (101 MHz, CDCl3): δ = 170.0 (C), 155.3 (C), 147.6 (C), 143.6 (2CH), 137.4 (CH), 136.7 (CH), 
130.7 (CH), 129.4 (CH), 128.8 (C), 127.5 (CH), 127.1 (CH), 126.1 (2CH), 120.7 (CH); 
HRMS (ES): m/z calculated for C15H11N3ONa: 272.0800, found 272.0791 (M+Na)
+. 
Ylide 94m 
A solution of thiophene-2-carboxylic acid (255 mg, 2.0 mmol) in CH2Cl2 (20 mL) 
was cooled to 0 °C. NEt3 (560 µL, 4.0 mmol) and ethyl chloroformate (210 µL, 
2.2 mmol) were added sequentially and the reaction mixture was stirred for 1 hour before the 
addition of N-aminopyridinium iodide (488 mg, 2.2 mmol), K2CO3 (662 mg, 4.8 mmol) and 
MeOH (5 mL). The reaction mixture was allowed to warm to room temperature and stirred for 
24 hours and then filtered through a 5 cm pad of silica gel. The filtrate was concentrated under 
reduced pressure the solid residue was dissolved in 2 M NaOH(aq) solution (20 mL) and CH2Cl2 (30 mL). 
The phases were separated and the aqueous phase was extracted with CH2Cl2 (2 x 20 mL). The 
combined organic phases were dried over Na2SO4, concentrated under reduced pressure and purified 
by flash column chromatography (0→10% MeOH in CH2Cl2) to give ylide 94m as a white solid 
(315 mg, 77%); mp: 214-215 °C; IR (neat): ν = 3098, 3066, 1556, 1466, 1422, 1358, 1294, 1171, 
859 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 8.89-8.82 (m, 2H), 7.92 (tt, J = 7.7, 1.3 Hz, 1H), 7.76 (dd, 
J = 3.6, 1.2 Hz, 1H), 7.72-7.62 (m, 2H), 7.37 (dd, J = 5.0, 1.2 Hz, 1H), 7.08 (dd, J = 5.0, 3.6 Hz, 1H); 
13C-NMR (101 MHz, CDCl3): δ = 166.7 (C), 143.3 (2CH), 141.7 (C), 136.9 (CH), 129.2 (CH), 128.3 (CH), 
127.3 (CH), 126.1 (2CH). Spectroscopic data matched those reported.[52] 
Ylide 94o 
Under an argon atmosphere N-aminopyridinium iodide (223 mg, 
1.0 mmol), K2CO3 (335 mg, 2.4 mmol), MeCN (7.5 mL) and 
3,5-bis(trifluoromethyl)phenyl isocyanate (350 µL, 2.0 mmol) were 
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sequentially added to a flask and the reaction mixture was stirred for 3 days. Filtration was carried 
out as in GP2. Purification by flash column chromatography (0→8% MeOH in CH2Cl2) afforded ylide 
94o as a white solid (282 mg, 80%); mp: 180-181 °C; IR (neat): ν = 3229, 3059, 2974, 1643, 1556, 
1471, 1390, 1274, 1239, 1159, 1115, 1042 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 8.82-8.73 (m, 2H), 
8.15 (s, 1H), 7.94-7.85 (m, 3H), 7.69-7.61 (m, 2H), 7.32 (s, 1H); 13C-NMR (101 MHz, CDCl3): δ = 
162.0 (C), 143.3 (2CH), 143.0 (C), 136.2 (CH), 131.9 (q, JC-F = 32.9 Hz, 2C), 126.3 (2CH), 123.6 (q, JC-F = 
272.6 Hz, 2CF3), 117.7-117.4 (m, 2CH), 113.9-113.5 (m, CH); 
19F{1H}-NMR (282 MHz, CDCl3): δ = -63.0; 
HRMS (ES): m/z calculated for C14H10F6N3O: 350.0728, found 350.0725 (M+H)
+. 
Ylide 266a 
Following GP2 using N-aminopyridinium iodide (490 mg, 2.2 mmol), K2CO3 
(730 mg, 5.3 mmol) and ester 263a (607 g, 2.65 mmol). Purification by flash 
column chromatography (0→5% MeOH in CH2Cl2) afforded ylide 266a as red solid (287 mg, 45%); 
mp: 88-90 °C; IR (neat): ν = 3111, 2969, 1679, 1581, 1468, 1449, 1240, 1164, 1122 cm-1; NMR shows a 
mixture of two rotamers: 1H-NMR (300 MHz, CDCl3): δ = 8.75-8.62 (m, 2H), 7.95-7.83 (m, 1H), 
7.71-7.56 (m, 2H), 5.96-5.77 (m, 1H), 5.24-5.06 (m, 2H), 4.09-3.91 (m, 4H), 1.47 (s, 9H); 
13C-NMR (101 MHz, CDCl3): δ = 173.3 (C), 156.1 (C), 143.3 and 143.1 (2CH), 136.9 (CH) 134.7 and 
134.61 (CH), 126.1 and 126.0 (2CH), 116.6 and 116.0 (CH2), 79.5 and 79.4 (C), 50.9 and 50.3 (CH2), 
50.0 and 49.6 (CH2), 28.7 and 28.6 (3CH3); HRMS (ES): m/z calculated for C15H22N3O3: 292.1661, found 
292.1651 (M+H)+. 
Ylide 266b 
Following GP2 using N-aminopyridinium iodide (185 mg, 0.83 mmol), K2CO3 
(276 mg, 2.0 mmol) and ester 263b (242 mg, 0.91 mmol). Purification by 
flash column chromatography (0→10% MeOH in CH2Cl2) afforded ylide 266b as red oil (99 mg, 36%); 
IR (neat): ν = 2926, 1693, 1580, 1470, 1414, 1232 cm-1; NMR shows a mixture of two rotamers in a ∼ 
0.9:1.1 ratio: 1H-NMR (400 MHz, CDCl3): δ = 8.59 and 8.32 (d, J = 6.1 Hz, 2H), 7.84-7.76 (m, 1H), 7.55 
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and 7.49 (appt. t, J = 7.1 Hz, 2H), 7.36-7.16 (m, 5H), 5.89-5.72 (m, 1H), 5.19-5.02 (m, 4H), 4.09-3.90 
(m, 4H); 13C-NMR (101 MHz, CDCl3): δ = 172.7 (C), 156.62 and 156.57 (C), 143.1 and 143.0 (2CH), 
137.4 (C), 137.1 (CH), 134.0 and 133.9 (CH), 128.35 (2CH), 127.8-127.7 (m, 3CH), 126.0 (2CH), 
117.0 and 116.5 (CH2), 67.1 and 66.8 (CH2), 51.1 and 50.5 (CH2), 50.0 and 49.6 (CH2); 
HRMS (ES): m/z calculated for C18H19N3O3Na: 348.1324, found 348.1327 (M+Na)
+. 
Ylide 266c 
Following GP2 using N-aminopyridinium iodide (480 mg, 2.2 mmol), K2CO3 
(717 mg, 5.2 mmol) and ester 263c (748 mg, 2.4 mmol). Purification by flash 
column chromatography (9:1 EtOAc:MeOH) afforded ylide 266c as red oil (100 mg, 12%); 
IR (neat): ν = 1306, 1589, 1526, 1472, 1346, 1156, 911 cm-1; 1H-NMR (400 MHz, CDCl3): δ = 
8.51-8.47 (m, 2H), 8.28-8.23 (m, 2H), 8.16-8.10 (m, 2H), 7.91 (tt J = 7.7, 1.2 Hz, 1H), 7.67-7.60 (m, 2H), 
5.76 (ddt, J = 17.0, 10.1, 6.3 Hz, 1H), 5.27-5.15 (m, 2H), 4.08 (s, 2H), 4.03 (d, J = 6.3 Hz, 2H); 
13C-NMR (101 MHz, CDCl3): δ = 171.2 (C), 149.7 (C), 146.8 (C), 142.7 (2CH), 137.6 (CH), 132.5 (CH), 
128.9 (2CH), 126.3 (2CH), 123.9 (2CH), 119.4 (CH2), 50.9 (CH2), 49.3 (CH2); HRMS (ES): m/z calculated 
for C16H17N4O5S: 377.0920, found 377.0916 (M+H)
+. 
Ylide 266d 
Following GP2 using N-aminopyridinium iodide (1.0 g, 4.5 mmol), K2CO3 (1.5 
g, 10.9 mmol) and ester 263d (1.5 g, 5.4 mmol). Purification by flash column 
chromatography (0→10% MeOH in CH2Cl2) afforded ylide 266d as a brown solid (962 mg, 62%); 
mp: 106-108 °C; IR (neat): ν = 3070, 1580, 1318, 1153, 1093 cm-1; 1H-NMR (400 MHz, CDCl3): 
δ = 8.50-8.45 (m, 2H), 7.89 (tt, J = 7.7, 1.2 Hz 1H), 7.81 (d, J = 8.2 Hz, 2H), 7.64-7.57 (m, 2H), 
7.24 (d, J = 8.2 Hz, 2H), 5.74 (ddt, J = 17.0, 10.2, 6.4 Hz, 1H), 5.24-5.17 (m, 1H), 5.16-5.11 (m, 1H), 
4.06 (d, J = 6.4 Hz, 2H), 3.98 (s, 2H), 2.37 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 171.9 (C), 
142.9 (2CH), 142.8 (C), 138.0 (C), 137.3 (CH), 133.3 (CH), 129.4 (2C), 127.6 (2C), 126.1 (2C), 
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118.8 (CH2), 51.1 (CH2), 49.4 (CH2), 21.6 (CH3); HRMS (ES): m/z calculated for C17H20N3O3S: 346.1225, 
found 346.1214 (M+H)+. 
Ylide 266f 
Following GP2 using N-aminopyridinium iodide (666 mg, 3.0 mmol), K2CO3 
(995 mg, 7.2 mmol) and ester 263f (1.07 g, 3.6 mmol). Purification by flash 
column chromatography (0→10% MeOH in CH2Cl2) followed by an additional recrystallisation by 
precipitation from CH2Cl2 with Et2O afforded ylide 266f a tan solid (350 mg, 32%);  
[α]D
20 = −8.3 (CHCl3, c = 1.0); mp: 123-125 °C; IR (neat): ν = 3078, 1584, 1468, 1327, 1240, 1153 cm
-1; 
1H-NMR (300 MHz, CDCl3): δ = 8.40-8.33 (m, 2H), 7.92-7.80 (m, 3H), 7.62-7.54 (m, 2H), 
7.22 (d, J = 8.0 Hz, 2H), 6.03-5.88 (m, 1H), 5.29-5.18 (m, 1H), 5.11-5.03 (m, 1H), 
 4.67 (q, J = 7.2 Hz, 1H), 4.31-4.20 (m, 1H), 4.16-4.05 (m, 1H), 2.38 (s, 3H), 1.43 (d, J = 7.2 Hz, 3H); 
13C-NMR (101 MHz, CDCl3): δ = 174.7 (C), 143.0 (2CH), 142.5 (C), 138.6 (C), 137.3 (CH), 137.2 (CH), 
129.3 (2CH), 127.9 (2CH), 125.9 (2CH), 116.1 (CH2), 56.5 (CH), 47.8 (CH2), 21.6 (CH3), 17.9 (CH3); 
HRMS (ES): m/z calculated for C18H21N3O3SNa: 382.1201, found 382.1199 (M+Na)
+. 
Ylide 266g 
Following GP2 using N-aminopyridinium iodide (666 mg, 3.0 mmol), K2CO3 
(995 mg, 7.2 mmol) and ester 263g (1.49 mg, 3.6 mmol). Purification by 
flash column chromatography (0→10% MeOH in CH2Cl2) followed by an 
additional recrystallisation by precipitation from CHCl3 with Et2O afforded 
ylide 266g as a tan solid (234 mg, 16%); [α]D = compound was not sufficiently soluble in a solvent 
appropriate for measurement; mp: 168-170 °C; IR (neat): ν = 3183, 1569, 1328, 1153, 1089 cm-1; 
1H-NMR (300 MHz, d6-DMSO): δ = 10.78 (s, NH), 8.16 (d, J = 5.6 Hz, 2H), 8.08 (t, J = 7.7 Hz, 1H), 
7.83-7.74 (m, 2H), 7.71 (d, J = 8.2 Hz, 2H), 7.50 (d, J = 7.8 Hz, 1H), 7.34 (d, J = 8.0 Hz, 1H), 
 7.28 (d, J = 8.2 Hz, 2H), 7.16 (d, J = 2.1 Hz, 1H), 7.10-7.03 (m, 1H), 7.01-6.93 (m, 1H), 
 5.92-5.74 (m, 1H), 5.19 (dd, J = 17.3, 1.2, 1H), 4.99 (dd, J = 10.2, 1.2, 1H), 
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 4.67 (dd, J = 8.4, 6.5 Hz, 1H), 4.43 (dd, J = 16.9, 6.8 Hz, 1H), 4.00 (dd, J = 16.9, 5.0, 1H),  
3.34 (dd, J = 14.3, 8.4 Hz, 1H), 2.95 (dd, J = 14.3, 6.5 Hz, 1H), 2.33 (s, 3H); 13C-NMR (101 MHz, 
d6-DMSO): δ = 171.9 (C), 142.5 (C), 142.4 (2CH), 138.4 (CH), 137.7 (C), 137.4 (CH), 136.1 (C), 129.2 
(2CH), 127.4 (2CH), 127.0 (C), 126.6 (2CH), 123.4 (CH), 120.8 (CH), 118.22 (CH), 118.20 (CH), 115.8 
(CH2), 111.3 (CH), 110.7 (C), 60.6 (CH), 47.0 (CH2), 27.6 (CH2), 21.0 (CH3); HRMS (ES): m/z calculated 
for C26H26N4O3SNa: 497.1623, found 497.1614 (M+Na)
+. 
Ylide 266h 
Following GP2 using N-aminopyridinium iodide (355 mg, 1.6 mmol), 
K2CO3 (531 mg, 3.8 mmol) and ester 263h (571 mg, 1.9 mmol). 
Purification by flash column chromatography (0→5% MeOH in CH2Cl2) afforded ylide 266h as red 
solid (330 mg, 57%); mp: 86-88 °C; IR (neat): ν = 1581, 1344, 1155, 1090, 959 cm-1;  
1H-NMR (300 MHz, CDCl3): δ = 8.55-8.48 (m, 2H), 7.90 (tt, J = 7.7, 1.3 Hz 1H), 7.82 (d, J = 8.3 Hz, 2H), 
7.66-7.57 (m, 2H), 7.25 (d, J = 8.3 Hz, 2H), 5.74 (ddt, J = 17.1, 10.3, 6.8 Hz, 1H), 5.10-4.95 (m, 2H),  
4.04 (s, 2H), 3.53-3.40 (m, 2H), 2.47-2.34 (m, 2H), 2.39 (s, 3H); 13C-NMR (101 MHz, CDCl3):  
δ = 172.0 (C), 143.0 (2CH), 142.7 (C), 138.0 (C), 137.3 (CH), 135.3 (CH), 129.4 (2CH), 127.7 (2CH), 
126.1 (2CH), 116.8 (CH2), 50.6 (CH2), 48.2 (CH2), 32.8 (CH2), 21.6 (CH3); HRMS (ES): m/z calculated for 
C18H22N3O3S: 360.1746, found 360.1751 (M+H)
+. 
Ylide 266i 
Following GP2 using N-aminopyridinium iodide (403 mg, 1.8 mmol), 
K2CO3 (602 mg, 4.4 mmol) and ester 263i (679 mg, 2.2 mmol). 
Purification by flash column chromatography (0→5% MeOH in CH2Cl2) afforded ylide 266i as red solid 
(428 mg, 63%); mp: 48-50 °C; IR (neat): ν = 2926, 1584, 1471, 1330, 1154, 1090 cm-1;  
1H-NMR (300 MHz, CDCl3): δ = 8.49-8.41 (m, 2H), 7.88 (t, J = 7.7 Hz, 1H), 7.78 (d, J = 8.0 Hz, 2H), 
7.64-7.55 (m, 2H), 7.22 (d, J = 8.0 Hz, 2H), 5.74 (ddt, J = 16.9, 10.3, 6.5 Hz, 1H), 5.01-4.86 (m, 2H), 
3.99 (s, 2H), 3.41-3.29 (t, J = 7.5 Hz, 2H), 2.35 (s, 3H), 2.03 (appt. q, J = 7.0 Hz, 2H),  
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1.71 (appt. quin, J = 7.5 Hz, 2H); 13C-NMR (101 MHz, CDCl3): δ = 171.8 (C), 142.8 (2CH), 142.6 (C), 
137.9 (CH), 137.8 (C), 137.4 (CH), 129.3 (2CH), 127.6 (2CH), 126.1 (2CH), 115.0 (CH2), 50.4 (CH2), 
48.2 (CH2), 30.9 (CH2), 27.2 (CH2), 21.50 (CH3); HRMS (ES): m/z calculated for 
C19H23N3O3SNa: 396.1358, found 396.1353 (M+Na)
+. 
Ylide 94p 
Following GP2 using N-aminopyridinium iodide (1.00 g, 4.5 mmol), K2CO3 
(1.48 g, 10.7 mmol) and ester 147p (1.35 g, 5.4 mmol). Purification by flash 
column chromatography (0→10% MeOH in CH2Cl2) afforded ylide 94p as 
red oil (983 mg, 70%); IR (neat): ν = 3360, 2960, 2867, 1577, 1467, 1339, 1269, 1090, 757 cm-1; 
1H-NMR (300 MHz, CDCl3): δ = 8.78-8.70 (m, 2H), 8.03-7.90 (m 1H), 7.76-7.64 (m, 2H),  
7.15-7.01 (m, 3H), 3.79 (s, 2H), 3.46 (hept, J = 6.8 Hz, 2H), 1.28 (d, J = 6.8 Hz, 12H);  
13C-NMR (101 MHz, CDCl3): δ = 174.0 (C), 144.0 (C), 143.3 (2CH), 142.1 (2C), 137.5 (CH), 126.3 (2CH), 
123.7 (2CH), 123.4 (CH), 54.5 (CH2), 27.9 (2CH), 24.4 (4CH3); HRMS (ES): m/z calculated for 
C19H25N3ONa: 334.1895, found 334.1909 (M+Na)
+. 
Ylide 94q 
Following GP2 using N-aminopyridinium iodide (4.44 g, 20 mmol), K2CO3 
(6.64 g, 48 mmol) and ester 147q (6.10 g, 22 mmol). Purification by flash 
column chromatography (0→10% MeOH in CH2Cl2) afforded ylide 94q as 
red solid (Note: in order obtain a solid after purification, hexane was added to the combined column 
fractions before they were concentrated, when this was not done the compound was isolated as a 
difficult to handle hygroscopic foam) (2.76 g, 41%); mp: 170-172 °C; IR (neat): ν = 2963, 2927, 2869, 
1670, 1590, 1469, 1349, 1259, 1192 cm-1; NMR shows a mixture of two rotamers in a ∼ 0.3:0.7 ratio: 
1H-NMR (300 MHz, CDCl3): δ = 8.71-8.62 (m, 2H), 8.68 and 8.17 (s, 1H), 7.93 and 7.87 (tt, J = 7.7, 
1.2 Hz, 1H), 7.70-7.57 (m, 2H), 7.37-7.26 (m, 1H), 7.23-7.15 (m, 2H), 4.25 and 4.13 (s, 2H), 3.47 and 
3.17 (hept, J = 6.8 Hz, 2H), 1.28-1.08 (m, 12H); 13C-NMR (101 MHz, CDCl3): δ = 171.6 and 171.2 (C), 
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164.7 and 163.8 (CH), 148.2 and 146.6 (2C), 143.0 and 142.7 (2CH), 137.8 and 137.1 (CH), 136.9 and 
136.1 (C), 129.3 and 128.8 (CH), 126.4 and 126.2 (2CH), 124.4 and 124.2 (2CH), 54.8 and 52.8 (CH2), 
28.6 and 28.0 (2CH), 25.1 and 24.6 (2CH3), 24.4 and 24.2 (2CH3); HRMS (ES): m/z calculated for 
C20H25N3O2Na: 362.1844, found 362.1832 (M+Na)
+. 
5.1.4: Precursors to Ynamides 
Sulfonamide 135a 
MsCl (3.8 mL, 49 mmol) was added to a solution of aniline (5 mL, 55 mmol) and pyridine 
(8.8 mL, 109 mmol) in CH2Cl2 (75 mL) at 0 °C. The reaction mixture was stirred at room 
temperature for 2 hours. 6 M NaOH(aq) solution (30 mL) and H2O (50 mL) were added. The organic 
phase was discarded and the aqueous phase was washed with CH2Cl2 (2 x 15 mL). The aqueous phase 
was acidified with conc. HCl(aq) to pH≈2 and extracted with CH2Cl2 (3 x 30 mL), these combined 
organic extracts were dried over Na2SO4 and the solvent was removed under reduced pressure to 
give sulfonamide 135a as a white solid (7.72 g, 92%); mp: 98-100 °C (lit.[189] 102-103 °C); IR (neat): ν = 
3253, 1495, 1471, 1393, 1320, 1145, 975, 752 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 7.42-7.31 (m, 2H), 
7.26-7.16 (m, 3H), 6.66 (br s, NH), 3.02 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 136.8 (C), 129.9 (2CH), 
125.6 (CH), 120.9 (2CH), 39.5 (CH3); Spectroscopic data matched those reported.
[189] 
Sulfonamide 135b 
MsCl (870 µL, 11.2 mmol), was added to a solution of allylamine (750 µL, 10.0 mmol) and 
NEt3 (1.55 mL, 11.1 mmol) in CH2Cl2 (40 mL) at 0 °C. The reaction mixture was stirred for 
2 hours at room temperature and satd. NH4Cl solution (30 mL) was added. The phases were 
separated and the aqueous phase was extracted with CH2Cl2 (2 x 30 mL). The combined organic 
extracts were dried over Na2SO4, concentrated under reduced pressure and purified by flash column 
chromatography (3:2 hexane:EtOAc) to give sulfonamide 135b as a colourless oil (1.19 g, 88%);  
1H-NMR (300 MHz, CDCl3): δ = 5.87 (ddt, J = 17.1, 10.2, 5.8 Hz, 1H), 5.30 (appt. dq, J = 17.1, 1.3 Hz, 
1H), 5.22 (appt. dq, J = 10.2, 1.3 Hz, 1H), 4.62 (br s, NH), 3.81-3.73 (m, 2H), 2.97 (s, 3H);  
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13C-NMR (101 MHz, CDCl3): δ = 133.6 (CH), 117.9 (CH2), 45.8 (CH2), 41.2 (CH3);  
MS (EI): m/z = 135.0 (M+, 5%), 120.0 (100), 108.0 (33), 79.0 (78), 56.1 (92). Spectroscopic data 
matched those reported.[190] 
Sulfonamide 135c 
Following a literature procedure,[191] MeNH2 (33% in EtOH, 65 mL, 527 mmol) was added to a 
flask fitted with a reflux condenser and MsCl (9 mL, 116 mmol) was added over 15 minutes 
whilst cooling with an ice/water bath. The reaction mixture was stirred for 18 hours at room 
temperature before CH2Cl2 (150 mL) was added to precipitate MeNH3Cl, which was removed 
filtration through a 5 cm pad of silica. The filtrate was concentrated under reduced pressure and 
purified by flash column chromatography (3:2 EtOAc:hexane) to give sulfonamide 135c as a 
colourless oil (8.34 g, 66%) (note that this product is water soluble); IR (neat): ν = 3290, 1405, 1301, 
1146, 1126, 1067, 969, 834, 751 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 4.32 (br s, NH), 2.95 (s, 3H), 
2.83 (d, J = 5.3 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ = 38.8 (CH3), 29.5 (CH3). Spectroscopic data 
matched those reported.[191] 
Carbamate 135d 
Methyl chloroformate (430 µL, 5.5 mmol), was added to a solution of BnNH2 (550 µL, 
5.0 mmol) and pyridine (450 µL, 5.5 mmol) in CH2Cl2 (15 mL) at 0 °C. The reaction mixture 
was stirred for 1 hour at room temperature and then washed sequentially with satd. NH4Cl(aq) 
solution (15 mL) and satd. Na2CO3(aq) solution (20 mL). The organic phase was dried over Na2SO4, 
concentrated under reduced pressure and purified by flash column chromatography 
(3:1 hexane:EtOAc) to give carbamate 135d as a white solid (584 mg, 70%); mp: 58-59 °C (lit.[192] 
62-63 °C); 1H-NMR (300 MHz, d4-MeOD): δ = 7.35-7.18 (m, 5H), 4.27 (s, 2H), 3.65 (s, 3H); 
13C-NMR (101 MHz, d4-MeOD): δ = 159.7 (C), 140.6 (C), 129.4 (2CH), 128.2 (2CH), 128.1 (CH), 
52.5 (CH2), 45.5 (CH3); MS (EI): m/z = 165.5 (M
+, 45%), 150.4 (61), 133.4 (31), 106.4 (31), 91.3 (65). 
Spectroscopic data matched those reported.[193] 
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Sulfonamide 135g 
TsCl (7.8 g, 41 mmol), was added to a solution of aniline (5 mL, 55 mmol) and pyridine 
(7.2 mL, 89 mmol) in CH2Cl2 (100 mL) and the reaction mixture was stirred for 20 hours. The 
reaction mixture was washed with 4 M HCl(aq) solution (2 x 50 mL), dried over Na2SO4 and the solvent 
was removed under reduced pressure to give sulfonamide 135g as a pink solid (9.59 g, 95%); mp: 94-
96 °C (lit.[194] 96-97 °C); IR (neat): ν = 3235, 1597, 1526, 1335, 1154, 1090, 754 cm-1; 1H-NMR (300 
MHz, CDCl3): δ = 7.64 (d, J = 8.3 Hz, 2H), 7.26-7.18 (m, 4H), 7.11 (tt, J = 8.3, 1.2 Hz, 1H), 7.08-7.02 (m, 
2H), 6.52 (br s, NH), 2.38 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 144.0 (C), 136.7 (C), 136.1 (C), 129.8 
(2CH), 129.4 (2CH), 127.4 (2CH), 125.3 (CH), 121.6 (2CH), 21.7 (CH3). Spectroscopic data matched 
those reported.[195] 
Sulfonamide 135i 
A solution of NaOH (2.10 g, 52.5 mmol) and MeNH2 (40% in H2O, 4.5 mL, 52 mmol) in 
H2O (45 mL) was cooled to 0 °C and TsCl (10.0 g, 52.5 mmol) was added over 5 minutes. The 
reaction mixture was stirred for 6 hours at room temperature and then extracted with EtOAc (2 x 
30 mL). The combined organic extracts were washed with H2O (30 mL) and brine (30 mL), dried over 
Na2SO4, and the solvent  was removed under reduced pressure to give sulfonamide 135i as a white 
solid (8.42 g, 87%); mp: 76-77 °C (lit.[196] 75-77 °C); IR (neat): ν = 3267, 1316, 1154, 1089, 820 cm-1; 
1H-NMR (300 MHz, CDCl3): δ = 7.75 (d, J = 8.2 Hz, 2H), 7.31 (d, J = 8.2 Hz, 2H), 4.69 (br q, NH), 2.62 (d, 
J = 5.4 Hz, 3H), 2.42 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 143.6 (C), 135.9 (C), 129.9 (2CH), 
127.4 (2CH), 29.4 (CH3), 21.6 (CH3). Spectroscopic data matched those reported.
[196] 
Sulfonamide 135j 
Benzylamine (870 µL, 8.0 mmol) was added to a solution of TsCl (1.72 g, 9.0 mmol) and NEt3 
(1.25 mL, 9.0 mmol) in CH2Cl2 (20 mL) at 0 °C. The reaction mixture was stirred for 3 hours at 
room temperature and satd. NH4Cl(aq) solution (30 mL) was added, the phases were separated, and 
the aqueous phase was extracted with CH2Cl2 (2 x 20 mL). The combined organic extracts were dried 
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over Na2SO4, concentrated under reduced pressure and purified by flash column chromatography 
(3:1 hexane:EtOAc) to give sulfonamide 135j as a white solid (1.86 g, 89%); mp: 109-110 °C (lit.[197] 
107-109 °C); 1H-NMR (300 MHz, CDCl3): δ = 7.76 (d, J = 8.3 Hz, 2H), 7.33-7.23 (m, 5H), 7.23-7.16 (m, 
2H), 4.88 (br t, J = 6.2 Hz, NH), 4.11 (d, J = 6.2 Hz, 2H), 2.44 (s, 3H); 13C-NMR (101 MHz, CDCl3):  
δ = 143.6 (C), 137.0 (C), 136.4 (C), 129.9 (2CH), 128.8 (2CH), 128.0 (3CH), 127.3 (2CH), 47.4 (CH2), 
21.6 (CH3); MS (EI): m/z = 261.1 (M
+, 20%), 196.1 (100), 180.1 (22), 165.1 (26). Spectroscopic data 
matched those reported.[198] 
Sulfonamide 135l 
A solution of allylamine (375 µL, 5.0 mmol) and NEt3 (780 µL, 5.6 mmol) in CH2Cl2 (4 mL) 
was added to a solution of 4-nitrobenzenesulfonyl chloride (1.27 g, 5.7 mmol) in 
CH2Cl2 (13 mL) at 0 °C. The reaction mixture was allowed to warm to room temperature and stirred 
for 3 hours. Satd. NH4Cl(aq) solution (30 mL) was added, the phases were separated, and the aqueous 
phase was extracted with CH2Cl2 (2 x 20 mL). The combined organic phases were dried over Na2SO4, 
concentrated under reduced pressure and purified by flash column chromatography 
(4:1 hexane:EtOAc) to give sulfonamide 135l as a yellow solid (1.12 g, 93%); mp: 110-112 °C;  
1H-NMR (300 MHz, CDCl3): δ = 8.37 (d, J = 9.0 Hz, 2H), 8.06 (d, J = 9.0 Hz, 2H), 5.71 (ddt, J=17.1, 10.2, 
5.8, 1H), 5.23-5.08 (m, 2H), 4.73 (t, J = 5.9 Hz, NH), 3.69 (apparent tt, J = 5.9, 1.5 Hz, 2H);  
13C-NMR (101 MHz, CDCl3): δ = 150.3 (C), 146.3 (C), 132.5 (CH), 128.5 (2CH), 124.6 (2CH), 118.6 (CH2), 
46.0 (CH2); MS (EI): m/z = 242.0 (M
+, 15%), 226.0 (10), 215.0 (8), 186.0 (49), 151.1 (28), 122.0 (100), 
92.0 (24) 76.0 (49). Spectroscopic data matched those reported.[199] 
Sulfonamide 135m 
MsCl (1,3 mL, 16.8 mmol), was added to a solution of (R)-(+)-α-methylbenzylamine 
(2.5 mL, 19.6 mmol) and NEt3 (4.7 mL, 34 mmol) in CH2Cl2 (30 mL) at 0 °C. The reaction 
mixture was stirred for 2 hours at room temperature and 2 M HCl(aq) solution (30 mL) was added. The 
phases were separated, the organic phase was dried over Na2SO4 and the solvent was removed 
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under reduced pressure to give sulfonamide 135m as a white solid (2.69 g, 80%); mp: 48-50 °C (lit.[90] 
46-48 °C); IR (neat): ν = 3283, 1316, 1148, 1086, 977, 755 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 7.41-
7.26 (m, 5H), 5.18 (br s, NH), 4.64 (appt. quin, J = 6.9 Hz, 1H), 2.60 (s, 3H), 1.54 (d, J = 6.9 Hz, 3H); 
13C-NMR (101 MHz, CDCl3): δ = 142.6 (C), 129.0 (2CH), 128.0 (CH), 126.4 (2CH), 53.9 (CH), 41.8 (CH3), 
24.1 (CH3). Spectroscopic data matched those reported.
[90] 
Formamide 137a 
Following a literature procedure[83b] a solution of sulfonamide 135j (724 mg, 2.8 mmol) in 
THF (12 mL) was cooled to 0 °C, nBuLi (2.5 M in hexane, 1.2 mL, 3.0 mmol) was added and 
the reaction mixture was stirred for 0.5 hours. A solution of N-formylbenzotriazole (338 mg, 
3.0 mmol) in THF (6 mL) was added and stirring was continued for 0.5 hours at 0 °C and 1.5 hours at 
room temperature before the reaction was quenched with satd. NH4Cl(aq) solution (15 mL) and 
extracted with EtOAc (3 x 30 mL). The combined organic phases were washed with 2 M NaOH(aq) 
solution (2 x 30 mL) and brine (30 mL), dried over Na2SO4, concentrated under reduced pressure and 
purified by flash column chromatography (17:3 hexane:EtOAc) to give formamide 137a as a white 
solid (673 mg, 84%); mp: 96-97 °C (lit.[83b] 95-96 °C); IR (neat): ν = 2988, 2902, 1699, 1408, 1365, 
1355, 1225, 1161, 1089, 1031, 897, 813, 755 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 9.19 (s, 1H), 7.56 (d, 
J = 8.4 Hz, 2H), 7.25-7.17 (m, 7H), 4.72 (s, 2H), 2.40 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 161.7 (CH), 
145.4 (C), 135.6 (C), 134.8 (C), 130.2 (2CH), 128.6 (2CH), 128.5 (2CH), 127.9 (CH), 127.5 (2CH), 
45.9 (CH2), 21.7 (CH3). Spectroscopic data matched those reported.
[83b] 
Dibromoenamide 169 
CBr4 (998 mg, 3.0 mmol), PPh3 (1.57 g, 6.0 mmol) and CH2Cl2 (20 mL) were added to a 
flask under an argon atmosphere whilst cooling at 0 °C. The reaction mixture was 
stirred for 1 hour, after which formamide 137a (436 mg, 1.5 mmol) was added and stirring was 
continued for a further 18 hours at room temperature. Satd. NaHCO3(aq) solution (20 mL) was added, 
the phases were separated, and the aqueous phase was extracted with CH2Cl2 (2 x 15 mL). The 
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combined organic extracts were dried over Na2SO4, concentrated under reduced pressure and 
purified by flash column chromatography (10% EtOAc in hexane) to give dibromoenamide 169 as a 
white solid (432 mg, 64%); mp: 130-131 °C; IR (neat): ν = 3065, 3035, 2996, 1599, 1495, 1441, 1351, 
1320, 1306, 1163, 1089, 954, 867, 755, cm-1; 1H-NMR (400 MHz, CDCl3): δ = 7.75-7.70 (m, 2H), 7.37-
7.26 (m, 7H), 6.61 (s, 1H), 4.54 (s, 2H), 2.46 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 144.4 (C), 135.9 
(C), 135.2 (C), 131.5 (CH), 130.0 (2CH), 128.8 (2CH), 128.7 (2CH), 128.2 (CH), 127.6 (2CH), 97.2 (C), 
52.9 (CH2), 21.8 (CH3); HRMS (ES): m/z calculated for C16H15NO2S
79Br81BrNa: 467.9067, found 
467.9050 (M+Na)+. 
Dichloroenamide 266 
 
Following a literature procedure,[83b] N,N'-dicyclohexylcarbodiimide (5.16 g, 25 mmol) was added 
over 10 minutes to a solution of formic acid (750 µL, 23 mmol) and sulfonamide 135g (2.47 g, 
10 mmol) in CH2Cl2 (10 mL) under an argon atmosphere. After stirring for 17 hours at room 
temperature the reaction mixture was filtered through celite (washing with CH2Cl2), concentrated 
under reduced pressure and purified by flash column chromatography (5→10% EtOAc in hexane) to 
give impure formamide 137b (contaminated with a small amount of 135g) (2.09 g). This mixture was 
added to a flask containing PPh3 (5.9 g, 22.5 mmol) and THF (75 mL) under an argon atmosphere. The 
reaction mixture was heated to 60 °C. and CCl4 (7.3 mL, 75 mmol) was added by syringe pump over 
7.3 hours; heating was continued for a further 10 hours. After cooling to room temperature, the 
solvent was removed under reduced pressure and the crude solid was taken up in satd. NaHCO3(aq) 
solution (30 mL) and extracted with CH2Cl2 (2 x 30 mL). The combined organic phases were dried over 
Na2SO4, concentrated under reduced pressure and purified by flash column chromatography (19:1 
hexane:EtOAc) to give dichloroenamide 266 as a white solid (1.50 g, 44% over two steps); mp: 111-
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113 °C (lit.[83b] 115-116 °C) ; IR (neat): ν = 3036, 1593, 1488, 1355, 1127, 1091, 927, 811 cm-1; 1H-NMR 
(300 MHz, CDCl3): δ = 7.47 (d, J = 8.3 Hz, 2H), 7.33-7.23 (m, 5H), 7.10-7.03 (m, 2H), 6.97 (s, 1H), 
2.43 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 144.8 (C), 138.4 (C), 134.4 (C), 129.9 (2CH), 129.2 (2CH), 
128.5 (2CH), 128.2 (CH), 127.9 (2CH), 126.3 (CH), 118.4 (C), 21.8 (CH3). Spectroscopic data matched 
those reported.[83b] 
Bromoacetylenes 133a-c 
 
Bromoacetylenes 133a-c were synthesised in >90% yields by mixing terminal acetylenes (1.0 eq.), 
NBS (1.1 eq.) and AgNO3 (5 mol%) in acetone (0.2 M) for 3 hours. Silica gel was added to the reaction 
mixture which was then concentrated under reduced pressure. The silica-absorbed crude reaction 
mixture was added to a 3 cm pad of silica gel and the product was eluted with hexane. The 
bromoacetylenes were stored in a freezer and used within 1 week. 
Alkyne 132d 
Following a literature procedure,[200] NaH (60% dispersion, 460 mg, 11.5 mmol) was 
suspended in DMF (10 mL) under an argon atmosphere and the suspension cooled to 0 °C. Propargyl 
alcohol (600 µL, 10 mmol) was added over 10 minutes and stirring was continued for a further 
20 minutes before addition of benzyl bromide (1.4 mL, 12 mmol). The reaction mixture was stirred 
for 14 hours at room temperature and then quenched with 2 M HCl(aq) solution (20 mL) and extracted 
with EtOAc (20 mL). The organic phase was washed with brine (20 mL), dried over Na2SO4, 
concentrated under reduced pressure and purified by flash column chromatography (0→5% EtOAc in 
hexane) to give alkyne 132d as a clear oil (969 mg, 64%); IR (neat): ν = 3291, 2857, 1722, 1073, 1027, 
738 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 7.41-7.27 (m, 5H), 4.62 (s, 2H), 4.18 (d, J = 2.4 Hz, 2H), 
2.47 (t, J = 2.4 Hz, 1H); Spectroscopic data matched those reported.[201] 
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5.1.4.1: General procedure for synthesis of dibromoalkenes (GP3) 
 
CBr4 (2.0 eq.) and PPh3 (4.0 eq.) were dissolved in CH2Cl2 (0.13 M with respect to aldehyde) under an 
argon atmosphere whilst cooling with an ice/water bath. The reaction mixture was stirred for 1 hour, 
after which aldehyde (1.0 eq.) was added and stirring was continued for a further 18 hours at room 
temperature. Satd. NaHCO3(aq) solution and additional CH2Cl2 were added until all solids were 
dissolved and the phases were separated. The organic phase was dried over Na2SO4, concentrated 
under reduced pressure and purified by flash column chromatography to give the dibromoalkene. 
Dibromoalkene 134a 
Following GP3 using CBr4 (1.33 g, 4.0 mmol), PPh3 (2.10 g, 8.0 mmol) and benzaldehyde 
(200 µL, 2.0 mmol). Purification by flash column chromatography (9:1 hexane:EtOAc) 
gave dibromoalkene 134a as a colourless oil (473 mg, 91%); 1H-NMR (300 MHz, CDCl3): δ =  
7.56-7.50 (m, 2H), 7.49 (s, 1H), 7.41-7.32 (m, 3H); MS (EI): m/z = 263.9 (M+, 48%), 261.9 (M+, 100), 
259.9 (M+, 54), 181.0 (22), 102.0 (42). Spectroscopic data matched those reported.[202] 
Dibromoalkene 134b 
Following GP3 using CBr4 (2.63 g, 7.9 mmol), PPh3 (4.23 g, 16 mmol) and 
4-anisaldehyde (490 µL, 4.0 mmol). Chromatography was replaced by 
filtration through a 5 cm pad of silica gel (eluting with hexane) to give dibromoalkene 134b as a pale 
yellow solid (1.14 g, 97%); mp: 33-34 °C (lit.[202] 37-38 °C); IR (neat): ν = 2964, 2840, 1603, 1567, 1507, 
1254, 1177, 1026, 863 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 7.51 (d, J = 8.8 Hz, 2H), 7.41 (s, 1H), 
6.89 (d, J = 8.8 Hz, 2H), 3.82 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 159.8 (C), 136.5 (CH), 130.0 (2CH), 
128.0 (C), 113.9 (2CH), 87.4 (C), 55.4 (CH3). Spectroscopic data matched those reported.
[203] 
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Dibromoalkene 134c 
Following GP3 using CBr4 (2.65 g, 8.0 mmol), PPh3 (4.23 g, 16 mmol) and 
4-nitrobenzaldehyde (609 mg, 4.0 mmol). Purification by flash column 
chromatography (9:1 hexane:Et2O) gave dibromoalkene 134c as a white solid (999 mg, 81%); 
mp: 92-94 °C (lit.[202] 93-94 °C); IR (neat): ν = 3103, 3078, 2927, 2835 1586, 1505, 1488, 1332, 1108, 
882, 859 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 8.23 (d, J = 8.8 Hz, 2H), 7.70 (d, J = 8.8 Hz, 2H), 7.56 (s, 
1H); 13C-NMR (101 MHz, CDCl3): δ = 147.4 (C), 141.6 (C), 135.1 (CH), 129.3 (2CH), 123.9 (2CH), 
94.3 (C). Spectroscopic data matched those reported.[204] 
Dibromoalkene 134d 
 
Under an Ar atmosphere nBuLi (2.5 M in hexane, 4 mL, 10 mmol) was added to a solution of 1-hexyne 
(1.15 mL, 10 mmol) in diethyl ether (4 mL) at −78 °C and the reaction mixture was stirred for 
30 minutes. DMF (1.16 mL, 15 mmol) was then added and the solution was allowed to warm to room 
temperature and stirred for a further 30 minutes. The reaction mixture was cooled to 0 °C and 
quenched with water (10 mL) and the solution was acidified with conc. HCl(aq) then neutralised with 
satd. NaHCO3(aq) before extraction with diethyl ether (3 x 10 mL). The combined organic fractions 
were dried over Na2SO4, filtered and carefully concentrated (300 mbar, 40 °C) to give a crude yellow 
solution of aldehyde 412. CBr4 (6.66 g, 20.1 mmol) in CH2Cl2 (10 mL) was cooled to 0 °C under an 
argon atmosphere, PPh3 (5.28 g, 20.1 mmol) and powdered zinc (13.3 g, 40.4 mmol) were added and 
the reaction mixture was stirred for 30 minutes at room temperature. The resulting red solution was 
cooled to 0 °C and the crude aldehyde 412 was added in CH2Cl2 (10 mL) and the reaction mixture was 
stirred for 18 hours at room temperature. The zinc residue was removed by filtration through a plug 
of silica before purification by flash column chromatography (hexane) gave dibromoalkene 134d as a 
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yellow oil (2.10 g, 79%); IR (neat): ν = 3018, 2932, 2871, 2215, 1574, 1465, 1427, 850 cm-1; 
1H-NMR (300 MHz, CDCl3): δ = 6.52 (t, J = 2.3 Hz, 1H), 2.32 (td, J = 6.9, 2.3 Hz, 2H), 1.60-1.50 (m, 2H), 
1.49-1.38 (m, 2H), 0.92 (t, J = 7.2 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ = 120.3 (CH), 100.2 (C), 
99.6 (C), 77.9 (C), 30.4 (CH2), 22.1 (CH2), 19.6 (CH2), 13.7 (CH3); HRMS (EI): m/z: calculated. for 
C8H10
79Br2: 263.9149, found 263.9142 (M)
+. 
5.1.5: Synthesis of Ynamides 
5.1.5.1: General procedure for synthesis of ynamides from terminal acetylenes (GP5) 
 
Following a literature procedure,[82] a 3 neck flask, with a volume at least 20 times greater than that 
of the solvent required, was charged with sulfonamide (5.0 eq.), Na2CO3 (2.0 eq.), and CuCl2 (0.2 eq.) 
and purged with O2 for 15 minutes. A balloon of O2 gas was attached. Pyridine (2.0 eq.) and 
toluene (1 mL / mmol of sulfonamide) were added and the reaction mixture was heated to 70 °C 
before a solution of terminal acetylene (1.0 eq, 0.2 M in toluene) was added over 6 hours by syringe 
pump, after which stirring was continued for a further 10 hours at 70 °C. After cooling to room 
temperature, the reaction mixture was filtered through a 5 cm pad of silica gel (eluting with CH2Cl2), 
concentrated under reduced pressure and purified by flash column chromatography to give the 
ynamide and, where stated, some recovered amide. 
Ynamide 84c 
Following GP5 using sulfonamide 135a (2.18 g, 20 mmol), Na2CO3 (844 mg, 
8.0 mmol), CuCl2 (108 mg, 0.8 mmol), pyridine (650 µL, 8.0 mmol) and 
phenylacetylene (440 µL, 4.0 mmol). Purification by flash column chromatography (10→30% EtOAc 
in hexane) gave ynamide 84c as a white solid (919 mg, 84%); mp: 74-76 °C (lit.[49] 75-77 °C); IR (neat): 
ν = 3078, 3010, 2923, 2243, 1589, 1485, 1365, 1165, 962 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 7.69-
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7.54 (m, 2H), 7.53-7.27 (m, 8H), 3.17 (s, 3H). Spectroscopic data matched those reported.[49] 
Sulfonamide 135a (634 mg, 5.8 mmol) was also recovered. 
Ynamide 84m 
Following GP5 using sulfonamide 135g (3.71 g, 15 mmol), Na2CO3 (636 mg, 
6.0 mmol), CuCl2 (81 mg, 0.6 mmol), pyridine (500 µL, 6.1 mmol) and 
trimethylsilylacetylene (415 µL, 3.0 mmol). Purification by flash column chromatography (5→20% 
EtOAc in hexane) gave ynamide 84m as a white solid (849 mg, 83%); mp: 92-94 °C (lit.[49] 88-91 °C); IR 
(neat): ν = 2962, 2166, 1490, 1365, 1160, 842 cm-1; 1H-NMR (400 MHz, CDCl3): δ = 7.55 (d, J = 8.3 Hz, 
2H), 7.32-7.19 (m, 7H), 2.43 (s, 3H), 0.15 (s, 9H); 13C-NMR (101 MHz, CDCl3): δ = 145.1 (C), 138.7 (C), 
133.0 (C), 129.5 (2CH), 129.2 (2CH), 128.5 (2CH), 128.3 (CH), 126.3 (2CH), 95.4 (C), 73.4 (C), 
21.9 (CH3), 0.2 (3CH3). Spectroscopic data matched those reported.
[49] Sulfonamide 135g (1.61 g, 
6.5 mmol) was also recovered. 
Ynamide 84r 
Following GP5 using sulfonamide 135i (930 mg, 5.0 mmol), Na2CO3 (213 mg, 
2.0 mmol), CuCl (27 mg, 0.2 mmol), pyridine (162 µL, 2.0 mmol) and alkyne 132d 
(146 µL, 1.0 mmol). Purification by flash column chromatography (17:3 hexane:EtOAc) gave 
ynamide 84r as a white solid (260 mg, 79%); mp: 84-86 °C; IR (neat): ν = 3072, 2864, 2235, 1595, 
1453, 1362, 1169, 1063, 1027, 1014, 821, 759 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 7.84-7.76 (d, 
J = 8.3 Hz, 2H), 7.39-7.28 (m, 7H), 4.53 (s, 2H), 4.28 (s, 2H), 3.09 (s, 3H), 2.43 (s, 3H); 
13C-NMR (101 MHz, CDCl3): δ = 145.0 (C), 137.6 (C), 133.5 (C), 130.0 (2CH), 128.6 (2CH), 128.2 (2CH), 
128.0 (CH), 127.9 (2CH), 81.6 (C), 71.2 (CH2), 65.8 (C), 57.6 (CH2), 39.3 (CH3), 21.8 (CH3); 
HRMS (ES): m/z calculated for C18H19NO3SNa: 252.0983, found 252.1000 (M+Na)
+. 
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Ynamide 171c 
Following GP5 using sulfonamide 135i (2.47 g, 10 mmol), Na2CO3 (421 mg, 
4.0 mmol), CuCl (55 mg, 0.4 mmol), pyridine (327 µL, 4.0 mmol) and hept-1-yne 
(263 µL, 2.0 mmol). Purification by flash column chromatography (5→15% EtOAc in hexane) gave 
ynamide 171c as a white solid (405 mg, 59%); mp: 25-26 °C; IR (neat): ν = 2955, 2939, 2859, 2257, 
1594, 1489, 1362, 1275, 1176, 1157, 1089, 935, 901, 815 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 
7.58-7.51 (d, J = 8.2 Hz, 2H), 7.35-7.22 (m, 7H), 2.43 (s, 3H), 2.28 (t, J = 7.0 Hz, 2H), 1.54-1.44 (m, 2H), 
1.39-1.24 (m, 4H), 0.94-0.85 (m, 3H); 13C-NMR (101 MHz, CDCl3): δ = 144.7 (C), 139.5 (C), 133.1 (C), 
129.4 (2CH), 129.0 (2CH), 128.4 (2CH), 128.0 (CH), 126.2 (2CH), 74.0 (C), 70.6 (C), 31.1 (CH2), 
28.7 (CH2), 22.3 (CH2), 21.8 (CH3), 18.6 (CH2), 14.2 (CH3); HRMS (ES): m/z calculated for 
C20H24NO2S: 342.1528, found 342.1514 (M+H)
+. Sulfonamide 135i (1.03 g, 4.1 mmol) was also 
recovered. 
5.1.5.2: General procedure for synthesis of ynamides from bromoacetylenes (GP4) 
 
Following a literature procedure[77b] a two-neck flask under an argon atmosphere was charged with 
the relevant amide (1.0 eq.), K3PO4 or K2CO3 (2.0 eq.), CuSO4·5H2O (10-20 mol%), 
1,10-phenanthroline (20-40 mol%), toluene (1 M with respect to amide) and bromoacetylene (1.1-
1.5 eq.) and heated at 70 °C for the stated time. After cooling to room temperature, the reaction 
mixture was filtered through a 5 cm pad of silica gel, concentrated under reduced pressure, and then 
purified by flash column chromatography. 
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Ynamide 84d 
Following GP4 using sulfonamide 135b (1.01 g, 7.5 mmol), K2CO3 (2.07 g, 15 
mmol), CuSO4·5H2O (187 mg, 0.75 mmol), 1,10-phenanthroline (270 mg, 1.5 
mmol) and 1-bromohept-1-yne (1.78 g, 10 mmol) for 18 hours. Purification by flash column 
chromatography (9:1 hexane:EtOAc) gave ynamide 84d as an orange oil (1.20 g, 70%); IR (neat): ν = 
2932, 2860, 2253, 1354, 1162 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 5.93 (ddt, J = 17.0, 10.2, 6.4 Hz, 
1H), 5.41-5.29 (m, 2H), 4.02 (appt. dt, J = 6.4, 1.1 Hz, 2H), 3.05 (s, 3H), 2.28 (t, J = 7.0 Hz, 2H), 1.55-
1.46 (m, 2H), 1.41-1.25 (m, 4H), 0.89 (t, J = 7.1 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ = 131.3 (CH), 
120.3 (CH2), 72.7 (C), 71.1 (C), 54.3 (CH2), 38.4 (CH3), 31.1 (CH2), 28.7 (CH2), 22.3 (CH2), 18.5 (CH2), 
14.1 (CH3); HRMS (ES): m/z calculated for C11H19NO2SNa: 252.1034, found 252.1030 (M+Na)
+. 
Ynamide 84e 
Following GP4 using sulfonamide 135l (143 mg, 0.59 mmol), K2CO3 (131 mg, 0.90 
mmol), CuSO4·5H2O (15 mg, 0.06 mmol), 1,10-phenanthroline (22 mg, 0.12 mmol) 
and (bromoethynyl)benzene (163 mg, 0.90 mmol) for 18 hours. Purification by flash column 
chromatography (9:1 hexane:EtOAc) gave ynamide 84e as a yellow solid (91.9 mg, 45%);  
mp: 59-61 °C (lit.[205] 65-67 °C); IR (neat): ν = 2233, 1606, 1529, 1346, 1311, 1172, 995 cm-1; 1H-NMR 
(300 MHz, CDCl3): δ = 8.36 (d, J = 9.0 Hz, 2H), 8.10 (d, J = 9.0 Hz, 2H), 7.36-7.22 (m, 5H), 5.74 (ddt, J = 
16.9, 10.2, 6.4 Hz, 1H), 5.33-5.18 (m, 2H), 4.09 (dt, J = 6.4, 1.1 Hz, 2H); 13C-NMR (101 MHz, CDCl3): δ = 
150.7 (C), 143.1 (C), 131.6 (CH), 130.2 (CH), 129.1 (2CH), 128.5 (4CH), 124.5 (2CH), 122.1 (C), 120.9 
(CH2), 81.0 (C), 71.6 (C), 54.9 (CH2). Spectroscopic data matched those reported.
[205] 
Ynamide 84g 
Following GP4 using sulfonamide 135c (811 mg, 7.4 mmol), K2CO3 (2.07 g, 15 mmol), 
CuSO4·5H2O (187 mg, 0.75 mmol), 1,10-phenanthroline (270 mg, 1.5 mmol) and 
(bromoethynyl)benzene (1.63 g, 9.0 mmol) for 18 hours. Purification by flash column 
chromatography (10→30% EtOAc in hexane) gave ynamide 84g as a pale yellow solid (1.51 g, 97%); 
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mp: 54-55 °C (lit.[206] 61-63 °C); IR (neat): ν = 2241, 1347, 1320, 1155, 1107, 957, 763 cm-1; 1H-NMR 
(300 MHz, CDCl3): δ = 7.46-7.37 (m, 2H), 7.36-7.27 (m, 3H), 3.30 (s, 3H), 3.13 (s, 3H); 
13C-NMR 
(101 MHz, CDCl3): δ = 131.7 (2CH), 128.5 (2CH), 128.2 (CH), 122.5 (C), 83.2 (C), 69.6 (C), 39.3 (CH3), 
36.9 (CH3). Spectroscopic data matched those reported.
[207] 
Ynamide 84h 
Following GP4 using amide 135d (498 mg, 3.0 mmol), K3PO4 (1.27 g, 6.0 mmol), 
CuSO4·5H2O (150 mg, 0.6 mmol), 1,10-phenanthroline (216 mg, 1.2 mmol) and 
(bromoethynyl)benzene (620 mg, 3.4 mmol) for 28 hours. Purification by flash column 
chromatography (5→10% EtOAc in hexane) gave ynamide 84h as a yellow oil (572 mg, 72%); 
IR (neat): ν = 3033, 2955, 2260, 2238, 1724, 1441, 1392, 1291, 1232, 753 cm-1; 1H-NMR (300 MHz, 
CDCl3): δ = 7.47-7.23 (m, 10H), 4.72 (s, 2H), 3.86 (s, 3H); 
13C-NMR (101 MHz, CDCl3): δ = 155.8 (C), 
136.1 (C), 131.3 (2CH), 128.8 (4CH), 128.4 (2CH), 128.3 (CH), 127.7 (CH), 123.3 (C), 83.2 (C), 71.4 (C), 
54.4 (CH3), 54.3 (CH2). Spectroscopic data matched those reported.
[77a] 
Ynamide 84k 
Following GP4 using indole (702 mg, 6.0 mmol), K3PO4 (2.55 g, 12 mmol), 
CuSO4·5H2O (150 mg, 0.6 mmol), 1,10-phenanthroline (216 mg, 1.2 mmol) and 
(bromoethynyl)benzene (1.47 g, 8.1 mmol) for 28 hours. Column chromatography was replaced by 
filtration through a 5 cm pad of silica with hexane and, after the solvent was removed under reduced 
pressure, the residue was recrystallised from hexane, isolated by filtration, and washed with ice-cold 
hexane (20 mL) to give ynamide 84k as a white solid (223 mg, 17%); mp: 54-56 °C; IR (neat): ν = 2246, 
1523, 1454, 1162, 1145, 746 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 7.71-7.62 (m, 2H),  
7.61-7.53 (m, 2H), 7.45-7.21 (m, 6H), 6.63 (dd, J = 3.4, 0.7, 1H); 13C-NMR (101 MHz, CDCl3): δ = 
138.3 (C), 131.6 (2CH), 129.0 (CH), 128.6 (2CH), 128.2 (CH), 128.0 (C), 123.7 (CH), 122.8 (C), 
122.1 (CH), 121.3 (CH), 111.5 (CH), 105.7 (CH), 80.9 (C), 70.7 (C). Spectroscopic data matched those 
reported.[94] 
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Ynamide 84l 
Following GP4 using oxazolidinone (695 mg, 8.0 mmol), K3PO4 (3.4 g, 16 mmol), 
CuSO4·5H2O (200 mg, 0.8 mmol), 1,10-phenanthroline (288 mg, 1.6 mmol) and 
(bromoethynyl)triisopropylsilane (1.64 g, 6.3 mmol) for 18 hours. Purification by flash column 
chromatography (10→15% EtOAc in hexane) gave ynamide 84l as a white solid (791 mg, 47%); 
mp: 70-72 °C; IR (neat): ν = 2943, 2865, 2177, 1758, 1479, 1463, 1399, 1103, 882 cm-1;  
1H-NMR (300 MHz, CDCl3): δ = 4.42 (dd, J = 8.8, 7.1 Hz, 2H), 3.94 (dd, J = 8.8, 7.1 Hz, 2H), 
1.11-1.04 (m, 21H); 13C-NMR (101 MHz, CDCl3): δ = 155.9 (C), 93.2 (C), 70.2 (C), 62.9 (CH2), 47.1 (CH2), 
18.7 (6CH3), 11.4 (3CH). Spectroscopic data matched those reported.
[82] 
Ynamide 84s 
Following GP4 using sulfonamide 135i (1.39 g, 7.5 mmol), K2CO3 (2.07 g, 15.0 mmol), 
CuSO4·5H2O (187 mg, 0.75 mmol), 1,10-phenanthroline (270 mg, 1.5 mmol) and 
(bromoethynyl)benzene (1.49 g, 8.2 mmol) for 22 hours. Purification by flash column 
chromatography (5→10% EtOAc in hexane) gave ynamide 84s as a pale yellow solid (1.46 g, 68%); 
mp: 60-62 °C (lit.[208] 79-81 °C); IR (neat): ν = 3241, 2234, 1594, 1579, 1359, 1167, 1115, 953, 
754 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 7.84 (d, J = 8.3 Hz, 2H), 7.42-7.33 (m, 4H), 7.32-7.27 (m, 3H), 
3.15 (s, 3H), 2.46 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 144.9 (C), 133.4 (C), 131.5 (2CH), 
129.9 (2CH), 128.4 (2CH), 128.0 (3CH), 122.9 (C), 84.1 (C), 69.2 (C), 39.5 (CH3), 21.8 (CH3). 
Spectroscopic data matched those reported.[208] 
Ynamide 84x 
Following GP4 using (-)-camphor sultam (2.15 g, 10 mmol), K2CO3 (2.76 g, 
20 mmol), CuSO4·5H2O (250 mg, 1.0 mmol), 1,10-phenanthroline (360 mg, 
2.0 mmol) and (bromoethynyl)benzene (2.0 g, 11 mmol) for 16 hours. 
Purification by flash column chromatography (10→15% EtOAc in hexane) gave ynamide 84x as a 
colourless viscous oil (2.97 g, 94%); IR (neat): ν = 2959, 2886, 2234, 1331, 1167, 1148, 815 cm-1; 
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1H-NMR (300 MHz, CDCl3): δ = 7.45-7.38 (m, 2H), 7.30-7.24 (m, 3H), 3.67 (dd, J = 8.1, 4.2 Hz, 1H), 3.29 
(s, 2H), 2.33-2.22 (m, 1H), 2.00-1.76 (m, 4H), 1.48-1.40 (m, 1H), 1.36-1.28 (m, 1H), 1.14 (s, 3H), 0.95 
(s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 131.8 (2CH), 128.3 (2CH), 128.0 (CH), 122.8 (C), 76.8 (C), 
72.8 (C), 67.3 (CH), 65.9 (C), 51.3 (C), 49.9 (CH2), 48.1 (C), 44.5 (CH), 34.5 (CH2), 31.7 (CH2), 27.1 (CH2), 
20.3 (CH3), 20.1 (CH3). Spectroscopic data matched those reported.
[209] 
Ynamide 84y 
Following GP4 using sulfonamide 135b (405 mg, 2.9 mmol), K2CO3 (830 mg, 
6.0 mmol), CuSO4·5H2O (75 mg, 0.3 mmol), 1,10-phenanthroline (108 mg, 0.6 mmol) 
and (bromoethynyl)benzene (600 mg, 3.3 mmol) for 18 hours. Purification by flash column 
chromatography (10→20% EtOAc in hexane) gave ynamide 84y as a yellow solid (571 mg, 83%); 
mp: 49-51 °C (lit.[49] 50-52 °C); IR (neat): ν = 3030, 2934, 2242, 1441, 1344, 1158, 1023, 972, 915 cm-1; 
1H-NMR (300 MHz, CDCl3): δ = 7.45-7.37 (m, 2H), 7.34-7.27 (m, 3H), 6.00 (ddt, J = 16.9, 10.2, 6.4 Hz, 
1H), 5.49-5.35 (m, 2H), 4.17 (d, J = 6.4 Hz, 2H), 3.14 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 131.6 (CH), 
131.0 (CH), 128.4 (2CH), 128.2 (2CH), 122.6 (C), 120.7 (CH2), 81.7 (C), 71.3 (C), 54.5 (CH2), 39.1 (CH3). 
Spectroscopic data matched those reported.[49] 
Ynamide 84z 
Following GP4 using sulfonamide 135m (1.19 g, 6.0 mmol), K2CO3 (1.66 g, 
12.0 mmol), CuSO4·5H2O (150 mg, 0.6 mmol), 1,10-phenanthroline (216 mg, 
1.2 mmol) and (bromoethynyl)benzene (1.19 g, 6.6 mmol) for 18 hours. Purification by flash column 
chromatography (10→15% EtOAc in hexane) gave ynamide 84z as a yellow solid (1.13 g, 63%); 
mp: 77-78 °C (lit.[90] 62-64 °C); IR (neat): ν = 2236, 1688, 1354, 1163, 1129, 1099, 964, 798, 756 cm-1; 
1H-NMR (300 MHz, CDCl3): δ = 7.55-7.49 (m, 2H), 7.45-7.29 (m, 8H) 5.23 (q, J = 7.1 Hz, 1H), 2.75 (s, 
3H), 1.78 (d, J = 7.1 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ = 139.8 (C), 131.5 (2CH), 128.9 (2CH), 
128.8 (CH), 128.5 (2CH), 128.1 (CH), 127.1 (2CH), 122.9 (C), 79.7 (C), 73.8 (C), 59.3 (CH), 39.1 (CH3), 
20.2 (CH3). Spectroscopic data matched those reported.
[90] 
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Ynamide 171a 
Following GP4 using sulfonamide 135i (429 mg, 2.3 mmol), K2CO3 (691 mg, 
4.6 mmol), CuSO4·5H2O (57 mg, 0.23 mmol), 1,10-phenanthroline (83 mg, 
0.46 mmol) and 1-bromohept-1-yne (608 mg, 3.48 mmol) for 16 hours. Purification by flash column 
chromatography (4:1 hexane:EtOAc) gave ynamide 171a as a colourless oil (427 mg, 66%); IR (neat): 
ν = 2930, 2859, 2253, 1597, 1456, 1363, 1277, 1171, 1089, 813, 757 cm-1; 1H-NMR (300 MHz, CDCl3): 
δ = 7.83-7.71 (d, J = 8.2 Hz, 2H), 7.40-7.29 (d, J = 8.2 Hz, 2H), 3.00 (s, 3H), 2.45 (s, 3H), 2.22 (t, 
J = 7.0 Hz, 2H), 1.53-1.38 (m, 2H), 1.38-1.22 (m, 4H), 0.95-0.81 (m, 3H); 13C-NMR (101 MHz, CDCl3): 
δ = 144.5 (C), 133.4 (C), 129.7 (2CH), 128.0 (2CH), 75.0 (C), 68.8 (C), 39.5 (CH3), 31.1 (CH2), 28.7 (CH2), 
22.3 (CH2), 21.8 (CH3), 18.5 (CH2), 14.1 (CH3); HRMS (ES): m/z calculated for C15H22NO2S: 280.1371, 
found 280.1377 (M+H)+. 
Ynamide 171b 
Following GP4 using sulfonamide 135j (524 mg, 2.0 mmol), K2CO3 (554 mg, 
4.0 mmol), CuSO4·5H2O (51 mg, 0.2 mmol), 1,10-phenanthroline (72 mg, 0.4 mmol) 
and 1-bromohept-1-yne (384 mg, 2.2 mmol) for 18 hours. Purification by flash column 
chromatography (9:1 hexane:EtOAc) gave ynamide 171b as a white solid (581 mg, 82%);  
mp: 32-33 °C (lit.[81] 45 °C); IR (neat): ν = 2255, 1427, 1354, 1168, 1088, 741 cm-1; 1H-NMR (300 MHz, 
CDCl3): δ = 7.72 (d, J = 8.3 Hz 2H), 7.34-7.21 (m, 7H), 4.41 (s, 2H), 2.42 (s, 3H), 2.13 (t, J = 6.9 Hz, 2H),  
1.34 (appt. quin, J = 6.9 Hz, 2H), 1.26-1.08 (m, 4H), 0.82 (t, J = 6.9 Hz, 3H); 13C-NMR (101 MHz, CDCl3): 
δ = 144.4 (C), 135.0 (C), 134.9 (C), 129.7 (2CH), 128.8 (2CH), 128.5 (2CH), 128.2 (CH), 127.8 (2CH), 
73.5 (C), 71.0 (C), 55.7 (CH2), 30.9 (CH2), 28.6 (CH2), 22.3 (CH2), 21.8 (CH3), 18.5 (CH2), 14.1 (CH3). 
Spectroscopic data matched those reported.[81] 
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5.1.5.3: General procedure for synthesis of ynamides from dibromoalkenes (GP6) 
 
Following a literature procedure,[81] a flask under an argon atmosphere was charged with 
amide (1.0 eq.), Cs2CO3 (4.0 eq.), CuI (12 mol%), dibromoalkene (1.3-1.5 eq.), 1,4-dioxane (0.5 M with 
respect to amide) and N,N’-dimethylethylenediamine (DMEDA) (18 mol%) and the reaction mixture 
was heated at 70 °C for the indicated time. After cooling to room temperature, the reaction mixture 
was filtered through a 5 cm pad of silica gel (eluting with CH2Cl2), concentrated under reduced 
pressure and purified by flash column chromatography. 
Ynamide 84f 
Following GP6 using sulfonamide 135l (818 mg, 3.4 mmol), Cs2CO3 (4.40 g, 
13.5 mmol), CuI (76 mg, 0.40 mmol), dibromoalkene 134d (1.16 g, 4.4 mmol) 
and DMEDA (65 µL, 0.60 mmol) for 18 hours. Purification by flash column chromatography 
(8:1 hexane:EtOAc) yielded ynamide 84f as a yellow solid (732 mg, 63%); mp: 75-79 °C; IR (neat): ν = 
3099, 2958, 2931, 2863, 2253, 2166, 1606, 1529, 1369, 1347 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 
8.42 (d, J = 9.0 Hz, 2H), 8.10 (d, J = 9.0 Hz, 2H), 5.70 (ddt, J = 17.0, 10.1, 6.3 Hz, 1H), 5.33-5.22 (m, 2H), 
4.04 (dt, J = 6.3, 1.2 Hz, 2H), 2.31 (t, J = 6.9 Hz, 2H), 1.59-1.33 (m, 4H), 0.92 (t, J = 7.2 Hz, 3H);  
13C-NMR (101 MHz, CDCl3): δ = 150.8 (C), 143.1 (C), 129.9 (CH), 129.1 (2CH), 124.6 (2CH), 121.2 (CH2), 
85.1 (C), 65.9 (C), 63.9 (C), 59.5 (C), 54.8 (CH2), 30.3 (CH2), 22.1 (CH2), 19.3 (CH2), 13.6 (CH3); 
HRMS (ES): m/z: calculated. for C17H18N2O4NaS: 369.0885, found 369.0842 (M+Na)
+. 
Ynamide 84j 
Following GP6 using 2-pyrrolidinone (190 µL, 2.5 mmol), Cs2CO3 (3.25 g, 10 mmol), 
CuI (57 mg, 0.30 mmol), dibromoalkene 134a (867 mg, 3.3 mmol) and 
DMEDA (50 µL, 0.46 mmol) for 14 hours. Purification by flash column chromatography 
(30→50% EtOAc in hexane) yielded ynamide 84j as a yellow oil (303 mg, 66%); IR (neat): ν = 2975, 
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2897, 2246, 1675, 1396, 1220 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 7.48-7.41 (m, 2H),  
7.34-7.27 (m, 3H), 3.83-3.75 (m, 2H), 2.53-2.45 (m, 2H), 2.24-2.12 (m, 2H); 13C-NMR (101 MHz, 
CDCl3): δ = 175.9 (C), 131.7 (2CH), 128.4 (2CH), 128.1 (CH), 122.8 (C), 80.5 (C), 72.8 (C), 50.3 (CH2), 
29.8 (CH2), 19.0 (CH2). Spectroscopic data matched those reported.
[82] 
Ynamide 84t 
Following GP6 using sulfonamide 135c (218 mg, 2.0 mmol), Cs2CO3 (2.60 
g, 8.0 mmol), CuI (48 mg, 0.25 mmol), dibromoalkene 134b (870 mg, 
3.0 mmol) and DMEDA (40 µL, 0.37 mmol) for 36 hours. Purification by flash column chromatography 
(20→30% EtOAc in hexane) yielded ynamide 84t as a white solid (455 mg, 92%); mp: 91-92 °C; 
IR (neat): ν = 3015, 2935, 2236, 1603, 1512, 1353, 1326, 1246, 1158, 1024, 959, 839 cm-1; 1H-NMR 
(300 MHz, CDCl3): δ = 7.36 (d, J = 8.9 Hz, 2H), 6.83 (d, J = 8.9 Hz, 2H), 3.81 (s, 3H), 3.28 (s, 3H), 3.11 (s, 
3H); 13C-NMR (101 MHz, CDCl3): δ = 159.8 (C), 133.7 (2CH), 114.4 (C), 114.1 (2CH), 81.8 (C), 69.3 (C), 
55.4 (CH3), 39.4 (CH3), 36.7 (CH3). Spectroscopic data matched those reported.
[206] 
Ynamide 84u 
Following GP6 using sulfonamide 135c (218 mg, 2.0 mmol), Cs2CO3 (2.60 g, 
8.0 mmol), CuI (48 mg, 0.25 mmol), dibromoalkene 134c (923 mg, 
3.0 mmol) and DMEDA (40 µL, 0.37 mmol) for 36 hours. Purification by flash column chromatography 
(20→30% EtOAc in hexane) yielded ynamide 84u as a yellow solid (182 mg, 36%); mp: 92-94 °C; 
IR (neat): ν = 3013, 2930, 2227, 1592, 1510, 1360, 1337, 1161, 1103, 958, 841 cm-1; 1H-NMR 
(400 MHz, CDCl3): δ = 8.16 (d, J = 8.8 Hz, 2H), 7.49 (d, J = 8.8 Hz, 2H), 3.35 (s, 3H), 3.15 (s, 3H); 
13C-
NMR (101 MHz, CDCl3): δ = 146.6 (C), 131.3 (2CH), 129.9 (C), 123.8 (2CH), 88.7 (C), 69.2 (C), 
39.3 (CH3), 37.7 (CH3); HRMS (ES): m/z calculated for C10H10N2O4SNa: 252.0983, found 
252.1000 (M+Na)+. 
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Ynamide 84n 
Following a literature procedure[49] a solution of ynamide 84m (406 mg, 3.0 mmol) in 
THF (10 mL) was cooled to 0 °C and TBAF (1 M in THF, 3.0 mL, 3.0 mmol) was added. 
The reaction mixture was allowed to warm to room temperature and stirred for 10 minutes before 
satd. NH4Cl(aq) solution (10 mL) was added and the aqueous phase was extracted with EtOAc (3 x 
20 mL). The combined organic phases were washed with brine, dried over Na2SO4, concentrated 
under reduced pressure and purified by flash column chromatography (5→10% EtOAc in hexane) to 
give ynamide 84n as a yellow solid (291 mg, 91%); mp: 77-78 °C (lit.[49] 76-78 °C); IR (neat): ν = 3276, 
2166, 2125, 1594, 1489, 1363, 1164, 1097, 1086, 807 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 7.58 (d, 
J = 8.4 Hz, 2H), 7.36-7.23 (m, 7H), 2.84 (s, 1H), 2.44 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 145.2 (C), 
138.4 (C), 133.0 (C), 129.7 (2CH), 129.3 (2CH), 128.5 (CH), 128.4 (2CH), 126.4 (2CH), 76.7 (C), 
59.0 (CH), 21.8 (CH3). Spectroscopic data matched those reported.
[49] 
Ynamide 84v 
Following a literature procedure[90] a solution of dichloroenamide 266 (239 mg, 
0.70 mmol) in THF (6 mL) was prepared under an argon atmosphere and cooled 
to −78 °C. nBuLi (2.5 M in hexane, 670 µL, 1.7 mmol) was added and the reaction mixture was stirred 
for 20 minutes before the addition of ethyl chloroformate (90 µL, 0.94 mmol). Stirring was continued 
for another 30 minutes at −78 °C and 2 hours at room temperature before the reaction was 
quenched by addition of satd. NH4Cl(aq) solution (20 mL) and Et2O (20 mL). The organic phase was 
separated, washed with brine (20 mL), dried over Na2SO4 and purified by flash column 
chromatography (9:1 hexane:EtOAc) to give ynamide 84v as a white solid (82 mg, 34%); mp: 118-
120 °C (lit.[90] 117-119 °C); IR (neat): ν = 2220, 1703, 1593, 1372, 1343, 1171, 1118, 1086 cm-1; 
1H-NMR (300 MHz, CDCl3): δ = 7.64 (d, J = 8.4 Hz, 2H), 7.40-7.29 (m, 5H), 7.24-7.16 (m, 2H), 4.23 (q, 
J = 7.1 Hz, 2H), 2.45 (s, 3H), 1.30 (t, J = 7.1 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ = 154.2 (C), 145.9 (C), 
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137.3 (C), 133.0 (C), 130.0 (2CH), 129.6 (2CH), 129.3 (CH), 128.5 (2CH), 126.8 (2CH), 82.3 (C), 66.6 (C), 
61.8 (CH2), 21.9 (CH3), 14.3 (CH3). Spectroscopic data matched those reported.
[90] 
Ynamide 84w 
Following a literature procedure[90] a solution of dichloroenamide 266 (513 mg, 
1.5 mmol) in THF (12 mL) was prepared under an argon atmosphere and cooled to 
−78 °C. nBuLi (2.5 M in hexane, 1.8 mL, 3.6 mmol) was added and the reaction mixture was stirred 
for 20 minutes before the addition of PhSO2SPh (413 mg, 1.65 mmol). Stirring was continued for 
another 30 minutes at −78 °C and 2 hours at room temperature before the reaction was quenched 
by addition of satd. NH4Cl(aq) solution (20 mL) and extracted with Et2O (2 x 10 mL). The combined 
organic phases were washed with brine, dried over Na2SO4 and purified by flash column 
chromatography (5→7.5% EtOAc in hexane) to give ynamide 84w as a tan solid (234 mg, 41%); 
mp: 110-111 °C (lit.[90] 113-114 °C); IR (neat): ν = 2927, 2164, 1583, 1345, 1156, 1088 cm-1; 1H-NMR 
(300 MHz, CDCl3): δ = 7.64 (d, J = 8.3 Hz, 2H), 7.39-7.18 (m, 12H), 2.46 (s, 3H); 
13C-NMR (101 MHz, 
CDCl3): δ = 145.3 (C), 139.0 (C), 134.2 (C), 133.4 (C), 129.8 (2CH), 129.3 (2CH), 129.2 (2CH), 
128.5 (CH), 128.5 (2CH), 126.6 (CH), 126.4 (2CH), 125.9 (2CH), 93.0 (C), 61.6 (C), 21.9 (CH3). 
Spectroscopic data matched those reported.[90] 
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5.1.6: Synthesis of Oxazoles 
5.1.6.1: General procedure for gold-catalysed oxazole synthesis (GP7) 
 
Pyridinium ylide (1.2-1.5 eq.), dichloro(2-pyridinecarboxylato)gold (1-5 mol%), and ynamide (1.0 eq.) 
were added to a flask under an argon atmosphere. Toluene (0.1 M with respect to ynamide) was 
added (where ynamides were oils these were added as a solution in toluene) and the reaction 
mixture was heated at 90 °C for the indicated time. After cooling to room temperature, the reaction 
mixture was filtered through a 5 cm plug of silica gel (washing with CH2Cl2 and then EtOAc) and the 
filtrate was concentrated under reduced pressure and purified by flash column chromatography. 
Oxazole 143a 
Following GP7 with ylide 94d (110 mg, 0.57 mmol), ynamide 84c (101 mg, 
0.37 mmol), and gold catalyst (7.6 mg, 5 mol%) for 1.5 hours. Purification by flash 
column chromatography (hexane:EtOAc 4:1) yielded oxazole 143a as a white solid 
(132 mg, 92%); mp: decomp. 160 °C; IR (neat): ν = 2986, 2936, 1644, 1605, 1585, 1492, 1351, 
1151 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 7.82-7.77 (m, 2H), 7.70-7.63 (m, 2H), 7.41-7.33 (m, 4H), 
7.32-7.22 (m, 2H), 3.22 (s, 3H), 1.68 (s, 9H); 13C-NMR (101 MHz, CDCl3): δ = 156.9 (C), 140.9 (C), 
140.3 (2C), 131.1 (C), 129.5 (2CH), 128.7 (2CH), 128.3 (CH), 127.9 (CH), 126.9 (2CH), 124.7 (2CH), 
85.9 (C), 38.5 (CH3), 28.0 (3CH3); HRMS (ES): m/z calculated for C20H22N2O4SNa: 409.1198, found 
409.1214 (M+Na)+. Degradation of this compound to a complex mixture was visible by NMR 
spectroscopy within 24 hours. 
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Oxazole 151a 
Following GP7 with ylide 94b (91.0 mg, 0.60 mmol), ynamide 84g (105 mg, 
0.50 mmol), and gold catalyst (4.1 mg, 2 mol%) for 1 hour. Purification by flash 
column chromatography (30→50% EtOAc in hexane) yielded oxazole 151a as a white 
solid (127 mg, 90%); mp: 122-124 °C; IR (neat): ν = 3010, 2934, 1638, 1608, 1593, 1451, 1373, 1337, 
1148, 1044, 967 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 7.84-7.77 (m, 2H), 7.44-7.35 (m, 2H),  
7.30 (tt, J = 7.4, 1.3 Hz, 1H), 4.09 (s, 3H), 3.24 (s, 3H), 3.14 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 
159.5 (C), 141.3 (C), 132.0 (C), 128.9 (2CH), 128.4 (CH), 126.9 (C), 124.7 (2CH), 58.3 (CH3), 37.8 (CH3), 
37.3 (CH3); HRMS (ES): calculated for C12H15N2O4S: 283.0753, found 283.0760 (M+H)
+. 
Oxazole 151b 
Following GP7 with ylide 94e (453 mg, 1.8 mmol), ynamide 84g (314 mg, 1.5 mmol) 
and gold catalyst (11.6 mg, 2 mol%) for 1 hour. Purification by flash column 
chromatography (30→50% EtOAc in hexane) yielded oxazole 151b as a white solid 
(553 mg, 97%); mp: 140-141 °C; IR (neat): ν = 3316, 2974, 1710, 1681, 1585, 1540, 1448, 1360, 1345, 
1273, 1226, 1152, 1070, 969 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 7.89 (d, J = 7.3 Hz, 2H), 
7.50-7.29 (m, 3H), 5.10 (br s, NH), 4.47 (d, J = 5.1 Hz, 2H), 3.25 (s, 3H), 3.12 (s, 3H), 1.48 (s, 9H); 
13C-NMR (101 MHz, CDCl3): δ = 158.3 (C), 155.6 (C), 146.1 (C), 133.4 (C), 129.3 (CH), 129.0 (2CH), 
126.7 (C), 125.4 (2CH), 80.5 (C), 38.5 (CH2), 38.0 (CH3), 37.1 (CH3), 28.5 (3CH3); HRMS (ES): m/z 
calculated for C17H23N3O5SNa: 404.1256, found 404.1247 (M+Na)
+. 
Oxazole 151c 
Following GP7 with ylide 94f (398 mg, 1.5 mmol), ynamide 84g (209 mg, 1.0 mmol), 
and gold catalyst (7.8 mg, 2 mol%) for 3 hours. Purification by flash column 
chromatography (30→40% EtOAc in hexane) yielded oxazole 151c as a white solid 
(314 mg, 79%); mp: 162-164 °C; [α]D
20 = −47.4 (c=1.0, CHCl3); IR (neat): ν = 2978, 2933, 1700, 1518, 
1345, 1247, 1153, 1069, 770 cm-1; 1H-NMR (300 MHz, CDCl3): 7.93-7.84 (m, 2H), 7.47-7.39 (m, 2H), 
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7.38-7.32 (m, 1H), 5.10-4.87 (m, 2H), 3.25 (s, 3H), 3.12 (s, 3H), 1.57 (d, J = 6.7 Hz, 3H), 1.47 (s, 9H); 
13C-NMR (101 MHz, CDCl3): δ = 161.9 (C), 155.0 (C), 145.8 (C), 133.2 (C), 129.2 (CH), 128.9 (2CH), 
126.7 (C), 125.4 (2CH), 80.3 (C), 45.2 (CH), 38.0 (CH3), 37.1 (CH3), 28.5 (3CH3), 20.1 (CH3); HRMS (ES): 
m/z calculated for C18H25N3NaO5S: 418.1413, found 418.1399 (M+Na)
+; e.r. = 97:3 (HPLC trace and 
conditions given on page 209). 
Oxazole 151d 
Following GP7 with ylide 94g (331 mg, 1.2 mmol), ynamide 84g (163 mg, 0.77 mmol) 
and gold catalyst (15.2 mg, 5 mol%) for 18 hours. Purification by flash column 
chromatography (1:1→2:1 EtOAc:hexane) yielded oxazole 151d as a pale pink solid 
(269 mg, 85%); mp: 160-163 °C; IR (neat): ν = 3374, 2990, 1669, 1624, 1517, 1494, 
1450, 1359, 1335, 1211, 1148, 1065, 978 cm-1; 1H-NMR (400 MHz, CDCl3): δ = 7.89-7.85 (m, 2H), 
7.71 (d, J = 15.6 Hz, 1H), 7.55-7.49 (m, 2H), 7.44-7.31 (m, 6H), 6.50 (d, J = 15.6 Hz, 1H),  
6.39 (br t, J = 5.4 Hz, NH), 4.70 (d, J = 5.4 Hz, 2H), 3.24 (s, 3H), 3.12 (s, 3H); 13C-NMR (101 MHz, CDCl3): 
δ = 166.0 (C), 157.8 (C), 146.3 (C), 142.5 (CH), 134.6 (C), 133.3 (C), 130.2 (CH), 129.4 (CH), 
129.02 (2CH), 128.92 (2CH), 128.1 (2CH), 126.5 (C), 125.4 (2CH), 119.7 (CH), 37.9 (CH3), 37.32 (CH2), 
37.28 (CH3); HRMS (ES): m/z calculated for C21H21N3O4SNa: 434.1150, found 434.1130 (M+Na)
+. 
Oxazole 151f 
Following GP7 with ylide 94i (36.5 mg, 0.30 mmol), ynamide 84g (41.8 mg, 0.20 mmol), 
and gold catalyst (3.9 mg, 5 mol%) for 2 hours. Purification by flash column 
chromatography (7:13 EtOAc/hexane) yielded oxazole 151f as a white solid (45.6 mg, 
90%); mp: 155-157 °C; IR (neat): ν = 3676, 3151, 2989, 2902, 1626, 1599, 1449, 1361, 1342, 1321, 
1239, 1148, 1061, 978, 849 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 8.00-7.90 (m, 2H), 7.82 (s, 1H), 
7.50-7.34 (m, 3H), 3.28 (s, 3H), 3.14 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 148.2 (CH), 146.0 (C), 
133.3 (C), 129.5 (CH), 129.0 (2CH), 126.6 (C), 125.6 (2CH), 38.0 (CH3), 36.9 (CH3); HRMS (ES): m/z 
calculated for C11H12N2O3SNa: 275.0466, found 275.0463 (M+Na)
+. 
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Oxazole 151g 
Note: To avoid degradation, room temperature water baths should be used when 
evaporating solvent from this compound.  
1.0 mmol scale: Following GP7 with ylide 94j (295 mg, 1.5 mmol), ynamide 84g 
(209 mg, 1.0 mmol) and gold catalyst (8.2 mg, 2 mol%) for 2.5 hours. Purification by flash column 
chromatography (80:20:1→50:50:1 hexane:EtOAc:NEt3) yielded oxazole 151g as a white solid 
(296 mg, 91%); mp: 108-110 °C; IR (neat): ν = 3016, 2956, 2909, 2833, 1451, 1358, 1337, 1324, 1152, 
1116, 1059, 961, 841, 763 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 7.98-7.93 (m, 2H), 7.48-7.41 (m, 2H), 
7.41-7.34 (m, 1H), 5.50 (s, 1H), 3.49 (s, 6H), 3.29 (s, 3H), 3.14 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 
156.4 (C), 146.5 (C), 133.2 (C), 129.5 (CH), 128.9 (2CH), 126.5 (C), 125.7 (2CH), 97.0 (CH), 53.9 (2CH3), 
38.0 (CH3), 37.2 (CH3); HRMS (ES): m/z calculated for C14H18N2O5SNa: 349.0834, found 
349.0840 (M+Na)+. 
4.8 mmol scale: Following GP7 with ylide 94j (1.03 g, 5.25 mmol), ynamide 84g (1.00 g, 4.8 mmol), 
gold catalyst (37 mg, 2 mol%) for 4 hours. After filtration and evaporation of the solvent under 
reduced pressure the crude residue was recrystallised by precipitation from CH2Cl2 with hexane to 
give oxazole 151g as a tan solid (790 mg, 51%); the filtrate was concentrated under reduced pressure 
and purified by flash column chromatography (70:30:1 hexane:EtOAc:NEt3) yielding additional 
oxazole 151g as a white solid (416 mg, 26% – combined to give a 77% overall yield for the process). 
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Oxazole 151h 
Following GP7 with ylide 94k (345 mg, 1.7 mmol), ynamide 84g (242 mg, 1.2 mmol) 
and gold catalyst (4.6 mg, 1 mol%) for 16 hours. Purification by flash column 
chromatography (EtOAc:hexane 2:1→3:1) yielded oxazole 151h as a white powder 
(284 mg, 75%); mp: 164-166 °C; IR (neat): ν = 3028, 2939, 1588, 1549, 1428, 1371, 
1338, 1150, 1066, 952, 856 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 8.80 (ddd, J = 4.8, 1.7, 0.9 Hz, 1H), 
8.16-8.03 (m, 3H), 7.87 (appt. td, J = 7.8, 1.7 Hz, 1H), 7.52-7.35 (m, 4H), 3.36 (s, 3H), 3.21 (s, 3H); 
13C-NMR (101 MHz, CDCl3): δ = 157.0 (C), 150.4 (CH), 146.9 (C), 145.5 (C), 137.3 (CH), 135.1 (C), 
129.6 (CH), 129.0 (2CH), 126.6 (C), 125.8 (2CH), 125.1 (CH), 122.3 (CH), 38.1 (CH3), 37.2 (CH3); 
HRMS (ES): m/z calculated for C16H15N3O3SNa: 352.0732, found 352.0733 (M+Na)
+. 
Oxazole 151i 
Following GP7 with ylide 94l (73.7 mg, 0.30 mmol), ynamide 84g (42.3 mg, 
0.20 mmol) and gold catalyst (3.9 mg, 5 mol%) for 1 hour. Purification by flash 
column chromatography (30→50% EtOAc in hexane) yielded oxazole 151i as a 
white solid (67.9 mg, 89%); mp: 225-227 °C; IR (neat): ν = 3012, 2931, 1615, 
1596, 1497, 1449, 1338, 1162, 1146, 969, 839, 760 cm-1; 1H-NMR (300 MHz, CDCl3): δ =  
8.33-8.26 (m, 2H), 8.20 (d, J = 8.6 Hz, 1H), 8.17-8.11 (m, 2H), 7.86 (d, J = 8.1 Hz, 1H),  
7.83-7.75 (m, 1H), 7.66-7.57 (m, 1H), 7.54-7.46 (m, 2H), 7.44-7.37 (m, 1H), 3.38 (s, 3H), 3.26 (s, 3H); 
13C-NMR (101 MHz, CDCl3): δ = 157.3 (C), 148.2 (C), 147.3 (C), 145.3 (C), 137.3 (CH), 135.3 (C), 
130.5 (CH), 130.3 (CH), 129.7 (CH), 129.0 (2CH), 128.4 (C), 128.0 (CH), 127.8 (CH), 126.6 (C), 126.0 
(2CH), 119.4 (CH), 38.1 (CH3), 37.4 (CH3); HRMS (ES): m/z calculated for C20H17N3O3SNa: 402.0888, 
found 402.0885 (M+Na)+. 
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Oxazole 151j 
Following GP7 with ylide 94m (123 mg, 0.60 mmol), ynamide 84g (105 mg, 
0.50 mmol), and gold catalyst (3.9 mg, 2 mol%) for 1 hour. Purification by flash 
column chromatography (CH2Cl2) yielded oxazole 151j as a white solid (162 mg, 
97%); mp: 154-156 °C; IR (neat): ν = 1613, 1572, 1335, 1151, 955, 851 cm-1; 1H-NMR (300 MHz, 
CDCl3): δ = 8.02-7.96 (m, 2H), 7.74 (dd, J = 3.7, 1.1 Hz, 1H), 7.50-7.42 (m, 3H), 7.41-7.34 (m, 1H), 
7.15 (dd, J = 5.0, 3.7 Hz, 1H), 3.32 (s, 3H), 3.20 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 154.9 (C), 
145.0 (C), 134.6 (C), 129.6 (C), 129.2 (CH), 129.1 (CH), 129.0 (2CH), 128.4 (CH), 128.2 (CH), 126.8 (C), 
125.4 (2CH), 38.1 (CH3), 37.1 (CH3); HRMS (ES): calculated for C15H14N2O3S2Na: 357.0344, found 
357.0341 (M+Na)+. 
Oxazole 151k 
Following GP7 with ylide 94o (105 mg, 0.30 mmol), ynamide 84g (43.1 mg, 0.20 
mmol) and gold catalyst (4.0 mg, 5 mol%) for 1 hour. Purification by flash column 
chromatography (4:1 hexane/EtOAc) yielded oxazole 151k as a white solid 
(44.7 mg, 45%); mp: 229-231 °C; IR (neat): ν = 3302, 1648, 1610, 1595, 1478, 1382, 
1334, 1273, 1150, 1125, 950, 876, 865 cm-1; 1H-NMR (300 MHz, d6-acetone): δ = 10.16 (s, NH),  
8.39 (s, 2H), 7.87-7.79 (m, 2H), 7.66 (s, 1H), 7.50-7.41 (m, 2H), 7.38-7.29 (m, 1H), 3.31 (s, 3H),  
3.27 (s, 3H); 13C-NMR (101 MHz, d6-acetone): δ = 153.9 (C), 141.7 (C), 140.0 (C), 134.4 (C),  
132.9 (q, JC-F = 33.1 Hz, 2C), 129.6 (2CH), 129.0 (CH), 128.0 (C), 125.2 (2CH), 124.5 (q, JC-F = 272.1 Hz, 
2CF3), 117.9-117.5 (m, 2CH), 115.7-115.3 (m, CH), 38.1 (CH3), 36.9 (CH3); 
19F{1H}-NMR (282 MHz, 
d6-acetone): δ = -63.7; HRMS (ES): m/z calculated for C19H16N3O3F6S: 480.0817, found 480.0807 
(M+H)+. 
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Oxazole 151l 
Ynamide 84g (1.00 g, 4.8 mmol), ylide 94c (1.04 g, 5.3 mmol), gold catalyst (18.3 mg, 
1 mol%) and unpurified toluene (48 mL) were added to an open flask, a reflux 
condenser was fitted and the reaction mixture was heated at 90 °C for 48 hours. After 
cooling to room temperature, the reaction mixture was filtered through a 5 cm pad of silica gel 
(eluting with CH2Cl2) and purified by flash column chromatography (CH2Cl2) to yield recovered 
ynamide 84g (299 mg, 30%) and oxazole 151l (923 mg, 59%); mp: 184-186 °C; IR (neat): ν = 3063, 
3021, 2974, 2936, 1617, 1557, 1494, 1447, 1364, 1338, 1327, 1237, 1145, 1065, 965, 847, 765; 
1H-NMR (300 MHz, CDCl3): δ = 8.11-7.99 (m, 4H), 7.53-7.43 (m, 5H), 7.41-7.34 (m, 1H), 3.33 (s, 3H), 
3.22 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 158.6 (C), 145.6 (C), 134.9 (C), 131.0 (CH), 129.2 (CH), 
129.0 (4CH), 127.1 (C), 127.0 (C), 126.5 (2CH), 125.5 (2CH), 38.1 (CH3), 37.1 (CH3); HRMS (ES) m/z: 
calc. for C17H17N2O3S: 329.0960, found 329.0955 (M+H)
+. 
Oxazole 154a 
Following GP7 using ylide 94c (58.4 mg, 0.29 mmol), gold catalyst (3.6 mg, 5 mol%) 
and a solution of ynamide 84i (70.1 mg, 0.20 mmol) in toluene (2 mL) for 5 hours. 
Purification by flash column chromatography (25→50% EtOAc in hexane) yielded 
oxazole 154a as a colourless oil (75.3 mg, 81%); IR (neat): ν = 3063, 2982, 2930, 1616, 1598, 1491, 
1448, 1386, 1254, 1049, 1019, 958, 774 cm-1; 1H-NMR (400 MHz, CDCl3): δ = 8.08-8.02 (m, 2H), 7.61-
7.56 (m, 2H), 7.48-7.42 (m, 3H), 7.32-7.22 (m, 5H), 7.18-7.14 (m, 3H), 4.69 (d, J = 7.3 Hz, 2H), 
4.13 (appt. quin, J = 7.1 Hz, 4H), 1.24 (td, J = 7.1, 0.9 Hz, 6H); 13C-NMR (101 MHz, CDCl3): δ = 158.0 (C), 
144.5 (d, JC-P = 6.2 Hz, C), 137.3 (d, JC-P = 4.2 Hz, C), 135.35 (C), 135.32 (C), 130.4 (CH), 129.3 (2CH), 
128.8 (2CH), 128.3 (5CH), 127.7 (CH), 127.6 (C), 126.3 (2CH), 125.7 (2CH), 63.2 (d, JC-P = 5.4 Hz, 2CH2), 
53.5 (d, JC-P = 5.1 Hz, CH2), 16.1 (d, JC-P = 7.3 Hz, 2CH3); 
31P{1H}-NMR (121 MHz, CDCl3): δ = 5.76; HRMS 
(ES): m/z calculated for C26H28N2O4P: 463.1787, found 463.1798 (M+H)
+. 
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Oxazole 154b 
Following GP7 using ylide 94c (60.0 mg, 0.30 mmol), ynamide 84k (42.8 mg, 0.20 
mmol) and gold catalyst (4.1 mg, 5 mol%) for 4 days. Purification by flash column 
chromatography (0→10% ethyl acetate in hexane) gave recovered ynamide 84k 
(11.9 mg, 28%) and oxazole 154b as a white solid (42.8 mg, 64%); mp: 120-121 °C; 
IR (neat): ν = 3141, 3061, 1741, 1709, 1624, 1454, 1309, 1211, 1184, 933 cm-1; 1H-NMR (300 MHz, 
CDCl3): δ = 8.13-8.04 (m, 2H), 7.67-7.57 (m, 1H), 7.48-7.38 (m, 3H), 7.32-7.26 (m, 2H), 7.25-7.17 (m, 
5H), 7.14-7.06 (m, 2H), 6.68 (d, J = 3.3 Hz, 1H); 13C-NMR (101 MHz, CDCl3): δ = 159.0 (C), 142.0 (C), 
136.2 (C), 133.5 (C), 131.0 (CH), 129.2 (C), 129.04 (2CH), 128.98 (2CH), 128.8 (CH), 127.6 (CH), 
127.1 (C), 127.0 (C), 126.6 (2CH), 125.1 (2CH), 122.9 (CH), 121.1 (CH), 121.0 (CH), 111.6 (CH), 
105.1 (CH); HRMS (ES): m/z calculated for C23H17N2O: 337.1341, found 337.1340 (M+H)
+. 
Oxazolone 155 
Following GP7 using ylide 94c (116 mg, 0.59 mmol), gold catalyst (8.1 mg, 5 mol%) 
and a solution of ynamide 84h (106 mg, 0.40 mmol) in toluene (4 mL) for 24 hours. 
Purification by flash column chromatography (10→50% EtOAc in petroleum ether) yielded recovered 
ynamide X as a yellow oil (70.8 mg, 67%) and oxazolone 155 as a white solid (14.3 mg, 14%); 
mp: 150-152 °C; IR (neat): ν = 3131, 3036, 1734, 1647, 1497, 1452, 1439, 1400, 1362, 1281, 1184, 
1097, 1023, 965, 731 cm-1; 1H-NMR (400 MHz, CDCl3): δ = 7.46-7.31 (m, 9H), 7.26 (tt, J = 7.3, 1.3 Hz, 
1H), 6.64 (s, 1H), 4.80 (s, 2H); 13C-NMR (101 MHz, CDCl3): δ = 155.2 (C), 139.5 (C), 135.4 (C), 
129.2 (2CH), 128.9 (2CH), 128.6 (CH), 128.3 (CH), 128.2 (2CH), 127.4 (C), 123.1 (2CH), 109.0 (CH), 
48.0 (CH2); HRMS (ES): m/z calculated for C16H14NO2: 252.1025, found 252.1024 (M+H)
+. 
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Ketone 156 
Following GP7 using ylide 94c (60.1 mg, 0.30 mmol), gold catalyst (4.1 mg, 5 mol%) 
and a solution of ynamide 84j (36.9 mg, 0.20 mmol) in toluene (2 mL) for 24 hours. 
Purification by flash column chromatography (30→100% EtOAc in hexane) yielded 
recovered ynamide 84j as an orange oil (21.7 mg, 59%) and ketone 156 as an orange oil (6.4 mg, 
16%); IR (neat): ν = 2922, 1677, 1449, 1290, 1226, 987, 758 cm-1; 1H-NMR (400 MHz, CDCl3): δ = 
7.99-7.93 (m, 2H), 7.60 (tt, J = 7.4, 1.6 Hz, 1H), 7.51-7.45 (m, 2H), 4.74 (s, 2H), 3.50 (t, J = 7.1 Hz, 2H), 
2.48 (t, J = 8.1 Hz, 2H), 2.17-2.06 (m, 2H); 13C-NMR (101 MHz, CDCl3): δ = 194.0 (C), 175.9 (C), 
135.1 (C), 133.9 (CH), 129.0 (2CH), 128.2 (2CH), 49.2 (CH2), 48.0 (CH2), 30.5 (CH2), 18.2 (CH2). 
Spectroscopic data matched those reported.[210] 
Oxazole 167 
Following GP7 using ylide 94c (59.6 mg, 0.30 mmol), ynamide 84n (53.9 mg, 0.20 mmol) 
and gold catalyst (3.9 mg, 5 mol%) for 1 hour. Purification by flash column 
chromatography (toluene) yielded oxazole 167 as a white solid (54.4 mg, 70%); 
mp: 122-124 °C; IR (neat): ν = 2926, 2865, 1583, 1344, 1232, 1160, 1089 cm-1; 1H-NMR (400 MHz, 
CDCl3): δ = 7.91-7.82 (m, 2H), 7.73 (s, 1H), 7.59 (d, J = 8.2 Hz, 2H), 7.38-7.30 (m, 5H), 7.28-7.21 (m, 
3H), 7.19 (d, J = 8.2 Hz, 2H), 2.35 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 160.1 (C), 144.1 (C), 
140.4 (C), 139.6 (C), 135.9 (C), 133.5 (CH), 130.7 (CH), 129.4 (2CH), 129.1 (2CH), 128.8 (4CH), 
128.6 (2CH), 128.2 (CH), 127.3 (C), 126.5 (2CH), 21.7 (CH3); HRMS (ES): m/z calculated for 
C22H19N2O3S: 391.1116, found 391.1111 (M+H)
+. 
Appendix 
176 
 
Oxazole 170 
 
KOH (85%, 1.21 g, 18.3 mmol) was dissolved in H2O (1 mL) and left to cool to room temperature 
before adding to a solution of dibromoenamide 169 (174 mg, 0.39 mmol) and BnNEt3Cl (75 mg, 
0.33 mmol) in CH2Cl2 (1.5 mL). The biphasic mixture was stirred for 6 hours after which H2O (10 mL) 
and CH2Cl2 (10 mL) were added. The phases were separated and the aqueous phase was extracted 
with CH2Cl2 (2 x 10 mL). The combined organic extracts were dried over Na2SO4, filtered through a 
5 cm pad of silica gel (eluting with CH2Cl2) and the filtrate was concentrated under reduced pressure 
to give crude ynamide 84q as a colourless oil. A magnetic stirrer bar, ylide 94c (116 mg, 0.58 mmol) 
and gold catalyst (7.8 mg, 5 mol%) were added to the flask containing crude ynamide 84q. This was 
then evacuated and back-filled with argon. Toluene (4 mL) was added and the reaction mixture was 
heated at 90 °C for 16 hours. After cooling to room temperature, the reaction mixture was filtered 
through a 5 cm plug of NEt3 deactivated silica gel (washing with CH2Cl2 and then EtOAc) and the 
filtrate concentrated under reduced pressure and purified by flash column chromatography 
(95:5:1→90:10:1 hexane:EtOAc:NEt3) yielded oxazole 170 as a white solid (43.7 mg, 23% over two 
steps); mp: 140-141 °C; IR (neat): ν = 3064, 3026, 2921, 1595, 1557, 1488, 1449, 1353, 1167, 1121, 
1090, 1064, 814 cm-1; 1H-NMR (400 MHz, CDCl3): δ = 7.87 (dd, J = 7.8, 1.6 Hz, 2H), 7.81 (d, J = 8.3 Hz, 
2H), 7.49-7.41 (m, 3H), 7.36 (d, J = 8.3 Hz, 2H), 7.33-7.29 (m, 2H), 7.29-7.22 (m, 3H), 4.60 (s, 2H), 
2.49 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 161.0 (C), 144.2 (C), 136.7 (C), 135.7 (C), 135.1 (C), 
131.1 (CH), 129.8 (2CH), 128.94 (2CH), 128.87 (2CH), 128.5 (4CH), 128.1 (CH), 126.6 (C), 126.2 (2CH), 
122.3 (C), 53.3 (CH2), 21.8 (CH3); HRMS (ES): m/z calculated for C23H20N2O3S
79Br: 483.0378, found 
483.0366 (M+H)+. 
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Compounds 172a and 173a 
 
Following GP7 using ylide 94b (91 mg, 0.60 mmol), gold catalyst (7.7 mg, 5 mol%) and a solution of 
ynamide 171a (111 mg, 0.40 mmol) in toluene (4 mL) for 6 hours. Purification by flash column 
chromatography (5→30% EtOAc in hexane) gave a colourless oil containing a mixture of products in 
the ratio 64:33:3 oxazole:E alkene:Z alkene (117 mg, 83%); ratio determined by 1H-NMR using the 
characteristic alkene signals and the CH2 signal α to C5 of the oxazole. HRMS (ES): m/z calculated for 
C17H25N2O4S: 353.1535, found 353.1531 (M+H)
+. 
Compounds 172b and 173b 
 
Following GP7 with ylide 94b (91 mg, 0.60 mmol), ynamide 171b (142 mg, 0.40 mmol) and gold 
catalyst (7.9 mg, 5 mol%) for 2 hours. Purification by flash column chromatography (5→30% EtOAc in 
hexane) gave a colourless oil containing a mixture of products in the ratio 85:15:trace  
oxazole:E alkene:Z alkene (132 mg, 77%); ratio determined by 1H-NMR using the characteristic alkene 
signals and the CH2 signal α to C5 of the oxazole. HRMS (ES): m/z calculated for 
C23H29N2O4S: 429.1848, found 429.1845 (M+H)
+. 
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Compounds 172c and 173c 
 
Following GP7 with ylide 94b (91 mg, 0.60 mmol), ynamide 171c (128 mg, 0.38 mmol) and gold 
catalyst (7.8 mg, 5 mol%) for 2 hours. Purification by flash column chromatography (5→30% EtOAc in 
hexane) gave oxazole 172c as a colourless oil (102 mg, 66%) and a mixture of alkenes 173c in a 
15:1 E:Z ratio as a pale yellow solid (32 mg, 21%). 
Oxazole 172c: IR (neat): ν = 2954, 2930, 2862, 1609, 1488, 1166, 1092, 813 cm-1; 1H-NMR (300 MHz, 
CDCl3): δ = 7.67-7.61 (m, 2H), 7.38-7.32 (m, 2H), 7.29-7.22 (m, 4H), 7.21-7.18 (m, 1H), 3.97 (s, 3H), 
2.62 (t, J = 7.6 Hz, 2H), 2.41 (s, 3H), 1.62-1.50 (m, 2H), 1.31-1.17 (m, 4H), 0.82 (t, J = 6.9 Hz, 3H); 
13C-NMR (101 MHz, CDCl3): δ = 159.0 (C), 145.5 (C), 143.7 (C), 140.5 (C), 136.0 (C), 131.7 (C), 
129.1 (2CH), 129.0 (2CH), 128.8 (2CH), 127.7 (2CH), 127.5 (CH), 57.9 (CH3), 31.3 (CH2), 27.1 (CH2), 
24.1 (CH2), 22.3 (CH2), 21.7 (CH3), 14.0 (CH3); HRMS (ES): m/z calculated for C22H26N2O4SNa: 437.1511, 
found 437.1502 (M+Na)+. 
Alkenes 173c: mp: 66-68 °C; ν = 2956, 2931, 2869, 1718, 1648, 1593, 1490, 1436, 1364, 1210, 1167, 
1064 cm-1; 1H-NMR (400 MHz, CDCl3) only peaks for the major (E) isomer are listed: δ = 7.72-7.66 (m, 
2H), 7.40-7.33 (m, 3H), 7.29-7.18 (m, 4H), 6.31 (dt, J = 15.8, 7.2 Hz, 1H), 5.59 (dt, J = 15.8, 1.2 Hz, 1H), 
3.74 (s, 3H), 2.42 (s, 3H), 1.93 (appt. qd, J = 7.2, 1.2 Hz, 2H), 1.20-1.11 (m, 2H), 1.08-0.98 (m, 2H), 
0.74 (t, J = 7.2 Hz, 3H); 13C-NMR (101 MHz, CDCl3) only peaks for the major (E) isomer are listed: δ = 
161.1 (C), 156.6 (C), 147.0 (CH), 144.6 (C), 137.7 (C), 135.5 (C), 130.3 (2CH), 129.6 (2CH), 129.3 (2CH), 
129.2 (3CH), 121.9 (CH), 53.5 (CH3), 32.4 (CH2), 30.1 (CH2), 21.82 (CH3), 21.77 (CH2), 13.8 (CH3); 
HRMS (ES): m/z calculated for C22H27N2O4S: 415.1692, found 415.1685 (M+H)
+. 
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Compounds 172d and 174d 
 
Following GP7 using ylide 94c (119 mg, 0.60 mmol), gold catalyst (7.7 mg, 5 mol%) and a solution of 
ynamide 171a (108 mg, 0.39 mmol) in toluene (4 mL) 2 hours. Purification by flash column 
chromatography (5→20% EtOAc in hexane) gave oxazole 172d as a white solid (102 mg, 66%) and a 
complex mixture containing 174d as the major component as a yellow oil (22.9 mg, <15%). 
Oxazole 172d: mp: 80-82 °C, IR (neat): ν = 2950, 2930, 2868, 1639, 1597, 1559, 1449, 1341, 1152, 
1087, 1042, 867, 806, 781 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 7.91-7.83 (m, 2H), 7.72-7.65 (m, 2H), 
7.46-7.39 (m, 3H), 7.30 (d, J = 8.1 Hz, 2H), 3.11 (s, 3H), 2.84 (t, J = 7.7 Hz, 2H), 2.44 (s, 3H), 
1.84-1.70 (m, 2H), 1.49-1.34 (m, 4H), 0.93 (t, J = 7.0 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ = 158.0 (C), 
149.5 (C), 143.8 (C), 135.0 (C), 134.6 (C), 130.2 (CH), 129.5 (2CH), 128.8 (2CH), 128.5 (2CH), 127.7 (C), 
126.0 (2CH), 37.4 (CH3), 31.6 (CH2), 27.3 (CH2), 24.7 (CH2), 22.4 (CH2), 21.7 (CH3), 14.1 (CH3); 
HRMS (ES): m/z calculated for C22H27N2O3S: 399.11742, found 399.1751 (M+H)
+. 
Alkene 174d: 1H-NMR (400 MHz, CDCl3) only peaks assigned to 174d are reported: δ = 7.78-7.74 (m, 
2H), 7.66-7.62 (m, 2H), 7.43-7.36 (m, 3H), 7.23 (d, J = 8.0 Hz, 2H), 5.94 (ddt, J = 15.2, 10.8, 1.3 Hz, 1H), 
5.62 (dt, J = 15.2, 7.0 Hz, 1H), 5.48 (d, J = 10.8 Hz, 1H), 2.99 (s, 3H), 2.36 (s, 3H), 1.98 (appt. q,  
J = 7.0 Hz, 2H), 1.36-1.26 (m, 2H), 0.80 (t, J = 7.4 Hz, 3H). 
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Compounds 172e and 174e 
 
Following GP7 with ylide 94c (118 mg, 0.60 mmol), ynamide 171b (143 mg, 0.40 mmol) and gold 
catalyst (8.0 mg, 5 mol%) for 5 hours. Purification by flash column chromatography (5→40% EtOAc in 
hexane) gave oxazole 172e as a clear oil (118 mg, 62%) and a complex mixture containing 174e as the 
major component as a yellow oil (15.7 mg, <8%). 
Oxazole 172e: IR (neat): ν = 2956, 2929, 2864, 1637, 1598, 1560, 1450, 1351, 1164, 1091, 1027, 
858 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 7.90-7.83 (m, 2H), 7.81-7.75 (m, 2H), 7.45-7.38 (m, 3H), 
7.37-7.20 (m, 7H), 4.57 (s, 2H), 2.50 (t, J = 7.5 Hz, 2H), 2.46 (s, 3H), 1.33-1.17 (m, 4H), 1.17-1.05 (m, 
2H), 0.84 (t, J = 7.1 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ = 157.9 (C), 151.8 (C), 143.8 (C), 136.03 (C), 
135.95 (C), 132.4 (C), 130.2 (CH), 129.6 (2CH), 129.2 (2CH), 128.8 (2CH), 128.5 (2CH), 128.4 (2CH), 
127.9 (CH), 127.7 (C), 126.1 (2CH), 53.3 (CH2), 31.5 (CH2), 27.1 (CH2), 24.4 (CH2), 22.4 (CH2), 
21.7 (CH3), 14.1 (CH3); HRMS (ES): m/z calculated for C28H31N2O3S: 475.2055, found 475.2062 (M+H)
+. 
Alkene 174e: 1H-NMR (400 MHz, CDCl3) only peaks assigned to 174e are reported: δ = 7.74-7.69 (m, 
2H), 7.67-7.63 (m, 2H), 7.54-7.49 (m, 1H), 7.45-7.19 (m, 9H), 5.89 (ddt, J = 15.2, 10.8, 1.3 Hz, 1H), 
5.57 (dt, J = 15.2, 7.0 Hz, 1H), 5.44 (d, J = 10.8 Hz, 1H), 4.61 (s, 2H), 2.42 (s, 3H), 2.06-1.97 (m, 2H), 
1.40-1.29 (m, 2H), 0.84 (t, J = 7.4 Hz, 3H). 
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Compounds 172f, 173f and 174f 
 
Following GP7 with ylide 94c (118 mg, 0.60 mmol), ynamide 171c (138 mg, 0.40 mmol) and gold 
catalyst (7.8 mg, 5 mol%) for 5 hours. Purification by flash column chromatography (5→50% EtOAc in 
hexane) gave oxazole 172f as a white solid (141 mg, 76%) and a 2 complex mixtures, the first 
containing 173f as the major component of a clear oil (6.5 mg, <4%), and the second containing 174f 
as a component of a clear oil (5.7 mg, <3%). 
Oxazole 172f: IR (neat): ν = 2931, 2863, 1635, 1594, 1557, 1486, 1450, 1357, 1167, 1092, 810 cm-1; 
1H-NMR (300 MHz, CDCl3): δ = 8.01-7.87 (m, 2H), 7.73-7.62 (m, 2H), 7.51-7.37 (m, 5H), 7.33-7.18 (m, 
5H), 2.82 (t, J = 7.6 Hz, 2H), 2.43 (s, 3H), 1.76-1.62 (m, 2H), 1.39-1.22 (m, 4H), 0.85 (t, J = 6.8 Hz, 3H); 
13C-NMR (101 MHz, CDCl3): δ = 157.9 (C), 150.5 (C), 143.8 (C), 140.5 (C), 135.9 (C), 134.9 (C), 
130.3 (CH), 129.2 (2CH), 129.00 (2CH), 128.96 (2CH), 128.8 (2CH), 128.0 (2CH), 127.8 (C), 127.6 (CH), 
126.1 (2CH), 31.5 (CH2), 27.3 (CH2), 24.5 (CH2), 22.4 (CH2), 21.8 (CH3), 14.0 (CH3); HRMS (ES): m/z 
calculated for C27H29N2O3S: 461.1899, found 461.1888 (M+H)
+. 
Alkene 173f: 1H-NMR (400 MHz, CDCl3) only peaks assigned to 173f are reported, aromatic peaks 
could not be assigned: δ = 6.33 (dt, J = 15.6, 7.2 Hz, 1H), 5.48 (dt, J = 15.6, 1.4 Hz, 1H), 2.40 (s, 3H), 
1.84-1.72 (m, 2H), 1.06-0.93 (m, 2H), 0.91-0.75 (m, 2H), 0.62 (t, J = 7.1 Hz, 3H). 
Alkene 174f: 1H-NMR (400 MHz, CDCl3) only peaks assigned to 174f are reported, aromatic peaks 
could not be assigned: δ = 5.93 (ddt, J = 15.0, 10.8, 1.2 Hz, 1H), 5.78 (d, J = 10.8 Hz, 1H), 5.63 (dt, 
J = 15.0, 7.0 Hz, 1H), 2.32 (s, 3H), 1.97 (appt. q, J = 7.0 Hz, 2H), 1.38-1.21 (m, 2H), 0.79 (t, J = 7.3, 3H). 
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Compounds 175a and 176a 
 
Following GP7 with ylide 94b (90 mg, 0.59 mmol), ynamide 84r (131 mg, 0.40 mmol) and gold 
catalyst (8.0 mg, 5 mol%) for 2 hours. Purification by flash column chromatography (10→50% EtOAc 
in hexane) gave oxazole 175a as a colourless oil (107 mg, 67%) and a mixture of enols 176a in a 
3.4:1 Z:E ratio as a white solid (11.2 mg, 9%). 
Oxazole 175a: IR (neat): ν = 3032, 2949, 1664, 1608, 1454, 1368, 1351, 1217, 1158, 1088, 1052, 
969 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 7.68-7.60 (m, 2H), 7.41-7.27 (m, 7H), 4.59 (s, 2H), 4.56 (s, 
2H), 3.90 (s, 3H), 3.04 (s, 3H), 2.43 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 160.2 (C), 144.0 (C), 
139.7 (C), 137.8 (C), 135.6 (C), 134.3 (C), 129.5 (2CH), 128.6 (2CH), 128.4 (2CH), 128.1 (2CH), 
127.9 (CH), 72.7 (CH2), 60.6 (CH2), 58.2 (CH3), 37.0 (CH3), 21.7 (CH3); HRMS (ES): m/z calculated for 
C20H23N2O5S: 403.1328, found 403.1331 (M+H)
+. 
Enols 176a: mp: 122-128 °C; IR (neat): ν = 2949, 1745, 1627, 1528, 1353, 1222, 1162, 1142, 1041, 
929 cm-1; 1H-NMR (400 MHz, CDCl3): δ = 9.52 (br s, OHZ), 9.39 (d, J = 4.0 Hz, 1HZ), 8.98 (d J = 7.8 Hz, 
1HE), 7.75-7.68 (m, 2HE+2HZ), 7.38-7.30 (m, 2HE+2HZ), 6.69 (br s, OHE), 6.49 (d, J = 7.8 Hz, 1HE), 
5.26 (d, J = 4.0 Hz, 1HZ), 3.78 (s, 3HE) 3.76 (s, 3HZ), 3.24 (s, 3HE), 3.07 (s, 3HZ), 2.44 (s, 3HE+3HZ); 
13C-NMR (101 MHz, CDCl3): δ = 190.0 (CHZ), 189.7 (CHE), 152.7 (CZ), 152.4 (CE), 149.6 (CZ), 149.0 (CE), 
145.6 (CE), 145.1 (CZ), 133.6 (CZ), 133.5 (CE), 130.4 (2CHE), 129.9 (2CHZ), 128.2 (2CHZ), 127.8 (2CHE), 
112.4 (CHE), 103.4 (CHZ), 53.4 (CH3E+CH3Z), 39.7 (CH3E), 37.3 (CH3Z), 21.8 (CH3E+CH3Z); HRMS (ES): m/z 
calculated for C13H17N2O5S: 313.0858, found 313.0852 (M+H)
+. 
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Compounds 175b and 176b 
 
Following GP7 with ylide 94c (119 mg, 0.60 mmol), ynamide 84r (131 mg, 0.40 mmol) and gold 
catalyst (7.9 mg, 5 mol%) for 3 hours. Purification by flash column chromatography (10→50% EtOAc 
in hexane) gave oxazole 175b as a colourless oil (117 mg, 66%) and a mixture of enols 176b in a 4.1:1 
Z:E ratio as a colourless oil (13.1 mg, 9%). 
Oxazole 175b: IR (neat): ν = 2864, 2259, 1637, 1450, 1352, 1163, 1089, 1070, 1050, 908 cm-1; 
1H-NMR (400 MHz, CDCl3): δ = 7.95-7.90 (m, 2H), 7.66-7.61 (m, 2H), 7.47-7.39 (m, 5H), 7.39-7.34 (m, 
2H), 7.33-7.27 (m, 3H), 4.78 (s, 2H), 4.67 (s, 2H), 3.14 (s, 3H), 2.44 (s, 3H); 13C-NMR (101 MHz, CDCl3): 
δ = 159.7 (C), 144.5 (C), 144.1 (C), 138.0 (C), 137.8 (C), 134.2 (C), 130.8 (CH), 129.6 (2CH), 128.8 (2CH), 
128.6 (2CH), 128.5 (2CH), 128.1 (2CH), 128.0 (CH), 127.2 (C), 126.5 (2CH), 73.0 (CH2), 61.0 (CH2), 
37.2 (CH3), 21.7 (CH3); HRMS (ES): m/z calculated for C25H25N2O4S: 449.1535, found 449.1538 (M+H)
+. 
Enols 176b: IR (neat): ν = 3301 (br), 2924, 2853, 1693, 1662, 1597, 1471, 1358, 1264, 1157, 1087, 
1023 cm-1; 1H-NMR (400 MHz, CDCl3) (the OH signal from the E isomer was not observed): δ = 
11.00 (br s, OHZ), 9.44 (appt. br s, 1HZ), 9.02 (d, J = 7.3 Hz, 1HE), 8.00-7.94 (m, 2HZ), 7.84-7.80 (m, 
2HE), 7.79-7.73 (m, 2HE+2HZ), 7.63-7.57 (m, 1HE+1HZ), 7.54-7.48 (m, 2HE+2HZ), 7.36 (d, J = 8.1 Hz, 2HE), 
7.32 (d, J = 8.1 Hz, 2HZ), 6.94 (d, J = 7.3 Hz, 1HE), 5.57 (d, J = 3.8 Hz, 1HZ), 3.35 (s, 3HE), 3.17 (s, 3HZ), 
2.45 (s, 3HE), 2.43 (s, 3HZ); 
13C-NMR (101 MHz, CDCl3) only peaks for the major (Z) isomer are listed: 
190.5 (CH), 165.1 (C), 149.3 (C), 145.1 (C), 133.8 (C), 133.2 (CH), 133.0 (C), 129.9 (2CH), 129.1 (2CH), 
128.4 (2CH), 128.1 (2CH), 104.1 (CH), 37.2 (CH3), 21.8 (CH3); HRMS (ES): m/z calculated for 
C18H18N2O4SNa, found 381.0878 (M+Na)
+. 
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Oxazole 250 
 
In an unoptimised procedure oxazole 151c (99 mg, 0.25 mmol) was deprotected by stirring in a 1:1 
trifluoroacetic acid:CH2Cl2 solution (4 mL) for 1 hour. The reaction mixture was poured into satd. 
NaHCO3(aq) solution (30 mL) and extracted with CH2Cl2 (3 x 10 mL). The combined organic extracts 
were dried over Na2SO4 and concentrated under reduced pressure. To the resulting crude primary 
amine was added K2CO3 (110 mg, 0.80 mmol), acetone (2.5 mL) and propargyl bromide (80% in 
toluene, 70 µL, 0.63 mmol). The reaction mixture was stirred at 50 °C for 22 hours, filtered through 
cotton and concentrated under reduced pressure. As the crude 1H-NMR showed a large amount of 
mono-propargylated product the crude reaction mixture was re-subjected to K2CO3 (200 mg, 
1.45 mmol) and propargyl bromide (80% in toluene, 100 µL, 0.90 mmol) in acetone (2.5 mL) for a 
further 5 hours. Again the reaction mixture was filtered through cotton, concentrated under reduced 
pressure, and then purified by flash column chromatography (1:1 EtOAc:hexane) to give oxazole 250 
as a colourless oil (38 mg, 41% over two steps); [α]D
20 = −42.5 (c=3.1, CHCl3); IR (neat): ν = 3287, 1342, 
1151, 964 cm-1; 1H-NMR (300 MHz, CDCl3): δ = 7.95-7.88 (m, 2H), 7.48-7.39 (m, 2H), 7.39-7.31 (m, 
1H), 4.18 (q, J = 7.1 Hz, 1H), 3.73-3.59 (m, 4H), 3.26 (s, 3H), 3.10 (s, 3H), 2.19 (t, J = 2.4, 2H),  
1.60 (d, J = 7.1 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ = 160.8 (C), 145.5 (C), 133.3 (C), 129.1 (CH), 
128.9 (2CH), 127.0 (C), 125.5 (2CH), 78.7 (2C), 73.4 (2CH), 53.9 (CH), 39.6 (2CH2), 38.2 (CH3), 
36.8 (CH3), 16.9 (CH3); HRMS (ES): m/z calculated for C19H22N3O3S: 372.1382, found 372.1393 (M+H)
+. 
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Oxazole 256a 
Oxazole 151b (95 mg, 0.25 mmol) was added to a suspension of NaH (60% 
dispersion, 20 mg, 0.50 mmol) in DMF (2.25 mL). The reaction mixture was stirred for 
10 minutes before allyl bromide (40 µL, 0.46 mmol) was added and stirring was 
continued for 4 hours. The reaction mixture was quenched with H2O (30 mL) and 
extracted with EtOAc (2 x 20 mL). The combined organic phases were washed with brine (25 mL), 
dried over Na2SO4, concentrated under reduced pressure and purified by flash column 
chromatography (2:1 hexane:EtOAc) to give oxazole 256a as a colourless oil (73 mg, 69%); IR (neat): 
ν = 2977, 2932, 1964, 1345, 1244, 1152 cm-1; NMR shows a mixture of two rotamers: 1H-NMR 
(400 MHz, CDCl3): δ = 7.92-7.85 (m, 2H), 7.46-7.37 (m, 2H), 7.34 (t, J = 7.2 Hz, 1H), 5.89-5.70 (m, 1H), 
5.24-5.05 (m, 2H), 4.59-4.37 (m, 2H), 4.06-3.87 (m, 2H), 3.23 (s, 3H), 3.10 (s, 3H), 1.48 and 1.43 (s, 
9H); 13C-NMR (101 MHz, CDCl3): δ = 158.5 and 158.2 (C), 155.3 and 155.0 (C), 145.9 and 145.7 (C), 
133.4 (CH), 133.3 (C) 129.1 (CH), 128.9 (2CH), 126.7 (C), 125.3 (2CH), 117.9 and 117.1 (CH2), 80.8 (C), 
50.1 (CH2), 43.9 and 43.4 (CH2), 38.0 (CH3), 36.9 (CH3), 28.5 and 28.4 (3CH3); HRMS (ES): m/z 
calculated for C20H27N3O5SNa: 444.1569, found 444.1574 (M+H)
+. 
Oxazole 151m 
Following GP7 using ylide 94p (402 mg, 1.3 mmol), ynamide 84g (180 mg, 
0.86 mmol) and gold catalyst (6.7 mg, 2 mol%) for 17 hours. Purification by 
flash column chromatography (15→20% EtOAc in hexane) yielded 
oxazole 151m as a white solid (266 mg, 70%); mp: 160-162 °C; IR (neat): ν = 
2966, 1452, 1364, 1342, 1069, 969, cm-1; 1H-NMR (300 MHz, CDCl3): δ = 7.93-7.83 (m, 2H), 7.50-7.33 
(m, 3H), 7.17-7.07 (m, 3H), 4.24 (s, 2H), 3.36 (hept, J = 6.8 Hz, 2H), 3.27 (s, 3H), 3.11 (s, 3H), 1.27 (d, 
J = 6.8 Hz, 12H); 13C-NMR (101 MHz, CDCl3): δ = 159.7 (C), 146.0 (C), 142.8 (2C), 141.6 (C), 133.2 (C), 
129.2 (CH), 128.9 (2CH), 126.7 (C), 125.4 (2CH), 124.8 (CH), 123.9 (2CH), 48.2 (CH2), 38.0 (CH3), 
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36.9 (CH3), 27.9 (2CH), 24.3 (4CH3); HRMS (ES): m/z calculated for C24H31N3O3SNa: 464.1984, found 
464.1995 (M+Na)+. 
Oxazole 371a 
Following GP7 using ylide 94q (611 mg, 1.8 mmol), ynamide 84g (314 mg, 
1.5 mmol) and gold catalyst (12 mg, 2 mol%) for 4 hours. Purification by flash 
column chromatography (25→50% EtOAc in hexane) yielded oxazole 371a as 
a white solid (549 mg, 78%); mp: 193-195 °C; IR (neat): ν = 2971, 2855, 1675, 
1495, 1348, 1153 cm-1; NMR shows a mixture of two rotamers in a ∼ 0.2:0.8 ratio: 1H-NMR (300 MHz, 
CDCl3): δ = 8.75 and 8.19 (s, 1H), 7.88-7.80 (m, 2H), 7.48-7.31 (m, 4H), 7.20 (d, J = 7.7 Hz, 2H), 4.90 
and 4.75 (s, 2H), 3.20 and 3.19 (s, 3H), 3.06 and 2.98 (s, 3H), 2.96 and 2.81 (hept, J = 6.9 Hz, 2H), 
1.18-1.03 (m, 12H); 13C-NMR (101 MHz, CDCl3): only the peaks for the major rotamer are reported δ = 
163.5 (CH), 155.9 (C), 148.1 (2C), 146.8 (C), 134.3 (C), 133.4 (C), 130.1 (CH), 129.4 (CH), 129.0 (2CH), 
126.5 (C), 125.5 (2CH), 124.7 (2CH), 43.9 (CH2), 38.0 (CH3), 36.9 (CH3), 28.5 (2CH), 25.3 (2CH3), 
23.8 (2CH3); HRMS (ES): m/z calculated for C25H31N3O4SNa: 492.1933, found 492.1943 (M+Na)
+. 
Oxazole 371b 
Following GP7 using ylide 94q (1.84 g, 5.4 mmol), ynamide 84t 
(1.08 g, 4.5 mmol) and gold catalyst (35 mg, 2 mol%) for 4 hours. 
Purification by flash column chromatography (30→50% EtOAc in 
hexane) yielded oxazole 371b as a white solid (1.64 mg, 73%); 
mp: 148-151 °C; IR (neat): ν = 2969, 1686, 1509, 1345, 1177, 1151, 837 cm-1; NMR shows a mixture of 
two rotamers in a ∼ 0.3:0.7 ratio: 1H-NMR (300 MHz, CDCl3): δ = 8.75 and 8.18 (s, 1H), 7.82-7.75 (m, 
2H), 7.41-7.31 (m, 1H), 7.20 (d, J = 7.7 Hz, 2H), 6.99-6.90 (m, 2H), 4.89 and 4.73 (s, 2H), 3.85 and 3.84 
(s, 3H), 3.18 and 3.16 (s, 3H), 3.04 and 2.96 (s, 3H), 2.95 and 2.81 (hept, J = 6.9 Hz, 2H), 1.19-1.02 (m, 
12H); 13C-NMR (101 MHz, CDCl3): only the peaks for the major rotamer are reported δ = 163.3 (CH), 
160.4 (C), 155.0 (C), 148.0 (2C), 146.9 (C), 134.2 (C), 131.8 (C), 130.0 (CH), 127.1 (2CH), 124.6 (2CH), 
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119.2 (C), 114.3 (2CH), 55.4 (CH3), 43.7 (CH2), 37.9 (CH3), 36.7 (CH3), 28.4 (2CH), 25.3 (2CH3), 
23.6 (2CH3); HRMS (ES): m/z calculated for C26H34N3O5S: 500.2219, found 500.2215 (M+H)
+. 
Oxazole 371c 
Following GP7 using ylide 94q (611 mg, 1.8 mmol), ynamide 84c (410 mg, 
1.5 mmol) and gold catalyst (12 mg, 2 mol%) for 4 hours. Purification by flash 
column chromatography (20→30% EtOAc in hexane) yielded oxazole 371c as 
a white solid (562 mg, 70%); mp: 185-187 °C; IR (neat): ν = 2964, 2868, 1663, 
1360, 1162, 967 cm-1; NMR shows a mixture of two rotamers in a ∼ 0.1:0.9 ratio: 1H-NMR (400 MHz, 
CDCl3): δ = 8.80 and 8.21 (s, 1H), 7.85-7.79 (m, 2H), 7.55-7.26 (m, 9H), 7.21 (d, J = 7.8 Hz, 2H), 4.98 
and 4.81 (s, 2H), 3.18 and 3.12 (s, 3H), 2.98 and 2.82 (hept, J = 6.8 Hz, 2H), 1.17-1.11 (m, 6H), 1.03 
and 0.96 (d, J = 6.8 Hz, 6H); 13C-NMR (101 MHz, CDCl3): only the peaks for the major rotamer are 
reported δ = 163.4 (CH), 155.6 (C), 148.2 (2C), 147.2 (C), 140.0 (C), 134.1 (C), 133.0 (C), 130.1 (CH), 
129.5 (3CH), 128.9 (2CH), 127.9 (CH), 127.0 (2CH), 126.3 (C), 125.6 (2CH), 124.7 (2CH), 43.7 (CH2), 
38.6 (CH3), 28.5 (2CH), 25.4 (2CH3), 23.6 (2CH3); HRMS (ES): m/z calculated for C30H33N3O4SNa: 
554.2089, found 554.2092 (M+Na)+. 
Oxazole 371d 
Following GP7 using ylide 94q (611 mg, 1.8 mmol), ynamide 84y (353 mg, 
1.5 mmol) and gold catalyst (12 mg, 2 mol%) for 4 hours. Purification by 
flash column chromatography (20→30% EtOAc in hexane) yielded oxazole 
371d as a white solid (552 mg, 74%); mp: 117-121 °C; IR (neat): ν = 2962 
2868, 1684, 1343, 1164, 964 cm-1; NMR shows a mixture of two rotamers a ∼ 0.1:0.9 ratio: 1H-
NMR (400 MHz, CDCl3): δ = 8.74 and 8.19 (s, 1H), 7.90-7.83 (m, 2H), 7.45-7.30 (m, 4H), 7.20 (d, J = 
7.8 Hz, 2H), 5.93-5.82 and 5.77-5.66 (m, 1H), 5.36-5.29 and 5.12-4.99 (m, 2H), 4.91 and 4.76 (s, 2H), 
4.18 and 4.14 (d, J = 6.7 Hz, 2H), 3.06 and 2.97 (s, 3H), 2.99 and 2.83 (hept, J = 6.9 Hz, 2H), 1.18-1.13 
(m, 6H), 1.10 and 1.06 (d, J = 6.9 Hz, 6H); 13C-NMR (101 MHz, CDCl3): only the peaks for the major 
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rotamer are reported δ = 163.4 (CH), 155.7 (C), 148.1 (2C), 148.0 (C), 134.3 (C), 131.71 (C), 131.66 
(CH), 130.1 (CH), 129.4 (CH), 128.8 (2CH), 126.5 (C), 125.6 (2CH), 124.7 (2CH), 120.2 (CH2), 53.8 (CH2), 
43.9 (CH2), 38.7 (CH3), 28.5 (2CH), 25.3 (2CH3), 23.8 (2CH3); HRMS (ES): m/z calculated for 
C27H33N3O4SNa: 518.2089, found 518.2084 (M+Na)
+. 
Oxazole 151n 
Trifluoroacetic acid (3.75 mL, 49 mmol) was added to a solution of 
oxazole 151g (248 mg, 0.76 mmol) and diisopropylaniline (160 µL, 
0.85 mmol) in toluene (7.5 mL). The reaction mixture was stirred for 
14 hours at room temperature before cooling in an ice/water bath whilst 
NEt3 (7.5 mL, 54 mmol) was added over 10 minutes resulting in a colour change from red to yellow. 
The solvent was removed under reduced pressure and the crude product was purified by flash 
column chromatography (80:20:1 hexane:EtOAc:NEt3) to give oxazole 151n as a yellow solid (331 mg, 
99%); mp: 198-202 °C; IR (neat): ν = 2967, 1618, 1451, 1345, 1154, 970 cm-1; 1H-NMR (400 MHz, 
CDCl3): δ = 8.14-8.08 (m, 2H), 8.02 (s, 1H), 7.53-7.40 (m, 3H), 7.22-7.14 (m, 3H), 3.37 (s, 3H), 3.21 (s, 
3H), 2.97 (hept, J = 6.9 Hz, 2H), 1.21 (d, J = 6.9 Hz, 12H); 13C-NMR (101 MHz, CDCl3): δ = 155.0 (C), 
148.6 (CH), 148.2 (C), 147.8 (C), 137.4 (2C), 135.4 (C), 130.3 (CH), 129.1 (2CH), 126.3 (2CH), 126.1 (C), 
125.4 (CH), 123.4 (2CH), 38.1 (CH3), 37.2 (CH3), 28.1 (2CH), 23.8 (4CH3); HRMS (ES): m/z calculated for 
C24H30N3O3S: 440.2008, found 440.1997 (M+H)
+. 
5.1.7: Diels-Alder Reactions of Oxazoles 
Furan 251 
A solution of oxazole 250 (31 mg, 83 µmol) in mesitylene (0.5 mL) was heated at 100 °C 
for 22 hours. After cooling to room temperature, the reaction mixture was directly 
purified by flash column chromatography (10→30% EtOAc in hexane) to give furan 
251 as a colourless oil (9.7 mg, 49%); [α]D
20 = +63.6 (c=0.4, CHCl3); IR (neat): ν = 3295, 
2922, 1602, 1375, 1077, 922, 760 cm-1; 1H-NMR (400 MHz, CDCl3): δ = 7.65-7.59 (m, 2H), 
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7.39-7.33 (m, 2H), 7.23 (tt, J = 7.4, 1.1 Hz, 1H), 6.55 (s, 1H), 4.21-4.12 (m, 1H), 4.00 (dd, J = 11.4, 
3.8 Hz, 1H), 3.84 (dd, J = 11.4, 3.6 Hz, 1H), 3.63 (AB part of an ABX system, JA-B = 17.5 Hz, 
JA-X ≈ JB-X = 2.3 Hz, 2H), 2.26 (appt. t, J = 2.3 Hz, 1H), 1.41 (d, J = 6.3 Hz, 3H); 
13C-NMR (101 MHz, 
CDCl3): δ = 159.0 (C), 157.9 (C), 131.5 (C), 128.8 (2CH), 127.2 (CH), 123.5 (2CH), 123.0 (C), 102.2 (CH), 
79.5 (C), 73.8 (CH), 56.1 (CH), 50.7 (CH2), 41.5 (CH2), 18.9 (CH3); HRMS (ES): m/z calculated for 
C16H16NO: 238.1232, found 2381228 (M+H)
+. 
Furan 255 
NaH (60% dispersion, 9.0 mg, 0.62 mmol) was suspended in DMF (2 mL) under an 
argon atmosphere and the solution cooled to 0 °C. Oxazole 151b (90 mg, 0.20 mmol) 
was added and after 5 minutes this was followed by propargyl bromide (80% in 
toluene, 25 µL, 0.28 mmol). After stirring for 90 minutes at room temperature TLC analysis showed 
that all the oxazole had been consumed and the reaction mixture was heated to 140 °C for 22 hours. 
After cooling to room temperature, the reaction mixture was purified directly by flash column 
chromatography (9:1 hexane:EtOAc) to give furan 255 as a white solid (5.1 mg, 9%) this compound 
was unstable and only characterised by proton NMR; 1H-NMR (300 MHz, CDCl3): δ = 7.66-7.59 (m, 
2H), 7.42-7.34 (m, 2H), 7.29-7.22 (m, 1H), 6.61 and 6.56 (s [2 conformers], 1H), 4.55-4.46 (m, 2H), 
4.43-4.34 (m, 2H), 1.52 (s, 9H). 
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5.1.7.1: General procedure for cascade oxazole formation and Diels-Alder reactions (GP8) 
 
Pyridinium ylide (1.2 eq.), dichloro(2-pyridinecarboxylato)gold (5 mol%), and ynamide (1.0 eq.) were 
added to a heat-gun dried flask under an argon atmosphere. Toluene (0.1 M with respect to 
ynamide) was added (where ynamides were oils these were added as a solution in toluene) and the 
reaction mixture was heated to 90 °C until all of the ynamide had consumed by TLC or for 4 hours. 
The temperature was then increased to 110 °C for 72 hours. After cooling to room temperature, the 
reaction mixture was filtered through a 5 cm plug of silica gel (washing with CH2Cl2 and then EtOAc) 
and the filtrate was concentrated and purified by flash column chromatography. 
Tetrahydropyridine 257a 
Following GP8 using ylide 266a (71.0 mg, 0.24 mmol), ynamide 84g (42.8 mg, 
0.20 mmol) and gold catalyst (3.9 mg, 5 mol%). Purification by flash column 
chromatography (10→30% EtOAc in hexane) yielded tetrahydropyridine 257a as a 
white solid (58.1 mg , 68%); mp: 133-134 °C; IR (neat): ν = 2976, 2888, 1689, 1582, 
1404, 1348, 1244, 1158, 1120, 960, 873 cm-1; NMR shows a mixture of two rotamers in a ∼ 1.2:1 
ratio: 1H-NMR (400 MHz, CDCl3): δ = 7.55-7.49 (m, 2H), 7.46-7.37 (m, 3H), 4.11-4.06 (m, 1Ha), 4.03-
3.97 (m, 1Hb), 3.94-3.86 (m, 1Ha), 3.05-2.96 (m, 1Hb), 2.81 and 2.80 (s, 3H), 2.76 and 2.73 (s, 3H), 
2.62-2.48 (m, 1Hd), 2.43-2.35 (m, 1Hc), 2.03-1.92 (m, 1Hc), 1.46 and 1.44 (s, 9H); 
13C-NMR (101 MHz, 
CDCl3): δ = 170.6 (C), 154.3 and 154.2 (C), 135.43 and 135.37 (C), 129.43 and 129.38 (CH), 128.78 
(2CH), 127.83 and 127.75 (2CH), 107.8 and 107.1 (C), 93.8 and 93.6 (C), 79.77 and 79.75 (C), 51.4 and 
50.8 (CH2b), 48.4 and 48.0 (CH2a), 45.2 and 44.5 (CHd), 39.94 and 39.91 (CH3), 35.6 and 35.5 (CH3), 
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33.6 and 33.4 (CH2c), 28.59 (3CH3); HRMS (ES): m/z calculated for C20H28N3O5S: 422.1750, found 
422.1759 (M+H)+. 
Tetrahydropyridine 257b 
Following GP8 using ylide 266b (92.1 mg, 0.28 mmol), ynamide 84g (49.0 mg, 
0.23 mmol) and gold catalyst (4.6 mg, 5 mol%). Purification by flash column 
chromatography (30→50% EtOAc in hexane) yielded tetrahydropyridine 257b as a 
white solid (65.7 mg, 63%); mp: 69-70 °C; IR (neat): ν = 2954, 1699, 1584, 1417, 
1348, 1158, 1114, 957 cm-1; NMR shows a mixture of two rotamers in a ∼ 1:1 ratio: 1H-NMR 
(400 MHz, CDCl3): δ = 7.55-7.49 (m, 2H), 7.46-7.28 (m, 8H), 5.20-5.09 (m, 2H, OCH2Ph), 4.20-4.13 (m, 
1Ha), 4.11-4.05 (m, 1Hb) 4.05-3.97 (m, 1Ha), 3.14-3.05 (m, 1Hb), 2.81 (s, 3H), 2.75 and 2.73 (s, 3H), 
2.64-2.52 (m, 1Hd), 2.46-2.37 (m, 1Hc), 2.05-1.94 (m, 1Hc); 
13C-NMR (101 MHz, CDCl3): δ = 170.7 (C), 
154.7 and 154.5 (C), 136.83 and 136.78 (C), 135.3 and 135.2 (C), 129.44 and 129.40 (CH), 128.8 (2CH), 
128.6 (2CH), 128.1 (CH), 128.0 and 127.9 (2CH), 127.8 and 127.7 (2CH), 107.7 and 106.9 (C), 93.8 and 
93.7 (C), 67.02 and 67.00 (CH2), 51.4 and 51.2 (CH2b), 48.4 and 48.2 (CH2a), 45.2 and 44.4 (CHd), 39.90 
and 39.87 (CH3), 35.6 and 35.5 (CH3), 33.6 and 33.4 (CH2c); HRMS (ES): m/z calculated for 
C23H25N3O5SNa: 478.1413, found 478.1406 (M+Na)
+. 
Tetrahydropyridine 257c 
Following GP8 using ylide 266c (101.1 mg, 0.27 mmol), ynamide 84g (46.8 mg, 
0.22 mmol) and gold catalyst (4.4 mg, 5 mol%). Purification by flash column 
chromatography (10→40% EtOAc in hexane) yielded tetrahydropyridine 257c as a 
white solid (39.8 mg, 36%); mp: 184-186 °C; IR (neat): ν = 1605, 1527, 1345, 1307, 
1164, 977 cm-1; 1H-NMR (400 MHz, CDCl3): δ = 8.31 (d, J = 8.8 Hz, 2H), 7.99 (d, J = 8.8 Hz, 2H), 
7.40-7.33 (m, 5H), 4.16 (d, J = 12.0 Hz, 1Ha), 4.03-3.95 (m, 1Hb), 3.81 (d, J = 12.0 Hz, 1Ha),  
2.87 (appt. t, J = 9.8 Hz, 1Hb), 2.79 (s, 3H), 2.65 (s, 3H), 2.59-2.49 (m, 1Hd), 2.37 (dd, J = 12.2, 7.6 Hz, 
1Hc), 1.87 (dd, J = 12.2, 3.2 Hz, 1Hc); 
13C-NMR (101 MHz, CDCl3): δ = 170.9 (C), 150.3 (C), 143.1 (C), 
Appendix 
192 
 
134.7 (C), 129.7 (CH), 128.7 (2CH), 128.6 (2CH), 127.8 (2CH), 124.5 (2CH), 106.9 (C), 93.8 (C), 
53.2 (CH2b), 49.8 (CH2a), 45.5 (CHd), 39.9 (CH3), 35.5 (CH3), 33.3 (CH2c); HRMS (ES): m/z calculated for 
C21H22N4O7S2Na: 529.0828, found 529.0835 (M+Na)
+. 
Tetrahydropyridine 257d 
Following GP8 using ylide 266d (82.9 mg, 0.24 mmol), ynamide 84g (41.9 mg, 
0.20 mmol) and gold catalyst (3.9 mg, 5 mol%). Purification by flash column 
chromatography (20→50% EtOAc in hexane) yielded tetrahydropyridine 257d as a 
white solid (65.6 mg, 69%) (this reaction was also run on 1.5 mmol scale, giving a 
68% yield); mp: 103-104 °C; IR (neat): ν = 2929, 1583, 1526, 1344, 1155, 1096, 958, 762 cm-1; 
1H-NMR (400 MHz, CDCl3): δ = 7.70 (d, J = 8.2 Hz, 2H), 7.44-7.36 (m, 5H), 7.28 (d, J = 8.2 Hz, 2H), 
4.11 (d, J = 11.8 Hz, 1Ha), 3.94-3.87 (m, 1Hb), 3.75 (d, J = 11.8 Hz, 1Ha), 2.83 (appt. t, J = 9.9 Hz, 1Hb), 
2.77 (s, 3H), 2.67 (s, 3H), 2.49-2.40 (m, 1Hd), 2.39 (s, 3H), 2.32 (dd, J = 12.0, 7.7 Hz, 1Hc),  
1.86 (dd, J = 12.0, 3.2 Hz, 1Hc); 
13C-NMR (101 MHz, CDCl3): δ = 170.8 (C), 143.8 (C), 135.1 (C), 
134.2 (C), 129.9 (2CH), 129.5 (CH), 128.8 (2CH), 127.9 (2CH), 127.6 (2CH), 107.5 (C), 93.8 (C), 
53.0 (CH2b), 49.6 (CH2a), 45.6 (CHd), 39.9 (CH3), 35.6 (CH3), 32.7 (CH2c), 21.7 (CH3); HRMS (ES): m/z 
calculated for C22H25N3O5S2Na: 498.1133, found 498.1123 (M+Na)
+. 
Tetrahydropyridine 257e 
Following GP8 using ylide 266d (82.7 mg, 0.24 mmol), ynamide 84s (57.2 mg, 
0.20 mmol) and gold catalyst (3.9 mg, 5 mol%). Purification by flash column 
chromatography (20→40% EtOAc in hexane) yielded tetrahydropyridine 257e as a 
white solid (60.4 mg, 55%); mp: 174-175 °C; IR (neat): ν = 1581, 1344, 1234, 1163, 
1078, 1014 cm-1; 1H-NMR (400 MHz, CDCl3): δ = 7.70 (d, J = 8.2 Hz, 2H), 7.46 (d, J = 8.2 Hz, 2H), 
7.40-7.34 (m, 5H), 7.29 (d, J = 8.2 Hz, 2H), 7.21 (d, J = 8.2 Hz, 2H), 4.13 (d, J = 11.8 Hz, 1Ha),  
3.96-3.88 (m, 1Hb), 3.68 (d, J = 11.8 Hz, 1Ha), 2.79 (appt. t, J = 9.9 Hz, 1Hb), 2.68 (s, 3H), 2.46-2.33 (m, 
1Hd), 2.41 (s, 3H), 2.39 (s, 3H), 2.28 (dd, J = 12.0, 7.6 Hz, 1Hc), 1.88 (dd, J = 12.0, 3.2 Hz, 1Hc);  
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13C-NMR (101 MHz, CDCl3): δ = 170.0 (C), 144.7 (C), 143.7 (C), 135.2 (C), 134.5 (C), 134.1 (C), 
129.9 (2CH), 129.5 (2CH), 129.2 (CH), 128.7 (2CH), 128.5 (2CH), 127.6 (2CH), 127.5 (2CH), 107.5 (C), 
94.0 (C), 52.9 (CH2b), 49.6 (CH2a), 45.6 (CHd), 35.4 (CH3), 32.4 (CH2c), 21.7 (CH3), 21.6 (CH3);  
HRMS (ES): m/z calculated for C28H30N3O5S2: 552.1627, found 552.1619 (M+H)
+. 
Tetrahydropyridine 257f 
Following GP8 using ylide 266d (82.9 mg, 0.24 mmol), ynamide 84a (69.5 mg, 
0.20 mmol) and gold catalyst (3.9 mg, 5 mol%). Purification by flash column 
chromatography (20→30% EtOAc in hexane) yielded tetrahydropyridine 257f as a 
white solid (73.1 mg, 60%); mp: 108-110 °C; IR (neat): ν = 1583, 1344, 1233, 1160, 
1089, 806 cm-1; 1H-NMR (400 MHz, CDCl3): δ = 7.71 (d, J = 8.2 Hz, 2H), 7.65 (d, J = 8.2 Hz, 2H), 7.28 (d, 
J = 8.2 Hz, 2H), 7.22 (d, J = 8.2 Hz, 2H), 7.08-7.00 (m, 2H), 6.99-6.89 (m, 4H), 6.85 (d, J = 7.3 Hz, 2H), 
6.64 (d, J = 7.5 Hz, 2H), 4.24 (d, J = 11.8 Hz, 1Ha), 3.97-3.89 (m, 1Hb), 3.72 (d, J = 11.8 Hz, 1Ha), 
2.73 (appt. t, J = 9.9 Hz, 1Hb), 2.53-2.44 (m, 1Hd), 2.42 (s, 3H), 2.38 (s, 3H), 2.15 (dd, J = 12.0, 7.6 Hz, 
1Hc), 1.68 (dd, J = 12.0, 3.2 Hz, 1Hc); 
13C-NMR (101 MHz, CDCl3): δ = 168.4 (C), 144.7 (C), 143.7 (C), 
135.5 (C), 134.5 (C), 134.0 (2C), 129.9 (2CH), 129.7 (2CH), 129.6 (2CH), 129.1 (2CH), 128.8 (CH), 
128.6 (2CH), 128.3 (CH), 127.9 (2CH), 127.5 (2CH), 126.9 (2CH), 108.1 (C), 93.8 (C), 52.7 (CH2b), 
49.7 (CH2a), 45.6 (CHd), 32.7 (CH2c), 21.8 (CH3), 21.6 (CH3); HRMS (ES): m/z calculated for 
C33H31N3O5S2Na: 636.1603, found 636.1595 (M+Na)
+. 
Tetrahydropyridine 257g 
Following GP8 using ylide 266d (82.7 mg, 0.24 mmol), ynamide 84t 
(47.6 mg, 0.20 mmol) and gold catalyst (3.8 mg, 5 mol%). Purification by 
flash column chromatography (70:30:1→60:40:1 hexane:EtOAc:NEt3) 
yielded tetrahydropyridine 257g as a white solid with approximately 95% 
purity (36.3 mg, 36%); mp: 90-92 °C; IR (neat): ν = 1581, 1518, 1343, 1246, 1158, 1093, 962 cm-1; 
1H-NMR (400 MHz, CDCl3): δ = 7.70 (d, J = 8.2 Hz, 2H), 7.33 (d, J = 8.8 Hz, 2H), 7.28 (d, J = 8.2 Hz, 2H), 
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6.91 (d, J = 8.8 Hz, 2H), 4.10 (d, J = 11.7 Hz, 1Ha), 3.90 (dd, J = 9.4, 8.3 Hz, 1Hb), 3.81 (s, 3H), 3.72 (d, 
J = 11.7 Hz, 1Ha), 2.86-2.78 (m, 4H, 1Hb+CH3), 2.69 (s, 3H), 2.49-2.41 (m, 1Hd), 2.40 (s, 3H), 2.29 (dd, 
J = 12.0, 7.6 Hz, 1Hc), 1.85 (dd, J = 12.0, 3.3 Hz, 1Hc); 
13C-NMR (101 MHz, CDCl3): δ = 171.0 (C), 
160.4 (C), 143.7 (C), 134.2 (C), 129.9 (2CH), 129.2 (2CH), 127.6 (2CH), 127.0 (C), 114.1 (2CH), 
107.3 (C), 93.6 (C), 55.5 (CH3), 52.9 (CH2b), 49.6 (CH2a), 45.7 (CHd), 40.0 (CH3), 35.5 (CH3), 32.7 (CH2c), 
21.7 (CH3); HRMS (ES): m/z calculated for C23H28N3O6S2: 506.1420, found 506.1418 (M+H)
+. 
Tetrahydropyridine 257h 
Following GP8 using ylide 266d (82.9 mg, 0.24 mmol), ynamide 84u 
(50.9 mg, 0.20 mmol) and gold catalyst (3.9 mg, 5 mol%). Purification by 
flash column chromatography (30→50% EtOAc in hexane) yielded 
tetrahydropyridine 257h as a pale yellow solid (48.6 mg, 47%); mp: 114-116 
°C; IR (neat): ν = 1598, 1522, 1344, 1158, 1096, 853, cm-1; 1H-NMR (400 MHz, CDCl3): δ = 8.28 (d, 
J = 8.8 Hz, 2H), 7.74 (d, J = 8.2 Hz, 2H), 7.63 (d, J = 8.8 Hz, 2H), 7.33 (d, J = 8.2 Hz, 2H), 4.13 (d, 
J = 11.9 Hz, 1Ha), 3.97-3.90 (m, 1Hb), 3.81 (d, J = 11.9 Hz, 1Ha), 2.87 (appt. t, J = 9.9 Hz, 1Hb), 2.82 (s, 
3H), 2.80 (s, 3H), 2.55-2.46 (m, 1Hd), 2.43 (s, 3H), 2.38 (dd, J = 12.0, 7.6 Hz, 1Hc), 1.86 (dd, J = 12.0, 
3.1 Hz, 1Hc); 
13C-NMR (101 MHz, CDCl3): δ = 169.6 (C), 148.3 (C), 143.9 (C), 142.0 (C), 134.1 (C), 
129.9 (2CH), 128.6 (2CH), 127.6 (2CH), 123.8 (2CH), 108.0 (C), 92.9 (C), 52.7 (CH2b), 49.4 (CH2a), 
45.5 (CHd), 39.8 (CH3), 35.8 (CH3), 33.4 (CH2c), 21.7 (CH3); HRMS (ES): m/z calculated for 
C22H25N4O7S2: 521.1165, found 521.1163 (M+H)
+. 
Tetrahydropyridine 257l 
Following GP8 using ylide 266d (82.9 mg, 0.24 mmol), ynamide 84w (75.9 mg, 
0.20 mmol) and gold catalyst (3.9 mg, 5 mol%). Reaction times were adjusted to 45 
minutes at 90 °C (at which point all ynamide was consumed by TLC) and 6 hours at 
110 °C (at which point all oxazole was consumed by TLC). Purification by flash 
column chromatography (1:4 EtOAc:hexane) yielded tetrahydropyridine 257l (119 mg, 92%); 
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mp: 184-186 °C; IR (neat): ν = 2951, 1582, 1518, 1343, 1242, 1158, 1093, 809 cm-1;  
1H-NMR (400 MHz, CDCl3): δ = 7.71 (d, J = 8.3 Hz, 2H), 7.64 (d, J = 8.3 Hz, 2H), 7.41-7.30 (m, 5H), 7.28-
7.18 (m, 5H), 7.16-7.10 (m, 2H), 7.09-7.04 (m, 2H), 4.14 (d, J = 12.1 Hz, 1Ha), 3.73 (d, J = 12.1 Hz, 1Ha), 
3.73-3.68 (m, 1Hb), 2.44 (s, 3H), 2.41 (s, 3H), 2.39-2.27 (m, 2H, 1Hb+1Hd), 1.56 (dd, J = 12.6, 7.1 Hz, 
1Hc), 1.26 (dd, J = 12.6, 2.6 Hz, 1Hc); 
13C-NMR (101 MHz, CDCl3): δ = 165.7 (C), 144.8 (C), 143.8 (C), 
135.5 (C), 134.3 (C), 134.1 (2CH), 133.7 (C), 130.0 (2CH), 129.8 (3CH), 129.74 (C), 129.69 (2CH), 
129.11 (2CH), 129.05 (2CH), 129.0 (CH), 128.8 (2CH), 127.6 (2CH), 106.9 (C), 97.3 (C), 52.1 (CH2b), 
49.6 (CH2a), 45.3 (CHd), 32.7 (CH2c), 21.8 (CH3), 21.6 (CH3); HRMS (ES): m/z calculated for 
C33H32N3O5S3: 646.1504, found 646.1513 (M+H)
+. 
Tetrahydropyridines 277 
Following GP8 using ylide 266d (207 mg, 0.60 mmol), ynamide 84x 
(158 mg, 0.50 mmol) and gold catalyst (9.7 mg, 5 mol%). Purification 
by flash column chromatography (25→50% EtOAc in hexane) 
yielded an inseparable mixture of diastereoisomers (4:1 ratio) of 
tetrahydropyridines 277 as a white solid (83.7 mg, 29%);  
mp: 128-133 °C; IR (neat): ν = 2958, 2879, 1568, 1333, 1234, 1160, 1140 cm-1; 1H-NMR (400 MHz, 
CDCl3): δ = 7.74-7.64 (m, 2Hmajor+2Hminor), 7.46-7.31 (m, 5Hmajor+5Hminor), 7.30-7.21 (m, 2Hmajor+2Hminor), 
4.18 (d, J = 11.9 Hz, 1Hminor), 4.14 (d, J = 11.7 Hz, 1Hmajor), 3.99-3.79 (m, 2Hmajor+2Hminor),  
3.77 (d, J = 11.9 Hz, 1Hminor), 3.62 (d, J = 11.7 Hz, 1Hmajor), 3.25-3.10 (m, 2Hmajor+2Hminor), 2.82-2.70 (m, 
1Hmajor+1Hminor), 2.54-2.31 (m, 5Hmajor+5Hminor), 2.11-1.72 (m, 6Hmajor+6Hminor), 1.43-1.23 (m, 
2Hmajor+2Hminor), 1.07 (s, 3Hminor), 0.98 (s, 3Hmajor), 0.87 (s, 3H); 
13C-NMR (101 MHz, CDCl3) only signals 
assigned to the major diastereoisomer are reported: δ = 168.7 (C), 143.7 (C), 134.1 (C), 133.8 (C), 
129.9 (2CH), 129.6 (CH), 129.1 (2CH), 128.0 (2CH), 127.5 (2CH), 107.6 (C), 93.5 (C), 67.3 (CH), 
53.2 (CH2), 52.4 (CH2), 49.7 (CH2), 49.6 (C), 47.8 (C), 45.5 (CH), 44.9 (CH), 38.0 (CH2), 33.0 (CH2), 
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30.9 (CH2), 26.5 (CH2), 21.6 (CH3), 20.8 (CH3), 20.0 (CH3); HRMS (ES): m/z calculated for 
C30H36N3O5S2: 582.2096, found 582.2097 (M+H)
+. 
Tetrahydropyridine 278 
Following GP8 using ylide 266h (86.3 mg, 0.24 mmol), ynamide 84g (41.9 mg, 
0.20 mmol) and gold catalyst (3.9 mg, 5 mol%). Purification by flash column 
chromatography (30→40% EtOAc in hexane) yielded tetrahydropyridine 278 as a 
white solid (51.0 mg, 52%); mp: 200-202 °C; IR (neat): ν = 1601, 1346, 1162, 1097, 
939 cm-1; 1H-NMR (400 MHz, CDCl3): δ = 7.70 (d, J = 8.2 Hz, 2H), 7.53-7.48 (m, 2H), 7.45-7.38 (m, 3H), 
7.32 (d, J = 8.2 Hz, 2H), 4.41 (d, J = 13.2 Hz, 1Ha), 3.86-3.78 (m, 1Hb), 3.19 (d, J = 13.2 Hz, 1Ha), 2.86 (s, 
3H), 2.68 (s, 3H), 2.43 (s, 3H), 2.42-2.33 (m, 2H, 1Hb+1Hd), 2.06-1.98 (m, 1Hc), 1.92-1.83 (m, 1He), 
1.65-1.53 (m, 2H, 1Hc+1Hd); 
13C-NMR (101 MHz, CDCl3): δ = 170.2 (C), 143.8 (C), 135.3 (C), 133.3 (C), 
129.8 (2CH), 129.3 (CH), 128.8 (2CH), 128.0 (2CH), 127.5 (2CH), 97.7 (C), 91.9 (C), 48.5 (CH2a), 
45.6 (CH2b), 39.8 (CH3), 38.2 (CHe), 35.9 (CH2d), 35.4 (CH3), 30.7 (CH2c), 21.7 (CH3); HRMS (ES): m/z 
calculated for C23H27N3O5S2Na: 512.1290, found 512.1281 (M+Na)
+. Crystals suitable for single crystal 
X-ray diffraction were grown by diffusion of hexane into a solution of 278 in CH2Cl2. 
Oxazole 279 
Following GP8 using ylide 266i (89.6 mg, 0.24 mmol), ynamide 84g (42.2 mg, 
0.20 mmol) and gold catalyst (4.0 mg, 5 mol%). Purification by flash column 
chromatography (7:3 hexane:EtOAc) yielded oxazole 279 as a white solid (81.6 mg, 
81%); mp: 128-130 °C; IR (neat): ν = 1333, 1309, 1162, 1148, 972 cm-1;  
1H-NMR (400 MHz, CDCl3): δ = 7.71-7.66 (m, 2H), 7.62 (d, J = 8.2 Hz, 2H), 7.42-7.31 (m, 3H),  
7.18 (d, J = 8.2 Hz, 2H), 5.76 (ddt, J = 17.0, 10.3, 6.6 Hz, 1H), 5.06-4.93 (m, 2H), 4.56 (s, 2H),  
3.32 (t, J = 7.5 Hz, 2H), 3.17 (s, 3H), 3.04 (s, 3H), 2.23 (s, 3H), 2.09 (appt. q, J = 7.1 Hz, 2H),  
1.76-1.66 (m, 2H); 13C-NMR (101 MHz, CDCl3): δ = 156.5 (C), 146.2 (C), 143.7 (C), 137.3 (CH), 
136.5 (C), 133.2 (C), 129.8 (2CH), 129.3 (CH), 128.8 (2CH), 127.1 (2CH), 126.3 (C), 125.3 (2CH), 
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115.5 (CH2), 47.9 (CH2), 44.0 (CH2), 37.9 (CH3), 36.9 (CH3), 30.6 (CH2), 27.2 (CH2), 21.4 (CH3); 
HRMS (ES): m/z calculated for C24H29N3O5S2Na: 526.1446, found 526.1439 (M+Na)
+. 
Tetrahydrofuran 283 
TsOH·H2O (190 mg, 1.0 mmol) was added to a solution of tetrahydropyridine 257d 
(95.1 mg, 0.20 mmol) in MeOH (2 mL) and the reaction mixture was stirred at room 
temperature for 20 minutes. Satd. NaHCO3(aq) solution (5 mL) was added and the 
mixture was extracted with CH2Cl2 (3 x 15 mL). The combined organic extracts were 
dried over Na2SO4, concentrated under reduced pressure and purified by flash column 
chromatography (40→75% EtOAc in hexane) to give tetrahydrofuran 283 as a white solid (76.1 mg, 
77%); mp: 88-90 °C; IR (neat): ν = 3398, 2928, 2861, 1683, 1341, 1158, 761 cm-1; 1H-NMR (400 MHz, 
CDCl3): δ = 7.66 (d, J = 8.2 Hz, 2H), 7.41-7.29 (m, 7H), 3.91 (d, J = 9.7 Hz, 1Ha), 3.43 (dd, J = 12.9, 
8.1 Hz, 1Hc), 3.35 (s, 3H), 3.30 (d, J = 9.7 Hz, 1Hb), 3.03-2.92 (m, 4H, CH3+1Hb), 2.85 (d, J = 9.7 Hz, 1Ha), 
2.60-2.51 (m, 1Hd), 2.43 (s, 3H), 2.12 (br s, 2OH), 1.79 (dd, J = 12.9, 9.2 Hz, 1Hc); 
13C-NMR (101 MHz, 
CDCl3): δ = 174.9 (C), 144.1 (C), 139.0 (C), 132.0 (C), 129.9 (2CH), 129.4 (2CH), 128.5 (CH), 
128.0 (2CH), 123.4 (2CH), 104.0 (C), 90.9 (C), 60.7 (CH2a), 53.1 (CH2b), 49.5 (CHd), 46.2 (CH2c), 
42.0 (CH3), 33.5 (CH3), 21.7 (CH3); HRMS (ES): m/z calculated for C22H27N3O6S2Na: 516.1239, found 
516.1251 (M+Na)+. Crystals suitable for single crystal X-ray diffraction were grown by diffusion of 
hexane into a solution of 283 in CH2Cl2. 
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Piperidine 284 
LiAlH4 (32 mg, 0.84 mmol) was added to a solution of tetrahydropyridine 257d 
(80.0 mg, 0.17 mmol) in THF (2 mL) and the reaction mixture was stirred at room 
temperature for 20 minutes. Satd. sodium potassium tartrate(aq) solution (10 mL) 
was added and the mixture was extracted with CH2Cl2 (3 x 10 mL). The combined organic extracts 
were dried over Na2SO4, concentrated under reduced pressure and purified by flash column 
chromatography (80→100% EtOAc in hexane) to give piperidine 284 as a white solid (41.0 mg, 65%); 
mp: 64-66 °C; IR (neat): ν = 3322, 2930, 1334, 1152, 1092, 1015, 702 cm-1; 1H-NMR (400 MHz, CDCl3): 
δ = 7.69-7.63 (m, 4H), 7.37-7.31 (m, 2H), 7.31-7.26 (m, 3H), 3.64-3.55 (m, 2H, 1Ha+1Hd), 3.39 (dd, 
J = 9.3, 7.1 Hz, 1Hc), 2.94-2.81 (m, 3H, 1Ha+1Hc+1Hd), 2.58 (appt. td, J = 10.4, 7.0 Hz, 1He),  
2.45-2.37 (m, 4H, CH3+1Hb), 1.84 (br s, 2H, OH+NH), 1.58 (appt. t, J = 12.5 Hz, 1Hb), 1.48-1.35 (m, 1Hf); 
13C-NMR (101 MHz, CDCl3): δ = 145.0 (C), 143.5 (C), 134.8 (C), 129.9 (2CH), 128.6 (2CH), 128.0 (CH), 
127.4 (2CH), 126.7 (2CH), 71.4 (C), 61.8 (CHe), 57.1 (CH2a), 51.4 (CH2d), 50.8 (CH2c), 41.29 (CHf), 
41.25 (CH2b), 21.7 (CH3); HRMS (ES): m/z calculated for C20H25N2O3S: 373.1586, found 
373.1576 (M+H)+. In order to obtain crystals suitable for X-ray diffraction 284 was dissolved in 
4 M HCl in 1,4-dioxane. The dioxane was removed under reduced pressure and crystals of 284.HCl 
were grown by dissolving in refluxing MeCN/H2O followed by slow evaporation of the solvent. 
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5.1.8: Imidazolium Salts 
5.1.8.1: General procedure for synthesis of NHC.HPF6 salts (GP9) 
 
Adapted from a literature procedure,[128] under an argon atmosphere POCl3 (3.0 eq.) was added to a 
solution of oxazole (1.0 eq.) in m-xylene (0.1 M with respect to oxazole) and the reaction mixture was 
heated at 140 °C for 64 hours. After cooling to room temperature, the impure NHC.HCl salt was 
isolated either by flash column chromatography (0→10% MeOH in CH2Cl2) or by filtration of the of 
the reaction mixture through a 5 cm pad of silica gel (washing first with CH2Cl2 to remove apolar 
impurities and then eluting the crude NHC.HCl salt with 10% MeOH in CH2Cl2). The resulting brown 
solid was taken up in refluxing H2O (~10 mL) and the hot solution was filtered through glass wool, the 
flask was then washed out with additional boiling H2O (~5 mL) which was also filtered though the 
glass wool. The aqueous filtrate was allowed to cool to room temperature and a saturated solution of 
KPF6(aq) (2.0 eq.) was added, leading to instant precipitation of the crude NHC.HPF6 salt. The solid was 
collected by filtration, washed with ice-cold water and Et2O, and then recrystallised from acetone by 
addition of Et2O to give the NHC.HPF6 salt. 
363a.HPF6 
Following GP9 using oxazole 371a (827 mg, 1.8 mmol) and POCl3 (500 µL, 
5.4 mmol), purification by flash column chromatography and ion exchange 
with KPF6 (644 mg, 3.5 mmol) gave 363a.HPF6 as a white solid (706 mg, 
67%); mp: 236-238 °C; IR (neat): ν = 3148, 2967, 1622, 1346, 1236, 1156, 1061, 830 cm-1; 1H-NMR 
(400 MHz, d6-acetone): δ = 9.81 (d, J = 1.5 Hz, 1H), 8.16-8.12 (m, 2H), 8.10 (d, J = 1.5 Hz, 1H), 
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7.77-7.69 (m, 4H), 7.55 (d, J = 7.8 Hz, 2H), 3.62 (s, 3H), 3.41 (s, 3H), 2.67 (hept, J = 6.8 Hz, 2H), 1.26 (d, 
J = 6.8 Hz, 6H), 1.24 (d, J = 6.8 Hz, 6H); 13C-NMR (101 MHz, d6-acetone): δ = 152.4 (C), 146.9 (2C), 
145.7 (C), 133.08 (CH), 133.05 (CH), 132.6 (C), 130.6 (2CH), 127.7 (2CH), 125.7 (C), 125.6 (2CH), 
121.8 (CH), 119.2 (C), 101.4 (CH), 40.1 (CH3), 37.1 (CH3), 29.2 (2CH), 24.7 (2CH3), 24.3 (2CH3); 
19F{1H}-NMR (282 MHz, Acetone): δ = -72.6 (d, JF-P = 708 Hz); 
31P{1H}-NMR (121 MHz, d6-acetone): 
δ = -145.2 (hept, JF-P = 708 Hz); HRMS (ES): m/z calculated for C25H30N3O3S: 452.2008, found 
452.2004 (M-PF6)
+; Anal. calculated for C25H30F6N3O3PS: C, 50.25; H, 5.06; N, 7.03. Found: C, 50.19; 
H, 4.86; N, 7.10. 
363b.HPF6 
Following GP9 using oxazole 371b (343 mg, 0.7 mmol) and POCl3 
(200 µL, 2.1 mmol), purification by flash column chromatography 
and ion exchange with KPF6 (254 mg, 1.4 mmol) gave 363b.HPF6 as 
a white solid (232 mg, 53%); mp: 146-148 °C; IR (neat): ν = 3148, 2969, 1620, 1608, 1346, 1261, 1178, 
1155, 830 cm-1; 1H-NMR (400 MHz, CDCl3): δ = 8.51 (d, J = 1.5 Hz, 1H), 7.84 (d, J = 9.0 Hz, 2H), 7.56 (t, 
J = 7.9 Hz, 1H), 7.33 (d, J = 7.9 Hz, 2H), 7.09 (d, J = 9.0 Hz, 2H), 7.03 (d, J = 1.5 Hz, 1H), 3.89 (s, 3H), 
3.42 (s, 3H), 3.18 (s, 3H), 2.39 (hept, J = 6.8 Hz, 2H), 1.21 (d, J = 6.8 Hz, 6H), 1.18 (d, J = 6.8 Hz, 6H); 
13C-NMR (101 MHz, CDCl3): δ = 162.9 (C), 152.5 (C), 146.0 (2C), 143.8 (C), 132.4 (CH), 131.0 (C), 
128.9 (2CH), 124.8 (2CH), 119.9 (CH), 116.4 (C), 116.1 (C), 115.4 (2CH), 99.4 (CH), 55.7 (CH3), 
40.2 (CH3), 36.9 (CH3), 28.7 (2CH), 24.6 (2CH3), 24.2 (2CH3); 
19F{1H}-NMR (282 MHz, CDCl3): 
δ = -72.9 (d, JF-P = 713 Hz); 
31P{1H}-NMR (121 MHz, CDCl3): δ = -144.6 (hept, JF-P = 713 Hz); 
HRMS (ES): m/z calculated for C26H32N3O4S: 482.2114, found 482.2117 (M-PF6)
+; Anal. calculated for 
C26H32F6N3O4PS: C, 49.76; H, 5.14; N, 6.70. Found: C, 49.81; H, 5.15; N, 6.77. 
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363c.HPF6 
Following GP9 using oxazole 371c (459 mg, 0.86 mmol) and POCl3 (240 µL, 
2.6 mmol), purification by filtration through silica gel and ion exchange with 
KPF6 (317 mg, 1.7 mmol) gave 363c.HPF6 as a white solid (154 mg, 27%); 
mp: 146-148 °C; IR (neat): ν = 3147, 2968, 1618, 1496, 1365, 1236, 1161, 1060, 966, 834, 766 cm-1; 
1H-NMR (400 MHz, CDCl3): δ = 9.03 (d, J = 1.3 Hz, 1H), 8.04-7.93 (m, 2H), 7.63-7.53 (m, 4H), 7.52-7.48 
(m, 2H), 7.42-7.29 (m, 5H), 7.17 (d, J = 1.3 Hz, 1H), 3.36 (s, 3H), 2.34 (hept, J = 6.8 Hz, 2H), 1.26 (d,  
J = 6.8 Hz, 6H), 1.21 (d, J = 6.8 Hz, 6H); 13C-NMR (101 MHz, CDCl3): δ = 153.6 (C), 145.5 (2C), 143.8 (C), 
138.0 (C), 132.9 (CH), 132.5 (CH), 131.0 (C), 130.6 (2CH), 129.6 (2CH), 129.4 (CH), 127.7 (2CH), 
125.7 (2CH), 124.8 (2CH), 123.6 (C), 120.8 (CH), 117.4 (C), 100.0 (CH), 41.0 (CH3), 29.0 (2CH), 
24.6 (2CH3), 24.0 (2CH3); 
19F{1H}-NMR (282 MHz, CDCl3): δ = -72.1 (d, JF-P = 713 Hz);  
31P{1H}-NMR (121 MHz, CDCl3): δ = -144.4 (hept, JF-P = 713 Hz); HRMS (ES): m/z calculated for 
C30H32N3O3S: 514.2164, found 514.2171 (M-PF6)
+; Anal. calculated for C30H32F6N3O3PS: C, 54.63; 
H, 4.89; N, 6.37. Found: C, 54.49; H, 4.76; N, 6.40. 
363d.HPF6 
Following GP9 using oxazole 371d (435 mg, 0.88 mmol) and POCl3 (250 µL, 
2.7 mmol), purification by flash column chromatography and ion exchange 
with KPF6 (324 mg, 1.8 mmol) gave 363d.HPF6 as a yellow solid (80 mg, 
14%); mp: 200-202 °C; IR (neat): ν = 2968, 2934, 1619, 1353, 1299, 1164, 1060, 842, 730 cm-1; 
1H-NMR (400 MHz, CDCl3): δ = 8.60 (s, 1H), 8.01-7.92 (m, 2H), 7.64-7.54 (m, 4H), 7.33 (d, J = 7.8 Hz, 
2H), 7.16 (s, 1H), 6.08-5.96 (m, 1H), 5.30 (d, J = 16.9 Hz, 1H), 5.17 (d, J = 10.0 Hz, 1H), 4.46-4.30 (m, 
2H), 3.18 (s, 3H), 2.32 (hept, J = 6.7 Hz, 2H), 1.19 (appt. d, J = 6.7 Hz, 12H); 13C-NMR (101 MHz, CDCl3): 
δ = 153.4 (C), 145.7 (2C), 144.0 (C), 132.7 (CH), 132.5 (CH), 131.2 (CH), 130.9 (C), 129.8 (2CH), 127.0 
(2CH), 124.8 (2CH), 123.9 (C), 123.1 (CH2), 119.9 (CH), 116.3 (C), 100.1 (CH), 53.9 (CH2), 41.2 (CH3), 
28.8 (2CH), 24.31 (2CH3), 24.27 (2CH3); 
19F{1H}-NMR (282 MHz, CDCl3): δ = -72.6 (d, JF-P = 713 Hz); 
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31P{1H}-NMR (121 MHz, CDCl3): δ = -144.5 (hept, JF-P = 713 Hz); HRMS (ES): m/z calculated for 
C27H32N3O3S: 478.2164, found 478.2161 (M-PF6)
+; Anal. calculated for C27H32F6N3O3PS: C, 52.00; 
H, 5.17; N, 6.74. Found: C, 51.82; H, 5.11; N, 6.85. 
5.1.9: Organometallic complexes 
5.1.9.1: General procedure for synthesis of (NHC)MCl complexes (GP10) 
 
Adapted from a literature procedure,[153b] a vial was charged sequentially with NHC.HX, the 
corresponding metal chloride, NEt3 (70 µL, 0.50 mmol) and acetone (2 mL). and heated at 60 °C for 
18 hours. The solvent was removed under reduced pressure and the crude mixture was taken up in 
CH2Cl2 (~10 mL) and washed with H2O (2 x 10 mL). The organic phase was dried over Na2SO4, 
concentrated under reduced pressure and purified by flash column chromatography to give the 
(NHC)MCl complex. 
(IPr)AuCl 
Following GP10 using IPr.HCl (85 mg, 0.20 mmol) and (DMS)AuCl (65 mg, 
0.22 mmol). Flash column chromatography was replaced by filtration 
through a 5 cm pad of silica gel (eluting with CH2Cl2) to give (IPr)AuCl as a 
white solid (68.6 mg, 55%); mp: decomp. 280 °C; IR (neat): ν = 2965, 2926, 2869, 1470, 1456, 1416, 
1059, 938, 808, 763, cm-1; 1H-NMR (400 MHz, CDCl3): δ = 7.50 (t, J = 7.8 Hz, 2H), 7.29 (d, J = 7.8 Hz, 
4H), 7.17 (s, 2H), 2.55 (hept, J = 6.9 Hz, 4H), 1.35 (d, J = 6.9 Hz, 12H), 1.22 (d, J = 6.9 Hz, 12H). 
Spectroscopic data matched those reported.[211] 
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(363a)AuCl 
Following GP10 using 363a.HPF6 (100 mg, 0.17 mmol) and (DMS)AuCl 
(59.2 mg, 0.20 mmol). Purification by flash column chromatography 
(30→50% EtOAc in hexane) gave (363a)AuCl as a white solid (99.6 mg, 
87%); mp: decomp. 230 °C; IR (neat): ν = 3144, 2968, 1621, 1351, 1158, 1055, 965 cm-1;  
1H-NMR (400 MHz, CDCl3): δ = 8.01-7.95 (m, 2H), 7.59-7.49 (m, 4H), 7.28 (d, J = 7.8 Hz, 2H), 6.79 (s, 
1H), 3.73 (s, 3H), 3.53 (s, 3H), 2.48-2.31 (m, 2H), 1.34-1.28 (m, 6H), 1.20-1.14 (m, 6H);  
13C-NMR (101 MHz, CDCl3): δ = 154.6 (C), 151.0 (C), 145.9 (C), 145.7 (C), 144.5 (C), 135.1 (C), 
131.5 (CH), 131.2 (CH), 129.4 (2CH), 126.1 (2CH), 125.4 (C), 124.5 (2CH), 118.0 (C), 97.4 (CH), 
43.0 (CH3), 37.8 (CH3), 28.6 (2CH), 24.7 (2CH3), 24.6 (CH3), 24.5 (CH3); Anal. calculated for 
C25H29AuClN3O3S: C, 43.90; H, 4.27; N, 6.14. Found: C, 44.10; H, 4.17; N, 6.15. Crystals suitable for 
single crystal X-ray diffraction were grown by slow evaporation of a solution of (363a)AuCl in EtOAc. 
(363c)AuCl 
Following GP10 using 363c.HPF6 (100 mg, 0.15 mmol) and (DMS)AuCl 
(53.5 mg, 0.18 mmol). Purification by flash column chromatography 
(20→50% EtOAc in hexane) gave (363c)AuCl as a white solid (85.5 mg, 
76%); mp: 258-260 °C; IR (neat): ν = 3127, 2967, 2930, 2873, 1671, 1616, 1364, 1230, 1162, 1063, 961 
cm-1; 1H-NMR (400 MHz, CDCl3): δ = 8.08-8.01 (m, 2H), 7.75-7.69 (m, 2H), 7.61-7.54 (m, 4H), 7.44-7.38 
(m, 2H), 7.38-7.31 (m, 3H), 6.88 (s, 1H), 3.72 (s, 3H), 2.52 (hept, J = 6.9 Hz, 1H), 2.37 (hept, J = 6.9 Hz, 
1H), 1.34 (d, J = 6.9 Hz, 3H), 1.30 (d, J = 6.9 Hz, 3H), 1.19 (d, J = 6.9 Hz, 3H), 1.17 (d, J = 6.9 Hz, 3H); 
13C-NMR (101 MHz, CDCl3): δ = 155.5 (C), 152.4 (C), 146.3 (C), 146.2 (C), 145.1 (C), 139.5 (C), 
135.8 (C), 132.0 (CH), 131.3 (CH), 130.4 (2CH), 129.6 (2CH), 128.2 (CH), 127.2 (2CH), 125.4 (C), 
124.7 (CH), 124.6 (CH), 124.4 (2CH), 117.9 (C), 97.9 (CH), 43.2 (CH3), 28.9 (2CH), 24.6 (2CH3), 
24.52 (CH3), 24.45 (CH3); Anal. calculated for C30H31AuClN3O3S: C, 48.30; H, 4.19; N, 5.63. 
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Found: C, 48.12; H, 3.85; N, 5.81. Crystals suitable for single crystal X-ray diffraction were grown by 
diffusion of pentane into a solution of (363c)AuCl in CH2Cl2. 
(363a)CuCl 
Following GP10 using 363a.HPF6 (100 mg, 0.17 mmol) and CuCl (34 mg, 
0.34 mmol). Purification by flash column chromatography (30% EtOAc in 
hexane) gave (363a)CuCl as a white solid (49.9 mg, 54%); mp: 216-217 °C; 
IR (neat): ν = 3149, 2962, 2926, 2869, 1620, 1351, 1157, 1057, 1036, 964 cm-1; 1H-NMR (400 MHz, 
CDCl3): δ = 8.01-7.95 (m, 2H), 7.58-7.48 (m, 4H), 7.29 (d, J = 8.0 Hz, 2H), 6.76 (s, 1H), 3.73 (s, 3H), 
3.48 (s, 3H), 2.44 (hept, J = 6.8 Hz, 1H), 2.35 (hept, J = 6.8 Hz, 1H), 1.29 (d, J = 6.8 Hz, 3H), 1.26 (d, 
J = 6.8 Hz, 3H), 1.19 (d, J = 6.8 Hz, 3H), 1.17 (d, J = 6.8 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ = 
159.2 (C), 150.5 (C), 145.9 (C), 145.7 (C), 145.1 (C), 135.5 (C), 131.3 (CH), 131.1 (CH), 129.4 (2CH), 
126.1 (2CH), 125.6 (C), 124.4 (2CH), 118.1 (C), 97.5 (CH), 43.1 (CH3), 37.3 (CH3), 28.6 (2CH), 25.1 (CH3), 
25.0 (CH3), 24.5 (CH3), 24.2 (CH3); Anal. calculated for C25H29ClCuN3O3S: C, 54.54; H, 5.31; N, 7.63. 
Found: C, 54,76; H, 5.32; N, 7.70. Crystals suitable for single crystal X-ray diffraction were grown by 
diffusion of pentane into a solution of (363a)CuCl in CH2Cl2/CDCl3. 
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(363a)Ir(CO)2Cl 
Inside a N2 filled glovebox NaO
tBu (21.0 mg, 0.22 mmol) was added to a 
solution of 363a.HPF6 (119 mg, 0.20 mmol) in THF (2 mL) and the 
suspension was stirred at room temperature for 20 minutes before 
filtration through a 3 cm pad of celite (washing with 1 mL of THF) into a vial 
containing [Ir(cod)Cl]2 (71.8 mg, 0.107 mmol, 1.07 eq.) and the resulting suspension was stirred for 1 
hour at room temperature. The vial was removed from the glovebox and the contents filtered 
through a 3 cm pad of silica gel and the filtrate purified by flash column chromatography (4:1 
hexane:EtOAc). The resulting yellow solid (363a)Ir(cod)Cl was dissolved in CH2Cl2 (3 mL) and CO 
(balloon pressure) was bubbled through the stirred solution for 5 minutes. The solvent was removed 
under reduced pressure and the resulting solid purified by flash column chromatography (3:1 
hexane:EtOAc) to give (363a)Ir(CO)2Cl as a yellow solid (43.0 mg, 29% over two steps); mp: 110-112 
°C; IR (CH2Cl2): ν = 2068.19 (CO), 1986.32 (CO) cm
-1; Restricted rotation around the metal-carbene 
bond results in 3 sets of signals (1 major, 2 minor); 1H-NMR (400 MHz, CDCl3): δ = 8.00-7.92 (m, 2H), 
7.61-7.50 (m, 4H), 7.37-7.28 (m, 2H), 6.80 (s, 1H), 3.75minor and 3.68major and 3.63minor (s, 3H), 3.71minor 
and 3.47major and 3.43minor (s, 3H), 2.87-2.76 (m, 1H), 2.53-2.41 (m, 1H), 1.44-1.40minor and 
1.36-1.27major (m, 6H), 1.13 (d, J = 6.7 Hz, 3H), 1.11-1.04 (m, 3H); 
 13C-NMR (101 MHz, CDCl3) Only the major rotamer is reported: δ = 180.4 (CO), 167.7 (CO), 159.8 (C), 
150.3 (C), 147.2 (C), 145.6 (C), 145.3 (C), 136.1 (C), 131.3 (CH), 131.0 (CH), 129.5 (2CH), 126.7 (2CH), 
125.5 (C), 124.5 (CH), 123.8 (CH), 119.7 (C), 99.0 (CH), 42.4 (CH3), 38.1 (CH3), 28.6 (2CH), 27.3 (CH3), 
26.4 (CH3), 23.5 (CH3), 22.1 (CH3); Anal. calculated for C27H29ClIrN3O5S: C, 44.10; H, 3.98; N, 5.71. 
Found: C, 44.29; H, 4.06; N, 5.43. 
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(363b)Ir(CO)2Cl 
Inside a N2 filled glovebox NaO
tBu (21.0 mg, 0.22 mmol) was added 
to a solution of 363b.HPF6 (125 mg, 0.20 mmol) in THF (2 mL) and 
the suspension was stirred at room temperature for 20 minutes 
before filtration through a 3 cm pad of celite (washing with 1 mL of 
THF) into a vial containing [Ir(cod)Cl]2 (70.0 mg, 0.104 mmol, 1.04 eq.) and the resulting suspension 
was stirred for 1 hour at room temperature. The vial was removed from the glovebox and the 
contents filtered through a 3 cm pad of silica gel and the filtrate purified by flash column 
chromatography (4:1 hexane:EtOAc). The resulting yellow solid (363b)Ir(cod)Cl was dissolved in 
CH2Cl2 (3 mL) and CO (balloon pressure) was bubbled through the stirred solution for 5 minutes. The 
solvent was removed under reduced pressure and the resulting solid purified by flash column 
chromatography (3:1 hexane:EtOAc) to give (363b)Ir(CO)2Cl as a yellow solid (34.2 mg, 22% over two 
steps); mp: 114-116 °C; IR (CH2Cl2): ν = 2067.92 (CO), 1985.97 (CO) cm
-1; Restricted rotation around 
the metal-carbene bond results in 3 sets of signals (1 major, 2 minor);  
1H-NMR (400 MHz, CDCl3): δ = 7.94-7.87 (m, 2H), 7.56-7.49 (m, 1H), 7.36-7.28 (m, 2H), 7.10-7.03 (m, 
2H), 6.78 (s, 1H), 3.89 (s, 3H), 3.74minor and 3.68major* and 3.62minor (s, 3H), 3.68minor* and 3.46major and 
3.42minor (s, 3H), 2.88-2.74 (m, 1H), 2.55-2.41 (m, 1H), 1.44-1.39 and 1.35-1.27 (m, 6H), 1.16-1.10 (m, 
3H), 1.10-1.03 (m, 3H); 13C-NMR (101 MHz, CDCl3) Only the major rotamer is reported: δ = 180.4 (CO), 
167.7 (CO), 161.9 (C), 159.3 (C), 150.5 (C), 147.3 (C), 145.5 (C), 145.4 (C), 136.1 (C), 131.0 (CH), 
128.4 (2CH), 124.5 (CH), 124.4 (C), 123.8 (CH), 117.8 (C), 114.9 (2CH), 98.9 (CH), 55.6 (CH3), 
42.4 (CH3), 38.0 (CH3), 28.62 (CH), 28.61 (CH), 27.3 (CH3), 26.4 (CH3), 23.5 (CH3), 22.1 (CH3); 
Anal. calculated for C28H31ClIrN3O6S: C, 43.94; H, 4.08; N, 5.49. Found: C, 44.25; H, 4.22; N, 5.32. *The 
overlap of these two signals was determined using an HSQC spectrum. 
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Alkyne 404 
Following a literature procedure,[212] under an argon atmosphere 
Pd(PPh3)4Cl2 (151 mg, 2 mol%), CuI (82 mg, 4 mol%), degassed THF (54 mL), PhI (2.19 g, 10.7 mmol), 
degassed NEt3 (10.5 mL) and 4-phenyl-1-butyne (1.54 g, 11.8 mmol) were added sequentially to a 
two neck flask and the reaction mixture was stirred for 20 hours at room temperature. After this 
time the mixture was concentrated to a volume of ~5 mL and filtered through a 5 cm plug of silica gel 
(eluting with Et2O) and the filtrate was concentrated under reduced pressure and purified by flash 
column chromatography (0→4% EtOAc in hexane) to give alkyne 404 as a colourless oil (1.46 g, 66%); 
IR (neat): ν = 3028, 2927, 1599, 1490, 1454, 1442, 753, 690 cm-1; 1H-NMR (400 MHz, CDCl3): δ = 7.38-
7.17 (m, 10H), 2.91 (t, J = 7.5 Hz, 2H), 2.67 (t, J = 7.5 Hz, 2H); 13C-NMR (101 MHz, CDCl3): δ = 140.9 (C), 
131.7 (2CH), 128.7 (2CH), 128.5 (2CH), 128.3 (2CH), 127.8 (CH), 126.5 (CH), 124.0 (C), 89.6 (C), 81.5 
(C), 35.3 (CH2), 21.8 (CH2). Spectroscopic data matched those reported.
[212] 
5.1.10: Hydration of alkyne 404 
 
Following a literature procedure,[167a] AgSbF6 (6.9 mg, 2 mol%), (NHC)AuCl (1 mol%), degassed 
1,4-dioxane (670 µL), alkyne 404 (206 mg, 1.0 mmol) and degassed H2O (330 µL) were added to a 
Schlenk tube under an argon atmosphere and the reaction mixture was heated at 70 °C for 17 hours. 
H2O (5 mL) was added and the mixture was extracted with CH2Cl2 (2 x 5 mL). The combined organic 
extracts were dried over Na2SO4 and purified by flash column chromatography (19:1 hexane:EtOAc) 
to give a mixture of ketones 405 and 406 as a clear oil. Product ratios were determined by 1H-NMR 
spectroscopy with comparison to the literature spectra for 405[213] and 406.[214] 
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5.2: HPLC Traces 
5.2.1: Ester 147f 
Using a Phenominex® Cellulose 1 column (250 x 4.6 mm) in 20% MeCN in H2O at 25 °C with a flow 
rate of 1 mL/min, injection volume of 20 µL and a detection wavelength of 210 nm. 
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5.2.2: Oxazole 151c 
Using a Phenominex® Cellulose 3 column (250 x 4.6 mm) in 35% MeCN in H2O at 25 °C with a flow 
rate of 0.75 mL/min, injection volume of 10 µL and a detection wavelength of 210 nm. 
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5.3: X-Ray Data 
5.3.1: Tetrahydropyridine 278 
 
 
 
 
 
 
Table 1 Crystal data and structure refinement for 278. 
Identification code 278 
Empirical formula C23H27N3O5S2 
Formula weight 489.59 
Temperature/K 100.00(10) 
Crystal system monoclinic 
Space group P21/n 
a/Å 10.94883(18) 
b/Å 10.88873(18) 
c/Å 19.5589(3) 
α/° 90 
β/° 102.1791(16) 
γ/° 90 
Volume/Å3 2279.31(7) 
Z 4 
ρcalcg/cm
3 1.427 
μ/mm-1 0.275 
F(000) 1032.0 
Crystal size/mm3 0.3425 × 0.1255 × 0.1122 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 6.038 to 52.742 
Index ranges -13 ≤ h ≤ 13, -13 ≤ k ≤ 13, -24 ≤ l ≤ 24 
Reflections collected 24092 
Independent reflections 4667 [Rint = 0.0263, Rsigma = 0.0205] 
Data/restraints/parameters 4667/0/301 
Goodness-of-fit on F2 1.045 
Final R indexes [I>=2σ (I)] R1 = 0.0326, wR2 = 0.0807 
Final R indexes [all data] R1 = 0.0391, wR2 = 0.0851 
Largest diff. peak/hole / e Å-3 0.38/-0.40 
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Table 2 Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement Parameters 
(Å2×103) for 278. Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
C1 5902.7(14) 2626.9(14) 2586.2(8) 12.1(3) 
C2 4947.7(14) 1770.1(14) 3316.2(8) 12.4(3) 
C3 5822.6(14) 2822.2(14) 3661.4(8) 12.7(3) 
C4 5087.9(14) 3983.9(14) 3329.9(8) 15.0(3) 
C5 5202.1(14) 3861.6(14) 2557.6(8) 13.5(3) 
C6 6521.0(14) 2352.6(14) 1984.0(8) 13.5(3) 
C7 5966.7(15) 4886.2(15) 2324.0(8) 16.7(3) 
C8 6393.1(15) 4544.7(15) 1658.3(8) 17.1(3) 
C9 4349.7(15) 811.8(17) 4354.7(8) 19.5(3) 
C10 3460.0(16) -761.8(15) 2771.4(9) 19.5(3) 
C11 6395.4(14) 2860.3(14) 4428.5(8) 14.0(3) 
C12 5785.8(16) 3436.9(16) 4897.9(9) 20.2(4) 
C13 6316.4(17) 3435.3(16) 5611.1(9) 22.5(4) 
C14 7463.6(17) 2886.7(16) 5860.7(9) 21.1(4) 
C15 8078.7(16) 2325.5(16) 5392.6(9) 21.2(4) 
C16 7547.5(15) 2305.5(15) 4682.6(8) 17.0(3) 
C17 7175.2(15) 2549.9(16) 488.3(8) 16.6(3) 
C18 7054.7(16) 1285.3(16) 404.1(9) 21.4(4) 
C19 6282.0(17) 808.2(17) -190.8(9) 24.3(4) 
C20 5619.0(16) 1585.5(17) -707.0(9) 21.2(4) 
C21 5768.2(16) 2847.6(17) -616.3(9) 21.3(4) 
C22 6539.1(15) 3339.5(16) -23.9(9) 19.1(3) 
C23 4748.9(18) 1068.6(19) -1343.2(10) 29.3(4) 
N1 5019.5(12) 1656.5(12) 2676.8(7) 13.0(3) 
N2 4050.2(12) 1213.6(12) 3617.8(7) 13.7(3) 
N3 7185.6(12) 3438.0(12) 1797.7(7) 14.6(3) 
O1 6765.4(9) 2701.1(10) 3250.9(5) 12.5(2) 
O2 2309.2(10) 1349.8(11) 2544.0(6) 20.0(3) 
O3 2051.7(10) 138.3(11) 3567.4(6) 18.0(2) 
O4 8951.1(10) 2197.9(12) 1574.1(6) 21.8(3) 
O5 8607.4(11) 4311.3(12) 1096.8(6) 23.2(3) 
S1 2824.0(3) 532.8(3) 3101.5(2) 13.08(10) 
S2 8117.8(4) 3151.4(4) 1259.4(2) 16.57(11) 
  
Table 3 Anisotropic Displacement Parameters (Å2×103) for 278. The Anisotropic displacement 
factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
Atom U11 U22 U33 U23 U13 U12 
C1 11.9(7) 12.7(7) 11.0(7) -0.1(6) 0.6(6) -0.8(6) 
C2 12.3(7) 10.8(7) 13.6(7) 0.2(6) 1.3(6) 1.2(6) 
C3 11.7(7) 12.6(7) 14.6(8) -0.7(6) 4.7(6) -0.4(6) 
C4 14.5(7) 13.4(8) 17.1(8) -1.1(6) 3.0(6) 1.1(6) 
C5 13.9(7) 11.7(8) 14.4(8) 0.2(6) 1.9(6) 0.3(6) 
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C6 15.4(7) 12.4(7) 13.4(7) 1.4(6) 4.8(6) -1.0(6) 
C7 19.5(8) 12.0(8) 18.0(8) 1.1(6) 2.7(6) -1.0(6) 
C8 19.8(8) 13.2(8) 18.2(8) 3.7(6) 3.7(6) -0.4(6) 
C9 18.8(8) 27.0(9) 12.6(8) 3.7(7) 3.2(6) -2.5(7) 
C10 19.8(8) 15.1(8) 25.2(9) -5.6(7) 8.7(7) -2.0(6) 
C11 15.9(7) 12.3(7) 14.2(8) -0.3(6) 3.9(6) -3.2(6) 
C12 19.9(8) 22.2(9) 19.0(8) -2.5(7) 4.9(7) 1.8(7) 
C13 29.8(9) 22.8(9) 17.2(8) -4.4(7) 10.0(7) -0.4(7) 
C14 30.7(9) 18.9(8) 12.8(8) -0.3(6) 2.3(7) -4.1(7) 
C15 21.5(8) 22.5(9) 17.8(8) 2.5(7) -0.1(7) 2.9(7) 
C16 18.7(8) 17.8(8) 14.6(8) -1.2(6) 3.7(6) 1.8(6) 
C17 14.9(8) 21.1(8) 15.4(8) 1.6(6) 6.6(6) 0.9(6) 
C18 22.5(8) 20.1(9) 22.0(9) 3.5(7) 5.5(7) 6.1(7) 
C19 27.2(9) 19.4(9) 26.8(9) -4.2(7) 7.2(7) 4.5(7) 
C20 17.4(8) 28.4(10) 19.8(9) -2.5(7) 8.8(7) 2.2(7) 
C21 17.1(8) 28.7(10) 18.8(8) 7.3(7) 5.1(7) 1.7(7) 
C22 18.6(8) 19.6(9) 20.8(8) 4.6(7) 7.8(7) -1.9(7) 
C23 25.7(9) 37.5(11) 24.8(10) -8.2(8) 5.5(8) 0.7(8) 
N1 14.4(6) 10.9(6) 13.8(6) 0.9(5) 3.4(5) -0.5(5) 
N2 13.5(6) 15.3(7) 12.3(6) 0.3(5) 2.9(5) -2.8(5) 
N3 14.7(6) 14.4(7) 15.7(7) 2.8(5) 5.6(5) -0.8(5) 
O1 11.2(5) 15.3(6) 11.1(5) 0.2(4) 2.6(4) 0.0(4) 
O2 17.4(6) 20.5(6) 19.8(6) 3.9(5) -1.5(5) -0.5(5) 
O3 15.2(5) 20.6(6) 19.1(6) -1.4(5) 5.9(5) -4.8(5) 
O4 15.0(6) 29.3(7) 21.6(6) 5.7(5) 4.8(5) 3.9(5) 
O5 21.5(6) 26.2(7) 23.3(6) 3.3(5) 7.8(5) -8.6(5) 
S1 12.28(19) 12.66(19) 14.34(19) -0.65(14) 2.90(14) -1.64(14) 
S2 13.35(19) 21.1(2) 16.0(2) 3.44(15) 4.70(15) -1.76(15) 
  
Table 4 Bond Lengths for 278. 
Atom Atom Length/Å   Atom Atom Length/Å 
C1 C5 1.543(2)   C12 C13 1.393(2) 
C1 C6 1.507(2)   C13 C14 1.383(3) 
C1 N1 1.4681(19)   C14 C15 1.388(2) 
C1 O1 1.4390(18)   C15 C16 1.388(2) 
C2 C3 1.553(2)   C17 C18 1.390(2) 
C2 N1 1.276(2)   C17 C22 1.390(2) 
C2 N2 1.3875(19)   C17 S2 1.7641(17) 
C3 C4 1.564(2)   C18 C19 1.387(3) 
C3 C11 1.500(2)   C19 C20 1.398(3) 
C3 O1 1.4413(17)   C20 C21 1.391(3) 
C4 C5 1.547(2)   C20 C23 1.508(2) 
C5 C7 1.522(2)   C21 C22 1.389(2) 
C6 N3 1.4734(19)   N2 S1 1.6733(13) 
C7 C8 1.519(2)   N3 S2 1.6433(13) 
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C8 N3 1.476(2)   O2 S1 1.4278(12) 
C9 N2 1.4754(19)   O3 S1 1.4336(11) 
C10 S1 1.7546(16)   O4 S2 1.4326(12) 
C11 C12 1.393(2)   O5 S2 1.4338(12) 
C11 C16 1.392(2)         
 
Table 5 Bond Angles for 278. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C6 C1 C5 116.50(13)   C18 C17 C22 120.44(16) 
N1 C1 C5 107.24(12)   C18 C17 S2 119.53(13) 
N1 C1 C6 111.56(12)   C22 C17 S2 120.02(13) 
O1 C1 C5 102.15(11)   C19 C18 C17 119.76(16) 
O1 C1 C6 113.56(12)   C18 C19 C20 120.73(17) 
O1 C1 N1 104.77(11)   C19 C20 C23 120.77(17) 
N1 C2 C3 109.74(13)   C21 C20 C19 118.49(16) 
N1 C2 N2 124.76(14)   C21 C20 C23 120.73(17) 
N2 C2 C3 124.36(13)   C22 C21 C20 121.45(16) 
C2 C3 C4 101.55(12)   C21 C22 C17 119.11(16) 
C11 C3 C2 123.00(13)   C2 N1 C1 103.11(12) 
C11 C3 C4 117.53(13)   C2 N2 C9 120.89(13) 
O1 C3 C2 97.98(11)   C2 N2 S1 119.13(10) 
O1 C3 C4 102.07(11)   C9 N2 S1 116.29(10) 
O1 C3 C11 111.25(12)   C6 N3 C8 113.50(12) 
C5 C4 C3 101.22(12)   C6 N3 S2 114.33(10) 
C1 C5 C4 100.45(12)   C8 N3 S2 117.19(10) 
C7 C5 C1 110.42(12)   C1 O1 C3 95.60(10) 
C7 C5 C4 113.13(13)   N2 S1 C10 104.35(7) 
N3 C6 C1 111.16(12)   O2 S1 C10 110.06(8) 
C8 C7 C5 111.46(13)   O2 S1 N2 108.79(7) 
N3 C8 C7 108.45(13)   O2 S1 O3 118.77(7) 
C12 C11 C3 120.96(14)   O3 S1 C10 109.04(8) 
C16 C11 C3 120.08(14)   O3 S1 N2 104.76(6) 
C16 C11 C12 118.96(15)   N3 S2 C17 106.73(7) 
C11 C12 C13 120.18(16)   O4 S2 C17 107.64(8) 
C14 C13 C12 120.63(15)   O4 S2 N3 106.72(7) 
C13 C14 C15 119.22(16)   O4 S2 O5 119.97(7) 
C14 C15 C16 120.52(16)   O5 S2 C17 108.42(8) 
C15 C16 C11 120.48(15)   O5 S2 N3 106.66(7) 
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Table 6 Torsion Angles for 278. 
A B C D Angle/˚   A B C D Angle/˚ 
C1 C5 C7 C8 50.89(17)   C11 C12 C13 C14 1.4(3) 
C1 C6 N3 C8 -53.83(17)   C12 C11 C16 C15 0.1(2) 
C1 C6 N3 S2 168.15(10)   C12 C13 C14 C15 -0.6(3) 
C2 C3 C4 C5 -68.17(13)   C13 C14 C15 C16 -0.5(3) 
C2 C3 C11 C12 -90.11(19)   C14 C15 C16 C11 0.7(3) 
C2 C3 C11 C16 89.32(19)   C16 C11 C12 C13 -1.1(2) 
C2 C3 O1 C1 46.80(12)   C17 C18 C19 C20 -0.2(3) 
C2 N2 S1 C10 69.39(13)   C18 C17 C22 C21 0.9(2) 
C2 N2 S1 O2 -48.07(13)   C18 C17 S2 N3 -94.54(14) 
C2 N2 S1 O3 -176.05(11)   C18 C17 S2 O4 19.72(15) 
C3 C2 N1 C1 -1.14(16)   C18 C17 S2 O5 150.90(13) 
C3 C2 N2 C9 -46.8(2)   C18 C19 C20 C21 1.1(3) 
C3 C2 N2 S1 155.66(12)   C18 C19 C20 C23 -178.13(16) 
C3 C4 C5 C1 3.23(14)   C19 C20 C21 C22 -1.0(2) 
C3 C4 C5 C7 -114.46(14)   C20 C21 C22 C17 0.1(2) 
C3 C11 C12 C13 178.30(15)   C22 C17 C18 C19 -0.8(2) 
C3 C11 C16 C15 -179.35(15)   C22 C17 S2 N3 84.17(14) 
C4 C3 C11 C12 37.3(2)   C22 C17 S2 O4 -161.57(12) 
C4 C3 C11 C16 -143.26(15)   C22 C17 S2 O5 -30.39(15) 
C4 C3 O1 C1 -56.90(13)   C23 C20 C21 C22 178.18(15) 
C4 C5 C7 C8 162.58(13)   N1 C1 C5 C4 71.34(14) 
C5 C1 C6 N3 43.91(18)   N1 C1 C5 C7 -168.99(12) 
C5 C1 N1 C2 -74.46(14)   N1 C1 C6 N3 167.50(12) 
C5 C1 O1 C3 59.83(12)   N1 C1 O1 C3 -51.91(13) 
C5 C7 C8 N3 -60.82(17)   N1 C2 C3 C4 73.44(15) 
C6 C1 C5 C4 -162.88(13)   N1 C2 C3 C11 -152.52(14) 
C6 C1 C5 C7 -43.21(18)   N1 C2 C3 O1 -30.70(15) 
C6 C1 N1 C2 156.86(13)   N1 C2 N2 C9 146.71(16) 
C6 C1 O1 C3 -173.89(12)   N1 C2 N2 S1 -10.9(2) 
C6 N3 S2 C17 60.08(12)   N2 C2 C3 C4 -94.83(16) 
C6 N3 S2 O4 -54.80(12)   N2 C2 C3 C11 39.2(2) 
C6 N3 S2 O5 175.82(11)   N2 C2 C3 O1 161.04(13) 
C7 C8 N3 C6 62.71(16)   N2 C2 N1 C1 167.07(14) 
C7 C8 N3 S2 -160.54(11)   O1 C1 C5 C4 -38.53(13) 
C8 N3 S2 C17 -76.32(13)   O1 C1 C5 C7 81.14(14) 
C8 N3 S2 O4 168.80(11)   O1 C1 C6 N3 -74.38(16) 
C8 N3 S2 O5 39.42(13)   O1 C1 N1 C2 33.58(15) 
C9 N2 S1 C10 -89.19(13)   O1 C3 C4 C5 32.70(14) 
C9 N2 S1 O2 153.36(11)   O1 C3 C11 C12 154.41(14) 
C9 N2 S1 O3 25.37(13)   O1 C3 C11 C16 -26.2(2) 
C11 C3 C4 C5 154.66(13)   S2 C17 C18 C19 177.86(13) 
C11 C3 O1 C1 176.93(12)   S2 C17 C22 C21 -177.81(12) 
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Table 7 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement Parameters (Å2×103) for 
278. 
Atom x y z U(eq) 
H4A 4223 3959 3374 18 
H4B 5473 4735 3539 18 
H5 4375 3805 2247 16 
H6A 7108 1682 2111 16 
H6B 5893 2097 1582 16 
H7A 5466 5628 2244 20 
H7B 6692 5054 2692 20 
H8A 5674 4382 1285 21 
H8B 6863 5217 1514 21 
H9A 3936 1338 4628 29 
H9B 5237 854 4529 29 
H9C 4071 -18 4386 29 
H10A 3871 -1269 3153 29 
H10B 4053 -504 2503 29 
H10C 2804 -1221 2478 29 
H12 5023 3824 4735 24 
H13 5895 3806 5922 27 
H14 7818 2894 6337 25 
H15 8853 1960 5556 25 
H16 7964 1919 4374 20 
H18 7491 761 745 26 
H19 6204 -38 -247 29 
H21 5342 3374 -960 26 
H22 6629 4186 29 23 
H23A 5025 262 -1440 44 
H23B 4749 1594 -1737 44 
H23C 3918 1020 -1258 44 
Crystal structure determination of [278] 
Crystal Data for C23H27N3O5S2 (M =489.59 g/mol): monoclinic, space group P21/n (no. 14), a = 
10.94883(18) Å, b = 10.88873(18) Å, c = 19.5589(3) Å, β = 102.1791(16)°, V = 2279.31(7) Å3, Z = 4, T = 
100.00(10) K, μ(MoKα) = 0.275 mm-1, Dcalc = 1.427 g/cm3, 24092 reflections measured (6.038° ≤ 2Θ ≤ 
52.742°), 4667 unique (Rint = 0.0263, Rsigma = 0.0205) which were used in all calculations. The 
final R1 was 0.0326 (I > 2σ(I)) and wR2 was 0.0851 (all data). 
Refinement model description 
Number of restraints - 0, number of constraints - unknown. Details: 1. Fixed Uiso At 1.2 times of: All 
C(H) groups, All C(H,H) groups At 1.5 times of: All C(H,H,H) groups. 2.a Ternary CH refined with riding 
coordinates: C5(H5). 2.b Secondary CH2 refined with riding coordinates: C4(H4A,H4B), C6(H6A,H6B), 
C7(H7A,H7B), C8(H8A,H8B). 2.c Aromatic/amide H refined with riding coordinates: C12(H12), 
C13(H13), C14(H14), C15(H15), C16(H16), C18(H18), C19(H19), C21(H21), C22(H22). 2.d Idealised Me 
refined as rotating group: C9(H9A,H9B,H9C), C10(H10A,H10B,H10C), C23(H23A,H23B,H23C) 
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5.3.2: Tetrahydrofuran 283 
 
 
 
 
 
 
 
Table 1 Crystal data and structure refinement for 283. 
Identification code 283 
Empirical formula C22H27N3O6S2 
Formula weight 493.58 
Temperature/K 99.99(10) 
Crystal system orthorhombic 
Space group P212121 
a/Å 8.34939(14) 
b/Å 10.43121(16) 
c/Å 26.3933(3) 
α/° 90 
β/° 90 
γ/° 90 
Volume/Å3 2298.70(6) 
Z 4 
ρcalcg/cm
3 1.426 
μ/mm-1 2.485 
F(000) 1040.0 
Crystal size/mm3 0.3004 × 0.1094 × 0.0566 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 6.698 to 136.482 
Index ranges -10 ≤ h ≤ 9, -12 ≤ k ≤ 12, -31 ≤ l ≤ 31 
Reflections collected 20637 
Independent reflections 4205 [Rint = 0.0316, Rsigma = 0.0211] 
Data/restraints/parameters 4205/0/310 
Goodness-of-fit on F2 1.091 
Final R indexes [I>=2σ (I)] R1 = 0.0302, wR2 = 0.0777 
Final R indexes [all data] R1 = 0.0311, wR2 = 0.0784 
Largest diff. peak/hole / e Å-3 0.47/-0.24 
Flack parameter 0.550(19) 
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Table 2 Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement Parameters 
(Å2×103) for 283. Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
C1 11490(3) 3935(3) 1254(1) 27.4(6) 
C2 10248(4) 3947(3) 1689.7(10) 30.2(6) 
C3 9952(3) 5368(3) 1775.5(10) 32.8(6) 
C4 11555(3) 5980(3) 1641.8(10) 29.2(6) 
C5 8801(3) 3247(3) 1472.5(10) 30.4(6) 
C6 10534(3) 3671(3) 765.2(10) 31.3(6) 
C7 12684(4) 5940(3) 2116(1) 32.6(6) 
C8 15178(4) 6188(3) 1574.3(10) 31.4(6) 
C9 15346(5) 4910(4) 2912.2(13) 47.8(8) 
C10 11423(3) 7376(3) 1480.4(10) 30.0(6) 
C11 12019(4) 7812(3) 1021.5(11) 32.7(7) 
C12 11907(4) 9088(3) 888.9(13) 38.9(7) 
C13 11169(4) 9946(3) 1210.4(13) 42.2(8) 
C14 10532(5) 9527(3) 1664.0(14) 48.1(9) 
C15 10667(4) 8256(4) 1801.3(12) 43.0(8) 
C16 7500(3) 1568(3) 503.7(10) 29.8(6) 
C17 8500(3) 1008(3) 148.8(10) 31.0(6) 
C18 8601(4) -312(3) 119.6(11) 36.4(7) 
C19 7706(4) -1103(3) 446.5(11) 37.5(7) 
C20 6698(5) -508(4) 790.1(14) 48.1(9) 
C21 6585(4) 814(3) 828.0(13) 41.8(8) 
C22 7880(5) -2537(4) 428.9(14) 50.7(9) 
N1 12709(3) 2987(2) 1323.1(10) 31.8(5) 
N2 8845(3) 3694(2) 940.0(8) 27.0(5) 
N3 14302(3) 6153(2) 2058.9(8) 28.7(5) 
O1 12139(2) 5230.1(19) 1231.9(7) 29.1(4) 
O2 12124(3) 5773(3) 2536.7(8) 54.1(7) 
O3 16967(2) 6651(3) 2432.8(8) 42.4(5) 
O4 14593(3) 7337(2) 2896.9(8) 44.6(6) 
O5 7804(3) 3786(2) 69.8(7) 36.2(5) 
O6 5948(2) 3577(2) 800.0(8) 35.5(5) 
S1 15373.3(8) 6386.8(7) 2596.3(2) 30.49(17) 
S2 7429.2(8) 3250.4(7) 555.6(2) 28.76(16) 
  
 
 
Table 3 Anisotropic Displacement Parameters (Å2×103) for 283. The Anisotropic displacement 
factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
Atom U11 U22 U33 U23 U13 U12 
C1 18.4(14) 37.7(15) 26.2(13) 3.0(11) -0.8(10) 3.4(12) 
C2 19.2(13) 49.9(17) 21.4(12) 7.2(11) 2.1(11) 3.4(13) 
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C3 20.1(14) 56.4(18) 21.8(12) -1.6(12) 1.2(10) 1.6(13) 
C4 20.1(14) 48.6(16) 18.8(13) -4.3(11) 1.5(10) 4.5(12) 
C5 23.5(14) 45.2(16) 22.5(12) 7.4(12) 3.1(10) 1.5(13) 
C6 16.8(13) 52.6(17) 24.5(12) 2.4(12) 0.3(11) -1.5(13) 
C7 20.8(14) 53.4(17) 23.7(13) 0.5(12) -0.2(11) 2.6(13) 
C8 23.4(14) 46.3(16) 24.6(12) -1.2(11) 6.5(11) -1.1(13) 
C9 48(2) 59(2) 36.4(15) 10.2(15) -11.0(16) 3.9(18) 
C10 19.9(14) 42.5(16) 27.7(14) -7.6(12) -5.5(11) 5.5(13) 
C11 30.9(16) 37.2(15) 30.1(14) -6.4(11) -0.1(12) 5.2(12) 
C12 36.0(18) 39.1(16) 41.5(17) -2.3(13) -4.0(14) 5.1(14) 
C13 36.9(17) 37.2(17) 52.3(19) -11.9(14) -13.8(15) 8.9(14) 
C14 40(2) 49.4(19) 55(2) -25.0(16) -7.4(17) 19.4(17) 
C15 34.6(17) 61(2) 33.6(15) -13.6(15) 0.1(13) 9.7(16) 
C16 21.1(13) 41.8(15) 26.6(12) 0.3(11) -1.0(11) -2.0(13) 
C17 19.0(14) 52.8(18) 21.3(13) -1.8(12) -2.3(10) -1.0(13) 
C18 25.4(15) 56.9(19) 26.8(14) -10.7(13) -1.8(12) 1.6(14) 
C19 36.4(18) 46.0(17) 30.1(14) -8.6(12) -8.2(13) -0.4(15) 
C20 50(2) 47.9(19) 46.1(19) 1.8(15) 15.2(17) -8.3(17) 
C21 37.7(18) 46.2(18) 41.4(17) -2.3(14) 18.5(15) -4.8(15) 
C22 53(2) 54(2) 45.3(19) -12.1(16) -4.6(17) -0.5(18) 
N1 21.1(12) 39.0(13) 35.4(13) 2.7(10) 1.7(11) 4.2(11) 
N2 17.7(11) 41.6(13) 21.8(11) 5.4(9) -0.5(9) -2.9(10) 
N3 19.8(12) 44.6(14) 21.7(10) 0.2(9) 0.2(9) 4.2(10) 
O1 26.7(10) 35.3(10) 25.1(9) 0.5(7) 6.5(8) 4.8(9) 
O2 23.9(11) 117(2) 21.4(10) 4.7(11) 1.7(9) -7.6(12) 
O3 23(1) 66.6(15) 37.6(11) -10.0(11) -0.8(9) -1.7(10) 
O4 34.5(12) 64.6(15) 34.7(11) -17(1) -2.7(10) 12.2(11) 
O5 30.3(11) 50.7(12) 27.8(10) 10.9(9) -4.4(8) -1.6(9) 
O6 18.1(10) 49.1(13) 39.2(11) -1.1(10) -2.3(8) 2.3(9) 
S1 20.2(3) 44.9(4) 26.4(3) -4.4(3) -1.3(3) 5.1(3) 
S2 17.6(3) 42.8(4) 25.9(3) 4.4(3) -2.4(3) -0.5(3) 
  
Table 4 Bond Lengths for 283. 
Atom Atom Length/Å   Atom Atom Length/Å 
C1 C2 1.549(4)   C11 C12 1.380(5) 
C1 C6 1.541(4)   C12 C13 1.378(5) 
C1 N1 1.431(4)   C13 C14 1.381(5) 
C1 O1 1.457(4)   C14 C15 1.379(5) 
C2 C3 1.519(4)   C16 C17 1.384(4) 
C2 C5 1.524(4)   C16 C21 1.391(4) 
C3 C4 1.524(4)   C16 S2 1.761(3) 
C4 C7 1.567(4)   C17 C18 1.381(5) 
C4 C10 1.522(4)   C18 C19 1.408(5) 
C4 O1 1.421(3)   C19 C20 1.384(5) 
C5 N2 1.481(3)   C19 C22 1.504(5) 
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C6 N2 1.484(3)   C20 C21 1.386(5) 
C7 N3 1.378(4)   N2 S2 1.625(2) 
C7 O2 1.217(4)   N3 S1 1.694(2) 
C8 N3 1.474(3)   O3 S1 1.426(2) 
C9 S1 1.752(4)   O4 S1 1.427(2) 
C10 C11 1.386(4)   O5 S2 1.433(2) 
C10 C15 1.399(4)   O6 S2 1.436(2) 
  
Table 5 Bond Angles for 283. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C6 C1 C2 106.0(2)   C17 C16 C21 120.6(3) 
N1 C1 C2 112.8(2)   C17 C16 S2 119.6(2) 
N1 C1 C6 110.6(2)   C21 C16 S2 119.8(2) 
N1 C1 O1 112.4(2)   C18 C17 C16 119.7(3) 
O1 C1 C2 105.7(2)   C17 C18 C19 121.1(3) 
O1 C1 C6 108.9(2)   C18 C19 C22 120.9(3) 
C3 C2 C1 103.2(2)   C20 C19 C18 117.5(3) 
C3 C2 C5 113.2(2)   C20 C19 C22 121.6(3) 
C5 C2 C1 104.3(2)   C19 C20 C21 122.3(3) 
C2 C3 C4 103.4(2)   C20 C21 C16 118.7(3) 
C3 C4 C7 109.4(2)   C5 N2 C6 108.3(2) 
C10 C4 C3 113.7(3)   C5 N2 S2 118.98(19) 
C10 C4 C7 107.0(2)   C6 N2 S2 119.52(18) 
O1 C4 C3 104.3(2)   C7 N3 C8 125.9(2) 
O1 C4 C7 112.8(2)   C7 N3 S1 116.71(19) 
O1 C4 C10 109.8(2)   C8 N3 S1 117.43(19) 
N2 C5 C2 100.7(2)   C4 O1 C1 110.6(2) 
N2 C6 C1 103.2(2)   N3 S1 C9 105.35(15) 
N3 C7 C4 119.9(2)   O3 S1 C9 109.05(17) 
O2 C7 C4 120.1(3)   O3 S1 N3 105.51(12) 
O2 C7 N3 120.0(3)   O3 S1 O4 117.37(16) 
C11 C10 C4 122.2(3)   O4 S1 C9 109.90(17) 
C11 C10 C15 118.4(3)   O4 S1 N3 108.93(13) 
C15 C10 C4 119.4(3)   N2 S2 C16 107.95(13) 
C12 C11 C10 120.9(3)   O5 S2 C16 108.13(13) 
C13 C12 C11 120.0(3)   O5 S2 N2 106.77(12) 
C12 C13 C14 120.0(3)   O5 S2 O6 119.85(13) 
C15 C14 C13 120.1(3)   O6 S2 C16 107.47(14) 
C14 C15 C10 120.5(3)   O6 S2 N2 106.17(12) 
  
Table 6 Hydrogen Bonds for 283. 
D H A d(D-H)/Å d(H-A)/Å d(D-A)/Å D-H-A/° 
N1 H1A O41 0.97(4) 2.29(5) 3.126(3) 144(4) 
N1 H1B O62 0.86(4) 2.35(4) 3.098(3) 146(3) 
13-X,-1/2+Y,1/2-Z; 21+X,+Y,+Z 
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Table 7 Torsion Angles for 283. 
A B C D Angle/˚   A B C D Angle/˚ 
C1 C2 C3 C4 -31.3(3)   C8 N3 S1 O4 130.2(2) 
C1 C2 C5 N2 -36.5(3)   C10 C4 C7 N3 -71.7(3) 
C1 C6 N2 C5 -30.5(3)   C10 C4 C7 O2 105.3(4) 
C1 C6 N2 S2 -171.1(2)   C10 C4 O1 C1 -148.8(2) 
C2 C1 C6 N2 5.9(3)   C10 C11 C12 C13 -1.1(5) 
C2 C1 O1 C4 6.5(3)   C11 C10 C15 C14 -0.5(5) 
C2 C3 C4 C7 -84.9(3)   C11 C12 C13 C14 -0.5(5) 
C2 C3 C4 C10 155.5(2)   C12 C13 C14 C15 1.5(5) 
C2 C3 C4 O1 35.9(3)   C13 C14 C15 C10 -1.0(5) 
C2 C5 N2 C6 42.6(3)   C15 C10 C11 C12 1.6(5) 
C2 C5 N2 S2 -176.6(2)   C16 C17 C18 C19 -0.2(4) 
C3 C2 C5 N2 74.9(3)   C17 C16 C21 C20 0.2(5) 
C3 C4 C7 N3 164.6(3)   C17 C16 S2 N2 -86.7(2) 
C3 C4 C7 O2 -18.4(4)   C17 C16 S2 O5 28.5(3) 
C3 C4 C10 C11 -124.7(3)   C17 C16 S2 O6 159.2(2) 
C3 C4 C10 C15 54.8(3)   C17 C18 C19 C20 1.3(5) 
C3 C4 O1 C1 -26.5(3)   C17 C18 C19 C22 -177.1(3) 
C4 C7 N3 C8 -12.2(5)   C18 C19 C20 C21 -1.7(6) 
C4 C7 N3 S1 168.2(2)   C19 C20 C21 C16 1.0(6) 
C4 C10 C11 C12 -178.9(3)   C21 C16 C17 C18 -0.6(4) 
C4 C10 C15 C14 180.0(3)   C21 C16 S2 N2 91.6(3) 
C5 C2 C3 C4 -143.5(2)   C21 C16 S2 O5 -153.2(3) 
C5 N2 S2 C16 -62.2(2)   C21 C16 S2 O6 -22.5(3) 
C5 N2 S2 O5 -178.2(2)   C22 C19 C20 C21 176.7(4) 
C5 N2 S2 O6 52.8(3)   N1 C1 C2 C3 139.5(2) 
C6 C1 C2 C3 -99.3(3)   N1 C1 C2 C5 -102.0(3) 
C6 C1 C2 C5 19.2(3)   N1 C1 C6 N2 128.5(3) 
C6 C1 O1 C4 120.0(2)   N1 C1 O1 C4 -117.0(2) 
C6 N2 S2 C16 74.3(2)   O1 C1 C2 C3 16.2(3) 
C6 N2 S2 O5 -41.7(3)   O1 C1 C2 C5 134.8(2) 
C6 N2 S2 O6 -170.7(2)   O1 C1 C6 N2 -107.5(2) 
C7 C4 C10 C11 114.4(3)   O1 C4 C7 N3 49.1(4) 
C7 C4 C10 C15 -66.1(3)   O1 C4 C7 O2 -133.9(3) 
C7 C4 O1 C1 92.0(3)   O1 C4 C10 C11 -8.2(4) 
C7 N3 S1 C9 67.8(3)   O1 C4 C10 C15 171.3(2) 
C7 N3 S1 O3 -176.9(2)   O2 C7 N3 C8 170.9(3) 
C7 N3 S1 O4 -50.1(3)   O2 C7 N3 S1 -8.8(4) 
C8 N3 S1 C9 -111.9(2)   S2 C16 C17 C18 177.7(2) 
C8 N3 S1 O3 3.4(3)   S2 C16 C21 C20 -178.0(3) 
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Table 8 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement Parameters (Å2×103) for 
283. 
Atom x y z U(eq) 
H2 10659 3526 1995 36 
H3A 9667 5537 2125 39 
H3B 9106 5682 1557 39 
H5A 8924 2324 1495 37 
H5B 7817 3501 1640 37 
H6A 10729 4330 513 38 
H6B 10810 2843 623 38 
H8A 15366 5329 1459 47 
H8B 16185 6617 1622 47 
H8C 14555 6643 1327 47 
H9A 14258 4672 2984 72 
H9B 15932 4980 3224 72 
H9C 15832 4267 2702 72 
H11 12502 7236 800 39 
H12 12328 9370 582 47 
H13 11100 10807 1122 51 
H14 10012 10102 1877 58 
H15 10251 7981 2110 52 
H17 9101 1517 -69 37 
H18 9272 -684 -120 44 
H20 6075 -1014 1003 58 
H21 5910 1190 1066 50 
H22A 8191 -2847 757 76 
H22B 8683 -2764 185 76 
H22C 6875 -2915 334 76 
H1A 13310(60) 3110(40) 1634(17) 63(13) 
H1B 13340(50) 3070(40) 1068(15) 46(11) 
Crystal structure determination of [283] 
Crystal Data for C22H27N3O6S2 (M =493.58 g/mol): orthorhombic, space group P212121 (no. 19), a = 
8.34939(14) Å, b = 10.43121(16) Å, c = 26.3933(3) Å, V = 2298.70(6) Å3, Z = 4, T = 99.99(10) K, 
μ(CuKα) = 2.485 mm-1, Dcalc = 1.426 g/cm3, 20637 reflections measured (6.698° ≤ 2Θ ≤ 136.482°), 
4205 unique (Rint = 0.0316, Rsigma = 0.0211) which were used in all calculations. The final R1 was 
0.0302 (I > 2σ(I)) and wR2 was 0.0784 (all data). 
 
Refinement model description 
Number of restraints - 0, number of constraints - unknown. Details: 1. Twinned data refinement 
Scales: 0.450(19) 0.550(19). 2. Fixed Uiso At 1.2 times of: All C(H) groups, All C(H,H) groups At 1.5 
times of: All C(H,H,H) groups. 3.a Ternary CH refined with riding coordinates: C2(H2). 3.b Secondary 
CH2 refined with riding coordinates: C3(H3A,H3B), C5(H5A,H5B), C6(H6A,H6B). 3.c Aromatic/amide H 
refined with riding coordinates: C11(H11), C12(H12), C13(H13), C14(H14), C15(H15), C17(H17), 
C18(H18), C20(H20), C21(H21). 3.d Idealised Me refined as rotating group: C8(H8A,H8B,H8C), 
C9(H9A,H9B,H9C), C22(H22A,H22B,H22C) 
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5.3.3: Piperidine 284.HCl 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 Crystal data and structure refinement for 284.HCl. 
Identification code 284.HCl 
Empirical formula C20H25ClN2O3S 
Formula weight 408.93 
Temperature/K 99.98(11) 
Crystal system triclinic 
Space group P-1 
a/Å 8.0819(4) 
b/Å 9.4116(6) 
c/Å 13.7236(8) 
α/° 97.294(5) 
β/° 96.498(4) 
γ/° 107.359(5) 
Volume/Å3 975.60(10) 
Z 2 
ρcalcg/cm
3 1.392 
μ/mm-1 2.928 
F(000) 432.0 
Crystal size/mm3 0.1938 × 0.1746 × 0.0597 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 6.578 to 138.278 
Index ranges -6 ≤ h ≤ 9, -11 ≤ k ≤ 11, -16 ≤ l ≤ 16 
Reflections collected 6365 
Independent reflections 3626 [Rint = 0.0301, Rsigma = 0.0378] 
Data/restraints/parameters 3626/0/257 
Goodness-of-fit on F2 1.041 
Final R indexes [I>=2σ (I)] R1 = 0.0386, wR2 = 0.1012 
Final R indexes [all data] R1 = 0.0458, wR2 = 0.1081 
Largest diff. peak/hole / e Å-3 0.54/-0.40 
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Table 2 Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement Parameters 
(Å2×103) for 284.HCl. Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
C1 2876(2) 8184(2) 5553.6(14) 15.1(4) 
C2 2409(2) 6481(2) 5265.7(14) 15.3(4) 
C3 3031(3) 6024(2) 4300.5(14) 15.8(4) 
C4 3189(2) 7239(2) 3620.4(14) 14.9(4) 
C5 1792(3) 8030(2) 3729.6(14) 17.1(4) 
C6 3169(3) 6086(2) 6217.7(15) 17.9(4) 
C7 2439(3) 8419(2) 6604.1(14) 16.1(4) 
C8 2983(2) 6525(2) 2532.5(14) 15.3(4) 
C9 4388(3) 6890(2) 2007.0(15) 17.5(4) 
C10 4189(3) 6239(2) 1012.2(16) 19.2(4) 
C11 2596(3) 5217(2) 539.6(15) 19.4(4) 
C12 1195(3) 4829(2) 1063.8(15) 18.3(4) 
C13 1389(3) 5481(2) 2052.9(15) 16.7(4) 
C14 5619(3) 8326(2) 8367.4(14) 15.7(4) 
C15 6905(3) 7702(2) 8110.1(15) 18.2(4) 
C16 8645(3) 8626(2) 8254.3(16) 20.2(4) 
C17 9114(3) 10158(2) 8654.6(16) 20.5(4) 
C18 7807(3) 10749(2) 8912.9(15) 19.8(4) 
C19 6061(3) 9842(2) 8771.7(15) 18.7(4) 
C20 11009(3) 11152(3) 8814.0(18) 26.3(5) 
N1 1871(2) 8749.4(19) 4796.8(12) 15.8(3) 
N2 2633(2) 7052.4(18) 6979.0(12) 15.9(3) 
O1 4822.3(18) 8433.7(16) 3915.1(11) 17.9(3) 
O2 2457.3(18) 7971.8(17) 8710.9(11) 19.9(3) 
O3 3329.6(18) 5672.3(16) 8271.2(11) 19.8(3) 
S1 3406.0(6) 7178.0(5) 8151.9(3) 15.08(14) 
Cl1 7967.9(6) 7843.8(5) 5093.8(4) 22.09(15) 
  
Table 3 Anisotropic Displacement Parameters (Å2×103) for 284.HCl. The Anisotropic displacement 
factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
Atom U11 U22 U33 U23 U13 U12 
C1 13.2(9) 15.8(9) 17.2(9) 4.1(7) 1.3(7) 5.8(7) 
C2 14.0(9) 15.4(9) 16.6(10) 2.7(7) 1.1(7) 5.2(7) 
C3 17.0(9) 15.1(9) 15.5(9) 2.0(7) 1.7(7) 6.0(7) 
C4 11.3(9) 14.5(9) 17.4(10) 1.1(7) 0.2(7) 3.1(7) 
C5 19.8(10) 18.9(10) 14.9(9) 2.0(7) 1.8(7) 10.2(8) 
C6 21.9(10) 16.7(9) 17.0(9) 1.5(7) 3.1(8) 9.4(8) 
C7 17.9(9) 16.4(9) 16.7(9) 3.5(7) 2.6(7) 8.9(8) 
C8 16.1(9) 15.4(9) 16.7(10) 4.1(7) 3.3(7) 7.9(7) 
C9 12.5(9) 18.4(10) 22.2(10) 4.0(8) 3.2(8) 5.7(7) 
C10 19.4(10) 20.2(10) 22.5(10) 6.2(8) 8.7(8) 9.9(8) 
C11 25(1) 20.7(10) 16(1) 2.8(8) 3.4(8) 12.4(8) 
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C12 17.6(9) 19.4(10) 17.4(10) 3.4(8) -0.6(8) 6.1(8) 
C13 14.7(9) 18.6(9) 19(1) 5.2(8) 4.4(7) 7.1(8) 
C14 13.6(9) 20.5(10) 13.4(9) 2.4(7) 0.9(7) 6.4(7) 
C15 19.5(10) 18.8(10) 18.5(10) 2.4(8) 3.3(8) 9.4(8) 
C16 17.2(10) 23.6(10) 22.7(10) 3.8(8) 4.3(8) 10.3(8) 
C17 17.5(10) 24.2(11) 21(1) 7.1(8) 2.4(8) 7.6(8) 
C18 20.7(10) 16.9(10) 20.8(10) 1.5(8) 0.8(8) 6.1(8) 
C19 19.2(10) 21.8(10) 19(1) 4.1(8) 4.9(8) 11.2(8) 
C20 19.4(11) 23.0(11) 34.8(12) 5.5(9) 3.5(9) 4.5(9) 
N1 16.4(8) 16.2(9) 16.8(8) 2.5(7) 2.2(6) 8.5(7) 
N2 17.5(8) 16.3(8) 14.5(8) 2.1(6) 2.1(6) 6.7(6) 
O1 14.1(7) 15.1(7) 22.1(7) 1.5(6) 1.1(6) 2.3(6) 
O2 17.1(7) 25.9(8) 19.5(7) 3.5(6) 6.1(6) 10.0(6) 
O3 19.0(7) 22.2(7) 19.9(7) 7.2(6) 3.7(6) 7.4(6) 
S1 13.5(2) 18.6(3) 14.8(2) 3.68(18) 3.54(17) 6.72(18) 
Cl1 15.5(2) 17.8(2) 32.8(3) 3.6(2) 0.33(19) 6.57(18) 
  
Table 4 Bond Lengths for 284.HCl. 
Atom Atom Length/Å   Atom Atom Length/Å 
C1 C2 1.520(3)   C10 C11 1.384(3) 
C1 C7 1.527(3)   C11 C12 1.392(3) 
C1 N1 1.493(2)   C12 C13 1.388(3) 
C2 C3 1.525(3)   C14 C15 1.394(3) 
C2 C6 1.517(3)   C14 C19 1.386(3) 
C3 C4 1.551(3)   C14 S1 1.760(2) 
C4 C5 1.537(3)   C15 C16 1.391(3) 
C4 C8 1.527(3)   C16 C17 1.397(3) 
C4 O1 1.431(2)   C17 C18 1.392(3) 
C5 N1 1.519(2)   C17 C20 1.512(3) 
C6 N2 1.484(2)   C18 C19 1.391(3) 
C7 N2 1.488(2)   N2 S1 1.6356(17) 
C8 C9 1.394(3)   O2 S1 1.4366(14) 
C8 C13 1.396(3)   O3 S1 1.4310(15) 
C9 C10 1.394(3)         
  
Table 5 Bond Angles for 284.HCl. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C2 C1 C7 104.59(15)   C13 C12 C11 120.07(19) 
N1 C1 C2 108.76(16)   C12 C13 C8 120.58(18) 
N1 C1 C7 114.89(15)   C15 C14 S1 119.41(16) 
C1 C2 C3 112.56(16)   C19 C14 C15 120.71(19) 
C6 C2 C1 100.76(15)   C19 C14 S1 119.87(15) 
C6 C2 C3 118.42(16)   C16 C15 C14 119.16(19) 
C2 C3 C4 111.51(15)   C15 C16 C17 120.94(18) 
C5 C4 C3 111.37(16)   C16 C17 C20 120.64(19) 
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C8 C4 C3 110.44(16)   C18 C17 C16 118.75(19) 
C8 C4 C5 108.91(16)   C18 C17 C20 120.61(19) 
O1 C4 C3 110.89(15)   C19 C18 C17 120.99(19) 
O1 C4 C5 104.15(15)   C14 C19 C18 119.44(18) 
O1 C4 C8 110.92(15)   C1 N1 C5 114.08(15) 
N1 C5 C4 112.68(16)   C6 N2 C7 111.00(15) 
N2 C6 C2 101.17(15)   C6 N2 S1 118.78(13) 
N2 C7 C1 101.97(14)   C7 N2 S1 119.51(13) 
C9 C8 C4 120.63(17)   N2 S1 C14 107.88(9) 
C9 C8 C13 118.99(18)   O2 S1 C14 107.29(9) 
C13 C8 C4 120.37(17)   O2 S1 N2 106.15(9) 
C8 C9 C10 120.32(18)   O3 S1 C14 108.94(9) 
C11 C10 C9 120.27(18)   O3 S1 N2 105.12(9) 
C10 C11 C12 119.75(19)   O3 S1 O2 120.85(9) 
  
Table 6 Hydrogen Bonds for 284.HCl. 
D H A d(D-H)/Å d(H-A)/Å d(D-A)/Å D-H-A/° 
N1 H1A Cl11 0.89(3) 2.32(3) 3.1534(18) 157(2) 
N1 H1B Cl12 0.94(3) 2.17(4) 3.1010(18) 179(3) 
O1 H1C Cl1 0.83(3) 2.30(3) 3.0866(16) 158(3) 
11-X,2-Y,1-Z; 2-1+X,+Y,+Z 
  
Table 7 Torsion Angles for 284.HCl. 
A B C D Angle/˚   A B C D Angle/˚ 
C1 C2 C3 C4 -26.0(2)   C8 C4 C5 N1 178.79(15) 
C1 C2 C6 N2 42.23(18)   C8 C9 C10 C11 -0.5(3) 
C1 C7 N2 C6 0.7(2)   C9 C8 C13 C12 -0.8(3) 
C1 C7 N2 S1 144.79(13)   C9 C10 C11 C12 -0.5(3) 
C2 C1 C7 N2 26.53(18)   C10 C11 C12 C13 0.8(3) 
C2 C1 N1 C5 -41.9(2)   C11 C12 C13 C8 -0.2(3) 
C2 C3 C4 C5 -33.2(2)   C13 C8 C9 C10 1.1(3) 
C2 C3 C4 C8 -154.34(16)   C14 C15 C16 C17 0.3(3) 
C2 C3 C4 O1 82.29(19)   C15 C14 C19 C18 0.6(3) 
C2 C6 N2 C7 -27.4(2)   C15 C14 S1 N2 -80.90(17) 
C2 C6 N2 S1 -171.72(13)   C15 C14 S1 O2 165.12(15) 
C3 C2 C6 N2 165.38(16)   C15 C14 S1 O3 32.70(18) 
C3 C4 C5 N1 56.8(2)   C15 C16 C17 C18 0.3(3) 
C3 C4 C8 C9 -113.7(2)   C15 C16 C17 C20 179.68(19) 
C3 C4 C8 C13 65.5(2)   C16 C17 C18 C19 -0.4(3) 
C4 C5 N1 C1 -17.1(2)   C17 C18 C19 C14 0.0(3) 
C4 C8 C9 C10 -179.64(18)   C19 C14 C15 C16 -0.7(3) 
C4 C8 C13 C12 179.96(18)   C19 C14 S1 N2 97.86(17) 
C5 C4 C8 C9 123.68(19)   C19 C14 S1 O2 -16.12(19) 
C5 C4 C8 C13 -57.1(2)   C19 C14 S1 O3 -148.53(16) 
C6 C2 C3 C4 -143.08(17)   C20 C17 C18 C19 -179.80(19) 
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C6 N2 S1 C14 74.34(16)   N1 C1 C2 C3 66.1(2) 
C6 N2 S1 O2 -170.92(14)   N1 C1 C2 C6 -166.74(15) 
C6 N2 S1 O3 -41.79(16)   N1 C1 C7 N2 145.69(16) 
C7 C1 C2 C3 -170.66(15)   O1 C4 C5 N1 -62.82(19) 
C7 C1 C2 C6 -43.53(18)   O1 C4 C8 C9 9.6(2) 
C7 C1 N1 C5 -158.68(16)   O1 C4 C8 C13 -171.17(16) 
C7 N2 S1 C14 -66.98(16)   S1 C14 C15 C16 178.07(15) 
C7 N2 S1 O2 47.75(16)   S1 C14 C19 C18 -178.18(15) 
C7 N2 S1 O3 176.89(14)             
  
Table 8 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement Parameters (Å2×103) for 
284.HCl. 
Atom x y z U(eq) 
H1 4137 8657 5569 18 
H2 1128 6041 5172 18 
H3A 2207 5072 3949 19 
H3B 4164 5879 4455 19 
H5A 1957 8804 3313 21 
H5B 637 7299 3496 21 
H6A 2662 5023 6249 21 
H6B 4436 6343 6288 21 
H7A 3255 9336 7005 19 
H7B 1251 8458 6592 19 
H9 5464 7570 2321 21 
H10 5129 6493 665 23 
H11 2463 4791 -126 23 
H12 128 4133 751 22 
H13 447 5220 2399 20 
H15 6603 6682 7846 22 
H16 9508 8216 8082 24 
H18 8105 11767 9184 24 
H19 5199 10249 8947 22 
H20A 11725 10566 8589 39 
H20B 11395 11555 9509 39 
H20C 11111 11967 8445 39 
H1A 2250(40) 9750(40) 4860(20) 31(7) 
H1B 690(50) 8470(40) 4890(20) 48(9) 
H1C 5580(40) 8050(30) 4110(20) 32(7) 
 
 
Crystal structure determination of [284.HCl] 
Crystal Data for C20H25ClN2O3S (M =408.93 g/mol): triclinic, space group P-1 (no. 2), a = 
8.0819(4) Å, b = 9.4116(6) Å, c = 13.7236(8) Å, α = 97.294(5)°, β = 96.498(4)°, γ = 107.359(5)°, V = 
975.60(10) Å3, Z = 2, T = 99.98(11) K, μ(CuKα) = 2.928 mm-1, Dcalc = 1.392 g/cm3, 6365 reflections 
measured (6.578° ≤ 2Θ ≤ 138.278°), 3626 unique (Rint = 0.0301, Rsigma = 0.0378) which were used in all 
calculations. The final R1 was 0.0386 (I > 2σ(I)) and wR2 was 0.1081 (all data). 
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Refinement model description 
Number of restraints - 0, number of constraints - unknown. Details: 1. Fixed Uiso At 1.2 times of: All 
C(H) groups, All C(H,H) groups At 1.5 times of: All C(H,H,H) groups. 2.a Ternary CH refined with riding 
coordinates: C1(H1), C2(H2). 2.b Secondary CH2 refined with riding coordinates: C3(H3A,H3B), 
C5(H5A,H5B), C6(H6A,H6B), C7(H7A,H7B). 2.c Aromatic/amide H refined with riding coordinates: 
C9(H9), C10(H10), C11(H11), C12(H12), C13(H13), C15(H15), C16(H16), C18(H18), C19(H19). 2.d 
Idealised Me refined as rotating group: C20(H20A,H20B,H20C) 
 
5.3.4: (363a)AuCl 
 
 
 
 
 
 
 
 
 
Table 1 Crystal data and structure refinement for (363a)AuCl. 
Identification code (363a)AuCl 
Empirical formula C25H29AuClN3O3S 
Formula weight 683.99 
Temperature/K 100.00(10) 
Crystal system monoclinic 
Space group P21/n 
a/Å 9.9647(3) 
b/Å 20.0858(10) 
c/Å 12.9728(4) 
α/° 90 
β/° 100.759(3) 
γ/° 90 
Volume/Å3 2550.85(16) 
Z 4 
ρcalcg/cm
3 1.781 
μ/mm-1 5.986 
F(000) 1344.0 
Crystal size/mm3 0.1924 × 0.1637 × 0.0228 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 6.052 to 52.738 
Index ranges -12 ≤ h ≤ 11, -21 ≤ k ≤ 25, -16 ≤ l ≤ 16 
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Reflections collected 13654 
Independent reflections 5207 [Rint = 0.0310, Rsigma = 0.0429] 
Data/restraints/parameters 5207/0/313 
Goodness-of-fit on F2 1.078 
Final R indexes [I>=2σ (I)] R1 = 0.0360, wR2 = 0.0728 
Final R indexes [all data] R1 = 0.0461, wR2 = 0.0779 
Largest diff. peak/hole / e Å-3 1.96/-1.59 
 
Table 2 Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement Parameters 
(Å2×103) for (363a)AuCl. Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
C1 3322(5) 3257(3) 5230(4) 16.7(11) 
C2 5280(5) 3872(3) 6507(4) 14.8(11) 
C3 5105(5) 4266(3) 7299(4) 13.8(11) 
C4 3043(5) 3976(3) 6494(4) 16.0(11) 
C5 1761(5) 3797(3) 6039(4) 16.8(11) 
C6 7069(6) 3045(3) 6337(5) 27.7(14) 
C7 6317(7) 4061(4) 4095(5) 35.3(16) 
C8 6056(5) 4584(3) 8147(4) 15.2(11) 
C9 5610(5) 5081(3) 8760(4) 17.0(11) 
C10 6484(5) 5343(3) 9608(4) 19.8(12) 
C11 7824(5) 5125(3) 9860(4) 21.9(12) 
C12 8286(5) 4635(3) 9256(4) 22.0(13) 
C13 7404(5) 4369(3) 8409(4) 19.2(12) 
C14 859(5) 3034(3) 4562(4) 16.2(11) 
C15 361(5) 3341(3) 3608(4) 17.0(11) 
C16 -734(6) 3030(3) 2948(5) 25.2(13) 
C17 -1294(6) 2452(3) 3265(5) 24.6(13) 
C18 -780(6) 2167(3) 4214(4) 24.2(13) 
C19 334(5) 2441(3) 4881(4) 19.6(12) 
C20 958(5) 3979(3) 3260(4) 22.0(13) 
C21 -126(6) 4513(3) 2899(5) 31.5(15) 
C22 1805(7) 3828(4) 2423(6) 38.1(17) 
C23 966(6) 2086(3) 5891(4) 23.7(13) 
C24 -89(6) 1922(3) 6574(5) 30.0(15) 
C25 1703(5) 1456(3) 5632(5) 23.6(13) 
Cl1 5277.5(13) 1790.9(7) 3647.5(11) 23.6(3) 
Au1 4184.2(2) 2586.0(2) 4441.5(2) 16.50(7) 
N1 3958(4) 3665(2) 5998(3) 13.9(9) 
N2 6465(4) 3712(2) 6146(3) 18.6(10) 
N3 1982(4) 3353(2) 5261(3) 16(1) 
O1 3707(3) 4355.6(19) 7308(3) 16.3(8) 
O2 8515(4) 4115(3) 5527(4) 40.0(12) 
O3 6627(4) 4901(2) 5634(3) 28.6(10) 
S1 7088.0(13) 4256.7(8) 5396.0(11) 24.0(3) 
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Table 3 Anisotropic Displacement Parameters (Å2×103) for (363a)AuCl. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
Atom U11 U22 U33 U23 U13 U12 
C1 16(2) 21(3) 11(3) 2(2) -2(2) -6(2) 
C2 12(2) 16(3) 15(3) -1(2) -1(2) -4(2) 
C3 8(2) 16(3) 17(3) 3(2) 0(2) -1(2) 
C4 17(2) 15(3) 16(3) -2(2) 3(2) 2(2) 
C5 13(2) 16(3) 20(3) 0(2) 0(2) 1(2) 
C6 20(3) 27(3) 32(4) -7(3) -7(2) 10(3) 
C7 38(4) 47(4) 20(3) -4(3) 3(3) -17(3) 
C8 15(2) 17(3) 12(3) 2(2) 1(2) -3(2) 
C9 11(2) 20(3) 19(3) -1(2) 2(2) 2(2) 
C10 21(3) 19(3) 20(3) -6(2) 5(2) -4(2) 
C11 21(3) 26(3) 18(3) -2(2) 0(2) -8(2) 
C12 14(2) 32(3) 20(3) -2(3) 4(2) -3(2) 
C13 16(2) 24(3) 17(3) -3(2) 3(2) 0(2) 
C14 12(2) 20(3) 14(3) -3(2) -5(2) -6(2) 
C15 12(2) 13(3) 25(3) 0(2) 0(2) -2(2) 
C16 27(3) 29(3) 16(3) 9(3) -6(2) -9(3) 
C17 25(3) 23(3) 21(3) 0(3) -9(2) -7(2) 
C18 28(3) 20(3) 21(3) 5(2) -6(2) -9(2) 
C19 23(3) 19(3) 14(3) -1(2) -4(2) 2(2) 
C20 21(3) 24(3) 18(3) 6(2) -2(2) -6(2) 
C21 28(3) 21(3) 44(4) 8(3) 4(3) -9(3) 
C22 42(4) 36(4) 41(4) 11(3) 21(3) -4(3) 
C23 29(3) 21(3) 17(3) 2(2) -10(2) -4(2) 
C24 41(4) 33(4) 15(3) 3(3) 1(3) 19(3) 
C25 15(3) 23(3) 31(3) 0(3) 2(2) 1(2) 
Cl1 19.7(6) 22.3(7) 31.1(8) -4.6(6) 10.6(6) -0.1(5) 
Au1 12.43(10) 19.03(12) 17.22(12) -3.23(9) 0.66(7) -2.21(8) 
N1 10.9(19) 16(2) 12(2) -4.5(18) -3.1(17) 0.0(17) 
N2 15(2) 23(3) 17(2) -3(2) 2.4(18) 4.2(19) 
N3 9.6(19) 18(2) 18(2) -2.1(19) -1.9(17) -0.1(18) 
O1 8.7(16) 23(2) 17(2) -6.3(16) 0.5(14) -4.3(15) 
O2 16(2) 68(4) 37(3) -15(2) 9.6(19) -9(2) 
O3 30(2) 26(2) 32(3) -5.9(19) 11.4(19) -10.7(19) 
S1 14.4(6) 37.3(9) 21.4(8) -8.1(7) 6.4(5) -6.8(6) 
  
Table 4 Bond Lengths for (363a)AuCl. 
Atom Atom Length/Å   Atom Atom Length/Å 
C1 Au1 1.982(6)   C12 C13 1.379(8) 
C1 N1 1.353(7)   C14 C15 1.389(8) 
C1 N3 1.357(6)   C14 C19 1.394(8) 
C2 C3 1.333(7)   C14 N3 1.451(6) 
C2 N1 1.421(6)   C15 C16 1.402(7) 
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C2 N2 1.387(6)   C15 C20 1.517(8) 
C3 C8 1.458(7)   C16 C17 1.383(8) 
C3 O1 1.407(6)   C17 C18 1.368(8) 
C4 C5 1.352(7)   C18 C19 1.388(8) 
C4 N1 1.363(6)   C19 C23 1.520(8) 
C4 O1 1.368(6)   C20 C21 1.532(8) 
C5 N3 1.395(7)   C20 C22 1.525(8) 
C6 N2 1.471(7)   C23 C24 1.532(8) 
C7 S1 1.763(6)   C23 C25 1.532(8) 
C8 C9 1.399(7)   Cl1 Au1 2.2841(14) 
C8 C13 1.392(7)   N2 S1 1.660(5) 
C9 C10 1.374(7)   O2 S1 1.429(4) 
C10 C11 1.386(8)   O3 S1 1.427(5) 
C11 C12 1.388(8)         
  
Table 5 Bond Angles for (363a)AuCl. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
N1 C1 Au1 127.1(4)   C18 C17 C16 121.0(5) 
N1 C1 N3 102.8(4)   C17 C18 C19 121.1(5) 
N3 C1 Au1 129.5(4)   C14 C19 C23 122.6(5) 
C3 C2 N1 106.8(4)   C18 C19 C14 117.0(5) 
C3 C2 N2 129.8(5)   C18 C19 C23 120.4(5) 
N2 C2 N1 123.3(5)   C15 C20 C21 112.9(5) 
C2 C3 C8 132.9(5)   C15 C20 C22 110.0(5) 
C2 C3 O1 110.8(4)   C22 C20 C21 111.9(5) 
O1 C3 C8 116.3(4)   C19 C23 C24 112.4(5) 
C5 C4 N1 109.4(5)   C19 C23 C25 109.7(5) 
C5 C4 O1 140.1(5)   C25 C23 C24 111.0(5) 
N1 C4 O1 110.5(4)   C1 Au1 Cl1 175.79(15) 
C4 C5 N3 102.9(4)   C1 N1 C2 141.8(5) 
C9 C8 C3 120.7(5)   C1 N1 C4 111.3(4) 
C13 C8 C3 120.7(5)   C4 N1 C2 106.9(4) 
C13 C8 C9 118.5(5)   C2 N2 C6 120.1(5) 
C10 C9 C8 120.5(5)   C2 N2 S1 118.7(4) 
C9 C10 C11 120.4(5)   C6 N2 S1 120.9(4) 
C10 C11 C12 119.8(5)   C1 N3 C5 113.7(4) 
C13 C12 C11 119.6(5)   C1 N3 C14 124.5(5) 
C12 C13 C8 121.2(5)   C5 N3 C14 121.8(4) 
C15 C14 C19 123.5(5)   C4 O1 C3 105.1(4) 
C15 C14 N3 117.8(5)   N2 S1 C7 105.7(3) 
C19 C14 N3 118.7(5)   O2 S1 C7 108.4(3) 
C14 C15 C16 117.0(5)   O2 S1 N2 105.7(3) 
C14 C15 C20 123.0(5)   O3 S1 C7 108.0(3) 
C16 C15 C20 120.0(5)   O3 S1 N2 107.5(2) 
C17 C16 C15 120.3(5)   O3 S1 O2 120.6(3) 
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Table 6 Torsion Angles for (363a)AuCl. 
A B C D Angle/˚   A B C D Angle/˚ 
C2 C3 C8 C9 167.3(6)   C16 C15 C20 C22 -74.1(7) 
C2 C3 C8 C13 -16.9(9)   C16 C17 C18 C19 -1.2(10) 
C2 C3 O1 C4 1.8(6)   C17 C18 C19 C14 2.9(9) 
C2 N2 S1 C7 -89.9(5)   C17 C18 C19 C23 -174.9(6) 
C2 N2 S1 O2 155.3(4)   C18 C19 C23 C24 -53.7(7) 
C2 N2 S1 O3 25.2(5)   C18 C19 C23 C25 70.2(7) 
C3 C2 N1 C1 -174.3(7)   C19 C14 C15 C16 0.5(8) 
C3 C2 N1 C4 2.7(6)   C19 C14 C15 C20 -178.8(5) 
C3 C2 N2 C6 107.3(7)   C19 C14 N3 C1 93.3(7) 
C3 C2 N2 S1 -78.9(7)   C19 C14 N3 C5 -86.9(7) 
C3 C8 C9 C10 175.0(5)   C20 C15 C16 C17 -179.3(6) 
C3 C8 C13 C12 -175.5(5)   Au1 C1 N1 C2 7.9(10) 
C4 C5 N3 C1 0.1(6)   Au1 C1 N1 C4 -169.1(4) 
C4 C5 N3 C14 -179.7(5)   Au1 C1 N3 C5 169.5(4) 
C5 C4 N1 C1 -2.1(6)   Au1 C1 N3 C14 -10.7(8) 
C5 C4 N1 C2 179.9(5)   N1 C1 N3 C5 -1.3(6) 
C5 C4 O1 C3 177.7(7)   N1 C1 N3 C14 178.5(5) 
C6 N2 S1 C7 83.8(5)   N1 C2 C3 C8 174.2(5) 
C6 N2 S1 O2 -31.0(5)   N1 C2 C3 O1 -2.8(6) 
C6 N2 S1 O3 -161.0(4)   N1 C2 N2 C6 -78.1(7) 
C8 C3 O1 C4 -175.7(5)   N1 C2 N2 S1 95.7(6) 
C8 C9 C10 C11 1.0(8)   N1 C4 C5 N3 1.2(6) 
C9 C8 C13 C12 0.4(8)   N1 C4 O1 C3 0.0(6) 
C9 C10 C11 C12 -0.5(9)   N2 C2 C3 C8 -10.5(10) 
C10 C11 C12 C13 0.0(9)   N2 C2 C3 O1 172.5(5) 
C11 C12 C13 C8 0.1(9)   N2 C2 N1 C1 10.0(10) 
C13 C8 C9 C10 -0.9(8)   N2 C2 N1 C4 -173.0(5) 
C14 C15 C16 C17 1.4(9)   N3 C1 N1 C2 178.9(6) 
C14 C15 C20 C21 -128.9(6)   N3 C1 N1 C4 2.0(6) 
C14 C15 C20 C22 105.2(6)   N3 C14 C15 C16 -179.3(5) 
C14 C19 C23 C24 128.6(6)   N3 C14 C15 C20 1.4(8) 
C14 C19 C23 C25 -107.4(6)   N3 C14 C19 C18 177.1(5) 
C15 C14 C19 C18 -2.6(8)   N3 C14 C19 C23 -5.2(8) 
C15 C14 C19 C23 175.1(5)   O1 C3 C8 C9 -15.9(7) 
C15 C14 N3 C1 -87.0(7)   O1 C3 C8 C13 159.9(5) 
C15 C14 N3 C5 92.8(6)   O1 C4 C5 N3 -176.6(7) 
C15 C16 C17 C18 -1.1(10)   O1 C4 N1 C1 176.4(4) 
C16 C15 C20 C21 51.8(7)   O1 C4 N1 C2 -1.6(6) 
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Table 7 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement Parameters (Å2×103) for 
(363a)AuCl. 
Atom x y z U(eq) 
H5 936 3936 6203 20 
H6A 7942 3079 6796 42 
H6B 7185 2851 5683 42 
H6C 6476 2769 6657 42 
H7A 5350 4133 4003 53 
H7B 6490 3603 3955 53 
H7C 6691 4340 3619 53 
H9 4716 5235 8591 20 
H10 6173 5668 10017 24 
H11 8413 5306 10432 26 
H12 9185 4487 9421 26 
H13 7717 4041 8007 23 
H16 -1086 3213 2295 30 
H17 -2030 2254 2826 30 
H18 -1183 1782 4415 29 
H20 1583 4159 3871 26 
H21A -734 4362 2280 47 
H21B 312 4917 2745 47 
H21C -636 4594 3445 47 
H22A 2493 3505 2687 57 
H22B 2233 4229 2245 57 
H22C 1221 3655 1808 57 
H23 1649 2384 6293 28 
H24A -470 2328 6786 45 
H24B 346 1681 7185 45 
H24C -805 1655 6180 45 
H25A 1069 1174 5183 35 
H25B 2065 1223 6269 35 
H25C 2435 1576 5282 35 
Crystal structure determination of [(363a)AuCl] 
Crystal Data for C25H29AuClN3O3S (M =683.99 g/mol): monoclinic, space group P21/n (no. 14), a = 
9.9647(3) Å, b = 20.0858(10) Å, c = 12.9728(4) Å, β = 100.759(3)°, V = 2550.85(16) Å3, Z = 4, T = 
100.00(10) K, μ(MoKα) = 5.986 mm-1, Dcalc = 1.781 g/cm3, 13654 reflections measured (6.052° ≤ 2Θ ≤ 
52.738°), 5207 unique (Rint = 0.0310, Rsigma = 0.0429) which were used in all calculations. The 
final R1 was 0.0360 (I > 2σ(I)) and wR2 was 0.0779 (all data). 
Refinement model description 
Number of restraints - 0, number of constraints - unknown. Details: 1. Fixed Uiso At 1.2 times of: All 
C(H) groups At 1.5 times of: All C(H,H,H) groups. 2.a Ternary CH refined with riding coordinates: 
C20(H20), C23(H23). 2.b Aromatic/amide H refined with riding coordinates: C5(H5), C9(H9), 
C10(H10), C11(H11), C12(H12), C13(H13), C16(H16), C17(H17), C18(H18). 2.c Idealised Me refined as 
rotating group: C6(H6A,H6B,H6C), C7(H7A,H7B,H7C), C21(H21A,H21B,H21C), C22(H22A,H22B,H22C), 
C24(H24A,H24B,H24C), C25(H25A,H25B,H25C) 
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5.3.5: (363c)AuCl 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 Crystal data and structure refinement for (363c)AuCl. 
Identification code (363c)AuCl 
Empirical formula C30H31AuClN3O3S 
Formula weight 746.05 
Temperature/K 100.00(10) 
Crystal system orthorhombic 
Space group P212121 
a/Å 9.41339(16) 
b/Å 13.4993(2) 
c/Å 23.0896(5) 
α/° 90 
β/° 90 
γ/° 90 
Volume/Å3 2934.10(9) 
Z 4 
ρcalcg/cm
3 1.689 
μ/mm-1 5.212 
F(000) 1472.0 
Crystal size/mm3 0.2982 × 0.2203 × 0.0968 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 6.036 to 54.964 
Index ranges -12 ≤ h ≤ 11, -17 ≤ k ≤ 17, -29 ≤ l ≤ 29 
Reflections collected 31735 
Independent reflections 6686 [Rint = 0.0350, Rsigma = 0.0295] 
Data/restraints/parameters 6686/0/358 
Goodness-of-fit on F2 1.047 
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Final R indexes [I>=2σ (I)] R1 = 0.0209, wR2 = 0.0389 
Final R indexes [all data] R1 = 0.0233, wR2 = 0.0400 
Largest diff. peak/hole / e Å-3 1.06/-1.02 
Flack parameter 0.502(5) 
 
 
Table 2 Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement Parameters 
(Å2×103) for (363c)AuCl. Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
C1 898(5) 4618(3) 2166.6(18) 16.8(10) 
C2 1186(5) 5100(3) 1070(2) 17.9(10) 
C3 510(5) 5852(3) 806(2) 18.9(10) 
C4 -290(5) 5821(3) 1699(2) 17.4(10) 
C5 -760(5) 5862(3) 2247(2) 19.6(10) 
C6 3617(5) 4452(3) 939(2) 18.2(10) 
C7 4137(5) 5135(3) 1335(2) 22.2(11) 
C8 5564(6) 5192(4) 1454(2) 26.6(11) 
C9 6519(6) 4594(4) 1158(2) 27.8(12) 
C10 6024(6) 3929(4) 753(2) 27.6(12) 
C11 4575(5) 3854(4) 637(2) 22.7(11) 
C12 1849(6) 2378(3) 951(2) 28.4(12) 
C13 586(5) 6313(3) 231.5(19) 19.6(10) 
C14 -325(6) 7092(4) 94(2) 34.2(13) 
C15 -234(7) 7553(4) -438(3) 39.2(15) 
C16 752(6) 7246(4) -837(2) 30.2(12) 
C17 1668(5) 6480(4) -711.7(19) 24.4(10) 
C18 1592(6) 6008(3) -174(2) 22.6(11) 
C19 -67(5) 4968(3) 3146(2) 16.8(10) 
C20 -1122(5) 4350(4) 3375(2) 19.5(10) 
C21 -1175(5) 4261(4) 3975(2) 24.1(11) 
C22 -248(5) 4782(4) 4327(2) 23.2(11) 
C23 775(5) 5394(3) 4082(2) 21.9(11) 
C24 902(5) 5502(3) 3486(2) 19.3(10) 
C25 -2204(6) 3828(3) 2998(2) 23.5(10) 
C26 -3629(5) 4366(4) 3038(3) 31.1(12) 
C27 -2374(6) 2732(3) 3151(2) 29.8(12) 
C28 2044(5) 6157(3) 3230(2) 23.0(11) 
C29 1772(6) 7243(4) 3364(2) 32.7(13) 
C30 3521(6) 5843(5) 3438(3) 44.0(17) 
Au1 2246.8(2) 3550.6(2) 2347.0(2) 15.53(5) 
Cl2 3820.6(12) 2304.6(8) 2515.8(5) 21.7(3) 
N1 683(4) 5076(3) 1648.6(17) 17.7(9) 
N2 2116(5) 4383(3) 837.9(16) 19.3(8) 
N3 -8(4) 5106(3) 2522.4(15) 16.7(8) 
O1 -435(3) 6309(2) 1189.5(13) 18.6(7) 
O2 1949(4) 3260(2) -37.9(14) 27.2(8) 
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O3 -149(3) 3554(3) 577.3(15) 29.7(8) 
S1 1343.7(13) 3389.2(9) 524.3(5) 21.7(3) 
  
Table 3 Anisotropic Displacement Parameters (Å2×103) for (363c)AuCl. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
Atom U11 U22 U33 U23 U13 U12 
C1 19(2) 18(2) 13(2) 0.2(16) 1.0(18) -0.7(18) 
C2 17(2) 20(2) 17(2) -0.5(19) 2(2) 3(2) 
C3 20(3) 20(2) 17(2) -5.2(18) 0(2) 1(2) 
C4 17(2) 20(2) 15(2) -0.7(18) -1.6(19) 3.2(19) 
C5 18(2) 21(2) 20(3) -2.4(18) -0.6(19) 1.9(18) 
C6 19(3) 19(2) 17(2) 5.3(18) 2.0(19) 1.1(19) 
C7 20(3) 16(2) 30(3) -9(2) 0(2) 3.5(19) 
C8 29(3) 21(2) 30(3) -6(2) -8(2) -3(2) 
C9 18(3) 30(3) 36(3) -2(2) -7(2) -1(2) 
C10 24(3) 29(3) 31(3) -3(2) 0(2) 6(2) 
C11 24(3) 27(3) 17(3) -2.4(19) -1(2) 1(2) 
C12 28(3) 20(2) 37(3) -1(2) 5(2) 0(2) 
C13 23(2) 20(2) 16(2) -0.8(18) -0.4(18) -1(2) 
C14 41(3) 37(3) 24(3) 2(2) 4(3) 16(3) 
C15 53(4) 36(3) 28(3) 2(2) -1(3) 21(3) 
C16 43(3) 28(3) 20(3) 4(2) -5(2) -1(3) 
C17 30(3) 20(2) 23(2) -6(2) 3(2) -6(3) 
C18 26(3) 18(2) 24(3) 0.5(19) 2(2) 3(2) 
C19 15(2) 21(2) 14(2) 0.0(18) 0.7(19) 5.4(19) 
C20 13(2) 22(2) 24(3) -1.3(19) 1.7(19) 2.9(19) 
C21 21(3) 28(3) 23(3) 3(2) 4(2) -2(2) 
C22 24(3) 29(3) 17(3) 4(2) 4(2) 4(2) 
C23 20(3) 23(3) 23(3) -1(2) -3(2) 2(2) 
C24 18(3) 18(2) 23(3) 0.5(19) 1(2) 5(2) 
C25 19(2) 27(2) 25(2) -0.2(18) 2(2) -3(2) 
C26 21(3) 26(3) 46(3) 1(2) -9(2) -2(2) 
C27 26(3) 24(2) 40(3) -5(2) -3(2) 3(2) 
C28 22(3) 27(2) 21(2) 2.1(17) 3(2) -3(2) 
C29 33(3) 26(3) 40(3) 1(2) 7(3) -4(2) 
C30 23(3) 50(4) 59(4) 24(3) 8(3) 0(3) 
Au1 14.46(7) 14.39(7) 17.73(8) 0.28(7) 2.04(7) 1.23(7) 
Cl2 17.8(5) 15.5(5) 31.9(7) 1.6(4) -0.5(4) 2.0(4) 
N1 13(2) 20(2) 20(2) -2.5(16) 2.0(17) 5.6(16) 
N2 20(2) 17.5(18) 20.5(19) -2.3(15) 3.0(18) 2.6(18) 
N3 14.7(19) 20.4(18) 15(2) -0.8(14) 1.5(14) 5.0(15) 
O1 19.0(16) 20.1(17) 16.7(16) 0.0(13) 0.3(13) 6.5(14) 
O2 30(2) 29.1(18) 23.1(18) -8.3(13) 1.9(15) -3.8(15) 
O3 18.1(17) 31.5(18) 39(2) -6(2) 2.6(15) -3.0(19) 
S1 20.9(6) 21.8(6) 22.4(6) -4.9(5) 1.4(5) -3.1(5) 
 
Appendix 
236 
 
Table 4 Bond Lengths for (363c)AuCl. 
Atom Atom Length/Å   Atom Atom Length/Å 
C1 Au1 1.965(4)   C14 C15 1.380(8) 
C1 N1 1.361(6)   C15 C16 1.372(8) 
C1 N3 1.355(5)   C16 C17 1.376(7) 
C2 C3 1.345(7)   C17 C18 1.397(7) 
C2 N1 1.417(6)   C19 C20 1.400(7) 
C2 N2 1.410(6)   C19 C24 1.403(7) 
C3 C13 1.468(6)   C19 N3 1.452(6) 
C3 O1 1.398(5)   C20 C21 1.393(7) 
C4 C5 1.343(6)   C20 C25 1.514(7) 
C4 N1 1.366(6)   C21 C22 1.384(7) 
C4 O1 1.354(5)   C22 C23 1.388(7) 
C5 N3 1.395(6)   C23 C24 1.389(7) 
C6 C7 1.388(7)   C24 C28 1.512(7) 
C6 C11 1.396(7)   C25 C26 1.528(7) 
C6 N2 1.435(6)   C25 C27 1.529(6) 
C7 C8 1.374(7)   C28 C29 1.520(7) 
C8 C9 1.388(7)   C28 C30 1.530(7) 
C9 C10 1.378(7)   Au1 Cl2 2.2750(11) 
C10 C11 1.394(7)   N2 S1 1.689(4) 
C12 S1 1.749(5)   O2 S1 1.428(3) 
C13 C14 1.393(7)   O3 S1 1.428(3) 
C13 C18 1.394(7)         
  
Table 5 Bond Angles for (363c)AuCl. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
N1 C1 Au1 128.0(3)   C19 C20 C25 122.5(4) 
N3 C1 Au1 129.4(3)   C21 C20 C19 116.9(4) 
N3 C1 N1 102.6(4)   C21 C20 C25 120.6(4) 
C3 C2 N1 106.6(4)   C22 C21 C20 121.2(5) 
C3 C2 N2 129.7(4)   C21 C22 C23 120.0(5) 
N2 C2 N1 123.4(4)   C22 C23 C24 121.7(5) 
C2 C3 C13 135.0(5)   C19 C24 C28 123.0(4) 
C2 C3 O1 110.3(4)   C23 C24 C19 116.4(4) 
O1 C3 C13 114.6(4)   C23 C24 C28 120.6(4) 
C5 C4 N1 109.3(4)   C20 C25 C26 109.5(4) 
C5 C4 O1 140.0(4)   C20 C25 C27 112.8(4) 
O1 C4 N1 110.6(4)   C26 C25 C27 110.7(4) 
C4 C5 N3 103.4(4)   C24 C28 C29 111.4(4) 
C7 C6 C11 119.0(4)   C24 C28 C30 111.2(4) 
C7 C6 N2 119.8(4)   C29 C28 C30 110.9(5) 
C11 C6 N2 121.2(4)   C1 Au1 Cl2 177.62(13) 
C8 C7 C6 120.9(5)   C1 N1 C2 142.0(4) 
C7 C8 C9 120.1(5)   C1 N1 C4 111.1(4) 
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C10 C9 C8 119.6(5)   C4 N1 C2 106.7(4) 
C9 C10 C11 120.5(5)   C2 N2 C6 120.4(4) 
C10 C11 C6 119.7(5)   C2 N2 S1 116.2(3) 
C14 C13 C3 119.7(4)   C6 N2 S1 122.9(3) 
C14 C13 C18 119.2(4)   C1 N3 C5 113.5(4) 
C18 C13 C3 121.0(4)   C1 N3 C19 124.2(4) 
C15 C14 C13 120.4(5)   C5 N3 C19 121.7(4) 
C16 C15 C14 120.2(5)   C4 O1 C3 105.8(3) 
C15 C16 C17 120.7(5)   N2 S1 C12 105.2(2) 
C16 C17 C18 119.8(5)   O2 S1 C12 107.9(2) 
C13 C18 C17 119.8(5)   O2 S1 N2 108.4(2) 
C20 C19 C24 123.7(4)   O3 S1 C12 109.9(2) 
C20 C19 N3 118.5(4)   O3 S1 N2 105.2(2) 
C24 C19 N3 117.7(4)   O3 S1 O2 119.3(2) 
  
Table 6 Torsion Angles for (363c)AuCl. 
A B C D Angle/˚   A B C D Angle/˚ 
C2 C3 C13 C14 178.4(6)   C20 C19 N3 C1 -99.2(5) 
C2 C3 C13 C18 -3.9(9)   C20 C19 N3 C5 89.8(5) 
C2 C3 O1 C4 1.2(5)   C20 C21 C22 C23 -1.1(8) 
C2 N2 S1 C12 -115.6(4)   C21 C20 C25 C26 74.1(6) 
C2 N2 S1 O2 129.2(3)   C21 C20 C25 C27 -49.6(6) 
C2 N2 S1 O3 0.5(4)   C21 C22 C23 C24 0.0(7) 
C3 C2 N1 C1 -173.7(6)   C22 C23 C24 C19 0.6(7) 
C3 C2 N1 C4 0.5(5)   C22 C23 C24 C28 -178.8(4) 
C3 C2 N2 C6 104.7(6)   C23 C24 C28 C29 -68.0(6) 
C3 C2 N2 S1 -83.4(6)   C23 C24 C28 C30 56.3(6) 
C3 C13 C14 C15 177.9(5)   C24 C19 C20 C21 -1.0(7) 
C3 C13 C18 C17 -178.1(4)   C24 C19 C20 C25 176.5(4) 
C4 C5 N3 C1 0.4(5)   C24 C19 N3 C1 83.7(5) 
C4 C5 N3 C19 172.3(4)   C24 C19 N3 C5 -87.3(5) 
C5 C4 N1 C1 -1.1(6)   C25 C20 C21 C22 -176.0(4) 
C5 C4 N1 C2 -177.3(4)   Au1 C1 N1 C2 -2.5(9) 
C5 C4 O1 C3 175.6(6)   Au1 C1 N1 C4 -176.6(3) 
C6 C7 C8 C9 3.2(8)   Au1 C1 N3 C5 176.8(3) 
C6 N2 S1 C12 56.2(4)   Au1 C1 N3 C19 5.2(7) 
C6 N2 S1 O2 -59.1(4)   N1 C1 N3 C5 -1.1(5) 
C6 N2 S1 O3 172.2(4)   N1 C1 N3 C19 -172.7(4) 
C7 C6 C11 C10 2.2(7)   N1 C2 C3 C13 175.8(5) 
C7 C6 N2 C2 9.6(7)   N1 C2 C3 O1 -1.1(5) 
C7 C6 N2 S1 -161.8(3)   N1 C2 N2 C6 -82.0(6) 
C7 C8 C9 C10 -1.5(8)   N1 C2 N2 S1 89.9(5) 
C8 C9 C10 C11 0.2(8)   N1 C4 C5 N3 0.4(5) 
C9 C10 C11 C6 -0.6(8)   N1 C4 O1 C3 -0.9(5) 
C11 C6 C7 C8 -3.5(7)   N2 C2 C3 C13 -10.0(10) 
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C11 C6 N2 C2 -169.3(4)   N2 C2 C3 O1 173.1(4) 
C11 C6 N2 S1 19.3(6)   N2 C2 N1 C1 11.6(9) 
C13 C3 O1 C4 -176.4(4)   N2 C2 N1 C4 -174.1(4) 
C13 C14 C15 C16 0.2(9)   N2 C6 C7 C8 177.6(5) 
C14 C13 C18 C17 -0.4(7)   N2 C6 C11 C10 -179.0(4) 
C14 C15 C16 C17 -0.4(9)   N3 C1 N1 C2 175.4(6) 
C15 C16 C17 C18 0.2(8)   N3 C1 N1 C4 1.3(5) 
C16 C17 C18 C13 0.2(7)   N3 C19 C20 C21 -177.9(4) 
C18 C13 C14 C15 0.1(8)   N3 C19 C20 C25 -0.4(7) 
C19 C20 C21 C22 1.6(7)   N3 C19 C24 C23 176.9(4) 
C19 C20 C25 C26 -103.3(5)   N3 C19 C24 C28 -3.8(6) 
C19 C20 C25 C27 133.0(5)   O1 C3 C13 C14 -4.8(6) 
C19 C24 C28 C29 112.6(5)   O1 C3 C13 C18 172.9(4) 
C19 C24 C28 C30 -123.0(5)   O1 C4 C5 N3 -176.1(6) 
C20 C19 C24 C23 -0.1(7)   O1 C4 N1 C1 176.5(4) 
C20 C19 C24 C28 179.3(4)   O1 C4 N1 C2 0.2(5) 
  
Table 7 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement Parameters (Å2×103) for 
(363c)AuCl. 
Atom x y z U(eq) 
H5 -1428 6291 2406 24 
H7 3510 5561 1521 27 
H8 5891 5631 1734 32 
H9 7487 4642 1233 33 
H10 6663 3527 555 33 
H11 4248 3407 361 27 
H12A 2866 2359 981 43 
H12B 1515 1777 776 43 
H12C 1443 2444 1330 43 
H14 -997 7302 362 41 
H15 -843 8075 -526 47 
H16 802 7558 -1195 36 
H17 2335 6278 -984 29 
H18 2210 5491 -87 27 
H21 -1846 3845 4143 29 
H22 -310 4723 4727 28 
H23 1391 5740 4323 26 
H25 -1877 3869 2595 28 
H26A -3974 4333 3429 47 
H26B -4300 4056 2783 47 
H26C -3507 5046 2928 47 
H27A -1476 2402 3110 45 
H27B -3056 2434 2896 45 
H27C -2695 2672 3544 45 
H28 2017 6076 2809 28 
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H29A 892 7444 3190 49 
H29B 2533 7637 3210 49 
H29C 1719 7334 3776 49 
H30A 3599 5956 3847 66 
H30B 4230 6223 3238 66 
H30C 3660 5151 3358 66 
Crystal structure determination of [(363c)AuCl] 
Crystal Data for C30H31AuClN3O3S (M =746.05 g/mol): orthorhombic, space group P212121 (no. 19), a = 
9.41339(16) Å, b = 13.4993(2) Å, c = 23.0896(5) Å, V = 2934.10(9) Å3, Z = 4, T = 100.00(10) K, 
μ(MoKα) = 5.212 mm-1, Dcalc = 1.689 g/cm3, 31735 reflections measured (6.036° ≤ 2Θ ≤ 54.964°), 
6686 unique (Rint = 0.0350, Rsigma = 0.0295) which were used in all calculations. The final R1 was 
0.0209 (I > 2σ(I)) and wR2 was 0.0400 (all data). 
Refinement model description 
Number of restraints - 0, number of constraints - unknown. 
Details: 1. Twinned data refinement Scales: 0.498(5) 0.502(5). 2. Fixed Uiso At 1.2 times of: All C(H) 
groups At 1.5 times of: All C(H,H,H) groups. 3.a Ternary CH refined with riding coordinates: C25(H25), 
C28(H28). 3.b Aromatic/amide H refined with riding coordinates: C5(H5), C7(H7), C8(H8), C9(H9), 
C10(H10), C11(H11), C14(H14), C15(H15), C16(H16), C17(H17), C18(H18), C21(H21), C22(H22), 
C23(H23). 3.c Idealised Me refined as rotating group: C12(H12A,H12B,H12C), C26(H26A,H26B,H26C), 
C27(H27A,H27B,H27C), C29(H29A,H29B, H29C), C30(H30A,H30B,H30C). 
5.3.6: (363a)CuCl.CDCl3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Crystal data and structure refinement for (363a)CuCl. 
Identification code  (363a)CuCl 
Empirical formula  C25H29ClCuN3O3S , CDCl3 
Formula weight  670.97 
Temperature  100(2) K 
Wavelength  0.71075 Å 
Crystal system  Monoclinic 
Space group  P 21/n 
Unit cell dimensions a = 16.9828(3) Å = 90°. 
 b = 10.1478(2) Å = 95.615(7)°. 
 c = 17.4535(12) Å  = 90°. 
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Volume 2993.5(2) Å3 
Z 4 
Density (calculated) 1.489 Mg/m3 
Absorption coefficient 1.189 mm-1 
F(000) 1376 
Crystal size 0.28 x 0.25 x 0.15 mm3 
Theta range for data collection 3.09 to 27.48°. 
Index ranges -22<=h<=22, -13<=k<=13, -21<=l<=22 
Reflections collected 39227 
Independent reflections 6850 [R(int) = 0.0259] 
Completeness to theta = 27.48° 99.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8418 and 0.7319 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6850 / 0 / 350 
Goodness-of-fit on F2 1.006 
Final R indices [I>2sigma(I)] R1 = 0.0319, wR2 = 0.0825 
R indices (all data) R1 = 0.0337, wR2 = 0.0836 
Largest diff. peak and hole 1.572 and -0.992 e.Å-3 
 
Notes: 
Selected Parameters: C(1)-Cu(1) = 1.8801 (17) Å, N(3)…Cu(1) = 3.530 (2) Å. 
The hydrogen and deuterium atoms have been fixed as riding models. 
 
Table 2. Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for (363a)CuCl. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1) 1976(1) 5179(2) 1260(1) 13(1) 
C(2) 978(1) 5916(2) 367(1) 15(1) 
C(3) 1632(1) 6648(2) 308(1) 13(1) 
C(4) 2899(1) 6980(2) 741(1) 12(1) 
C(5) 2676(1) 7871(2) 189(1) 13(1) 
C(6) 673(1) 4037(2) 1205(1) 14(1) 
C(7) 706(1) 2758(2) 906(1) 17(1) 
C(8) 161(1) 1843(2) 1139(1) 21(1) 
C(9) -396(1) 2206(2) 1627(1) 23(1) 
C(10) -419(1) 3481(2) 1906(1) 22(1) 
C(11) 120(1) 4430(2) 1709(1) 17(1) 
C(12) 1299(1) 2359(2) 350(1) 21(1) 
C(13) 2031(1) 1710(2) 773(1) 28(1) 
C(14) 934(1) 1440(2) -292(1) 32(1) 
C(15) 130(1) 5801(2) 2060(1) 21(1) 
C(16) 535(2) 5755(2) 2885(1) 35(1) 
C(17) -694(1) 6398(2) 2053(2) 39(1) 
C(18) 3064(1) 8977(2) -152(1) 14(1) 
C(19) 3743(1) 9554(2) 224(1) 19(1) 
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C(20) 4079(1) 10647(2) -98(1) 22(1) 
C(21) 3754(1) 11156(2) -796(1) 24(1) 
C(22) 3082(1) 10584(2) -1173(1) 23(1) 
C(23) 2735(1) 9504(2) -851(1) 18(1) 
C(24) 3694(1) 7029(2) 2011(1) 18(1) 
C(25) 4169(1) 4254(2) 1003(1) 22(1) 
N(1) 1211(1) 5021(1) 957(1) 13(1) 
N(2) 2223(1) 6193(1) 830(1) 12(1) 
N(3) 3627(1) 6785(2) 1169(1) 13(1) 
O(1) 1886(1) 7667(1) -100(1) 14(1) 
O(2) 4228(1) 6119(1) -14(1) 20(1) 
O(3) 5054(1) 6320(1) 1234(1) 21(1) 
S(1) 4329(1) 5931(1) 803(1) 13(1) 
Cl(1) 3353(1) 3548(1) 2984(1) 23(1) 
Cu(1) 2572(1) 4346(1) 2087(1) 15(1) 
C(101) 6798(1) 5186(2) 1406(1) 18(1) 
Cl(11) 6913(1) 3538(1) 1686(1) 48(1) 
Cl(12) 7430(1) 5585(1) 698(1) 41(1) 
Cl(13) 6996(1) 6249(1) 2201(1) 24(1) 
 
Table 3. Bond lengths [Å] and angles [°] for (363a)CuCl. 
 
C(1)-N(1) 1.363(2) C(10)-H(10) 0.9500 C(19)-H(19) 0.9500 
C(1)-N(2) 1.364(2) C(11)-C(15) 1.520(3) C(20)-C(21) 1.387(3) 
C(1)-Cu(1) 1.8801(17) C(12)-C(13) 1.531(3) C(20)-H(20) 0.9500 
C(2)-C(3) 1.350(2) C(12)-C(14) 1.541(3) C(21)-C(22) 1.387(3) 
C(2)-N(1) 1.402(2) C(12)-H(12) 1.0000 C(21)-H(21) 0.9500 
C(2)-H(2) 0.9500 C(13)-H(13A) 0.9800 C(22)-C(23) 1.388(3) 
C(3)-O(1) 1.350(2) C(13)-H(13B) 0.9800 C(22)-H(22) 0.9500 
C(3)-N(2) 1.368(2) C(13)-H(13C) 0.9800 C(23)-H(23) 0.9500 
C(4)-C(5) 1.349(2) C(14)-H(14A) 0.9800 C(24)-N(3) 1.482(2) 
C(4)-N(3) 1.394(2) C(14)-H(14B) 0.9800 C(24)-H(24A) 0.9800 
C(4)-N(2) 1.420(2) C(14)-H(14C) 0.9800 C(24)-H(24B) 0.9800 
C(5)-O(1) 1.4018(19) C(15)-C(17) 1.524(3) C(24)-H(24C) 0.9800 
C(5)-C(18) 1.457(2) C(15)-C(16) 1.534(3) C(25)-S(1) 1.7629(19) 
C(6)-C(7) 1.402(3) C(15)-H(15) 1.0000 C(25)-H(25A) 0.9800 
C(6)-C(11) 1.405(2) C(16)-H(16A) 0.9800 C(25)-H(25B) 0.9800 
C(6)-N(1) 1.449(2) C(16)-H(16B) 0.9800 C(25)-H(25C) 0.9800 
C(7)-C(8) 1.400(2) C(16)-H(16C) 0.9800 N(3)-S(1) 1.6520(15) 
C(7)-C(12) 1.521(2) C(17)-H(17A) 0.9800 O(2)-S(1) 1.4315(13) 
C(8)-C(9) 1.383(3) C(17)-H(17B) 0.9800 O(3)-S(1) 1.4348(13) 
C(8)-H(8) 0.9500 C(17)-H(17C) 0.9800 Cl(1)-Cu(1) 2.1125(5) 
C(9)-C(10) 1.384(3) C(18)-C(23) 1.397(2) C(101)-Cl(11) 1.7475(19) 
C(9)-H(9) 0.9500 C(18)-C(19) 1.398(2) C(101)-Cl(12) 1.7605(18) 
C(10)-C(11) 1.395(3) C(19)-C(20) 1.391(3) C(101)-Cl(13) 1.7636(18) 
 
N(1)-C(1)-N(2) 101.98(13) C(12)-C(13)-H(13B) 109.5 C(20)-C(21)-H(21) 120.0 
N(1)-C(1)-Cu(1) 131.72(13) H(13A)-C(13)-H(13B) 109.5 C(21)-C(22)-C(23) 120.06(18) 
N(2)-C(1)-Cu(1) 126.21(12) C(12)-C(13)-H(13C) 109.5 C(21)-C(22)-H(22) 120.0 
C(3)-C(2)-N(1) 103.69(14) H(13A)-C(13)-H(13C) 109.5 C(23)-C(22)-H(22) 120.0 
C(3)-C(2)-H(2) 128.2 H(13B)-C(13)-H(13C) 109.5 C(22)-C(23)-C(18) 120.36(17) 
N(1)-C(2)-H(2) 128.2 C(12)-C(14)-H(14A) 109.5 C(22)-C(23)-H(23) 119.8 
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C(2)-C(3)-O(1) 140.34(15) C(12)-C(14)-H(14B) 109.5 C(18)-C(23)-H(23) 119.8 
C(2)-C(3)-N(2) 108.61(15) H(14A)-C(14)-H(14B) 109.5 N(3)-C(24)-H(24A) 109.5 
O(1)-C(3)-N(2) 111.05(14) C(12)-C(14)-H(14C) 109.5 N(3)-C(24)-H(24B) 109.5 
C(5)-C(4)-N(3) 130.58(15) H(14A)-C(14)-H(14C) 109.5 H(24A)-C(24)-H(24B) 109.5 
C(5)-C(4)-N(2) 106.33(14) H(14B)-C(14)-H(14C) 109.5 N(3)-C(24)-H(24C) 109.5 
N(3)-C(4)-N(2) 123.09(14) C(11)-C(15)-C(17) 112.74(17) H(24A)-C(24)-H(24C) 109.5 
C(4)-C(5)-O(1) 110.50(14) C(11)-C(15)-C(16) 109.68(16) H(24B)-C(24)-H(24C) 109.5 
C(4)-C(5)-C(18) 134.54(15) C(17)-C(15)-C(16) 110.30(19) S(1)-C(25)-H(25A) 109.5 
O(1)-C(5)-C(18) 114.94(14) C(11)-C(15)-H(15) 108.0 S(1)-C(25)-H(25B) 109.5 
C(7)-C(6)-C(11) 123.33(16) C(17)-C(15)-H(15) 108.0 H(25A)-C(25)-H(25B) 109.5 
C(7)-C(6)-N(1) 118.51(15) C(16)-C(15)-H(15) 108.0 S(1)-C(25)-H(25C) 109.5 
C(11)-C(6)-N(1) 118.10(15) C(15)-C(16)-H(16A) 109.5 H(25A)-C(25)-H(25C) 109.5 
C(8)-C(7)-C(6) 117.03(16) C(15)-C(16)-H(16B) 109.5 H(25B)-C(25)-H(25C) 109.5 
C(8)-C(7)-C(12) 120.46(17) H(16A)-C(16)-H(16B) 109.5 C(1)-N(1)-C(2) 113.55(14) 
C(6)-C(7)-C(12) 122.52(16) C(15)-C(16)-H(16C) 109.5 C(1)-N(1)-C(6) 124.78(14) 
C(9)-C(8)-C(7) 120.88(18) H(16A)-C(16)-H(16C) 109.5 C(2)-N(1)-C(6) 121.66(13) 
C(9)-C(8)-H(8) 119.6 H(16B)-C(16)-H(16C) 109.5 C(1)-N(2)-C(3) 112.15(14) 
C(7)-C(8)-H(8) 119.6 C(15)-C(17)-H(17A) 109.5 C(1)-N(2)-C(4) 141.23(14) 
C(8)-C(9)-C(10) 120.69(17) C(15)-C(17)-H(17B) 109.5 C(3)-N(2)-C(4) 106.60(13) 
C(8)-C(9)-H(9) 119.7 H(17A)-C(17)-H(17B) 109.5 C(4)-N(3)-C(24) 119.00(13) 
C(10)-C(9)-H(9) 119.7 C(15)-C(17)-H(17C) 109.5 C(4)-N(3)-S(1) 120.15(11) 
C(9)-C(10)-C(11) 121.12(18) H(17A)-C(17)-H(17C) 109.5 C(24)-N(3)-S(1) 118.88(11) 
C(9)-C(10)-H(10) 119.4 H(17B)-C(17)-H(17C) 109.5 C(3)-O(1)-C(5) 105.48(12) 
C(11)-C(10)-H(10) 119.4 C(23)-C(18)-C(19) 119.39(16) O(2)-S(1)-O(3) 119.86(8) 
C(10)-C(11)-C(6) 116.93(17) C(23)-C(18)-C(5) 119.52(15) O(2)-S(1)-N(3) 107.15(7) 
C(10)-C(11)-C(15) 120.97(17) C(19)-C(18)-C(5) 121.04(15) O(3)-S(1)-N(3) 105.49(8) 
C(6)-C(11)-C(15) 122.03(16) C(20)-C(19)-C(18) 119.76(17) O(2)-S(1)-C(25) 108.70(9) 
C(7)-C(12)-C(13) 111.32(16) C(20)-C(19)-H(19) 120.1 O(3)-S(1)-C(25) 107.65(9) 
C(7)-C(12)-C(14) 112.35(16) C(18)-C(19)-H(19) 120.1 N(3)-S(1)-C(25) 107.37(8) 
C(13)-C(12)-C(14) 109.90(17) C(21)-C(20)-C(19) 120.50(17) C(1)-Cu(1)-Cl(1) 173.29(5) 
C(7)-C(12)-H(12) 107.7 C(21)-C(20)-H(20) 119.7 Cl(11)-C(101)-Cl(12) 110.94(10) 
C(13)-C(12)-H(12) 107.7 C(19)-C(20)-H(20) 119.7 Cl(11)-C(101)-Cl(13) 110.94(10) 
C(14)-C(12)-H(12) 107.7 C(22)-C(21)-C(20) 119.92(17) Cl(12)-C(101)-Cl(13) 109.19(10) 
C(12)-C(13)-H(13A) 109.5 C(22)-C(21)-H(21) 120.0   
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
 
Table 4. Anisotropic displacement parameters (Å2x 103)for (363a)CuCl. The anisotropic 
displacement factor exponent takes the form: -2 2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
C(1) 11(1)  14(1) 15(1)  -1(1) 1(1)  -1(1) 
C(2) 12(1)  16(1) 15(1)  2(1) -2(1)  -1(1) 
C(3) 12(1)  15(1) 13(1)  1(1) -2(1)  1(1) 
C(4) 9(1)  14(1) 13(1)  -1(1) 1(1)  -1(1) 
C(5) 10(1)  15(1) 14(1)  -2(1) -1(1)  0(1) 
C(6) 10(1)  17(1) 14(1)  3(1) -2(1)  -3(1) 
C(7) 15(1)  20(1) 16(1)  2(1) -1(1)  -2(1) 
C(8) 23(1)  20(1) 21(1)  0(1) -1(1)  -7(1) 
C(9) 18(1)  29(1) 23(1)  6(1) 0(1)  -10(1) 
C(10) 14(1)  31(1) 21(1)  4(1) 3(1)  -2(1) 
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C(11) 12(1)  22(1) 16(1)  3(1) -1(1)  1(1) 
C(12) 24(1)  19(1) 23(1)  -1(1) 7(1)  -1(1) 
C(13) 23(1)  27(1) 33(1)  -7(1) 3(1)  2(1) 
C(14) 34(1)  35(1) 25(1)  -8(1) 2(1)  2(1) 
C(15) 20(1)  23(1) 21(1)  1(1) 4(1)  3(1) 
C(16) 50(1)  28(1) 25(1)  -4(1) -5(1)  2(1) 
C(17) 30(1)  34(1) 54(2)  1(1) 9(1)  12(1) 
C(18) 14(1)  12(1) 16(1)  0(1) 3(1)  0(1) 
C(19) 15(1)  19(1) 23(1)  2(1) -2(1)  -1(1) 
C(20) 16(1)  19(1) 32(1)  1(1) 0(1)  -4(1) 
C(21) 22(1)  18(1) 32(1)  5(1) 6(1)  -3(1) 
C(22) 29(1)  20(1) 21(1)  6(1) 0(1)  -3(1) 
C(23) 21(1)  16(1) 18(1)  1(1) -1(1)  -2(1) 
C(24) 17(1)  23(1) 14(1)  -3(1) -2(1)  0(1) 
C(25) 23(1)  15(1) 29(1)  3(1) 9(1)  1(1) 
N(1) 10(1)  16(1) 14(1)  2(1) 0(1)  -1(1) 
N(2) 9(1)  13(1) 12(1)  0(1) -2(1)  0(1) 
N(3) 10(1)  18(1) 12(1)  -1(1) -1(1)  1(1) 
O(1) 11(1)  16(1) 16(1)  4(1) -2(1)  -2(1) 
O(2) 18(1)  25(1) 17(1)  2(1) 5(1)  4(1) 
O(3) 10(1)  25(1) 27(1)  0(1) -2(1)  0(1) 
S(1) 9(1)  15(1) 16(1)  2(1) 2(1)  0(1) 
Cl(1) 20(1)  27(1) 21(1)  9(1) -4(1)  2(1) 
Cu(1) 12(1)  17(1) 15(1)  4(1) -1(1)  -1(1) 
C(101) 17(1)  20(1) 16(1)  0(1) 1(1)  1(1) 
Cl(11) 79(1)  21(1) 40(1)  3(1) -18(1)  3(1) 
Cl(12) 32(1)  65(1) 27(1)  -19(1) 16(1)  -22(1) 
Cl(13) 29(1)  26(1) 16(1)  -5(1) 2(1)  2(1) 
 
Table 5. Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 103) 
for (363a)CuCl. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
H(2) 476 5990 77 18 
H(8) 173 960 959 25 
H(9) -766 1574 1772 28 
H(10) -809 3713 2237 26 
H(12) 1477 3180 100 26 
H(13A) 2255 2294 1185 42 
H(13B) 2425 1550 410 42 
H(13C) 1880 871 995 42 
H(14A) 835 572 -74 47 
H(14B) 1300 1347 -689 47 
H(14C) 433 1815 -522 47 
H(15) 451 6385 1749 25 
H(16A) 241 5160 3196 52 
H(16B) 544 6641 3108 52 
H(16C) 1078 5433 2877 52 
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H(17A) -963 6355 1530 58 
H(17B) -650 7320 2219 58 
H(17C) -1000 5904 2404 58 
H(19) 3973 9202 698 23 
H(20) 4535 11048 162 27 
H(21) 3991 11894 -1016 28 
H(22) 2859 10931 -1651 28 
H(23) 2271 9121 -1107 22 
H(24A) 4050 7775 2134 27 
H(24B) 3906 6242 2283 27 
H(24C) 3170 7231 2170 27 
H(25A) 3660 3973 739 33 
H(25B) 4161 4134 1559 33 
H(25C) 4595 3723 822 33 
D(101) 6238 5324 1185 22 
 
Table 6. Torsion angles [°] for (363a)CuCl. 
________________________________________________________________ 
N(1)-C(2)-C(3)-O(1) -179.7(2) 
N(1)-C(2)-C(3)-N(2) 0.78(19) 
N(3)-C(4)-C(5)-O(1) 178.04(16) 
N(2)-C(4)-C(5)-O(1) -1.73(18) 
N(3)-C(4)-C(5)-C(18) -3.1(3) 
N(2)-C(4)-C(5)-C(18) 177.15(18) 
C(11)-C(6)-C(7)-C(8) -0.9(3) 
N(1)-C(6)-C(7)-C(8) -177.99(15) 
C(11)-C(6)-C(7)-C(12) 178.81(16) 
N(1)-C(6)-C(7)-C(12) 1.7(2) 
C(6)-C(7)-C(8)-C(9) 1.6(3) 
C(12)-C(7)-C(8)-C(9) -178.11(17) 
C(7)-C(8)-C(9)-C(10) -0.9(3) 
C(8)-C(9)-C(10)-C(11) -0.5(3) 
C(9)-C(10)-C(11)-C(6) 1.2(3) 
C(9)-C(10)-C(11)-C(15) -175.67(17) 
C(7)-C(6)-C(11)-C(10) -0.5(3) 
N(1)-C(6)-C(11)-C(10) 176.63(15) 
C(7)-C(6)-C(11)-C(15) 176.36(16) 
N(1)-C(6)-C(11)-C(15) -6.5(2) 
C(8)-C(7)-C(12)-C(13) -84.2(2) 
C(6)-C(7)-C(12)-C(13) 96.1(2) 
C(8)-C(7)-C(12)-C(14) 39.5(2) 
C(6)-C(7)-C(12)-C(14) -140.16(18) 
C(10)-C(11)-C(15)-C(17) -46.3(2) 
C(6)-C(11)-C(15)-C(17) 137.02(19) 
C(10)-C(11)-C(15)-C(16) 77.1(2) 
C(6)-C(11)-C(15)-C(16) -99.7(2) 
C(4)-C(5)-C(18)-C(23) 163.67(19) 
O(1)-C(5)-C(18)-C(23) -17.5(2) 
C(4)-C(5)-C(18)-C(19) -19.0(3) 
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O(1)-C(5)-C(18)-C(19) 159.88(16) 
C(23)-C(18)-C(19)-C(20) 0.3(3) 
C(5)-C(18)-C(19)-C(20) -177.04(17) 
C(18)-C(19)-C(20)-C(21) -1.1(3) 
C(19)-C(20)-C(21)-C(22) 0.9(3) 
C(20)-C(21)-C(22)-C(23) 0.0(3) 
C(21)-C(22)-C(23)-C(18) -0.7(3) 
C(19)-C(18)-C(23)-C(22) 0.5(3) 
C(5)-C(18)-C(23)-C(22) 177.97(17) 
N(2)-C(1)-N(1)-C(2) -1.06(18) 
Cu(1)-C(1)-N(1)-C(2) 175.65(13) 
N(2)-C(1)-N(1)-C(6) 178.97(15) 
Cu(1)-C(1)-N(1)-C(6) -4.3(3) 
C(3)-C(2)-N(1)-C(1) 0.2(2) 
C(3)-C(2)-N(1)-C(6) -179.83(15) 
C(7)-C(6)-N(1)-C(1) -82.8(2) 
C(11)-C(6)-N(1)-C(1) 99.9(2) 
C(7)-C(6)-N(1)-C(2) 97.21(19) 
C(11)-C(6)-N(1)-C(2) -80.0(2) 
N(1)-C(1)-N(2)-C(3) 1.55(18) 
Cu(1)-C(1)-N(2)-C(3) -175.41(12) 
N(1)-C(1)-N(2)-C(4) -179.88(19) 
Cu(1)-C(1)-N(2)-C(4) 3.2(3) 
C(2)-C(3)-N(2)-C(1) -1.5(2) 
O(1)-C(3)-N(2)-C(1) 178.77(13) 
C(2)-C(3)-N(2)-C(4) 179.40(14) 
O(1)-C(3)-N(2)-C(4) -0.30(18) 
C(5)-C(4)-N(2)-C(1) -177.4(2) 
N(3)-C(4)-N(2)-C(1) 2.8(3) 
C(5)-C(4)-N(2)-C(3) 1.24(18) 
N(3)-C(4)-N(2)-C(3) -178.56(15) 
C(5)-C(4)-N(3)-C(24) 113.9(2) 
N(2)-C(4)-N(3)-C(24) -66.3(2) 
C(5)-C(4)-N(3)-S(1) -82.2(2) 
N(2)-C(4)-N(3)-S(1) 97.51(17) 
C(2)-C(3)-O(1)-C(5) 179.7(2) 
N(2)-C(3)-O(1)-C(5) -0.72(18) 
C(4)-C(5)-O(1)-C(3) 1.55(18) 
C(18)-C(5)-O(1)-C(3) -177.57(14) 
C(4)-N(3)-S(1)-O(2) 30.27(15) 
C(24)-N(3)-S(1)-O(2) -165.86(13) 
C(4)-N(3)-S(1)-O(3) 159.05(13) 
C(24)-N(3)-S(1)-O(3) -37.08(15) 
C(4)-N(3)-S(1)-C(25) -86.35(15) 
C(24)-N(3)-S(1)-C(25) 77.52(15) 
N(1)-C(1)-Cu(1)-Cl(1) 178.4(3) 
N(2)-C(1)-Cu(1)-Cl(1) -5.6(6) 
________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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